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SUMMARY 
 
Severe isolated patellofemoral arthritis is a highly debilitating disease. 
Total knee arthroplasty is considered the gold standard treatment, 
however, patellofemoral arthroplasty has certain advantages. This ‘less 
invasive’ procedure preserves the tibiofemoral joint and cruciate 
ligaments, facilitating a more rapid recovery and allows for a relatively 
straightforward revision if required in the future. As the use of 
patellofemoral arthroplasty steadily gains popularity in the orthopaedic 
community, it is important to establish a consensus on which treatment 
should be the primary intervention of choice. Through background 
reading and expert opinion, three areas of research were chosen for 
further investigation:  
1. Extensor mechanism efficiency 
2. Survival and complication proportions following patellofemoral 
arthroplasty and total knee arthroplasty 
3. Assessment of differences in function and quality of life outcomes 
following patellofemoral arthroplasty and total knee arthroplasty  
 
The purpose of this thesis was to further inform the debate between the 
choice of total knee arthroplasty and patellofemoral arthroplasty for the 
treatment of severe isolated patellofemoral arthritis. 
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Study I: The cadaveric biomechanics study compared the extensor 
mechanism efficiency of the native knee, patellofemoral arthroplasty, 
cruciate-retaining total knee arthroplasty and posterior-stabilising total 
knee arthroplasty. Patellofemoral resultant force, peak pressure and 
contact area were also analysed. The data produced a bimodal 
distribution during the flexion-extension cycle for all four conditions. The 
results showed patellofemoral arthroplasty produced the greatest 
extensor mechanism efficiency in the range of mid flexion to extension 
(50° to 0°). Further research is required to determine whether this 
efficiency translates to the clinical setting. 
 
Study II: The systematic review compared the survival and complication 
proportions of patellofemoral arthroplasty and total knee arthroplasty. The 
patellofemoral arthroplasty studies were divided into seven groups 
depending on femoral component design. Thirty-six out of the forty 
studies identified were uncontrolled retrospective case series’ and 
therefore subject to reporting and selection biases and overall provided 
low quality evidence. A meta-analysis could not be performed due to high 
clinical heterogeneity. Other limitations included variations in study design 
and length of follow-up. Despite, these weaknesses the review 
established inlay designs produced the poorest survival and complication 
outcomes. Malpositioning/misalignment and disease progression were 
the most common complications.  
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Study III: The double-blind randomised clinical trial assessed for 
differences in function and quality of life outcomes between 
patellofemoral arthroplasty and total knee arthroplasty. The trial failed to 
show evidence of a difference between the two interventions. 
Complication rates were overall low but greater in the total knee 
arthroplasty group. Tests for significance were not performed due to the 
small numbers involved. Although, the study was underpowered, the data 
did not support superiority of patellofemoral arthroplasty over total knee 
arthroplasty. Therefore, future studies should test for non-inferiority and 
involve multiple centres to increase generalizability to the wider 
orthopaedic community. 
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   Score 
UHMWPE  Ultra high molecular weight polyethylene 
VAS   Visual Analogue Score 
VI   Vastus intermedius 
VL   Vastus lateralis 
VLO   Vastus lateralis obliquus 
VM   Vastus medialis 
VMO   Vastus medialis obliquus 
WOMAC Western Ontario and McMaster Universities 
Osteoarthritis Index 
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Chapter 1 Introduction 
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1.1 Patellofemoral Arthritis 
1.1.1 Definition, Incidence, Aetiology and Demographics 
Isolated patellofemoral arthritis is a degenerative disease confined to the 
knee cap joint. In severe cases it is highly debilitating, manifesting in 
extreme pain particularly on rising from a chair and stair-climbing. This 
disorder affects a considerable number of patients and has a significant 
impact on quality of life (Duncan et al., 2009).  
 
 A hospital-based study (Ledingham et al., 1993) of patients 
referred with knee arthritis and a community-based study (Duncan et al., 
2006) of adults with knee pain both found the radiological prevalence of 
this disease to be 24%. A cross-sectional radiographic study performed 
by McAlindon et al. (1992) found 11% of men and 24% of women, over 
the age of 55 years, had isolated patellofemoral arthritis of which 2% and 
8% of these men and women were symptomatic, respectively. 
Conversely, a radiographic study (Lacey et al., 2008) carried out on a 
similar age group of symptomatic patients, reported a higher prevalence 
of symptomatic patellofemoral arthritis in the male population. This study 
reported 34.8% prevalence in men age 50 to 64 years compared to 
18.5% in the equivalent female population. This disparity in prevalence 
between genders was not evident in the over 65 years group in which 
23.9% of men and 20.9% of women had isolated patellofemoral arthritis.  
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 A higher prevalence in men has not been shown in previous 
studies (Duncan et al., 2006; Ledingham et al., 1993; McAlindon et al., 
1992). Lacey et al. (2008) suggests occupational exposure may in part 
explain this difference. However, there is little evidence on lifetime 
occupational exposure to support this possible theory. In addition, the co-
existence of other painful, non-articular diseases may lead to an 
underestimate of the presence of symptomatic patellofemoral arthritis in 
the associated female population. Furthermore, a number of studies have 
reported that the prevalence of patellofemoral arthritis is higher in women 
than men (Arendt, 2006; Dejour & Allain, 2004; Mihalko et al., 2007; 
Saleh et al., 2005). Other causal factors such as selective non-
participation bias may explain the difference in prevalence between 
genders in this particular North Staffordshire population. At present, there 
is still more evidence suggesting patellofemoral arthritis is more common 
in women. 
 Our current understanding of aetiological factors associated with 
isolated patellofemoral arthritis is limited. Previous research has focused 
primarily on the tibiofemoral joint and has shown the development and 
progression of tibiofemoral osteoarthritis to be multifactorial. Such factors 
include age, trauma, gender and obesity, but it appears that not all these 
findings are applicable to the patellofemoral joint. The average age of 
those affected tends to be significantly lower than those with severe 
generalised arthritis (Davies et al., 2002).  A cross-sectional study (Tamm 
et al., 2008) showed an association between increased body mass index 
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and tibiofemoral osteoarthritis but not patellofemoral arthritis. The same 
study also identified that early knee trauma strongly correlated with 
patellofemoral arthritis; this association was not present in the 
tibiofemoral osteoarthritis group. An earlier study (Cicuttini et al., 1997) 
found an inverse relationship between premenopausal status and 
patellofemoral arthritis, not seen in patients with tibiofemoral 
osteoarthritis. In addition, histological and biomechanical human and 
animal studies have shown disparity in the patterns of patellofemoral 
arthritis disease progression (Clark, 2008) and in the volume of the 
articular cartilage of the patellofemoral joint compared to the tibiofemoral 
joint (Teichtahl et al., 2006). These differences, coupled with the inherent 
complexities of the patellofemoral joint, suggest that the aetiological 
factors for development of patellofemoral arthritis may differ from those 
associated with tibiofemoral osteoarthritis or generalised knee 
osteoarthritis. Dejour et al. (2010) found idiopathic (primary) 
patellofemoral arthritis occurs in 49% of patients presenting with 
patellofemoral arthritis. Under 10% of patients will have suffered trauma 
to the patella and develop post-traumatic arthritis and a similar number 
will have chrondrocalcinosis. One third of patients develop patellofemoral 
arthritis as a result of patellar instability. These patients give a clear 
history of objective patellar dislocation.  
 Patellar instability secondary to misalignment of the patellofemoral 
joint or congenital trochlear dysplasia has been recognised as a risk 
factor for the development of patellofemoral arthritis (Mäenpää & Lehto, 
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1997b). Previous studies have reported between 4% and 70% 
development rate of patellofemoral arthritis following operative treatment 
for patellar instability (Nomura et al., 2007; Sillanpää et al., 2008). 
Sillanpää et al. (2010) detected evidence of patellofemoral arthritis in 
78% of patients who had undergone non-anatomical procedures 
(Goldthwaite and Krogius) between 10 and 21 years prior to follow-up. 
The defects were most commonly seen in the medial facet and may 
therefore be a direct consequence of the operative procedure. Non-
operative long-term outcomes have been reported by a small number of 
studies. Cofield and Bryan (1977) and Mäenpää and Lehto (1997a) 
published the outcomes of 50 and 100 non-operatively managed patellar 
dislocations with average follow-up times of 10 and 13 years, 
respectively. Both studies concluded better outcomes were achieved 
following non-operative management compared with non-anatomical 
operative management, although the latter methods of treatment are 
seldom used in current practice. Further research is required to identify 
the long-term effects of anatomical operative management, such as 
trochleoplasty (Schottle & Weiler, 2007) on the preservation of 
patellofemoral cartilage and thus progression to patellofemoral arthritis. 
 Patients with patellofemoral arthritis tend to present with anterior 
knee pain. Often this pain is exacerbated by prolonged flexion or 
descending stairs. Many anatomical abnormalities can result in 
patellofemoral disorders, these range from pelvic geometry anomalies, 
femoral anteversion or tibial torsion to increased varus/valgus angles at 
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the knee joint; all of which alter the mechanical axes of the lower limb and 
lead to abnormal alignment and contact pressures at the patellofemoral 
joint. Variations in the Q angle (intersection of two lines: tibial tubercle to 
patella and anterior superior iliac spine to patella) have been reported as 
having significant importance in the development of patellar instability and 
progression to patellofemoral arthritis (Mihalko et al., 2007). Normal Q 
angles have been reported as ranging between 8° to 14° for males and 
10° and 20° for females (Aglietti et al., 1983; Freeman, 1987). Hughston 
(1968) advised any Q angle greater than 10° requires corrective surgery. 
Although this approach is quite aggressive the principle theory is very 
relevant. An increased Q angle can result in increased valgus force on 
the patella and consequential subluxation of the patella and increased 
compression forces on the lateral facet. Other abnormalities such as 
atrophied vastus medialis muscle and patella alta can also contribute to 
the development of patellofemoral arthritis. 
 Once the diagnosis of symptomatic patellofemoral arthritis has 
been established treatment is required to provide maximum pain control 
and minimise disability. The treatment offered is dependent on disease 
severity, patient age, co-morbidity and expectations. A number of non-
operative and operative treatment modalities have been described for 
isolated patellofemoral arthritis (van Jonbergen et al., 2010a). However, 
in the presence of severe disease the efficacy of non-operative 
treatments is limited. Interventions such as physiotherapy, taping and 
intra-articular injections/visco-supplementations offer only short-term 
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relief (Clarke et al., 2005; Cushnaghan et al., 1994; Quilty et al., 2003). 
Therefore operative treatment may be the only effective option. Surgical 
treatment of patellofemoral arthritis has included arthroscopic 
debridement, total or partial patellectomy and tibial tubercle osteotomies 
(Heatley et al., 1986; Jenny et al., 1996; Schepsis et al., 1994) but with 
limited success. Arthroscopic surgery is seldom beneficial in severe 
disease and patellectomy often leads to poor long-term function due to 
weakness of the extensor mechanism (Lennox et al., 1994). Total knee 
arthroplasty (TKA) and more recently, patellofemoral arthroplasty (PFA) 
have all been indicated. Total knee arthroplasty (TKA) is effective (Dalury, 
2005; Laskin & van Steijn, 1999; Mont et al., 2002; Parvizi et al., 2001) 
but in a younger, more active patient is highly likely to require at least one 
revision. Patellofemoral arthroplasty (PFA) removes less bone, preserves 
near normal knee kinematics, and should be much simpler to revise. 
Therefore in these patients the definitive management choice is usually 
between TKA and PFA.  
 
1.1.2 Patellofemoral Arthroplasty and Total Knee Arthroplasty 
Although more recent studies have shown improvements in survivorship, 
the use of PFA has been associated with higher failure rates than TKA 
since its inception. Problems with understanding the indications and with 
the actual prosthetic designs are both partly to blame. Despite the 
advances made in both areas, a recent report from the National Joint 
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Registry for England and Wales (NJR) suggests the revision rate of PFA 
is almost four times that of TKA at three years (Wales, 2012). 
Furthermore, recent analysis of NJR data, over a seven year period, 
found unexplained pain to be the main cause of early revision, occurring 
in 46%, and not disease progression which was reported in only 14% of 
cases (Baker et al., 2012). The cause of the pain, however, could not be 
determined from the registry data. Pre-existing tibiofemoral joint 
degeneration may have been the cause in a number of cases in light of 
the evidence published by Williams et al. (2013). This study suggests that 
a number of failures occurred as a direct result of ignoring these early 
tibiofemoral changes. The findings from both studies (Baker et al., 2012; 
Williams et al., 2013) strengthen the argument that PFA surgery should 
be carried out in specialist centres allowing a select number of surgeons 
to develop greater knowledge and skills in managing PFA patients. These 
concerns and the fact that PFA has been steadily gaining popularity over 
the last decade, suggest a systematic review of the outcomes associated 
with this type of prosthesis would be beneficial.  
 
1.1.2.1 Design and Categorisation of Patellofemoral Arthroplasty 
Poor results with early PFA were attributed to poor patient selection, 
prosthetic design, and failure to correct abnormal patellofemoral 
biomechanics. 
Prosthetic design has evolved significantly over the last three 
decades. The early prostheses, which were predominantly inlay designs, 
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were associated with poor alignment (Blazina et al., 1979; Tauro et al., 
2001). Better understanding of the biomechanics led to considerable 
changes in prosthetic design in the late 1980’s to 1990’s. This may have 
resulted in superior clinical outcomes (Ackroyd et al., 2007; Odumenya et 
al., 2010) although this association in terms of prosthetic design and 
outcome has not been formerly assessed. Recent designs have focused 
on recreating a more anatomical appearance, however the theoretical 
advantage of this feature is not reflected in recent evidence (Wales, 
2012). 
One of the challenges in patellofemoral prosthesis design is 
balancing constraint and congruence. Critical characteristics of trochlear 
component geometry include the level of constraint, medial-lateral width, 
thickness, distal sagittal arc of curvature, and proximal extension of the 
anterior flange.  
The main differences between the early and newer PFAs were 
changes to the geometry of the trochlear component. The early 
prostheses were typically inlaid into the trochlea, generally had a smaller 
surface area, length and width, and a deeper, more constraining trochlear 
groove (Figure 1-1A-B). The principle of the inlay design was to prevent 
overstuffing the patellofemoral joint. However, such a deep central groove 
required more bone resection. Conversely, the later trochlear 
components are mainly onlay designs and are wider (Figure 1-1C-F). The 
aim is to restore normal trochlear offset. By restoring the offset the soft 
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tissue tensions and the mechanical advantage of the extensor 
mechanism can be normalised. 
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Figure 1-1 A-G [A] Lubinus, [B] Richards III, [C] Avon, [D] FPV, [E] Journey, [F] Zimmer 
Gender Solution, [G] Arthrosurface HemiCAP® WAVE 
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Unlike the inlay design, the positioning of the onlay device is not 
completely determined by the geometry of the native trochlea. Rather, the 
trochlear component may be implanted in an orientation decided by the 
surgeon, to improve tracking. In the presence of a hypoplastic lateral 
femoral condyle the component can be rotated into varus to prevent its 
distal lateral edge being too prominent. However, there may be a conflict 
between patellar tracking along the groove, versus the desire to avoid a 
step in the articular surface, and that may risk catching and clunking 
symptoms (Figure 1-2 A-B) (Amis et al., 2005). In trochlear dysplasia, the 
groove is usually medialised; in some cases simple lateral placement of 
an onlay component will allow the correct coronal alignment without 
creating lateral prominence. 
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Figure 1-2 [A] An Avon prosthesis in-situ in-vitro is shown. [B] An example of an erratic 
tracking pattern for patellar tilt caused by the patella catching on the distal edge of the 
femoral component when the knee is extended is shown. The “X” marks represent knee 
flexion and the black squares represent knee extension. Permission to use image granted 
by copyright owners Lippincott Williams & Wilkins. Amis AA, Senavongse W, Darcy P. 
Biomechanics of patellofemoral joint prostheses. Clin Orthop 2005; 436:20-29. 
 
The newer, onlay designs also have a longer anterior flange that 
extends proximally, ensuring that the patellar component remains in 
contact with the trochlear component in full knee extension (Figure 1-3 
B). This avoids the need for the patella to negotiate a step in early knee 
flexion. 
 
 
A 
B 
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Figure 1-3 [A] The short anterior flange of the Lubinus prosthesis causes the patella to 
catch or sublux as it moves from the native femoral articular surface to the prosthesis in 
the initial 30° of knee flexion. [B] The Avon prosthesis has a much longer proximal 
extension of the anterior flange ensuring the patellar component remains in articulation 
with the trochlear component in full extension. 
Permission to use image granted by copyright owners Lippincott Williams & Wilkins. 
Lonner JH, Patellofemoral arthroplasty: pros, cons and design considerations. Clin Orthop 
2004; 428:158-165. 
 
Prostheses have been classified by ‘generation’ but this is not helpful as it 
defines by date of inception and gives no indication of design. An 
alternative, more useful approach is to initially categorise by design 
principles such as inlay/onlay, symmetrical/asymmetrical, non-
anatomical/anatomical/patient-specific and secondarily by constraint 
within each category. Based on the available literature, practical 
experience with the prostheses and the description according to the 
manufacturers, six distinct groups have been established, shown in Table 
1-1. 
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Table 1-1 Prosthesis Categorisation 
Year of 
inception 
Implant  Implant Design characteristics 
Onlay/ 
Inlay 
Asymmetric/
Symmetric 
Anatomical/ 
Non-
anatomical 
Constraint 
1974/76/84 Richards I, II, 
III 
Inlay Symmetric Non-anatomical Highly constrained 
1975 Lubinus Inlay Asymmetric Non-anatomical Highly (S) 
Unconstrained (XL) 
1976 CSF-Wright Inlay Symmetric Non-anatomical Unconstrained 
1980 Autocentric I, II Inlay Asymmetric Non-anatomical Constrained 
1987 Spherocentric Inlay Asymmetric Non-anatomical Constrained 
1997 LCS Inlay Asymmetric Anatomical Highly constrained
1996 Avon Onlay Symmetric Non-anatomical Unconstrained 
1997 Hermes Onlay Asymmetric Anatomical Semi-constrained
2004 Vanguard Onlay Asymmetric Anatomical Unconstrained
2008 Natural Knee II Onlay Asymmetric Anatomical Semi-constrained
1996 FPV Onlay Asymmetric Anatomical *Highly constrained 
2005 Journey Onlay Asymmetric Anatomical Semi-constrained
2008 Zimmer Onlay Asymmetric Anatomical Semi-constrained
1994 Custom 
Performa 
Knee 
Onlay Asymmetric Anatomical- 
patient specific 
Semi-constrained 
1995 Kinematch Onlay Asymmetric Anatomical- 
patient specific 
Semi-constrained 
This table lists the prostheses in terms of design categorisation: inlay or onlay, asymmetric 
or symmetric, non-anatomical or anatomical and degree of constraint. The earlier 
prostheses were mainly inlay, asymmetric designs with variable constraint. The more 
recent designs are onlay, asymmetrical, anatomical and semi-constrained. 
* The FPV patellar component is multifacetted, creating a highly constrained prosthetic 
joint. In contrast, the FPV femoral component has a wide sulcus angle and is less 
constraining when combined with an axisymmetric patellar button.  
 
 
1.1.3 Current Clinical and Biomechanical Issues with Arthroplasty 
Treatment 
Whilst some surgeons consider TKA the gold standard, providing good 
function and low revision rates (Dalury, 2005; Laskin & van Steijn, 1999; 
Mont et al., 2002; Parvizi et al., 2001; Thompson et al., 2001), others 
believe PFA is a better treatment as it preserves healthy bone and native 
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soft tissue restraints and offers an easier operative environment should 
revision surgery to TKA be required (Argenson et al., 2005; Cartier et al., 
2005; Lonner et al., 2006; Merchant, 2004; Sisto & Sarin, 2006). Although 
the majority of surgeons are aware of the advantages of both types of 
arthroplasty, the decision regarding which procedure to perform is often a 
difficult one in the absence of a consensus.  
 
1.1.3.1 Clinical Issues 
The main clinical issues resulting in this lack of consensus lie in the 
differences in opinion regarding indications and contraindications, which 
ultimately impacts functional, survival and complication outcomes. Some 
surgeons advocate PFA should be reserved for patients with isolated 
severe patellofemoral arthritis secondary to trochlear dysplasia, a prior 
patellar fracture and those with a near neutral Q angle (Argenson et al., 
2005; Cartier et al., 2005; Nicol et al., 2006). Argenson et al. (2005) 
reported a disproportionate number of patients with idiopathic 
patellofemoral arthritis experienced disease progression (tibiofemoral 
osteoarthritis) compared with those who had a history of patellar 
dislocation or trauma to the patella. Nicol et al. (2006) reported 0% 
disease progression in all patients with trochlear dysplasia at seven years 
compared with a 16% rate in those with primary patellofemoral arthritis. 
Although these findings are convincing, other authors have reported 
results in groups of patients with idiopathic patellofemoral arthritis that are 
comparable to those seen in patients with trochlear dysplasia (Merchant, 
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2005; Sisto & Sarin, 2006). Anatomical variant, patella baja (low lying 
patella) is a recognised contraindication for PFA. 
 There is little consensus on the most appropriate age group to 
whom PFA surgery should be offered. Sisto & Sarin (2006) chose not to 
perform PFA in any patient over the age of 55 years. They took the view 
of PFA being temporary surgery rather than definitive. On the contrary, 
some advocate PFA to be a suitable operation for elderly patients who 
are unlikely to develop disease progression during the remainder of their 
lives. While others argue that young active patients should receive TKA 
as this operation near guarantees improvement in symptoms and return 
to activities of daily living and avoids the risk of disease progression 
(Diduch et al., 1997). 
 This broad variation in whom best to offer PFA surgery cannot be 
determined from systematically reviewing the literature due to the current 
level of evidence available (predominantly retrospective uncontrolled 
case series’). However, a systematic review to first ascertain the survival 
and complications outcomes following PFA and TKA by design 
differences may inform the choice debate. The definitive study is a 
randomised clinical trial comparing PFA with TKA, assessing function, 
prosthesis survival and complication outcomes. 
 
1.1.3.2 Biomechanical Issues 
The main biomechanical challenges with TKA and PFA are restoring 
knee kinematics whilst maintaining extensor mechanism integrity. The 
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integrity of the knee extensor mechanism is crucial for the performance of 
daily activities such as rising from a chair, normal walking and stair 
climbing. Existing literature describes the effects on the extensor 
mechanism following TKA but fall shorts of providing any data on the 
effects following PFA. Patients who have undergone TKA surgery tend to 
rise from a chair more slowly compared with those without knee 
pathology and also tend to rely on the unaffected leg (Mizner et al., 
2005).  
  Quadriceps strength insufficiency can remain for a number of 
years after TKA, as demonstrated by Huang et al. (1996). In this study, 
the authors compared posterior cruciate retaining and sacrificing 
prostheses and found no significant difference between them in terms of 
hamstring to quadriceps ratio. When compared with healthy individuals 
this measurement was found to be higher in patients who had undergone 
arthroplasty (between six and thirteen years ago). Potential reasons for 
this include disuse atrophy due to low pre- and post-operative activity in 
order to preserve prosthesis survivorship. Secondly, during the 
experiments some patients did not exhibit maximal performance out of 
fear that their TKA may fail under extreme exertion and thirdly, anterior 
cruciate deficient knees generally have a lower level of quadriceps 
strength with no effect on hamstring strength (Kannus, 1988). 
 Decreased walking and stair climbing speed have also been 
reported as indicators of quadriceps weakness by Walsh et al. (1998); a 
finding further supported by more recent studies (Mizner et al., 2005; 
  
46
Mizner & Snyder-Mackler, 2005). Prosthetic design has the potential to 
enhance this weakness or improve the efficiency of the extensor 
mechanism. 
 Traditionally, knee flexion and extension were thought to occur 
around changing instant centres of rotation, this theory resulted in the 
design of multi-radius knee prostheses. However, Huang et al. (1996) 
reported that these designs do not restore the extensor mechanism 
moment arm to normal. The current belief is that there is a single, fixed 
flexion-extension axis located near the transepicondylar axis (Churchill et 
al., 1998). In theory, this relatively more posterior (single radius) axis of 
rotation (compared with that of the multi-radius TKA) lengthens the 
extensor mechanism moment arm and results in a better functioning 
extensor mechanism. This improved function is theoretically due to the 
inverse effect that increase in quadriceps moment arm has on quadriceps 
force, that is, less force is required at higher quadriceps moment arms for 
knee extension to occur. The overall effect is improved efficiency of the 
extensor mechanism (Mahoney et al., 2002). There are two types of TKA 
that allow for this theoretical posterior displacement: posterior cruciate 
retaining (CR-TKA) and posterior cruciate substituting/stabilising (PS-
TKA). Posterior sacrificing designs are no longer popular as in the 
absence of both cruciate ligaments anterior displacement occurs, which is 
firstly non-anatomical and secondly shortens the moment arm thus 
decreasing the efficiency of the extensor mechanism. Bolanos et al. 
(1998) found no difference in flexion moments during level walking or 
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stair climbing between substituting and retaining compared to Dorr et al. 
(1988) who compared sacrificing with retaining. This difference may be 
due to the PS-TKA having a cam mechanism to substitute for the function 
of the posterior cruciate ligament and thus allowing rollback of the femoral 
component on the tibial component during knee flexion. This prosthesis 
permits a wider range of motion compared with a cruciate-sacrificing 
prosthesis and is theoretically mechanically beneficial for the quadriceps 
muscle, potentially promoting increased quadriceps strength (Insall et al., 
1982; Scuderi & Insall, 1992). Critical appraisal of these studies along 
with other relevant literature is required to determine the plausibility of 
these conclusions. 
 Previous studies assessing extensor mechanism function following 
single radius versus multi-radius TKA have shown varied outcomes. 
Studies evaluating PS-TKA have reported single radius PS-TKA as 
superior (Gomez-Barrena et al., 2010; Mahoney et al., 2002). Conversely, 
other investigations assessing CR-TKA found no difference between 
single and multi-radius (Hall et al., 2008). Currently, there are no review 
articles or randomised trials to determine whether single radius is 
mechanically more favourable than multi-radius for CR-TKA or PS-TKA 
femoral designs. 
 More recent literature has focused on comparing the migration of 
tibial components following single radius CR-TKA and PS-TKA or stability 
of single radius versus multi-radius CR-TKA (Jo et al., 2014; Molt & 
Toksvig-Larsen, 2014) rather than directly comparing CR- and PS-TKA 
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with regards to the effects on extensor mechanism. Efficiency of the 
extensor mechanism following PFA has not been assessed. The extensor 
mechanism is the primary support of the knee during standing and 
walking. In light of this importance, it is imperative to identify which type of 
arthroplasty provides the most efficient extensor mechanism. This 
information may influence the decision to perform TKA or PFA in future 
patients with isolated patellofemoral arthritis. 
 
1.2 Rationale for PhD 
 
Analysis of knee arthroplasty through objective and subjective 
assessment has brought to light important information for the orthopaedic 
community (Dawson et al., 1998; Ewald, 1989; Insall et al., 1976; Murray 
et al., 2014). Conventionally, a clinical review of a patient following TKA 
or PFA consists of radiographs and clinical outcomes. These outcomes 
are used to evaluate function, complications and implant survival. This 
data is vital for determining such factors on a pragmatic level but limited 
in providing any inference regarding prosthetic design or specific muscle 
efficiency. Investigating the influence of TKA and PFA design on extensor 
performance is important for the future development of these 
interventions. It is for these reasons the focus of this thesis was on both 
the clinical and biomechanical aspects of TKA and PFA. 
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To date there are no published randomised clinical trials comparing TKA 
with PFA for the treatment of severe isolated PFOA. The use of PFA is 
now rapidly increasing and it is therefore extremely important to 
determine both for the NHS and patient welfare, whether this procedure 
offers better knee function than TKA. Performing such a study would also 
provide data to support a larger multicentre trial. 
 
One meta-analysis reported on the complications of PFA compared with 
TKA (Dy et al., 2012). However, the prostheses were grouped based on 
time of inception rather than component design. Furthermore, the 
heterogeneity that exists within these groups is high and therefore the 
appropriateness of performing a meta-analysis is questionable. A more, 
meaningful approach would be to assess the survival and complication 
proportions associated with prosthetic designs. 
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1.2.1 Research Objectives 
The overall aim of this thesis is to inform the PFA versus TKA debate by 
determining the differences in extensor mechanism efficiency, survival, 
functional and complication outcomes following TKA and PFA treatment 
for severe isolated patellofemoral arthritis. This will be achieved by 
completing the following thesis objectives: 
 
1. To conduct a comparative cadaveric biomechanical study to 
determine the differences in extensor mechanism efficiency 
following TKA and PFA. 
2. To systematically review the survival and complication proportions 
following TKA and PFA (using the design categorisation system) 
for severe isolated patellofemoral arthritis.  
3. To perform a pragmatic randomised clinical trial to identify whether 
a difference exists between TKA and PFA in terms of functional 
outcomes for severe isolated patellofemoral arthritis. 
1.2.2 Targets for Research 
Strategic Research Targets  Research Projects  Strategic Research Targets 
 
 
 
 
 
 
 
 
 
 
 
Biomechanics Study 
Systematic Review 
Randomised Clinical Trial 
Understanding the 
differences in extensor 
mechanism efficiency 
following PFA and TKA 
Understanding the 
differences in survival, 
functional outcome and 
complication proportions 
following PFA and TKA 
Informing the debate in 
choice between PFA 
and TKA for the 
treatment of severe 
isolated patellofemoral 
arthritis 
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1.2.3 Potential Impact 
The potential impact of this research is to further inform the debate 
regarding the use of PFA and TKA for severe isolated patellofemoral 
arthritis. The biomechanics study could act as the benchmark to more 
translational studies. The systematic review will act as a good reference 
for determining what the literature advises on the use of both treatment 
modalities. The randomised clinical trial will offer unbiased results on the 
functional outcome of both treatments, which until now has not been 
available. 
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Chapter 2 Extensor Mechanism Efficiency 
Following Patellofemoral Arthroplasty 
and Total Knee Arthroplasty 
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2.1 Abstract 
Objectives 
Extensor mechanism weakness following TKA is a recognised 
phenomenon. However, the effect on quadriceps function following PFA 
has not been evaluated.  The purpose of this study was to first establish a 
broad overview of the literature related to prosthetic design and extensor 
mechanism function through carrying out a narrative literature review and 
secondly perform an experimental cadaveric study assessing the effect of 
geometrical differences between PFA and TKA on extensor mechanism 
efficiency, patellofemoral resultant force, peak pressure and contact area. 
  
Methods 
Eight fresh frozen cadaveric knees were mounted in a kinematic rig. 
Constant load was applied to the quadriceps muscles and ITB. Each 
knee was subject to four conditions: native knee, Zimmer PFA, CR-TKA 
and PS-TKA. Repeated measures of all four parameters were performed 
under each condition for all eight knees. Extensor mechanism efficiency 
was measured from 120° to 0° at 10° increments using a calibrated strain 
gauge device connected to the rig. The other three parameters were 
measured using Tekscan sensors placed between the patella and 
trochlea. Analysis was performed using one-way ANOVA and post-hoc 
paired t-test with a corrected significance level of p < 0.00833. 
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Results 
The results show extensor mechanism efficiency was significantly greater 
for PFA between mid flexion to full extension (50° to 0°) when compared 
with the native knee, CR-TKA and PS-TKA. The reverse occurred in deep 
flexion, although the differences between the arthroplasty conditions were 
not significant. No difference in resultant force was detected between the 
arthroplasty conditions. A significant reduction in PFA peak pressure in 
deep flexion (90° and 120°) corresponded with increased contact area as 
the patellar button came into articulation with the native femoral condyle. 
High peak pressures greater than four times that measured in the native 
knee were detected in all three arthroplasty conditions at 0°. 
 
Conclusion 
Despite previous reports in the literature, no difference in any of the 
parameters was found between CR-TKA and PS-TKA. The greatest 
extensor mechanism efficiency was produced by PFA in mid flexion to full 
extension. Further work is required to determine whether this increased 
efficiency provides benefit during the performance of ADLs such as 
walking. The methodology of this study will provide the benchmark for 
such future translational research.  
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2.2 Literature Review: The Effects on the Extensor Mechanism 
following Patellofemoral Arthroplasty and Total Knee 
Arthroplasty 
2.2.1 Introduction 
The integrity of the knee extensor mechanism is the most important factor 
that determines a patient’s ability to climb stairs or rise from a chair. 
These movements, along with normal walking, are an integral part of daily 
living, which if compromised, can be highly debilitating. This problem is 
not uncommon following total knee arthroplasty (TKA). 
 
There is much controversy associated with the use of TKA and 
patellofemoral arthroplasty (PFA) for the treatment of isolated 
patellofemoral arthritis. Current literature focuses on differences in clinical 
functional outcome; the difference in extensor mechanism function 
between the two prostheses remains unknown. 
 
The aim of this narrative literature review was to address the broader 
issues related to knee extensor mechanism function following PFA and 
TKA through achieving the following objectives: 
1. To summarise the relevant anatomy of the patellofemoral joint 
2. To summarise the biomechanics of the knee extensor 
mechanism, abnormal patellofemoral biomechanics and 
biomechanics related to PFA 
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3. To determine the clinical importance of quadriceps weakness 
following knee arthroplasty 
4. To determine the impact of TKA prosthetic design in terms of 
cruciate retaining, sacrificing or substituting on extensor 
mechanism function 
5. To determine the impact of TKA prosthetic design in terms of 
femoral component radii: multi-radius versus single radius on 
extensor mechanism function 
6. To propose theoretical extensor mechanism function following 
PFA 
 
For each of the objectives the relevant literature was identified impartially. 
Although not a systematic review by definition, efforts were made to 
reduce bias by using established search databases, such as Medline and 
EMBASE. Search terms used were applicable to the specific objectives 
stated above. Relevant peer-reviewed studies in English were included. 
Synthesis of the literature and evaluation of the strength of the evidence 
provided the necessary information to make an informed judgement 
about how to design and rationalise the methodology of the subsequent 
experimental study. 
 
2.2.2 Anatomy of the Knee Extensor Mechanism 
The patella, the largest sesamoid bone, has the thickest articular cartilage 
found in the body. It has seven articular facets: the medial and lateral 
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facets, which are both divided into equal third sections and the most 
medial portion called the odd facet. Throughout the entire flexion-
extension cycle, some aspect of the patellar articular surface is loaded 
with the exception of the earliest degrees of knee flexion (Grelsamer & 
Weinstein, 2001). The patellofemoral contact surface area in the native 
knee is illustrated in Figure 2-1; Table 2-1 describes the articular location 
of this contact on both joint surfaces. 
 
Figure 2-1 Patellofemoral Contact Areas at knee flexion angles (Goodfellow et al., 1976)  
 
Table 2-1 Patellofemoral Joint Contact Surface Locations 
Flexion angle Patella articulation Femoral articulation 
0° Minimal bony contact Femoral sulcus 
20°-30° Inferior facet Middle femoral sulcus 
60° Middle facets Superior femoral notch 
90° Middle and superior lateral facets Superior femoral notch 
120° Lateral middle and superior facets Superior femoral notch and 
lateral femoral condyle 
135° Lateral middle, lateral superior and 
odd facets 
Lateral femoral condyle 
and lateral surface of 
medial femoral condyle 
 
Contact between the patella and trochlea that covers a larger surface 
area will distribute the load over a greater area. At 30° knee flexion, the 
area of patellofemoral contact is approximately 20mm2 in the native knee. 
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The area of contact gradually increases as the knee is flexed. At 90° of 
knee flexion contact area triples, increasing up to 60mm2. The contact 
area increases in size as the patellofemoral joint becomes more 
congruent. The motion of the patella and hence maintenance of this 
congruency is largely dependent on the soft tissue constraints of the joint. 
 The patella acts as a central point of attachment for the extensor 
ligaments and tendons and therefore governs the alignment of the entire 
extensor mechanism. The most proximal aspect of the patella is extra-
articular and lies within the quadriceps tendon. The articular surface 
extends from the quadriceps tendon to the inferior pole of the patella. 
 The extensor mechanism consists of three distinct, convergent 
layers that insert into the proximal patella. The superficial layer is 
comprised of the rectus femoris muscle, which constitutes approximately 
15% of the cross-section of the extensor mass (Clarke et al., 2001). This 
muscle originates from the ilium as two heads, which unite to form one 
muscle that travels distally in the anterior thigh. Approximately 5 to 8cm 
proximal to the superior pole of the patella the muscle tapers and become 
tendinous (Reider et al., 1981). These fibres pass onto the anterior 
aspect of the patella and become continuous with the patellar tendon. 
Beneath lie the vasti lateralis (VL) and medialis (VM) in the intermediate 
layer, which converge to form a tendinous structure holding the patella in 
a central position. The VL originates at the proximal part of the 
trochanteric line and runs to the midpoint of the linea aspera. The distal 
margin of fibrous tissue merges with the lateral patellar retinaculum, 
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attaching to the tibia. The VM originates from the distal aspect of the 
trochanteric line and extends to the distal medial portion of the linea 
aspera; the most distal fibres arise from the adductor magnus tendon and 
insert into the quadriceps tendon. The deepest layer contains the vastus 
intermedius, which originates from the anterolateral aspect of the femoral 
shaft and is covered anteriorly by an aponeurosis that is continuous with 
the quadriceps tendon. All three layers unite as the quadriceps tendon 
and for this reason the tendon is often described as having a trilaminar 
structure, although in reality the structure is more complex (Reider et al., 
1981). 
 Both VL and VM have distinct oblique heads formed from distal 
fibres that insert into respective patellar retinaculae. The vastus medialis 
obliquus (VMO) inserts at an angle approximately 50° to the femoral axis 
(Lieb & Perry, 1968) allowing it to function effectively as an active medial-
lateral stabiliser; it is not involved in knee extension. This is equally true 
for the vastus lateralis obliquus (VLO) acting on the opposing side (Amis 
& Farahmand, 1996). The dynamic equilibrium between these structures, 
aided by the effective angles of insertion, allows for maintenance of 
medial-lateral balance and patellar tracking. In addition to these active 
stabilisers, the retinacular structures, most importantly the medial 
patellofemoral ligament (MPFL), which attaches to the patella and under 
surface of the VMO and vastus intermedius aponeurosis, provide passive 
restraint against lateral patellar subluxation (Conlan et al., 1993). The 
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lateral aponeurosis extends from the ilio-tibial band to the patella and in 
part opposes the action of the medial retinacular structures.  
 Distally, the quadriceps tendon attaches to the base and sides of 
the patella via an aponeurotic expansion anterior to the patella. This thin 
sheet continues distally and passes into the patellar tendon and medial 
and lateral patellar retinaculae. The patellar tendon is a strong, 
ligamentous structure connecting the inferior pole of the patella to the 
tibial tuberosity. The pull of the quadriceps tendon on the patellar tendon 
is not a straight line due to the inclination of the femoral shaft (defined as, 
a line adjoining the anterior superior iliac spine and the centre of the 
patella) and alignment of the tibial tuberosity (a line between the anterior, 
central aspect of the tibial tuberosity and centre of the patella). The axis 
of both tendinous structures crossing at the central aspect of the patella 
forms the Q angle, which dictates the direction of pull. The angle is 
always valgus with mean values of 14° in men and 17° in women (Aglietti 
et al., 1983), which predisposes the patella to lateral displacement. 
However, the lateral slope of the femoral trochlea, VMO and medial 
retinaculum resist this movement.  
 
2.2.3 Biomechanics of the Knee Extensor Mechanism 
During level walking the forces across the tibiofemoral joint can reach five 
times body weight, although the peak during the gait cycle is usually 
between 2 and 4 times body weight (Morrison, 1970). The force across 
the patellofemoral joint during the same activity is of the order of half 
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body weight (Reilly & Martens, 1972). The precise level of loading 
depends on internal factors such as alignment between the femur and 
tibia and any residual deformity and external factors, such as the speed 
of walking and environmental conditions. Ascending and descending 
stairs has little effect on the tibiofemoral forces in contrast to those 
created at the patellofemoral joint. The force increases significantly in this 
joint, up to 1.5 to 2 times body weight on ascent and 2.5 to 3 times body 
weight on descent. This 3 to 6 fold increase in patellofemoral force is 
primarily due to the increased activity of the quadriceps. However, greater 
forces are exerted across the patellofemoral joint during rising from a 
chair unaided by arms. During this activity, the patellofemoral forces 
reach 3.5 times body weight (whereas tibiofemoral forces are 4 times 
body weight). More strenuous activities such as running, squatting and 
jumping will significantly increase the magnitude of these patellofemoral 
forces.  
 The knee extensor mechanism is essential for simple walking. 
Specifically, it is responsible for the propulsion action during the stance 
phase. The magnitude of the force created is primarily due to the 
quadriceps action resulting in knee extension and the gastrocnemius 
plantar flexing the foot, the overall effect being forward propulsion of the 
body.  
 The main role of the patella is to enhance the efficiency of the 
extensor mechanism through the following two biomechanical functions. 
Firstly, the patella displaces the patellar tendon anteriorly, away from the 
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surface of the femur, resulting in lengthening of the extensor moment 
arm. This effect becomes less significant when the knee is in deep 
flexion. In this position the patella is engaged in the intercondylar notch 
and only marginally displaces the quadriceps tendon anteriorly; and 
therefore has little effect on the extensor moment arm. Secondly, the 
patella increases the surface area over which the joint compressive 
forces are applied. The significance of the patella in increasing the length 
of the extension moment arm depends on the degree of knee flexion.  
 
During terminal knee extension the patella disengages from the 
trochlea and is pulled laterally by the force of the vastus lateralis. 
Conversely, during the initial 30° of knee flexion the patella moves 
relatively medially and the lateral facets of both the patella and proximal 
trochlear groove engage. After which the patella travels along the 
trochlear groove, parallel to the mechanical axis of the femur in the 
coronal plane (Ahmed et al., 1999; Amis et al., 2006; Heegaard et al., 
1994; Nagamine et al., 1995). Engagement of the patella is maintained as 
it passes into the distal portion of the trochlear groove in deep flexion. 
Here it bridges the femoral intercondylar notch and femoral rollback 
occurs.  
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2.2.3.1 Abnormal patellofemoral biomechanics and biomechanics related 
to patellofemoral arthroplasty  
In patients with patellar maltracking lateral displacement of the patella 
can occur, the severity of which is dependent on the integrity of the 
surrounding soft tissue stabilisers and bony alignment. A trochlear 
component that engages the patella early, has a groove with sufficient 
depth and has adequate coverage when reaching the intercondylar notch, 
could prevent mild lateral subluxation. However, if the lateral facet of the 
trochlea is too prominent, it may lead to retinacular impingement and 
pain, creating a similar effect as the Albee procedure (Albee, 1915).   
It is important to appropriately balance the soft tissues, recognising 
that a high proportion of cases have lateral misalignment with a tight 
lateral retinaculum related to longstanding trochlear dysplasia. This can 
be corrected in various ways, including lengthening of the retinaculum by 
a subperiosteal lateral peripatellar release (Ackroyd, 2005). The medial 
retinacular structures and medial patellofemoral ligament (MPFL) stretch 
over time, presenting a further problem for soft tissue balance. In some 
instances, MPFL reconstruction or, albeit rarely, tibial tuberosity 
anteromedialisation may be indicated (Dejour et al., 1994; Schöttle et al., 
2005). 
The mechanics of medial-lateral stability, rotation in the sagittal 
plane (flexion-extension) and rotation and translation in the coronal plane 
are of crucial importance (Rhoads et al., 1990). During the initial 30° of 
tibiofemoral flexion there is a lag discrepancy between tibiofemoral flexion 
and patellar flexion due to the distal translation of the patella that occurs. 
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Beyond this, the patella rotates around the arc of the femoral articular 
geometry in the sagittal plane, with 55° of patellar flexion at 90° 
tibiofemoral flexion (Amis et al., 2005). A femoral component with a low-
profile would allow this motion to occur smoothly and thus avoid the 
‘catching’ or ‘snapping’ symptoms caused by a bulky anterior flange that 
forces the patella into extension during initial engagement. 
A previous study (Amis et al., 2005) assessed the pre- and post-
operative tracking kinematics in vitro of four different patellofemoral 
arthroplasties and found the Avon (Stryker) and Leicester (Corin Group, 
Cirencester, England) implants had tracking paths that most resembled 
the native knee (Figure 2-2). Unsurprisingly, the Richards (Smith & 
Nephew) (Blazina) had a comparatively linear pattern following 
engagement into the V-shaped trochlear groove. The Lubinus (Link Co.) 
demonstrated an inconsistent pattern in some of the specimens, most 
likely due to abrupt changes in patellar tilt occurring at the transition point 
between the trochlear component and the native femoral condyles. 
 
Figure 2-2 Variation of trochlear sulcus angle with flexion around femoral components and 
intact natural knees are shown. On the x-axis, 0° = view along femur and 90° = AP view. 
Permission to use image granted by copyright owners Lippincott Williams & Wilkins. Amis 
AA, Senavongse W, Darcy P. Biomechanics of patellofemoral joint prostheses. Clin Orthop 
2005; 436:20-29. 
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Figure 2-3 Forces acting on the patella in the sagittal plane. Quadriceps tension (Q), 
patellar tendon tension (PT) and joint force (JF). The JF moves proximally across the 
patella as the knee flexes, rising significantly with increase in knee flexion for the same PT. 
Permission to use image granted by copyright owners Lippincott Williams & Wilkins. Amis 
AA, Senavongse W, Darcy P. Biomechanics of patellofemoral joint prostheses. Clin Orthop 
2005; 436:20-29. 
 
Patellofemoral joint reaction forces occur as a result of the tension 
in the extensor mechanism. The force vectors in the sagittal plane are 
composed of the quadriceps and patellar tendon tensions (Figure 2-3). In 
the coronal plane this force has a dominant lateral component caused by 
the Q angle (Neumann, 2002). The compressive nature of the joint force 
suggests that loosening is unlikely, but the force moves across both the 
trochlea and patella during knee flexion, and so rocking micromotion must 
be resisted. As knee flexion increases the forces created are larger and 
move closer to the proximal edge of the patella. The native patella can 
accommodate such forces but the periphery of a patellar button consists 
of a flat skirt and therefore small contact areas are subjected to very high 
forces during daily activities (Table 2-2 (Andriacchi et al., 1980; Boccardi 
et al., 1981; Dahlkvist et al., 1982; Ellis et al., 1984; Ericson & Nisell, 
1987; Huberti & Hayes, 1984; Kuster et al., 1993; Matthews et al., 1977; 
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Morrison, 1970; Nisell, 1985; Reilly & Martens, 1972; Winter, 1983) cited 
from (Kuster et al., 1997). 
Table 2-2 Reported patellofemoral joint loads for several daily activities 
Author Activity Patellofemoral joint load 
(Body weight multiples) 
Ericson Cycling 1.2 
 
Reilly and Martens Level Walking 0.5 
Matthews (Morrison)  0.7 
Nisell (Boccardi)  1.3 
Kuster  1.8 
 
Nisell (Andriacchi) Stair ascending 2.1 
Reilly & Martens  3.3 
Matthews (Morrison)  2.5 
 
Nisell (Andriacchi) Stair descending 5.6 
Reilly & Martens  3.3 
Matthews (Morrison)  2.5 
 
Matthews (Morrison) Downhill walking 1.8 
Kuster  7.0 
 
Ellis Rising from a chair 3.1 
 
Nisell (Winter) Jogging 7.0 
 
Dahlkvist Squat descent 7.6 
 
Huberti Isometric contraction at 90° 
flexion 
6.5 
NB: The data for the joint load calculations taken from secondary sources are indicated in 
the parentheses. Reproduced with permission and copyright © of the British Editorial 
Society of Bone and Joint Surgery (Kuster et al., 1997). 
 
It is believed that fibrous tissue forms around the patella and 
buffers some of this load (Cameron & Cameron, 1987). For this reason 
some surgeons advocate using a smaller patellar component, leaving a 
bony rim of cancellous surface around the button to allow this ‘patellar 
meniscus’ to form. Numerous fixation pegs cemented into the patellar 
bone may resist potential rocking/loosening displacement of the 
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component. A previous study found an increased rate of patellar fracture 
associated with one-peg compared with three-peg patellar component 
design (Larson et al., 2001). Earlier, Gioir et al. (1990) established that 
the stability of a prosthesis subjected to shear forces is in part dependent 
on the number, size (length/diameter ratio) and positioning/proximity of 
the peg fixations; a prosthesis with multiple small pegs that has the same 
shear yield value as a prosthesis with fewer, larger pegs will have a stiffer 
shear fixation as smaller pegs offer more shear stability per unit volume.  
In the native knee the trochlea is asymmetrical. The lateral 
articular facet is approximately 50% larger than the medial to 
accommodate the higher load. This arises because, although the trochlea 
is aligned to the femoral mechanical axis (Iranpour et al., 2010b), the 
quadriceps muscles are aligned along the femoral anatomical axis 
(Farahmand et al., 1998a). It therefore seems logical that a femoral 
component should mimic this geometry, particularly when considering 
that a significant number of patients will have a history of patellar 
instability with a tendency to track laterally. 
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2.2.4 Clinical Importance of Quadriceps Weakness following Knee 
Arthroplasty 
Quadriceps strength deficit after TKA surgery, at mid- to long-term follow-
up, has been reported to be as high as 30 to 40% in comparison to age-
matched groups (Berman et al., 1991; Gore et al., 1986; Silva et al., 
2003; Walsh et al., 1998). A reduction in walking and stair climbing speed 
are considered manifestations of quadriceps weakness (Walsh et al., 
1998), although Wilson et al. (1996) disputed this association. More 
recent studies have since been published that further support quadriceps 
deficiency as the main cause (Mizner et al., 2005; Mizner & Snyder-
Mackler, 2005). The literature in this section assesses the impact of 
quadriceps weakness following TKA. 
 
 Berman et al. (1991) performed a prospective comparative study 
on two groups of patients receiving unilateral TKA, Total Condylar 
Prosthesis II (TCP II) (Zimmer, Warsaw, Indiana) who at the time of the 
index procedure had unilateral disease. The first group of 68 patients 
underwent Cybex II isokinetic testing, the second group of 36 patients 
were evaluated using the Hospital for Special Surgery (HSS) knee rating 
scale, gait analysis and the Cybex. Both groups were assessed pre- and 
post-operatively at specific time intervals. The eligibility criteria for both 
groups were patients with degenerative arthritis of the knee not requiring 
any walking aids, who did not have other musculoskeletal or systemic 
pathology impacting gait and were available for follow-up.  The Cybex II 
measured the quadriceps and hamstring torque, peak torque, and 
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hamstring to quadriceps ratio or flexion to extension (FE) ratio. 
Measurements were taken at varying flexion intervals using a 
dynamometer while the patient was seated in a chair. The analysis was 
also performed on the ‘normal’ side for each patient for comparison. 
Group one pre-operative mean peak torque in flexion was approximately 
a third less than the contralateral ‘normal’ knees mean value; in extension 
it was approximately half the ‘normal’ knees mean. The pre-operative FE 
ratio, was 0.89 for the implanted knees and 0.55 for the normal knees 
(normal range (0.50-0.60). Between 7 and 12 months the authors 
reported a significant improvement in flexion peak torques and FE ratio 
although they did not provide any statistical data to support this 
observation. There was minimal change in extension peak torque 
implying a residual deficit in quadriceps strength. At 24 months the FE 
ratio normalised. The assessment on group two, at mean follow-up 28 
months (24-39 months), showed an increase in walking velocity and 
decrease in two-foot stance post-operatively.  The FE ratio normalised 
and all post-operative HSS scores were comparatively greater than the 
pre-operative scores. There was correlation between FE ratio and gait 
velocities and two-foot stance but not peak torques.  
 In summary, this study found FE ratio normalisation is associated 
with improved gait, normal hamstring strength is restored within a year 
and quadriceps strength remains suboptimal at two years. This study is 
weakened by the lack of statistical evidence for the differences observed 
despite the authors inferring that a clinical difference exists. Other 
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limitations included the 12 knees that required arthroplasty surgery during 
the evaluation period. It is possible that the ‘normal’ values produced by 
these ‘normal’ knees were lower than that which would be found in an 
unaffected knee due to the undetected degenerative disease. 
Furthermore, the strength of the control knees may have been reduced 
as a direct impact of the limitations imposed by the affected knee. It may 
have been more plausible to identify a matched group with bilateral 
normal knees for comparison. It is also not clear who performed the TKAs 
and whether this was a multi-surgeon or single surgeon series. 
 Silva et al. (2003) performed a prospective comparative study 
assessing the difference in knee strength between a group of high-level 
functioning TKAs and a control group. Fifty-two ‘normal’ knees in 31 
patients were in the control group. The eligibility criteria for this group 
consisted of no pain or other restrictions. The study group consisted of 32 
TKAs in 19 patients of which 13 were bilateral. All the knees in this group 
met the criteria of ‘excellent’. All the implants were cemented PS-TKA 
with polyethylene patellar components. Each knee was evaluated post-
operatively using the Knee Society Scoring System (KSS) for clinical 
function and a dynamometer for measuring FE ratio, peak extension and 
flexion torques during knee flexion from 0° to 90° at 15° increments. In 
summary, this study demonstrated peak extension and flexion torques 
were greater in controls than in TKA at all positions following adjustment 
for demographic differences (age, height, weight and BMI). KSS 
positively correlated with peak extension torques (r = 0.57; P = 0.004) 
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and negatively correlated with FE ratio (r = -0.78; P = <0.0001), 
suggesting higher quadriceps strength was associated with higher KSS 
scores. Older patients with TKA produced lower extension peak torques 
than the younger TKA patients. The authors reported a moderate strength 
of association between high BMI and quadriceps weakness (r = 0.44; P = 
0.007). However, these findings were undermined by the following 
limitations of the study. 
 Multiple analyses were performed in this study thus increasing the 
risk of a Type I error. The authors performed statistical adjustments for 
age, height and BMI due to the significant difference in these 
demographics between the control and TKA groups. However this 
method does not control for multiple confounding variables, which is likely 
to be the case in this study. Thus the statistically significant differences in 
peak extension and flexion torques found between the control and TKA 
groups could be due to these confounding factors. In addition, the control 
group included patients with only one normal knee, which may have 
altered the overall functional outcome due to lack of mutual exclusivity. 
Gender and bilaterality were two other confounding factors that were not 
adjusted for that may have influenced the observed difference in peak 
extension torques reported. Subgroup analysis was performed on an 
already small sample size thus introducing the risk of a Type II error and 
ultimately diminishing the strength of the evidence. Although the implants 
are all stated to be PS-TKA, designs can vary significantly in terms of 
symmetry/asymmetry, depth of trochlear recess and flange dimensions. 
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All of these geometric variables can influence prosthesis function due to 
the impact on, for example, the angle of engagement of the cam post 
mechanism, which ultimately affects the peak torques produced. This 
may explain the high variability observed. 
Walsh et al. (1998) performed a retrospective comparative study of 
29 patients who had undergone TKA and 40 matched control patients. 
Eight of the TKA patients were bilateral. The purpose of the study was to 
determine physical impairments by measuring knee ROM and muscle 
torque using a dynamometer. Walking and stair climbing were slower, 
stride length and knee joint excursion were reduced in the TKA patients. 
The mean peak force on knee extension was greater than knee flexion. 
The FE ratio was greater for TKA than control patients. The results were 
consistent with the two previous studies discussed, as were the study 
limitations. 
 The mean peak extension and flexion torques in the ‘normal knee’ 
of TKA patients, although stronger than the TKA knee, were 27% and 
12% lower than the torques measured in the control group, respectively. 
Furthermore, reduced peak torques were still present at 1 year post-op in 
both the ‘normal’ and TKA knees of the TKA group. Thus reaffirming 
using the contralateral ‘normal’ knee may not be the most suitable 
control. Although, the control patients were matched on age and gender, 
the higher weights and body fat percentages observed in the TKA group 
are confounding factors. Another limitation is that patient selection 
consisted of volunteers. Volunteers have been shown to be healthier and 
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have better function (Sackett, 1979). Such individuals may be more 
determined to have a successful outcome and therefore the observed 
difference is significantly influenced by personality trait rather than the 
independent variable. This would be considered a failure in internal 
validity. Therefore, both the TKA and control groups may not be 
representative of their respective populations. The type of prosthesis (CS-
or CR- or PS-TKA) was not stated by the authors and therefore the 
reader cannot draw specific conclusions related to prosthetic design. 
Despite these limitations the study did show that although pain is reduced 
following TKA, function is still impaired in terms of ADLs when compared 
with normal knees. How this is related to quadriceps strength deficit is not 
sufficiently demonstrated by this study although likely to be a contributing 
factor. 
Huang et al. (1996) carried out a retrospective comparative study 
assessing muscle strength ratios and whether the ratio returned to normal 
levels in the long term. A single surgeon series of 36 patients underwent 
50 TKA, of which 14 patients were bilateral. Nine patients (16 knees) 
were in the control group. The post-operatively follow-up time ranged 
from six to thirteen years. Three types of TKA were used: 14 Total 
Condylar (TC) (Howmedica, Rutherford, New Jersey), 21 Low Contact 
Stress meniscal bearing (LCSmb) (Depuy, Warsaw, Indiana) and 15 Low 
Contact Stress rotating platform (LCSrp) (Depuy, Warsaw, Indiana). The 
TC and LCSrp were CS-TKA designs; LCSmb was CR-TKA. The TKA 
group FE ratio for all 3 prostheses were higher than for the control group, 
  
75
significant at P <0.05, suggesting the quadriceps strength was weaker in 
the TKA group; no difference was seen between CR- and CS-TKA. The 
authors concluded this difference in FE ratio may be due to disuse 
atrophy, patient reluctance to exert themselves in order to preserve the 
prosthetic joint and/or ACL deficiency. Previous studies have shown 
quadriceps strength reductions associated with ACL deficient knee 
(Kannus, 1988). 
The main limitations with this study were the small sample size 
and sub group analysis performed which renders the data susceptible to 
Type II error. In addition, the control and TKA groups were statistically 
different in terms of body weight and within the TKA group there were 
significant differences in follow-up time. These known confounding factors 
along with the unknown confounding factors weaken the quality of the 
evidence. 
 Andriacchi et al. (1982) evaluated the relationship between gait 
and TKA design during level walking and stair-climbing. Thirty-six TKAs 
(26 patients) were assessed and compared to a group of 14 control 
subjects. The TKA patients were analysed in 5 subgroups based on 
prosthesis design: 7 Geomedic (CR-TKA), 8 Cloutier (least constrained 
CR-TKA), 7 Gunston (retention of both ACL and PCL TKA), 8 TC (CS-
TKA) and 6 Duopatellar (CR-TKA). The results show walking speed and 
stride length were greater in the control group than TKA group; no 
difference between the five groups was observed. The range of motion 
(ROM) for the TKA group was less than the control group, except for the 
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Cloutier prosthesis subgroup that had the same ROM as the control 
group during stair climbing. The authors believed the normal ROM in this 
subgroup was a result of both cruciate ligaments being retained, the flat 
minimally constrained tibial component and a more posterior femorotibial 
contact position, giving the quadriceps a mechanical advantage. They 
argue that a more constrained component would prevent posterior 
positioning of the femorotibial component and therefore not produce the 
same moment arm. These conclusions have not been evaluated in this 
study. 
 The study is weakened by the lack of matching and thus an 
imbalance of known (ipsilateral limb pathology, bilaterality, variations in 
prosthetic design) and unknown confounding factors between the TKA 
and control group. In addition, poor choice of primary outcome (ROM) 
makes the inferences drawn regarding quadriceps function unreliable. 
 Bolanos et al. (1998) performed a retrospective single surgeon 
comparative study of 14 patients with bilateral TKAs- one CR-TKA and 
one PS-TKA. Three CR-TKAs were used: 8 anatomic graduated 
components (Biomet, Warsaw, Indiana), 3 Cruciate Condylar 
(Howmedica, Rutherford, New Jersey) and 3 Kinematic Condylar 
(Howmedica, Rutherford, New Jersey). All fourteen PS-TKAs were IB II. 
The authors carried out isokinetic testing and gait analysis. No difference 
was found between CR- and PS-TKA in terms of peak torques, 
endurance, stride time, stance phase and double limb support time, ROM 
and stair climbing. Statistically significant differences were demonstrated 
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between the TKAs and controls for the majority of these parameters. The 
authors concluded there was no functional difference between CR- and 
PS-TKA, although not conclusive due to the following limitations. 
The decision regarding which knee received PS- or CR-TKA was 
dependent on the severity of the symptoms and radiological findings. This 
introduces selection bias and implies the groups were not equal in terms 
of disease characteristics. Other issues, such as difference in muscle 
strength, are more likely to be present in the knee with more severe 
arthritic disease and, as stated earlier, the knees are not mutually 
exclusive. Additionally, the sample size was small and three different 
types of PS-TKA were used. The effects of a number of unknown and 
known confounding variables including component designs, persistent 
abnormal gait patterns prior to surgery are immeasurable due to the study 
design.  All of these limitations weaken the credence of the conclusions 
drawn from these results. 
 Wilson et al. (1996) carried out a retrospective comparative study 
to determine the functional outcomes of 16 patients with IB II PS-TKAs 
and 32 age-matched control subjects (two groups of 16) using the HSS 
and KSS scores, gait analysis and EMG studies. The mean follow-up was 
46 months. No difference in gait analysis, isokinetic tests or stair ascent 
ROM was seen between the TKA group and control group. Level walking 
and stair descent ROM was statistically significantly greater in the control 
group in the absence of decreased muscle strength.  
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These findings are dissimilar to previous studies that have 
demonstrated quadriceps weakness and high FE ratios (Berman et al., 
1991; Huang et al., 1996; Walsh et al., 1998). The authors believe this 
may be due to a combination of differences in prosthetic geometry and 
control groups, poor proprioception and residual gait abnormalities. 
Although, none of these potential causes were assessed. In addition, 
other factors such as study design, small sample size, unmatched and 
two different control groups for gait analysis and muscle testing are likely 
contributing factors. These limitations would have increased the risk of 
falsely not detecting muscle strength deficit. The authors concluded PS-
TKA provides better function than CS-TKA and is equivalent to CR-TKA. 
However, there is insufficient evidence to support this statement.  
Mizner et al. (2005) carried out a prospective experimental study to 
determine the impact of muscle activation and muscle atrophy in the early 
loss of quadriceps strength following knee arthroplasty.  Twenty patients 
were assessed 10 days pre-operatively and at mean 27 days following 
unilateral TKA. The TKAs were performed by a number of surgeons who 
all used an incision extending into the quadriceps tendon. Muscle 
contraction force was measured by using a stimulator to assess the need 
for augmentation to reach maximum recruitment. Muscle cross-sectional 
area was also calculated using MRI to determine the association between 
this parameter and strength.  The results showed a significant post-
operative reduction in quadriceps strength by 62% (P < 0.001), muscle 
activation by 17% (P = 0.002) and muscle cross-sectional area by 10% (P 
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= 0.004) compared with pre-operative values. Positive correlation (r = 
0.85; P < 0.001) was observed between loss of quadriceps strength and 
the combination of voluntary muscle activation failure and atrophy. 
Multiple regression analysis demonstrated a stronger association 
between quadriceps strength loss and voluntary muscle activation failure 
than with reduced quadriceps cross-sectional area. There was weak 
association between extent of activation failure and pain (r = 0.20; P = 
0.05). The authors concluded an exercise programme targeting intense 
muscle contraction might assist in activation and minimise the effects of 
quadriceps weakness in the first post-operative month.  
 This study highlights the relationship between muscle activation 
failure and quadriceps strength loss in the immediate short term. Whilst 
this is interesting, no long-term inferences can be drawn from the data. 
One considerable limitation is the unknown effect of the surgical 
approach to the proximal quadriceps tendon; this could have greatly 
influenced the loss of quadriceps strength in the initial post-operative 
period.  
 The relationship between quadriceps weakness and function 
following TKA was assessed by Mizner and Snyder-Mackler (2005). This 
prospective multi-surgeon study involved 14 patients who underwent TKA 
(prostheses undisclosed). Each patient was assessed three months 
following TKA surgery using motion analysis, EMG testing, function- stair 
climbing and rising from a chair, and pain levels. The contralateral knees 
were used as the control group. The results showed the quadriceps in the 
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TKA group were weaker than the control group by 65% (P < 0.001). 
Quadriceps strength negatively correlated with the time taken to ascend 
stairs (r = -0.65; P < 0.01) and positively correlated with distance walked 
in six minutes (r = 0.64; P < 0.01). Despite the significantly lower peak 
knee flexion angle and knee excursion during weight acceptance in the 
gait cycle in the TKA group compared with the control group (P = 0.02 
and P < 0.01, respectively), no difference was found in peak knee 
extensor moment between the two groups (P = 0.43). The authors 
believe the patients showed high reliance on the control limb based on 
the lower peak torques and quadriceps muscle recruitment during sit-to-
stand motion. They suggest this may have contributed to the persistent 
quadriceps weakness in the TKA limb. 
 This study showed correlation between quadriceps strength and 
function in the short term. However, the causal relationship between 
these two variables was not sufficiently demonstrated due to the 
confounding factors. Other limitations include the use of the contralateral 
limb as the control group, small sample size and short follow-up.  
 
2.2.4.1 Section Summary 
 This section consists of two prospective comparative studies, five 
retrospective comparative studies and two prospective non-comparative 
studies. Eight out of the nine studies assessed found evidence of 
quadriceps strength deficit. Overall, the evidence supports the argument 
that quadriceps weakness is a serious problem following TKA in the 
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short- and long-term despite the limitations of the studies appraised. The 
impact of this deficit however may be dependent on the prosthesis 
geometry. 
 
2.2.5 Impact of Prosthesis Design: cruciate –retaining, sacrificing and 
substituting on extensor mechanism function 
Early prosthesis designs were simple hinge devices, which had a high 
rate of loosening because they did not allow normal translation and 
rotation (about all three axes) of the knee to occur. Later, more complex 
design technology led to the production of condylar prostheses (cruciate-
sacrificing TKA, CR-TKA and PS-TKA). These implants have varying 
degrees of constraint, with the least constraining being CR-TKA and PS-
TKA. These prostheses attempt to re-create near anatomical knee 
kinematics. Unfortunately, not all implants have been successful in 
replicating physiological motion or extensor mechanism function. 
 Anterior displacement of the femur on the tibia during flexion has 
been observed following CR-TKA (Dennis et al., 1996; Kim et al., 1997; 
Stiehl et al., 1995). In contrast, PS-TKA has been shown to have a more 
posterior tibiofemoral contact point (Dennis et al., 1996; Dennis et al., 
1998). 
 In theory, a more posterior contact point between the femoral and 
tibial components will result in a longer extensor moment arm. The longer 
the extensor moment arm, the lower the quadriceps force required to 
produce equivalent extensor moments occurring in the presence of a 
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relatively anterior contact area or shorter extensor moment arm (Insall et 
al., 1982). The following studies assess the impact of these prosthetic 
designs on quadriceps strength and knee kinematics, particularly femoral 
rollback. 
 
 Dorr et al. (1988) performed a single surgeon series comparative 
study assessing function using gait analysis and EMG testing following 
CS-TKA (TC prosthesis) and CR-TKA (Duopatellar or Robert Brigham; 
Johnson & Johnson, Braintree, Massachusetts) on a group of 11 patients. 
Each patient received bilateral TKAs: one CS-TKA and one CR-TKA. 
Evaluations were carried out at 6 months and 2 years. The purpose of 
this study was to identify whether sacrifice of the PCL affected function in 
terms of gait, muscle activity and functional scores. The results showed 
reduced single limb stance time; both CS-TKA and CR-TKA groups had 
means of 34%  (normal is 40% of gait cycle). CR-TKA group had lower 
post-operative knee ROM than CS-TKA; statistical significance was not 
reported. The CS-TKA group had statistically higher flexion moments 
throughout loading and higher varus moments compared with CR-TKA. 
The authors believed the latter finding was due to the PCL centralising 
the moment about the knee in the CR-TKA and therefore producing lower 
varus moments. The EMG studies revealed significantly more active 
vastus lateralis (VL) and long head of biceps femoris during level walking 
as a consequence of the larger varus moment arm in the CS-TKA group. 
During stair climbing the same increase in muscle activity was seen along 
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with the additional use of forward trunk lean for stair ascent in order to 
compensate for the varus moment arm and because the quadriceps were 
already working at maximum capacity. The HSS scores for both groups 
improved post-operatively and no difference was found. The authors 
stated that CS-TKA performed less efficiently during level walking and 
stair climbing. They suggested the higher varus moment associated with 
the CS-TKA could increase wear due to increased tension in the lateral 
compartment and increased medial compression. This theoretical 
argument is based on the occurrence of medial tibiofemoral joint arthritis 
in PCL deficient knees as a result of increased compression in the medial 
compartment. The authors concluded CR-TKA was more efficient than 
CS-TKA, as it required less muscle activity and may have better 
survivorship as a result of lower medial tibiofemoral joint loading and joint 
reaction forces. 
The main limitation of this study was the sample size. Such small 
numbers increase the chances of a type II error. The larger varus 
moments observed in the CS-TKA group could have been related to 
component positioning rather than an absent PCL, which brings this 
association into question. Treating each knee as an individual subject in 
patients with bilateral TKAs assumed statistical independence, which may 
have led to false interpretations. Cruciate sacrificing prostheses are no 
longer in widespread use due to suboptimal outcomes; more recent 
comparisons have been between posterior cruciate stabilising/substituting 
(PS) and CR. 
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 Another prospective comparative study (Becker et al., 1991) 
assessed 30 patients, each with one CR-TKA and PS-TKA.  The CR-TKA 
prostheses used were 11 TC, 18 anatomic graduate components –AGC 
(Biomet, Warsaw, Indiana) and one Kinematic (Howmedica, International 
Ltd). All the PS-TKAs were IB II. The aim of the study was to determine 
the difference in functional outcome using the HSS score, ROM, stair-
climbing and knee preference. The data were collected at two to five 
years follow-up. No difference was found between the pre- and post-
operative results of the CR-TKAs and PS-TKAs for HSS scores, ROM, 
stair-climbing ability or knee preference. Again, factors such as sample 
size, bilaterality, within group prosthesis variation (for CR-TKAs), 
unvalidated assessment tools and selection bias all weaken the strength 
and generalisability of the evidence. It is unlikely that such a study design 
would detect a difference even if one did exist because of these 
limitations. Conclusions of ‘no difference’, based on the fact the patients 
did not favour one design over the other is misleading.  
 Conversely, a larger study performed by Hirsch et al. (1994) did 
find a functional difference between PS-TKA and both CR-TKA and CS-
TKA. The retrospective comparative study involved three groups of 
patients: Group I (CS-TKA)- 77 PFCs in 70 patients, Group II (CR-TKA)- 
80 PFCs in 70 patients and Group III (PS-TKA)- 85 IB II in 81 patients. 
The surgery was carried out by or under one senior surgeon. All the 
patients received the same post-op rehabilitation. Assessments were 
performed pre-operatively, at six months and at one year using KSS 
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score and ROM. Nine knee (eight patients) were excluded from follow-up; 
reasons were stated. The results showed Group III (PS-TKA) had a 
greater ROM than CS-TKA and CR-TKA. No difference was found 
between the clinical scores. Complications reported included seven 
patellar fractures and two infections, which were equally spread between 
the groups. The authors concluded that the greater ROM detected with 
the PS-TKAs would increase mobility and ability to carry out ADLs which 
required higher degrees of flexion. No difference was found between CS-
TKAs and CR-TKAs possibly due to PCL insufficiency despite being 
retained.  
 This study had larger sized groups than previous studies. Although 
not statistically demonstrated, the authors showed the patient 
demographics were similar between the groups except for underlying 
condition. Group I had a lower number of patients with osteoarthritis and 
a higher number of patients with rheumatoid arthritis likely to have been 
statistically significant. One of the data collectors was the senior author, 
which introduces observer bias. There was no attempt to improve the 
quality of the ROM parameter by blinding or calculating the intra-class 
correlation coefficient (ICC) for intra-observer or inter-observer reliability. 
 Stiehl et al. (1995) investigated the femorotibial contact point in 47 
CR-TKAs compared with 4 control knees using fluoroscopic video 
analysis. The CR-TKA patients were selected based on high KSS 
scoring. Five different prostheses were used: 8 Porous Coated Anatomic 
(Howmedica, Rutherford, New Jersey), 11 Ortholoc (Wright Medical 
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Technology, Arlington, Tennessee), 9 Genesis (Richards Inc., Memphis, 
Tennessee), 10 Anatomic Modular Knee  (Depuy, Warsaw, Indiana) and 
9 Miller-Galante II (Zimmer, Warsaw, Indiana). The results for the control 
data showed in full extension, the tibia contacted the femur anterior to the 
midline in the sagittal plane of the tibial joint surface. The converse was 
true for the 47 CR-TKAs, which demonstrated contact posterior to the 
mid-sagittal line. Posterior femoral rollback was not visualised with the 
CR-TKAs, instead anterior translation associated with erratic motion 
occurred with increasing flexion. Dissimilarly, the control knees exhibited 
smooth posterior translation during flexion. Assessment of the patellar 
tendon and patella rotation demonstrated constraint motion with smooth 
patellar tracking in the control knees. Conversely, the CR-TKA exhibited 
abnormal patellar tracking with high variability. No statistical analyses 
were performed. In conclusion, this study demonstrated the CR-TKAs did 
not perform femoral rollback and the normal pattern of patellar constraint 
is not reproduced with the patellar resurfacing designs of these 
prostheses. This investigation clearly demonstrates the abnormal motion 
occurring with the CR-TKAs. However, the comparator control group is 
not sufficient in terms of size and matching. Also, the study group 
consisted of 5 different prostheses, which may have contributed to the 
significant variability in the results. These limitations undermine the 
conclusions drawn.  
 Dennis et al. (1996) investigated knee kinematics using an in vivo 
weight-bearing method. Four groups were analysed: 16 normal knees, 10 
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ACL deficient knees, 13 CR-TKAs and 25 PS-TKAs. Both TKAs were 
PFC prosthesis. Each knee performed three successive deep squats to 
maximum flexion under fluoroscopic surveillance in the sagittal plane. 
The femorotibial contact position was determined using three-dimensional 
analysis and two-dimensional digitisation. The results for the normal knee 
demonstrated an anterior femorotibial contact position in the mid-sagittal 
plane in full extension and during femoral rollback the contact point 
moved posteriorly. The ACL deficient knees and CR-TKAs exhibited 
similar patterns of motion. Both types displayed a high degree of 
variability. Three patterns of movement were seen: (1) paradoxical 
anterior translation during mid-flexion, (2) persistent posterior position 
throughout flexion and (3) an amalgam of patterns (1) and (2). Generally, 
anterior translation occurred at 30° to 60° and 60° to 90°. The PS-TKAs 
most closely reproduced normal knee kinematics. In full extension the 
femorotibial contact position was anterior to the mid-sagittal plane but not 
as far forward as the normal knee. Posterior femoral rollback occurred 
during flexion, similar to the normal knee but not to the same extent. The 
authors demonstrated graphically the highly inconsistent femorotibial 
position associated with CR-TKA and ACL-deficient knees compared with 
PS-TKA and normal knees. The authors concluded normal posterior 
femoral rollback is not reproduced by either CR- or PS-TKA despite the 
latter more closely replicating normal knee kinematics. They also 
suggested the posterior translation that occurred in full extension for both 
the ACL deficient knees and CR-TKA was as a result of an absent ACL 
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and anterior translation was due to insufficient PCL (poor tension). The 
high variability in femorotibial contact position was attributed to surgical 
technique and the anterior translation observed linked to early 
polyethylene failure in the CR-TKA designs with flat, non-conforming 
femoral surfaces.  
 Anteriorisation of the femur on the tibia during flexion in an ACL 
deficient knee or CR-TKA has been demonstrated in this study and 
others (Draganich et al., 1987; Stiehl et al., 1995). Anteriorisation of the 
femorotibial contact point is thought to inhibit maximum flexion due to the 
relatively anterior flexion axis, cause early soft tissue impingement of the 
posterior structures and tighten the extensor mechanism. The quality of 
this study could have been improved if the sample sizes and group 
characteristics/demographics were matched. The results represent PFC 
prosthesis in patients with high functional outcome; the narrow inclusion 
reduces the external validity and generalisability of the findings. 
 A later study (Kim et al., 1997) was conducted to further analyse in 
vivo posterior femoral rollback following CR-TKA using lateral 
radiographs. The investigation involved 49 CR-TKAs (Genesis Total Knee 
System, Smith & Nephew Orthopaedics Memphis, Tennessee) in 38 
patients (11 bilateral, 27 unilateral). Four surgeons performed the 
procedures, each surgeon ensuring that the PCL was intact at the end of 
each procedure. The patients were selected consecutively providing they 
had a good to excellent KSS score, ≥ 90° of flexion and appropriate 
radiographs and follow-up was performed at one year. Three radiographs 
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were observed: 1) lateral (hip to ankle) standing in full extension- to 
measure femorotibial contact position 2) anteroposterior (hip to ankle) 
standing in full flexion- to measure tibiofemoral varus/valgus angle 3) 
unloaded knee at 90° in the seated position- to measure femorotibial 
contact position. The distance between the two femorotibial contact 
positions was measured relative to the distance from the anterior aspect 
of the tibial tray and second reference, the anterior rim of the tibial 
plateau. The results showed no evidence of posterior femoral rollback, 
rather anterior translation was observed. There was no correlation 
between posterior tibial slope and amount of femoral translation on the 
tibia. The authors concluded posterior femoral rollback does not 
consistently occur in CR-TKA and no correlations were identified between 
posterior tibial slope, tibiofemoral angle (pre- or post-operative) and 
amount of femorotibial contact position shift.  
There were a number of limitations such as the absence of a 
comparator group and inappropriate statistical methodology. The authors 
used paired t-test to calculate intra-interobserver reliability instead of 
calculating the intraclass correlation coefficient. The paired t-test value 
gives no indication of the level of reproducibility achieved by the 
observers. Contrary to the findings of Walker and Garg (1991), the 
authors concluded posterior tibial slope does not effect femoral 
translation. This study may have failed to detect such an association 
because the measurements taken were carried out on a small number of 
patients at only 2 points in knee motion. Furthermore the analysis method 
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used was inadequate. Measuring femorotibial contact position on a lateral 
radiographs may result in a high error rate due to the superimposed 
femoral condyles. The variability in the results may also reflect surgeon 
inconsistency/experience despite all four using the same technique.  
 Insall et al. (1982) performed a retrospective comparative study to 
determine whether the theoretical design advantages of PS-TKA resulted 
in improved knee function. The authors assessed function using the HSS 
score, ADLs and ROM. Radiographic parameters such as, radiolucency 
and component positioning were also measured. The two prostheses 
compared were: 1) 64 TC TKAs (CR-TKA) and 2) 66 IB TKAs (PS-TKA); 
both procedures were performed or supervised by the senior author. The 
results showed a post-operative improvement in HSS score compared 
with pre-operative values; no difference was seen between the CR-TKA 
and PS-TKA scores. The post-operative ROM was greater in the PS-TKA 
group compared with the CR-TKA group, significant at P <0.05, as 
similarly demonstrated by Hirsch et al. (1994). In the PS-TKA group 76% 
were able to walk for unlimited distances and climb stairs without the aid 
of the bannisters compared with 22% in the CR-TKA. Component 
malpositioning rates and radiolucency were not found to be different 
between the groups, although this finding was not supported by statistical 
evidence. Although a higher number of patellar fractures occurred in the 
PS-TKA group due to suspected overstuffing, the authors concluded the 
IB PS-TKA offers good function without compromise to fixation. They 
attributed this more superior outcome to a longer extensor moment arm 
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due to the more posterior tibiofemoral contact position. In this position 
lower quadriceps force is required to produce equivalent extensor 
moments occurring in the presence of a relatively anterior contact 
position or shorter extensor moment arm thought to be associated with 
CR-TKA. 
 The main strength of this study was the use of a comparator 
group, which allowed for direct referencing of prosthesis performance. 
The authors attempted to demonstrate similarities in patient 
demographics but failed to support this observation with statistical 
evidence. The study reported significant differences in the ability of the 
groups to achieve stair-climbing unaided and unlimited walking but did 
not provide any indications of the pre-operative ability of each group. 
Additionally, the authors concluded the observed differences in function 
are as a result of the effects of prosthetic design on extensor mechanism 
performance. Although this might be true, the chosen outcome measures 
coupled with insufficient exclusion of other plausible causative factors 
undermines this conclusion.  
 
2.2.5.1 Section Summary 
 The evidence in this section consists of one prospective 
comparative study, three retrospective comparative clinical studies, two 
retrospective comparative radiological studies and one retrospective non-
comparative radiological study. The prospective study did not find a 
functional difference between CR-TKA and PS-TKA. Two out of three of 
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the retrospective comparative clinical studies found no difference in 
validated functional scores between CR-TKA and PS-TKA. However, 
both reported PS-TKA had significantly greater ROM than CR-TKA. The 
results of the radiological studies were in general agreement, concluding 
CR-TKA showed high variability in motion abnormal to the anatomic 
motion of the knee and no evidence of femoral rollback. However, there 
was no evidence of PS-TKA exhibiting normal femoral rollback. The 
majority of these studies had multiple limitations such as the use of 
unvalidated outcomes, lack of matching between comparator groups, 
confounding factors and small sample sizes. Based on the findings and 
limitations of these studies no robust evidence was found to suggest CR-
TKA is less favourable than PS-TKA. 
 
2.2.6 Impact of Femoral Component Design: multi-radius versus single 
radius on extensor mechanism function 
 
The dispute between multi-radius (MR) and single radius (SR) femoral 
component designs still exists and is based on theoretical interpretation 
of knee motion axes. Traditional kinematics theory of Reuleaux (1875), 
cited by Mahoney et al. (2002), stated that knee flexion and extension 
occurred around changing centres of rotation with the axis of rotation 
relatively anterior and proximal in extension, shifting distal and posterior 
into the femoral condyles with flexion. This kinematic theory has been 
incorporated in the MR femoral component designs. However, studies 
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have shown TKAs with a MR sagittal profile do not re-create normal 
extensor moment arms, especially in the final 30° of extension (Huang et 
al., 1996; Lewandowski et al., 1997; Singh & Schmalzried, 1996). 
Furthermore, anatomic studies have disputed the existence of two 
simultaneous rotations occurring about fixed axes (Panjabi et al., 1982). 
Panjabi et al. (1982) performed an anatomic study demonstrating, 
through the use of mathematical models, the unlikely existence of two 
simultaneous rotations occurring about a fixed axes. In summary, the 
authors showed that other theoretical estimations (upon which the MR 
designs are based) are open to a wide margin of error. These findings 
were further supported in a later study (Hollister et al., 1993) that 
suggested knee motion occurs about a single fixed axis of rotation 
located in the posterior femoral condyles. This study established the two 
knee axes: flexion-extension axis and longitudinal rotational axis were not 
in the coronal and sagittal planes, respectively. The authors found the 
motion about each axis was a combination of flexion-extension, 
varus/valgus and internal/external rotation. This theory supported the 
‘screw-home mechanism’, that is, a combination of external rotation of the 
tibia with extension, as a result of the deviation from the standard plane of 
the flexion-extension axis and rotation about the longitudinal rotational 
axis. The arguments of this study are compelling although limited by the 
small number of specimens assessed and MRI analysis used to ascertain 
knee motion. No reference was given to the thickness of the MRI slices 
and therefore the degree of assumption made between data points is 
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unknown. Furthermore, because this was a non-comparative study, no 
suggestion was made regarding the potential biomechanical impact of 
interpreting knee motion using simultaneous axes theory. Later, Churchill 
et al. (1998) showed the location of this flexion-extension axis could be 
accurately estimated using the transepicondylar axis. A more posteriorly 
located axis would theoretically lengthen the extensor moment arm and 
improve extensor mechanism efficiency. Single radius TKA designs are 
based on this rationale. The following studies compare both SR and MR 
femoral component designs in relation to extensor mechanism function. 
 
 Hall et al. (2008) designed a prospective, randomised comparative 
study to assess whether knee ROM and function are obtained earlier with 
a single radius (SR) femoral component compared with a multi-radius 
(MR) femoral component of a CR-TKA. The two prostheses were: (1) 
single sagittal radius- Scorpio (Howmedica, Stryker Orthopaedics, 
Mahwah, New Jersey) and (2) multi-radius – Press Fit Condylar Sigma- 
PFC (Johnson & Johnson PFC; Depuy, Johnson & Johnson, Warsaw, 
Indiana). Each arm consisted of 50 patients who met the inclusion criteria 
and were selected at random to receive either Scorpio or PFC. Both 
groups received the same peri- and post-operative management; two 
surgeons carried out the procedures. The following outcomes were 
assessed pre-operatively, at four to six weeks, three months and one 
year: active ROM, KSS score, rising from a chair (assisted/unassisted) 
and anterior knee pain. The results showed no difference between 
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demographics, functional score or percentage of patients able to rise from 
a chair unassisted. Extension improved in both groups significantly at four 
to six weeks and one year although no clinical significant difference was 
found. The authors did not identify a relationship between femoral 
component condylar radius and extensor mechanism function based on 
ability to rise independently from a chair. They also concluded extensor 
mechanism function following either single radius or multi-radius femoral 
components is comparable in modern CR-TKA designs.  
This is the only randomised study observed in this literature 
review. It met some of the CONSORT reporting requirements: adequate 
abstract content, sufficient background information and study rationale, 
study design description, explicit eligibility criteria, clear description of 
interventions including similarities, statistical methods explained, 
participant flow described and the interpretation was consistent with the 
results.  
The most significant concern with this study is the main conclusion 
is based on an outcome measure (ability to rise from a chair unassisted) 
that is not solely reliant on quadriceps function; other biomechanical 
mechanisms may influence this outcome. The use of unvalidated test 
methods weakens the strength of the inferences drawn due to the 
unknown sensitivity and specificity of the test method for that particular 
application. Another limitation, is the geometry of the prostheses differed 
on more than just the number of radii on the femoral component design. 
The surface geometry of the polyethylene inserts were different; the 
  
96
Scorpio had a deeper sagittal curvature and a single coronal radius 
across both compartments. Additionally, the slope of the tibial component 
was neutral (0°) on the Scorpio whereas on the PFC it was 5°, although 
the Scorpio polyethylene insert had a built in 4° slope. These geometrical 
differences are confounding factors that were not taken into consideration 
during the design of the study.  It is not clear whether an equal number of 
the two types of TKA were performed by each surgeon. This is another 
potential confounding factor if there is a discrepancy in numbers 
performed and surgeon ability. 
 Mahoney et al. (2002) believed the more anterior flexion-extension 
axis of the MR TKAs may cause shorter extensor moment arms and thus,  
a relatively posterior axis would lengthen the moment arm and enhance 
the extensor mechanism performance. Therefore, the aim of this 
retrospective comparative, consecutive series was to compare one MR 
PS-TKA with an SR PS-TKA. Two groups of 100 knees: the most recent 
100 knees that received the 7000 PPSK (Osteonics, Allendale, New 
Jersey) (MR PS-TKA) and the first 100 knees that received the Scorpio 
(Osteonics, Allendale, New Jersey) (SR PS-TKA) were selected. Both 
knee replacement systems used the same tibial component, which had a 
cam-post mechanism that engaged between 60° to 70° of knee flexion. 
No statistical difference between group demographics was observed. 
Functional evaluation was carried out at pre-operatively, six weeks, three 
months, six months, one year and two years using KSS. Extensor 
mechanism assessment was performing by asking patients to rise from a 
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chair 16 inches above ground level without using arm support. Three 
questions were asked during this task: 
1. Could they rise without using their arms?  
2. Any anterior knee pain while rising? 
3. Any painful crepitus? (indicating soft tissue impingement) 
No difference in pre- and post-operative KSS scores was observed 
between the two groups. The difference in ROM was only significant at 
six weeks, with the SR group achieving greater ROM by this time point. 
After this time point there was no difference. More patients in the SR 
group were able to independently rise compared with the MR group at six 
weeks, one year and two years. Fewer patients complained of anterior 
knee pain during the chair rising task in the SR group. The authors found 
the ability to chair rise independently was associated with lower rates of 
anterior knee pain. They attributed this difference as well as the reduction 
in painful crepitus, to lower compressive force between the patellar button 
and femoral component as a result of the longer recessed trochlear 
groove. The study inferred SR design improves extensor mechanism 
function.  
 The concept of this study was current and useful. The authors 
used one validated outcome measure (KSS) and explicitly stated the 
methodology. However, other aspects of the study undermined the 
results and subsequent conclusions drawn. 
Although the authors demonstrated the groups were similar, in 
terms of age, gender and BMI, there were distinct differences in time of 
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selection (first 100 knees for SR group compared with last 100 knees for 
MR group) and number of bilateral cases (25 patients in the SR group 
and nine patients in the MR group). Both factors could be confounding. 
The authors claimed the chair rise test is a more focused assessment of 
extensor mechanism function, however a number of other factors 
influence the outcome of this test such as height, bilaterality, coexisting 
co-morbidities and core strength. The authors believed that the observed 
differences between the groups are unlikely to be secondary to other 
factors due to the relatively large sample sizes of the groups and the fact 
the study was a single surgeon series. Whilst these factors strengthen the 
study, the patients were not randomized and therefore unknown variables 
were not balanced between the groups. Besides variation in radii the 
femoral components had other external geometric differences. The 
Scorpio had a recessed and longer trochlea that extended further distally 
and a polyethylene insert with a higher degree of conformity in the 
anteroposterior plane. These additional variables undermine weaken the 
actuality confidence of the associations detected. The evaluations were 
all carried out by the operating surgeon who was not blinded, which 
therefore introducing observer bias. All these limitations reduced the 
reliability of the evidence and weakened the concluding opinion that SR 
design features improve extensor mechanism function. The variation in 
trochlear design may have more influence than a difference in radius of 
curvature. 
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 A similar retrospective comparative study (Gomez-Barrena et al., 
2010) assessed the difference in functional outcome (AKSS), muscular 
performance and gait cycle between SR (Scorpio, Stryker Orthopaedics, 
Mahwah, New Jersey) and MR (NexGen, Zimmer, Inc. Warsaw, Indiana)  
PS-TKAs. Thirty patients in each group were evaluated. None of the 
patients were bilateral or had a symptomatic contralateral limb. Each 
patient was able to flex beyond 90° and walk unaided. The demographics 
and clinical factors of each group were compared and deemed not 
significantly different. The results showed AKSS function score was 
greater for the SR compared with MR group; no difference was found 
between the groups for the AKSS clinical score. The SR group required 
less physiotherapy and were using only one crutch sooner than the MR 
group. Isokinetic testing revealed no difference in peak angles in 
extension, although in flexion peak angles and peak torques were higher 
in the MR group than the SR. Conversely, peak torque in extension was 
higher and the hamstring: quadriceps ratio was lower in the SR group 
compared with the MR group. The authors concluded SR femoral 
components provide better functional performance in the short-term.  
 The study limitations included non-randomisation of patients, 
short-term follow-up, additional geometric variables between the 
prosthesis and variability in patellar resurfacing. All of these additional 
confounding factors mean it is difficult to conclude with confidence that 
the observed differences are a result of femoral component design. It is 
possible that any one of these potential confounding factors is causative.  
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 D’Lima et al. (2001) performed a cadaveric study involving six 
knees to determine the effects of changing centre of rotation of the knee 
on quadriceps tension. Three conditions were assessed: 1. Normal knee, 
2. Scorpio (SR CR-TKA) and 3. Series 7000 (Howmedica, Osteonics, 
Allendale, New Jersey) (MR CR-TKA). Each knee was subject to testing 
under all three conditions in an Oxford knee rig using an EMG tracking 
system and load cell to measure quadriceps tension. Physiological loads 
were used to replicate peak knee flexion moments occurring during stair 
climbing after TKA. The patellofemoral forces were also measured using 
a load cell device, which detected compressive, medial and lateral shear 
forces during knee extension. Each knee was digitised before testing to 
create set coordinate systems within the femur and tibia. The femoral 
coordination system centre was the mid point of the transepicondylar axis 
and the tibial coordination system centre was the midpoint of the tibial 
plateau. Along with variation in radii of the femoral component, the 
Scorpio had a deeper trochlear groove and different polyethylene insert. 
Femoral rollback, tibiofemoral rotation, varus and valgus angulation and 
quadriceps tension were analysed for differences between the three 
conditions. No significant differences in knee kinematics (femoral 
rollback, tibiofemoral rotation and varus/valgus angulation) were detected 
between the two CR-TKAs. Both implants demonstrated a 6mm to 7mm 
posterior tibiofemoral position relative to that found in the normal knee at 
0° and showed negative rollback (rollforward) of 4mm±12mm from 0° to 
90° knee flexion, which was approximately 10mm anterior to that found in 
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the normal knee. The normal knees created higher quadriceps tension 
than the knee arthroplasty conditions. At flexion angles greater than 50° 
the Scorpio (SR group), consistently generated statistically lower 
quadriceps tension (P < 0.05) compared with Series 7000 (MR group). 
The authors concluded this reduced quadriceps tensile force may assist 
in performing ADLs and thus shorten rehabilitation following TKA. 
However, they acknowledged that changes in the centre of rotation do not 
benefit or disadvantage knee kinematics given no difference in knee 
kinematics was demonstrated between the SR and MR CR-TKA. 
 Failure to control for the other geometric variables, along with the 
multiple tests performed, rendered the results susceptible to a Type I 
error. It may have been more appropriate to adjust the alpha for the 
number of variables tested. In addition, the other differences in geometry 
of the tested prostheses are likely to have influenced the outcome. A 
larger sample size with a greater number of trials per condition using 
geometrically better matched prosthesis would have provided more 
conclusive results. 
 
2.2.6.1 Section Summary 
 Three out of four of the studies concluded SR femoral components 
improved extensor mechanism function compared to MR designs. 
However, the randomised study, arguably the most reliable, did not find a 
difference. Neither type (SR or MR), irrespective of cruciate retaining or 
posterior substituting demonstrated normal knee kinematics. Overall, the 
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strength of the evidence was compromised by confounding factors such 
as additional geometrical differences between the femoral components 
and polyethylene insert articular surfaces, use of unvalidated outcomes, 
lack of matching between groups and observer bias. Therefore firm 
conclusions cannot be drawn from any of the studies. No literature was 
identified that assessed the difference in extensor mechanism function 
between single or multi- radius CR- and PS-TKA. 
 
2.2.7 Theoretical Extensor Mechanism Efficiency following 
Patellofemoral Arthroplasty 
As highlighted above, there are a number of studies assessing extensor 
mechanism function following TKA but there are no reports in the 
literature on the effects following PFA. In theory, the knee kinematic 
following PFA should resemble normal knee kinematics more closely than 
that existing after TKA, because of the preservation of the cruciate 
mechanism.  
 In the native knee, both the anterior cruciate ligament and 
posterior cruciate ligament control femoral rollback. This allows for high 
flexion and avoids posterior bony impingement. This element of knee 
kinematics should not alter following PFA since the tibiofemoral joint and 
cruciate ligaments remain intact. Some modern TKAs, in an attempt to re-
create maximal flexion while providing a more congruous (dished) design, 
have a more posterior tibiofemoral contact point and steeper posterior 
slope. It is possible that this contact point is more posterior than that 
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existing in the native knee although this more posterior contact point has 
yet to be satisfactorily demonstrated. 
 If a more posterior tibiofemoral contact point is achieved, one 
could postulate that TKA could potentially offer a more efficient extensor 
mechanism compared with PFA. Other factors need to be taken into 
consideration such as the geometry of the anterior flange, asymmetry of 
femoral condyles and depth of trochlear recess. Depending on surgeon 
technique, the design of the PFA: onlay versus inlay will also make a 
difference to the patellar offset and hence extensor mechanism efficiency. 
 
2.2.8 Conclusion 
The purpose of this literature review was to establish the evidence for 
extensor mechanism function following PFA and TKA in terms of 
quadriceps weakness and the impact of prosthetic design. No reports on 
quadriceps weakness following PFA were identified. The evidence 
provided convincing support for the belief that quadriceps weakness is an 
important problem following TKA surgery irrespective of implant design. 
In contrast, the evidence for PS-TKA and single radius femoral 
components offering better extensor mechanism function was weak and 
inconclusive. 
 Retrospective study designs, small sample sizes, poorly matched 
comparator groups and inappropriate statistical analyses were common 
weaknesses. The commonest limitation involved the sampling method, 
which was subject to selection bias due to the majority of patients being 
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surgeon selected. Invariably, sampling error, due to the lack of 
randomisation, and systematic error, in the case of self-selected 
volunteers, also contributed to the limitations and thus narrowed the 
generalisability of the inferences. Failure to control or adjust for known 
confounding variables, such as other geometrical differences or 
inconsistencies between comparator groups, may have led to false 
conclusions. 
 Identifying which arthroplasty treatment maximises extensor 
mechanism function would further inform the debate regarding prosthesis 
choice. The main deficit in this review is the lack of literature on the 
impact of PFA on extensor mechanism function and how this compares 
with extensor mechanism function following CR-TKA and PS-TKA. This 
shortfall in the literature led to the development of the following cadaveric 
biomechanical study. 
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2.3 Funding 
BOA Joint Action Research 2011 
Grant Reference: GA1189 
Amount: £8900 
2.4 Study Design 
Biomechanical cadaveric knee, lab based, comparative study. 
2.5 Good Clinical Practice & Research Ethics Committee Approval 
The conduct of this study is in agreement with Good Clinical Practice 
guidelines. The National Research Ethics Service Committee West 
Midlands – Staffordshire reviewed handling and transfer of the specimens 
and other ethics related aspects of the study. On 23th September 2011 
the study was granted a favourable ethical opinion by the committee. The 
Research Ethics Committee reference is 11/WM/0253. 
 
2.6 Background 
2.6.1 Rationale for Study 
The literature review for this study identified there were no current studies 
comparing extensor mechanism function following patellofemoral 
arthroplasty and total knee arthroplasty. Investigating this subject further 
informs the debate regarding the use of these arthroplasty treatments for 
isolated patellofemoral arthritis. With this principal outcome in mind, the 
results of this study provide the benchmark data and methodology upon 
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which other more sophisticated translational research can be developed, 
whilst still providing valuable information for clinicians and engineers. 
This study focused on testing hypotheses on extensor mechanism 
efficiency, patellofemoral resultant force, peak pressure and contact area. 
The kinematics of the patellofemoral and tibiofemoral joints are altered 
following arthroplasty surgery. As discussed in the literature review, the 
degree of femoral rollback (or the lack of) has been a central point of 
focus when determining which type of prosthesis, CR-TKA or PS-TKA, 
more closely resembles the anatomical knee. Patellofemoral kinematics 
vary due to differences in the points of contact, timing of engagement of 
the patella in the trochlear groove and bearing surface forces generated 
within the joint. 
 Figure 2-4 illustrates the quadriceps force, represented by the line 
FQ and the patella tendon force, represented by the line FP. Each force is 
a vector quantity (magnitude and direction). The forces are not equal; the 
patella does not act as a simple pulley system. Change to FP is a factor of 
FQ, which varies according to the angle of knee flexion. The resultant 
force (R) is the combined force of the quadriceps muscle and the patellar 
tendon. The more flexed the knee the greater will be the resultant 
patellofemoral joint force for the same quadriceps muscle force. In theory, 
extensor mechanism efficiency should be high when the patellofemoral 
joint resultant force is low because extensor moment efficiency is directly 
proportional to the extensor moment arm; when the extensor moment 
arm is long the resultant force is reduced. Patellofemoral joint resultant 
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force decreases as the knee extends, that is, as the angle at the knee 
becomes less acute the quadriceps lever arm increases. This is 
illustrated in Figure 2-4 to Figure 2-6. 
 
 
Figure 2-4 Quadriceps and patellar tendon force and angle of resultant force 
 
 
Figure 2-5 Low resultant force at low knee flexion angle 
 
 
Figure 2-6 High resultant force at increased knee flexion angle 
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Based on this theory and the literature reviewed, the following research 
questions and hypotheses were generated. 
 
2.7 Research Questions 
1. At a constant quadriceps tension, is the extensor moment 
efficiency greater following TKA compared with PFA during the 
range of knee flexion 0° to 120°? 
2. If so, does this result in a difference in patellofemoral joint reaction 
forces following TKA compared with PFA during the range of knee 
flexion 0° to 120°? 
3. What is the effect on peak pressure and contact area following 
TKA compared with PFA during the range of knee flexion 0° to 
120°? 
2.8 Hypotheses 
1. The extensor mechanism efficiency will be greater following PFA 
compared with TKA throughout the range of flexion-extension 
cycle 120° to 0°. The extensor moment produced at a given 
quadriceps tension would be greater following PFA compared with 
TKA due to the more posterior tibiofemoral contact point 
associated with the native tibiofemoral joint resulting in a relatively 
longer extensor moment arm and therefore lower quadriceps force 
requirements and lower patellofemoral joint reaction forces.  
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2. There will be no difference between the extensor moment 
efficiency for CR-TKA compared with PS-TKA. The effect of the 
intact PCL in the CR-TKA compared with the cam-post mechanism 
will not result in a significantly shorter extensor moment arm. Both 
prostheses will give rise to higher patellofemoral resultant forces 
than PFA or native knee. 
3. Peak pressures will be greater for CR-TKA and PS-TKA compared 
with PFA and native knee throughout the range of knee flexion due 
to the bearing surfaces and surface contact area. The native knee 
will generate the lowest peak pressures. 
4. The contact area will be greater for PFA compared with CR-TKA 
and PS-TKA at higher levels of knee flexion when the patellar 
button begins to articulate with the native femoral condyle. There 
will be no difference between CR-TKA and PS-TKA. The native 
knee will produce the highest contact area throughout the entire 
range of knee flexion. 
2.9 Null Hypothesis 
1. There is no difference in the extensor moment produced at a given 
quadriceps tension during knee flexion to extension following CR-
TKA, PS-TKA and PFA.  
2. Therefore, there is no difference in patellofemoral joint reaction 
forces following CR-TKA, PS-TKA compared with patellofemoral 
arthroplasty. 
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2.10 Aim and Objectives 
Aim 
To determine whether the biomechanical and geometrical differences 
between CR-TKA, PS-TKA and PFA result in dissimilar extensor 
mechanism efficiencies. 
 
Objectives 
The objectives of this study were to measure four parameters under four 
conditions:  
 
1. Normal/native knee  
2. Patellofemoral arthroplasty: Zimmer Gender Solutions Patello-
Femoral Joint System (Zimmer, Warsaw, Indiana, USA). 
3. Cruciate retaining total knee arthroplasty (CR-TKA): Zimmer 
NexGen CR-Flex System (Zimmer, Warsaw, Indiana, USA). 
4. Posterior-stabilising total knee arthroplasty (PS-TKA): Zimmer 
NexGen LPS-Flex System (Zimmer, Warsaw, Indiana, USA). 
 
Parameters: 
1. Extensor moment efficiency 
2. Patellofemoral joint reaction (compression) forces 
3. Peak pressure 
4. Contact area 
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2.11 Study Method Summary 
This study was performed in the Biomechanical Engineering Department 
at Imperial College London under the supervision of Professor Andrew 
Amis. A total of ten cadaveric knees were required, of which two knees 
were used to formulate and refine the methodology. The remaining eight 
cadaveric knees were used to carry out the biomechanical assessments. 
Four conditions were tested sequentially on each knee: normal, 
patellofemoral arthroplasty, cruciate-retaining total knee arthroplasty (CR-
TKA) and posterior-stabilising total knee arthroplasty (PS-TKA). All three 
prostheses were Zimmer Systems with comparable geometry. 
 The cadaveric knees were acquired from University Hospitals 
Coventry and Warwickshire NHS Trust. All the knees were healthy and 
'non-arthritic' (no macroscopic arthritis) with normal alignment. The 
storage and handling of these knees followed the Imperial College 
London tissue handling guideline rules. 
 For the purpose of this in vitro study a transpatellar approach was 
used for each knee. This approach involved splitting the patella off-centre 
in a longitudinal fashion; this split was extended both proximally and 
distally in the line of the quadriceps and patellar tendons, respectively. 
Although not the standard approach used in vivo, the aim was to keep the 
strength and integrity of the extensor mechanism near constant for each 
condition tested and, by doing so, avoid confounding from variations in 
strength of extensor mechanism repair associated with the parapatellar 
approach. Anterior referencing was used for all three arthroplasty 
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procedures. The method of surgical implantation for the prostheses 
followed the manufacturer recommendations.  
 Each knee was mounted in a kinematic test rig.  This rig allowed 
the tibia to remain unconstrained, permitting passive flexion-extension 
knee motion. A combined load was applied to the quadriceps muscles 
and ITB to produce a known quadriceps tension. The extensor moment 
efficiency was measured across a range of 0° and 120° knee flexion. A 
pressure sensor was inserted into the patellofemoral joint to measure 
patellofemoral resultant force, peak pressures and contact area.  
 Data analysis involved the use of one-way ANOVA and post-hoc 
paired t test for evaluating the four conditions at knee flexion angles 
between 0° and 120° for all four parameters. The significance level was 
adjusted to p < 0.00833 for comparison of the four conditions to each 
other. 
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2.12 Outcome Measures 
2.12.1 Measurement of Outcomes 
Primary Outcome: Extensor Mechanism Efficiency (EME) 
The EME is essentially a ratio of input and output. The definition of EME 
is the knee extensor moment produced per Netwon of quadriceps 
tension, that is, the extensor moment (Newton metres, Nm) produced 
(output) per Newton put in (input). 
This measurement was calculated using the following equation: 
Force(N)Distance(m)
ConstantForce(N)
 Nm
NQT
 EME(Nm / NQT )  
Force (N) is calculated using the force multiplication factor described in 
section 2.14.5. The distance (m) was constant, set at 0.25m and equated 
to the distance from the centre of rotation to the point of force application. 
The constant force was the quadriceps tension kept at 205N load. 
 
In theory, the EME should be high when the resultant force is low 
because moment efficiency is directly proportional to the extensor 
moment arm. To confirm this theory and test the hypotheses stated in 
section 2.8, the following secondary outcomes were measured. 
 
Secondary Outcomes: Resultant force, Peak pressure and Contact area 
The resultant force (N), peak pressure (MPa) and contact area (mm2) 
were all computed by the Tekscan software used to measure these 
outcomes as described in section 2.14.3. 
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2.13 Sample size 
Application of a standard formula was not feasible as a number of 
factors were unknown, such as the population means, potential varying 
standard deviations for each group at each angle of knee flexion due to 
the replication factor and the variation in clinically relevant (meaningful) 
differences in extensor moment efficiency (and other secondary 
outcomes) between the groups. Thus the ‘expected’ data needs to be 
estimated. In general, there are three ways in which the means and 
standard deviations could have been guesstimated:  
 
1. A review of relevant literature 
2.  A pilot study 
3. Cohen’s effect size guidance (the difference of two group means 
divided by the pooled standard deviation).  
 
The first option was chosen for this current study. 
 
 At the time of designing this study there were no published studies 
that could have been used to indicate estimated means of extensor 
mechanism efficiency, standard deviations or effect size. However, 
previous studies that used a similar experimental set up (rig) to the 
current study, had reported the use of sample size calculations. These 
cadaveric biomechanical studies performed power calculations which 
showed eight knees would allow identification of significant change in 
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extensor mechanism length: 2.1mm medial patellofemoral ligament and 
4.4mm lateral retinaculum (Ghosh et al., 2009), change of patellar lateral 
translation of 7mm (Stephen et al., 2013) and change of femoral 
translation and of rotation of approximately 2.1mm and 1.2 with 95% 
confidence and 80% power (Kondo et al., 2011). None of these 
investigations stated the standard deviation used however this was 
determined using the information provided. In order to utilise this 
information, the following assumption was made: 
 
 
  
The ‘behaviour’ of the data and the degree of change 
deemed as clinically relevant in these studies is proportional 
to the amount of change that is likely to be of clinical 
importance in extensor moment efficiency variance between 
the conditions assessed in the current study. 
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Based on this assumption, using the sample size data in the Stephen et 
al. (2013) study and setting the significance level, α, at 0.05 and the 
power, β, at 80%, the following equation was applied: 
 
n  (t 2  t )
2
2
  2 2
 
α = 0.05 
β = 0.80 
t 2 = 2.365  
t  = 0.896  
 2 = 62 (This standard deviation was calculated using PS – Power and 
Sample Size Calculations, software, version 3.0.0043, (Dupont & 
Plummer, 2009)) 
2  = 72 
n  (2.3650.896)
2
7
6 2  
 
n  10.634
1.361
 
n = 7.813 
n ≅ 8 
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The anticipated effect size: 
  1 2  
  7
6
 1.16 6 
 
Once the results of the current study were obtained, the actual effect 
size(s) were calculated to demonstrate whether the chosen sample size 
of 8 was the appropriate sample size to use. 
 
 
2.14 Methodology 
2.14.1 Materials: Specimens and Preparation 
Ten fresh-frozen human cadaveric knees with intact soft tissue envelope 
and knee ligaments were used. These were obtained from University 
Hospitals Coventry and Warwickshire (UHCW) NHS Trust.  This trust had 
acquired these cadaveric knees from Science Care (Phoenix, Arizona, 
USA), a tissue bank accredited by the American Association of Tissue 
Banks (AATB) and Accreditation Council for Continuing Medical 
Education (ACCME). This organisation is responsible for screening the 
donors and obtaining consent for donation for training and professional 
education and medical research use. A Material Transfer Agreement was 
established between the two sites and the cadaveric knees were securely 
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transported from UHCW NHS Trust Surgical Training Suite to the 
Biomechanical Engineering Laboratory at Imperial College London. Each 
knee was allocated an assigned number for tracking purposes from the 
point of lab entry to disposal. The knees were stored at -20°C until time of 
use, when they were transferred to a designated refrigerator for 24 hour 
for thawing. Normal saline was used to maintain moisture of the knees. 
The kinematic experiments were performed the following day once 
thawing was complete.  
 
Two cadaveric knees were used to finalise the methodology. The 
demographics of the remaining 8 cadaveric knees consisted of: 5 male (2 
right, 3 left) and 3 female (1 right, 2 left) with a mean age of 74.6 years 
(61-82). The results of these eight knees were used for data analysis.  
 
All ten cadaveric knees were devoid of macroscopic arthritis; this 
was initially confirmed using radiographs- lateral, anteroposterior and 
skyline views and further on dissection. In addition, none of the cadaveric 
knees had any other anatomical defects or undergone previous knee 
surgery. The skin and subcutaneous adipose tissue were excised from 
each knee and dissection was performed. The muscle, knee capsule, 
ligaments, quadriceps, patellar tendon and iliotibial band (ITB) remained 
intact. The quadriceps was separated into six components: rectus femoris 
(RF), vastus intermedius (VI), vastus lateralis longus (VLL), vastus 
lateralis obliquus (VLO), vastus medialis longus (VML) and vastus 
  
119
medialis obliquus (VMO). The distal tendinous fibres of the muscles are 
usually merged and were therefore left intact to ensure the actions of the 
muscles were as physiological as possible.  
 Approximately 20cm of femur proximal to the knee joint and 15cm 
of tibia distally were preserved. Intramedullary rods were inserted and 
fixed with polymethylmethacrylate (PMMA) bone cement into the tibia to 
extend it distally and the femur to aid attachment to the rig. 
2.14.2 Apparatus 
Rig Design 
The basic structure of the rig had previously been designed and 
constructed (Stephen et al., 2013). This construct consisted of two black 
Perspex sheets mounted parallel to one another on a flat MDF (medium-
density fibreboard) surface. The base of each sheet was bolted to the 
MDF with polyethylene reinforcements. The Perspex sheet to which the 
strain gauge device was attached was reinforced on both sides, framing 
the base and distal halves of the front and back edges; only the outer 
aspect of the other sheet was reinforced. The polyethylene frame 
increased the rigidity and had a sliding mechanism that allowed height 
adjustments to be made to the Perspex sheet if required (see Figure 2-7). 
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Figure 2-7 Rig without crank mechanism 
A Perspex sheets with 10° increments from 0° to 120° 
 
B Polyethylene reinforcements to increase rigidity and allow for height adjustments 
 
C MDF base  
 
D Knee mount aspect of rig: polyethylene block with adjustable metal block, 
angled metal rods and upper pulley system 
 
The Perspex sheets were connected by a crank device that consisted of 
two parallel high-density plastic arms linked by a perpendicular steel rod 
via bolts (see Figure 2-8 and Figure 2-9).  
A
B B
A
D
C
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Figure 2-8 Crank device 
A High-density plastic arms 
 
B Horizontal metal rod 
 
C Aluminium bar reinforcing metal rod, reducing torque in the system  
 
D Stainless steel sheet reinforcement to reduce torque 
 
E Pivot point of crank mechanism 
A A 
B
C
D 
E E 
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Figure 2-9 Crank device attached to rig 
A High-density plastic arms 
 
B Horizontal metal rod 
 
C Aluminium bar reinforcing metal rod, reducing torque in the system  
 
D Stainless steel sheet reinforcement to reduce torque 
 
E Pivot point of crank mechanism 
 
The knee mount aspect of the rig consisted of a polyethylene block with a 
height adjustable metal block fixed to the MDF base equidistance from 
each Perspex sheet (see Figure 2-7). The metal block had a central 
tunnel to accommodate the femoral rod. The rod position was adjustable 
within the central tunnel, allowing for the epicondylar axis of the knee 
(centre of rotation) to be aligned with the axis of the strain gauge-crank 
mechanism. The femoral rod was secured within the tunnel with four bolts 
to prevent rotation (see Figure 2-10).  
A A
B
C
D
E
E
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Figure 2-10 Knee mount aspect of rig: adjustable metal block with central tunnel to 
accommodate femoral rod 
A Femoral intramedullary rod 
 
B Central tunnel in metal block to accommodate femoral rod 
 
C Adjustable metal block to aid alignment of the epicondylar axis with the pivot 
point of the crank mechanism 
 
D Polyethylene block base securing adjustable metal block and posterior black 
plastic discs  
 
E Four securing bolts to fix intramedullary rod and prevent rotation within the 
tunnel 
 
Attached to the posterior aspect of the polyethylene block were multiple 
high-density plastic black disc skewered on a pitched rod which was 
bolted to the pulley mechanism. Steel rods were interposed between the 
plastic discs at fixed angles that replicated those existing in the 
quadriceps muscles. A rod with a pulley was also interposed to 
accommodate the iliotibial band (ITB) (see Figure 2-11).  
A
B
C
D
E
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Figure 2-11 Steel rod interposition to replicate individual quadriceps muscles and ITB 
direction of pull 
A Black plastic discs 
 
B Interpositioned metal rods placed in the physiological direction of pull 
 
C  Rod with pulley for ITB 
 
D Upper pulley system 
 
E Lower pulley system 
 
Each angled rod had a squared-off end with a hole to accommodate the 
rope attached to the corresponding part of the quadriceps. Each rope was 
tensioned with the corresponding load via individual pulleys, which were 
situated a fixed distance behind allowing for adequate excursion of each 
rope. The pulleys were positioned along the perpendicular bar bolted to 
the pitched rod (see Figure 2-12 and Figure 2-13).  
A
B
C
D
E
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Figure 2-12 Upper pulley system 
 
 
Figure 2-13 Lower pulley system 
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The plastic black discs were adjustable, allowing for the angle of the rods 
to be altered depending on whether a left or right knee was mounted (see 
Figure 2-10). The load for each muscle was suspended from the end of 
each rope. Each point of rotation was lubricated to ensure smooth 
continuous motion without seizing in the system or wear to the 
components.  
 
Rig Design Modifications 
Following testing, with two methodology knees, the rig underwent minor 
modifications to meet the demands of the current experimental set-up: 
1. A thin sheet of stainless steel was required to reinforce the crank 
mechanism to reduce the torque (see Figure 2-14).  
2. In order to balance the crank lever the clockwise torque of the 
crank lever was balanced with a rod and larger metal disc counter 
clockwise torque (see Figure 2-15). 
3. An aluminium bar was fixed above and parallel to the rod of the 
crank. This enabled contact with the tibial rod throughout the whole 
range of flexion (see Figure 2-8 and Figure 2-9). 
 
Overall, these modifications made the construct more rigid and balanced, 
thus increasing the threshold for deformation to occur. 
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Figure 2-14 Stainless steel reinforcement to reduce torque  
A Thin stainless steel strip secured with two screws 
 
 
Figure 2-15 Crank Counter lever 
A Rod and cylinder counter lever 
 
A
A
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Knee Mounting 
Figure 2-16 shows a knee mounted in the rig. The six individual muscles 
of the quadriceps and the ITB were bound in cloth and rope (Bull et al., 
1999). Hanging weights were attached to each of the seven components 
via the rope and aligned by the upper and lower pulley system 
demonstrated in Figure 2-12 and Figure 2-13, respectively. The total load 
of 175N was applied to the quadriceps and 30N to the ITB, therefore a 
total of 205N was used. The total load chosen was based on previous 
studies that used similar experimental set-ups and did not experience 
tearing of the muscles with this degree of tension (Christoforakis et al., 
2006; Farahmand et al., 1998b; Merican & Amis, 2009; Senavongse & 
Amis, 2005). The distribution of tension applied to the quadriceps was 
determined in accordance with the physiological cross-sectional area of 
each muscle (Farahmand et al., 1998a). The cross-sectional areas of 
each muscle, physiological direction of load in relation to the femoral axis 
(the orientation of pull of the muscle) and the assigned load attached are 
listed in Table 2-3. 
Table 2-3 Quadriceps physiological cross-sectional area and proportional tension 
distribution 
Muscles and ITB Cross-sectional 
Area (%)a 
Angle of 
Orientation (°) 
Assigned Load (N) 
RF 15% 0° lat, 0° ant 26.25N 
VI 20% 0° lat, 0° ant 35N 
VLL 33% 14° lat, 0° ant 57.75N 
VLO 9% 35° lat, 33° post 15.75N 
VML 14% 15° med, 0° ant 24.5N 
VMO 9% 47° med, 44° post 15.75N 
ITB - 0° lat, 6° post 30N 
aAs a percentage of total quadriceps muscle 
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The epicondylar axis was aligned with the attachment points of the crank 
mechanism. The Tekscan sensor was attached to the Tekscan handle 
seen balancing on a rectangular box on the right. Blue nylon sutures 
securing the sensor in place are visible on the lateral aspect of the knee 
(labelled D).  
 
Figure 2-16 Knee mounted in rig 
A Cadaveric knee 
 
B Individual muscles and ITB bound in clothe and rope tensioned in physiological 
direction of pull. Rope inserted through eyelet type entry points of each metal 
rod 
 
C Tekscan sensor tab visible, matrix part of sensor inserted into patellofemoral 
joint 
 
D Nylon sutures used to secure Tekscan sensor in place visible on medial aspect 
of knee 
 
E Tekscan handle hardware with tab of sensor inserted. Handle protected in 
transparent polyethylene bag to avoid fat or fluid entering the device 
 
F Box stabilising and supporting weight of Tekscan handle hardware 
 
 
A
E
B
C
D
F
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Patellofemoral resultant force, peak pressure and contact area 
measurements 
 
Tekscan versus Fuji Film  
Bachus et al. (2006) performed a study aimed at determining the 
performance and accuracy of Fuji Film compared with Tekscan Sensor 
System. Two methods of calculating parameters using Fuji Film were 
tested: Erase Method and Threshold Method. The Erase Method involves 
deleting pigmented areas suspected to be outside the boundary of the 
pressure stain. The Threshold Method consists of predetermining a 
binary colour gradient whereby the pixels are highlighted white or black 
based on the extent of pigmentation detected. The number of coloured 
pixels on the Fuji Film is digitally analysed by programmed computer 
software once the film has been calibrated. The investigation involved 
application of known loads producing known contact areas, forces and 
pressures to the materials. The measured values of each parameter were 
compared with the known values to quantify the accuracy of the systems. 
The authors defined the acceptable degree of data variation as ±5%. The 
results of this study are summarised in Table 2-4 to Table 2-9. 
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Table 2-4 Accuracy of contact area measurements at lowest applied loads 
 
Material 
 
Overestimation
 
Underestimation
 
Difference
 
Statistically 
Significant 
 
 
Fuji Film Erase 
Method 
 

  
  
1% 
 
N 
 
Fuji Film Threshold 
Method 
 
  
  
 
27% 
 
Y 
Loads < 3375N 
 
Tekscan 
 
 
 
 
 
2% 
 
N 
 
Table 2-5 Accuracy of contact area measurements at highest applied loads 
 
Material 
 
Overestimation
 
Underestimation
 
Difference
 
Statistically 
Significant 
 
 
Fuji Film Erase 
Method 
 

  
  
7% 
 
Loads > 2375N 
 
Fuji Film Threshold 
Method 
 
 
  
  
2% 
 
Loads < 3375N 
 
Tekscan 
 
 
  
 
3% 
 
N 
 
Table 2-6 Accuracy of force measurements at lowest applied loads 
 
Material 
 
Overestimation
 
Underestimation
 
Difference
 
Statistically 
Significant 
 
 
Fuji Film Erase 
Method 
 

  
  
4% 
 
N 
 
Fuji Film Threshold 
Method 
 
 
  
  
4% 
 
N 
 
Tekscan 
 
 
  

 
 
2% 
 
N 
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Table 2-7 Accuracy of force measurements at highest applied loads 
 
Material 
 
Overestimation
 
Underestimation
 
Difference
 
Statistically 
Significant 
 
 
Fuji Film Erase 
Method 
 
 
  
 
2% 
 
N 
 
Fuji Film Threshold 
Method 
 
  
  
 
13% 
 
N 
 
Tekscan 
 
 
  

 
 
3% 
 
N 
 
Table 2-8 Accuracy of pressure measurements lowest applied loads 
 
Material 
 
Overestimation
 
Underestimation
 
Difference
 
Statistically 
Significant 
 
 
Fuji Film Erase 
Method 
 

  
  
4% 
 
N 
 
Fuji Film Threshold 
Method 
 
 
  
  
41% 
 
Loads < 2375N 
 
Tekscan 
 
 
  

 
 
2% 
 
N 
 
Table 2-9 Accuracy of pressure measurements highest applied loads 
 
Material 
 
Overestimation
 
Underestimation
 
Difference
 
Statistically 
Significant 
 
 
Fuji Film Erase 
Method 
 
 
  
 
9% 
 
Loads ≥ 1875N 
 
Fuji Film Threshold 
Method 
 
  
  
 
5% 
 
Loads < 2375N 
 
Tekscan 
 
 
  

 
 
4% 
 
N 
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The results clearly demonstrate the Fuji Film produces a higher degree of 
variability than the Tekscan. These findings are also supported by Harris 
et al. (1999). Although all three methods produced accurate and 
reproducible measurements for applied force, this was not seen on 
assessment of contact area. Neither the Erase Method nor Threshold 
Method for Fuji Film results met the acceptable ±5% margin of error for 
true contact area or pressure.  
This study strongly suggests the Tekscan system is a more 
reproducible, accurate and technically practical system to use than the 
alternative Fuji Film, irrespective of the analysis method used. Unlike with 
Fuji Film, no caution need be applied when measuring high or low loads 
as the variation in accuracy remains below 5%. Other advantages of the 
Tekscan system are the sensors have a thinner profile than the Fuji Film 
and data acquisition using the Tekscan system occurs real time in situ 
whereas the Fuji Film does not allow for this due to material design. 
 
Based on these compelling findings, the Fuji film method was not used 
due to lower reproducibility, accuracy and inability to collect real time data 
in situ.  
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Tekscan System 
The secondary outcomes were therefore all measured via a 
pressure sensor device placed in the patellofemoral joint, using the 
Tekscan system (Tekscan, I-Scan™ Version 7.0, Boston, MA).  
An individual sensor is made up of two sheets of polyester, each 
with a configured layer of electrical conductor material. The two sheets 
are held together with a coating of semiconductive ink separating the 
configuration of the conductor. Where one conductor on one sheet 
crosses the conductor of the other sheet a sensing element (sensel) is 
formed (at a row and column intersection). Application of force results in 
compression of the ink layer and alters the electrical resistance across a 
sensing element. This change in resistance is dependent (in part) on the 
force applied during the calibration process. The sensor is connected to a 
computer via handle hardware (Evolution®, Tekscan Inc., Boston, 
Massachusetts, USA). The I-Scan® software (Tekscan, I-Scan™ Version 
7.0, Boston, Massachusetts, USA) allowed for calibration, for recording 
and analysing data and for converting the measured resistances into 
estimates of resultant force, peak pressure and contact area. 
Based on review of previous studies (Anglin et al., 2010; 
Brimacombe et al., 2009; Gill et al., 2004; Martinelli et al., 2006; Wilson et 
al., 2003), the sensor most commonly used to assess patellofemoral joint 
mechanics was Tekscan sensor model 5051. However, the specific psi 
(pounds per square inch) or MPa varied considerably between 
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experiments. To determine the most appropriate sensor a number of 
5051 sensors with different MPas were tested. 
 
Sensor Selection 
Selecting the appropriate sensor full-scale pressure range required 
testing of the sensor in the experimental set-up under each condition. 
Each sensor was loaded in a methodology knee and the Colour Pressure 
Legend was opened and set from 0 to 255 (Tekscan eight-bit full raw 
digital output scale). The maximum sensel output is 255 Raw DO (Digital 
Output). The application pressure should nearly saturate the sensor 
output. If, under constant load, peak pressure was below the maximal 
sensel output throughout the range of knee flexion, for example, 
approximately 240 DO, then this sensor full-scale range was deemed to 
be the most appropriate. If a sensel reached 255 DO at any point during 
the range of motion, higher pressures and forces occurring at other points 
of knee flexion would go undetected as the sensor had already reached 
full saturation and therefore no greater output would register. The 
selected sensor full-scale range had to satisfy this requirement under all 
four conditions. The 5051 pressure sensor, psi 350 (Tekscan, I-Scan™ 
Version 7.0, Boston, MA) met this criterion and was therefore used to 
calculate patellofemoral joint reaction force, peak pressure and contact 
area. The matrix of this sensor was comprised of 1936 sensels, size (w) 
55.9mm x (h) 55.9mm x (d) 0.1mm, with a saturation pressure of 
2.41MPa. 
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Sensor Preparation 
A new sensor that has not undergone optimisation may lack uniformity 
and produce a non-linear response to applied force or pressure. 
Hysteresis (the difference in the sensor output during loading and 
unloading the same force) and drift (change in sensor output under a 
constant force over a period of time) are also other sensor characteristics, 
which if not minimised, can influence the accuracy of the sensor output.  
Optimisation of a sensor’s performance involves three steps: 
conditioning, equilibration (if required) and calibration.  
Conditioning is the repeated loading (‘exercising’) of a sensor in order to 
reduce the effects of drift and hysteresis. The sensor is loaded to 120% of 
the pressure expected during the actual test application. Similar material 
to that in the test application (native knee and prosthesis) is used during 
application of pressure. 
 Equilibration is the normalisation of each sensel output to the 
mean output of all the sensels on the matrix. This is achieved by applying 
a known uniform pressure to all the sensels using the Tekscan 
equilibration bladder. The software determines the scale factor that is 
applied to each sensel, which results in a uniform output at that pressure. 
Equilibration is necessary when the sensor is loaded repeatedly in the 
same region on the sensor. The sensels in this area undergo degradation 
with time whilst those in the unloaded area remain intact and hold a 
higher sensitivity level. Equilibration compensates for a calculated 
decrease in sensitivity over time and provides a more uniform sensor 
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output (sensitivity). The Tekscan system available did not have an 
equilibration bladder. Attempting to equilibrate without this bladder may 
have resulted in unevenly applied pressure and created a bias in the 
sensor output. In this circumstance, it is more accurate to not equilibrate. 
Conveniently, equilibration was not deemed essential for this experiment 
for the following reason. During knee flexion, the points of contact in the 
patellofemoral joint vary with change in knee angle and test condition (to 
an extent) thus the area of sensels loaded also varies, minimising the risk 
of sensor output inaccuracy. 
 Calibration is the process by which the DO is converted to an 
actual engineering unit, such as MPa or PSI. Calibration allows for the 
outputs of the same sensor, under different conditions, to be compared 
and enables the calibrated outputs of various sensors to be compared. 
Each sensor was calibrated using an electromechanical load frame 
designed to test materials in tension or compression (Instron 5565 dual 
column table top model, High Wycombe, Bucks, UK). The driver system 
moves the cross head down to apply a pre-defined compressive load on 
the specimen. A load transducer (load cell), mounted in series with the 
specimen, measures the applied load. The load cell converts the load into 
an electrical signal that the control system measures and displays. The 
control system is via an Instron proprietary software program designed 
specifically for material testing (BlueHill® 2, Instron, High Wycombe, 
Bucks, UK). 
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Two calibrations were performed: native knee and prosthetic conditions. 
The native knee condition was simulated using 3mm thick silicone rubber 
with a Young’s modulus of approximately 0.7MPa, replicating that found 
in patellofemoral cartilage (Drewniak et al., 2007; Wilson et al., 2003). A 
square of silicone rubber measuring 55.9mm x 55.9mm was placed either 
side of the sensor. The three materials were placed between two flat 
metal plates and a known compressive load was applied, distributing 
equal pressure. The prosthetic condition was replicated using 8mm thick 
ultra-high molecular weight polyethylene and a steel cylinder. Due to the 
relative stiffness between the metal and plastic, and amount of force 
applied, the extent of deformation resulting from the conditioning and 
calibrating was negligible and therefore the type of metal used was not 
critical (see Figure 2-17 and Figure 2-18). Five conditioning cycles were 
performed at 120% of the average raw pressure, 5.55MPa. Two-
parameter power calibration was performed at 20% and 80% of the 
expected maximum applied joint pressure- 0.8MPa and 3.2MPa, using 
the I-Scan V7.0 software. The sensitivity level was adjusted to allow for 
higher pressures to be measured without reaching saturation. This 
allowed for readings to be obtained that exceeded the manufacturer listed 
pressure range. During conditioning and calibration the surfaces were 
coated with surgical lubricant to reduce shear loads (Teflon). 
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Figure 2-17 Calibration of Tekscan Sensor 1 
A Polyethylene 
B Metal cylinder 
C Tekscan sensor and handle 
D Instron load cell device 
A
B
C
D
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Figure 2-18 Calibration of Tekscan sensor 2 
A Sensor matrix; approximate 80% surface area covered 
B Polyethylene 
C Metal cylinder 
D Lubricant between metal-sensor-polyethylene interfaces 
 
For both conditioning and calibrating the load was increased steadily over 
5 seconds, held for 10 seconds and reduced to 0.0005N over 5 seconds 
then left unloaded for 60 seconds. This time frame was similar to that 
used in each test application in order to minimise the effects of drift. One 
optimised sensor was used per knee for all four conditions. 
 
  
A
B
C
D
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Sensor Insertion 
Reinforcement duct tape was attached to each side of the sensor, 
adjacent to but not obstructing the matrix. To the most distal end of each 
strip of tape, 2’0 Ethilon sutures on a straight 60mm needle (Ethicon™, 
Somervile, New Jersey, USA) were fastened. These sutures aided in 
insertion and maintenance of the sensor position within the patellofemoral 
joint. Only the central quadriceps muscles were raised to insert the 
sensor into the joint via the suprapatellar pouch, avoiding overstretching 
of the retinaculum. The needles were passed either side of the patellar 
tendon insertion, through the soft tissues, pulling the sensor downwards. 
Once the sensor was positioned in the joint the sutures were tied on the 
outside at that level, fixing the sensor in place (see Figure 2-19 to Figure 
2-21).  
 
Figure 2-19 Tekscan sensor insertion 1 
 
B
A
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Figure 2-20 Tekscan sensor insertion 2 
 
 
Figure 2-21 Tekscan sensor insertion 3 
A Reinforcement duct tape 
B Ethilon sutures attached to duct tape to enable anchoring of sensor 
C Insertion via the suprapatellar pouch 
D Sensor seated centrally within the patellofemoral joint 
C
D
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Data Acquisition 
The corresponding calibration file was loaded prior to commencing 
measuring. Initially, the planned data collection involved measuring at 
each 10° increment four times under each condition. However, tests with 
the methodology knees revealed significant sensor degradation. The 
methodology was therefore modified until sensor degradation was no 
longer detectable; the number of trials was reduced to two and the 
increment was increased to 30°. Two to three 0.5mm pin markers were 
inserted at the level of the superior pole and lateral or medial facet of the 
patella. Light pressure was applied to the sensor, enough to register on 
the software system and thus confirm orientation during data analysis 
(see Figure 2-22 and pin marker location coordinates (18,1) and (33,12) 
in   Figure 2-24). Temperature and humidity readings were taken at 
regular intervals to monitor changes in the external environment 
significant enough to impact the behaviour of the sensor and ultimately 
the data. 
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Figure 2-22 Pin markers for patellofemoral joint orientation 
A Superior pole marker 
B Medial facet marker 
C Lateral facet marker 
 
  
A
B
C
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At each angle for each condition a movie data file was generated as 
shown in Figure 2-23. This movie file was duplicated and saved using a 
higher sensitivity setting in order to detect the markers.  
 
 
 
 
 
 
0° NATIVE  
 
 
 
 
 
 
30° NATIVE  
 
 
 
 
 
 
60° NATIVE  
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90° NATIVE  
 
 
 
 
 
 
120° NATIVE 
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0° PFA  
 
 
 
 
 
 
30° PFA  
 
 
 
 
 
 
60° PFA  
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90° PFA  
 
 
 
 
 
 
120° PFA  
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0° CR-TKA  
 
 
 
 
 
 
30° CR-TKA  
 
 
 
 
 
 
60° CR-TKA  
  
150
 
 
 
 
 
 
90° CR-TKA  
 
 
 
 
 
 
120° CR-TKA  
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0° PS-TKA  
 
 
 
 
 
 
30° PS-TKA  
 
 
 
 
 
 
60° PS-TKA  
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90° PS-TKA  
 
 
 
 
 
 
120° PS-TKA  
Figure 2-23 Movie files at 0°, 30°, 60° 90°, 120° of knee flexion for each condition 
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  Figure 2-24 Example ASCII file 
 This ASCII file illustrates the patellofemoral contact areas at 90° of knee flexion. The variation in colour represents the different contact pressures (green 
low, red high). The numbers within each cell are the pressure readings measured in MPa. The pink cells, co-ordinate locations 18,1 and 33,12, represent 
the patellar superior and medial borders, respectively.  
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2.14.3 Measurements: Patellofemoral Force, Peak Pressure & Contact 
Area 
The movie file was also saved as an ASCII (American Standard Code for 
Information Interchange) file and then converted to an excel file via a 
macro as shown in   Figure 2-24. The macro file was coded to enable 
automatic input of data, already acquired by the Tekscan software, into 
the excel file. This included all three parameters: contact area (mm2), 
pressure (MPa) and force (N). In addition, the macro was programmed to 
calculate percentage peak pressure achieved to assist with detecting 
spurious results. All data that appeared to be spurious were deleted. A 
conservative approach was taken in order to avoid deleting genuine 
contact areas. 
 
2.14.4 Prosthesis Implantation 
A previously validated patellar splitting (transpatellar) approach was used 
to ensure the integrity of the extensor mechanism remained equal 
between conditions. This reduced the number of confounding factors 
such as variation in suture tensioning affecting the extensor retinaculae 
length changes following closure of a standard medial parapatellar 
approach.  
The initial part of the transpatellar approach involved preparing two holes 
for accurate screw fixation following splitting of the patella (see Figure 
2-25 and Figure 2-26). Two straight 1.3-mm wires were inserted, across 
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the width (medial-lateral direction) of the patella, one proximal and one 
distal. These holes were then over drilled using a 2.7mm cannulated drill 
bit. Using a fine saw blade 0.1mm thick, the patella was split from 
proximal to distal along its length, 10mm lateral to the midline (see Figure 
2-25 and Figure 2-27). The split was performed under a sufficient amount 
of quadriceps tension, to stabilise the patella, with the knee at 90° flexion. 
An osteotome was used to widen the gap between the two fragments 
superficial to the articular surface, which was finally incised with a scalpel. 
This final cut was extended 10mm proximally and distally through and 
parallel to the quadriceps tendon and patellar tendon fibres, respectively. 
The two fragments were then approximated with two 4.0mm partially 
threaded cannulated cancellous screws (see Figure 2-28). 
 
 
Figure 2-25 Transpatellar approach - patellar splitting 
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Figure 2-26 Parallel proximal and distal holes for accurate screw fixation 
 
 
Figure 2-27 Splitting of the patella off-centre after screw holes drilled 
 
 
Figure 2-28 Approximation of the two fragments with cannulated cancellous screws 
 
 This approach was performed prior to the native knee condition 
experiments to minimise variability between the four conditions. Prior 
work had shown that this approach did not alter the patellar tracking or 
retinacula significantly (Merican et al., 2009). Care was taken to ensure 
the patella remained intact and the screw fixation did not interfere with 
subsequent implantation of the patellar button for the other three 
conditions. The patellar button was cemented in with ease; no obstruction 
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was caused by the transpatellar approach and screw fixation (see Figure 
2-22). The screws were positioned superficial enough, both proximally 
and distally, allowing for an adequate patellar resection to be performed. 
The split in the quadriceps tendon was opposed with a continuous stitch, 
which was released to ease prosthesis implantation. The patellar tendon 
split was not repaired, as loading the knee during flexion does not cause 
separation of the tendon. 
 All three types of knee arthroplasty were performed on each knee 
specimen in accordance with the manufacturer’s guidelines (Zimmer, 
Warsaw, Indiana, USA). The same surgeon, a knee arthroplasty 
orthopaedic consultant, implanted all the prostheses. 
 Four cycles were carried out per condition. The order of 
experiments was native, PFA, CR-TKA and PS-TKA. Between each 
arthroplasty condition, the cement was excised and reapplied for the 
components that required exchanging. The same patellar button was 
used for all three arthroplasty conditions. The same tibial tray was used 
for the CR-TKA and PS-TKA. It was not possible to randomise the order 
of tests, in view of the progressive bone removal. 
 
2.14.5 Measurement: Extensor Mechanism Efficiency 
In order to measure this primary outcome two preliminary experiments 
were performed:  
Experiment 1. Strain gauge calibration  
Experiment 2. Attachment and testing of strain gauge  
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Experiment 1: Strain Gauge Calibration 
The strain gauge elements were configured in a full bridge strain gauge 
circuit (Wheatstone Bridge) arrangement whereby two strain gauge 
elements were bonded to either side of the bar so that those on the 
superior surface detected compression changes and those on the inferior 
side detected tensile changes. The schematic view of this configuration is 
illustrated in Figure 2-29 (Kuphaldt, 2006). 
 
 
Figure 2-29 Full bridge strain gauge circuit 
(Kuphaldt, 2006) 
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Each strain gauge was active in the configuration. The function of each 
strain gauge is illustrated in Figure 2-30 (Kuphaldt, 2006). 
 
Figure 2-30 Single strain gauge 
(Kuphaldt, 2006) 
 
Silicone sealant was used to protect the strain gauge elements and 
minimise the effect of external factors such as changes in temperature 
and humidity Figure 2-31. The strain gauge was connected to a strain 
gauge amplifier system, Sangamo Schlumberger type C56 (Sangamo 
Company, Bogner Regis, UK) which converted the strain gauge input 
(mV) into mA readings Figure 2-32. 
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Figure 2-31 Bonded strain gauges and silicone sealant 
 
 
 
 
Figure 2-32 Strain gauge amplifier system 
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The strain gauged beam was held in a clamp parallel to the ground. The 
clamp was 90cm above ground level, allowing for adequate clearance of 
the weights applied to the strain gauge. The distance from the strain 
gauge elements to the point of weight application, moment arm, 
measured 25cm. The weights, force, were applied in increments of 5N up 
to 50N, therefore 10 data points were collected. The torque or moment at 
each 5N increment was calculated. Four sensitivity levels were assessed: 
1, 2.5, 10 and 25, to determine the setting that produced the least 
variability in mA readings with increase in Newtons. Four trials were 
performed at each sensitivity level and an average was taken of the four 
trials. The average values were multiplied by the moment and the trend 
assessed (see Table 2-10 and Figure 2-33). 
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Table 2-10 Strain gauge calibration 
Sensitivity 
Level Trial Moment (Nm) 
  1.25 2.5 3.75 5 6.25 7.5 8.75 10 11.25 12.5 
1 1 82 166/7 241/2 308/9 390/1 469/8 527 597/8 674/5 765/6 
 2 81 156 243 334 384/5 474/5 538/9 632/3 701/2 808/9 
 3 81 152 227/8 303 391/2 470/1 551/2 626/7 679/80 752/3 
 4 79 166/7 249/50 327/8 398 463/4 527/8 597/8 675 849/50 
 Mean 81 160 240 318 391 470 536 614 683 794 
 MF 0.015479876 0.015600624 0.015600624 0.015710919 0.015979546 0.015974441 0.016320821 0.016299919 0.016480498 0.015743073 
 Mean MF 
 
0.015919034 
 
         
            
2.5 1 32 61 91 122 150 180 211 240 270 301 
 2 32 64 97 129 158 188 211 243 273 301 
 3 32 64 95 127 157 188 220 250 281 313 
 4 32 64 97 129 158/9 191 221/2 249/50 281 317 
 Mean 32 61 91 122 150 180 211 240 270 301 
 MF 0.0390625 0.040983607 0.041208791 0.040983607 0.041666667 0.041666667 0.041469194 0.041666667 0.041666667 0.041528239 
 Mean MF 
 
0.04119026 
          
            
10 1 8 16 24 32 39/40 48 55 63 71 79/80 
 2 8 16 24 32/3 40 48 56 64 72 80 
 3 8 16 24 32 40 48 56 63 71 79 
 4 8 16 24 33 40 48 56 64 72 80 
 Mean 8 16 24 33 40 48 56 64 72 80 
 MF 0.15625 0.15625 0.15625 0.151515152 0.15625 0.15625 0.15625 0.15625 0.15625 0.15625 
 Mean MF 
 
0.155776515 
          
            
25 1 3 7 10 13 16 19 22 25 28 32 
 2 3 7 10 13 16 19 22 25 29 32 
 3 3 7 10 13 16 19 22 25 28 31/2 
 4 3 7 10 13 16 19 22 25 29 32 
 Mean 3 7 10 13 16 19 22 25 28 32 
 MF 0.416666667 0.357142857 0.375 0.384615385 0.390625 0.394736842 0.397727273 0.4 0.401785714 0.390625 
 Mean MF 
 
0.390892474 
 
         
This table shows the output readings at increasing moments for four different sensitvity settings on the amplifier system. Each setting was tested 
four times at each moment and an average value was calculated. The Multiplication Factor (MF) was calculated by dividing the moment value by the 
mean output reading.  
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Figure 2-33 Calibration plot 
This calibration plot illustrates the output reading for each sensitivity level tested at 
moments ranging from 1.25 to 12.5Nm, at increments of 1.25Nm. Sensitivity levels 10 and 
25 produced low output readings below 100 for the entire range, demonstrating low risk of 
producing values beyond the measuring capacity of the amplifier system. In contrast, 
sensitivity levels 1 and 2.5 demonstrated higher gradients and thus a high risk of 
exceeding the maximum output reading of the amplifier system. 
 
Figure 2-33 demonstrates the linear relationship between increase in 
moment and change in mA readings generated by the amplifier 
(transducer). Sensitivity setting 1 had such a high gradient that it is likely 
higher moments (due to increased force) would have produced readings 
exceeding the maximum reading output of the amplifier system. In 
addition, the variability in multiplication factor (MF) (see Table 2-10) was 
greater than in comparison to the other settings. Sensitivity setting 2.5 
was also not appropriate to use, although the gradient was not as high, 
the variability in multiplication factor would lead to unreliable data. 
Therefore the choice remained between settings 10 and 25, both of which 
had very low gradients and were unlikely to result in readings exceeding 
0
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those that could be outputted by the transducer. Sensitivity level 10 
produced the most consistent multiplication factor and was therefore the 
setting of choice. This moment multiplication factor (0.1558) was 
converted to ‘force’ multiplication factor (0.6231) in order to calculate the 
extensor mechanism efficiency. 
 
Experiment 2. Attachment and Testing of the Strain Gauged Beam 
Two metal discs were joined to each end of the strain gauged aluminium 
bar using adhesive. Each disc had a central hole to aid mounting and 
securing of the device to the outer right side of the rig as shown in Figure 
2-34. The disc nearest to the strain gauge elements was connected to the 
crank mechanism. This connection was reinforced with a thin strip of 
stainless steel to reduce the amount of play (potential additional torque) 
in the system that could have impacted on the results. A metal shaft was 
inserted in the central hole of the disc furthest from the strain gauge 
elements and was used to position the strain gauge and crank 
mechanism at the appropriate flexion angle. The position of the strain 
gauge device in relation to the crank mechanism was checked at each 
angle to ensure it remained parallel. An additional counter balance was 
placed on the outer left side of the rig to ensure this position was 
maintained. 
  
165
 
Figure 2-34 Strain gauge device attached to outer aspect of rig 
 
The calibrated strain gauge was tested on the rig (without a knee) to 
ensure the level of consistency found in Experiment 1 was reproducible. 
The tests were repeated at two time points during the day to assess for 
significant variations in readings as a result of unknown and known 
external factors such as humidity and temperature (see Table 2-11 and 
Figure 2-35). 
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Table 2-11 Calibration Assessment on Rig 
Angle  Morning Trials Afternoon Trials 
 Trial 1: 0° to 120° Trial 2: 120° to 0° Trial 3: 0° to 120° Trial 4: 0° to 120° 
0° -22 -22 -21 -21 
10° -21 -21 -20 -21 
20° -20 -20 -20 -20 
30° -19 -20 -19 -19 
40° -19 -18 -18 -19 
50° -18 -17 -17 -17 
60° -17 -16 -15 -16 
70° -15 -15 -15 -14 
80° -14 -15 -13 -14 
90° -13 -13 -13 -14 
100° -13 -13 -12 -13 
110° -10 -11 -10 -10 
120° -8 -8 -8 -8 
This table shows the results of the unloaded strain gauge at each flexion angle for four 
trials: two tests in the morning and two tests in the afternoon. 
 
  
 
Figure 2-35 Calibration on Rig Plot 
This calibration plot demonstrates all four trials produce similar values at each flexion 
angle.  
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Statistical analysis for significant variation between the trials yielded two 
positive results. The level of significance was set at p = 0.00833 using the 
Bonferroni adjustment to reduce the risk of a Type I error (see Table 
2-12). Significant differences occurred between morning and afternoon 
results but this was not consistent for both morning and afternoon trials. 
The detected difference may have been related to changes in 
temperature and humidity. No significant difference occurred between the 
two trials in the morning or between the two trials performed in the 
afternoon. Furthermore, the intraclass correlation coefficient was 
calculated as 0.996, demonstrating excellent intraclass reliability 
(consistency of the output data, thus indicating the number of trials (four) 
is sufficient. 
 
Table 2-12 Statistical Assessment for Variation 
Time Comparison P value 
Morning (m) Trial 1m vs Trial 2m 1 
Afternoon (a) Trial 1a vs Trial 2a 0.054360123 
Morning vs Afternoon Trial 1m vs Trial 1a 0.005161681 
Morning vs Afternoon Trial 1m vs Trial 2a 0.190151431 
Morning vs Afternoon Trial 2m vs Trial 1a 0.005161681 
Morning vs Afternoon Trial 2m vs Trial 2a 0.273483563 
 
Calibration on the rig without a knee demonstrated at each angle of 
flexion some degree of strain was detected. In order to ‘zero’ the raw data 
obtained with the knees in situ, measurements were taken before each 
condition was tested without the knees. These figures were subtracted 
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from the raw data and the corrected mean was used to calculate the 
extensor mechanism efficiency. 
 
Following completion of calibration, each knee was mounted in the rig 
under constant quadriceps tension (205N), the extension force 
generated, at each measured angle of knee flexion, was applied to the 
aluminium bar (see label C in Figure 2-9) perpendicular to the tibial shaft. 
This force was detected by the strain gauges. This was repeated four 
times per condition for each knee tested. 
 
2.15 Interventions 
2.15.1 Patellofemoral Arthroplasty 
The Zimmer Gender Solutions Patello-Femoral Joint System (Zimmer, 
Warsaw, Indiana, USA) trochlear component is an asymmetrical onlay 
component made from forged cobalt chrome. The femoral trochlear 
groove is wide and the lateral facet prominent to ensure engagement of 
the patella in the first 30° of knee flexion (see Figure 2-36). The anterior 
flange is relatively long allowing for the patellar button to maintain contact 
in full extension and low profile to avoid overstuffing. The intercondylar 
segment of the prosthesis is tapered towards the notch to ensure a 
smooth transition from prosthesis to native femoral condyle in deep knee 
flexion. The under-surface of the trochlear component has three pegs, 
which are configured to maximise secure cement hold of the component 
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medial 
during knee motion (see Section 2.2.3.1). The patellar button made from 
ultra-high molecular weight polyethylene (UHMWPE) is axisymmetric and 
also has pegs on the under surface to add stability and fixation. Both 
articulating areas are resected using jigs and clamps respectively. The 
trochlear implant and patellar button are both cemented in place. The 
native tibiofemoral joint and cruciate ligaments remain in situ. The 
trochlear prosthesis is available in five sizes. Sizes 1-4 have the same 
patellar contact geometry as the NexGen CR-TKA and PS-TKA used in 
this study and therefore were the only sizes selected, following 
confirmation with the product engineer designers. 
 
Figure 2-36 Patello-Femoral Joint System, Zimmer 
 
2.15.2 Total Knee Arthroplasty 
The Cruciate retaining total knee arthroplasty (CR-TKA): Zimmer 
NexGen CR-Flex System (Zimmer, Warsaw, Indiana, USA) and 
Posterior-stabilising total knee arthroplasty (PS-TKA): Zimmer NexGen 
LPS-Flex System (Zimmer, Warsaw, Indiana, USA) were used in the 
study. Both femoral components were made of cobalt chromium 
lateral 
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molybdenum alloy and have been designed with minimised width and 
thickness of the anterior flange to relieve tension on the extensor 
mechanism and restore normal joint function. The intercondylar geometry 
of both components is identical to that of the Zimmer PFA. These 
components are asymmetrical and multi-radius. The trochlear groove is 
deepened to accommodate the axisymmetric patellar button and reduce 
the risk of overstuffing. 
 The cruciate retaining femoral component is shown in Figure 2-37. 
The space between the posterior condyles accommodates the native 
posterior cruciate ligament. The tibial polyethylene insert is highly 
congruent and fixed to the tibial base plate. The tibial cut created a 7° 
posterior slope. The same base plate was used for the PS-TKA.  
The posterior stabilising femoral component, shown in, Figure 2-37 has 
an additional horizontal metal construct between the two posterior 
condyles. This articulates with the polyethylene tibial post, forming a post-
cam mechanism. All the metal implants were cemented to bone with poly 
methyl methacrylate (PMMA).  
 
 
Figure 2-37 Posterior-stabilising TKA, Zimmer (left), Cruciate-retaining TKA, Zimmer (right) 
 
  
171
2.16 Adverse Events Management 
Each cadaver was used for the purpose of this study alone. All tissue 
handling was carried out in accordance with the Tissue Handling 
Guidelines and The Biomechanics Laboratory manual for ‘working 
practices relating to biological safety’. Both documents instructed on 
collection, use, storage and disposal of biological tissue. Any deviation 
from these guidelines was considered an adverse event. All reportable 
incidences, such as contamination of a lab worker with human material, 
followed the incident event protocol. This involved first aid attention and 
the departmental safety officer and head of the lab being informed. 
2.17 End of Study 
The study was deemed complete when all 8 cadaveric knees had a set of 
four clean results. 
2.18 Data Management 
2.18.1 Statistical Analysis 
A sample size calculation, based on previous cadaveric knee 
biomechanics test data, established 8 knees were sufficient for detecting 
change of meaningful significance with 95% confidence at 80% power 
(Stephen et al., 2013). Other studies have also performed power 
calculations supporting this sample size (Cohen et al., 2001; Stephen et 
al., 2012). The kinematic data was analysed using a one-way repeated 
measures ANOVA. The single factor evaluated was the knee condition: 
native, PFA, CR-TKA, PS-TKA at each 10° increment of knee flexion. The 
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dependent variables were the primary outcome: extensor mechanism 
efficiency and secondary outcomes: patellofemoral resultant force, peak 
pressure and contact area (dependent variables).  When the F test was 
significant (P < 0.05) the null hypothesis was rejected. Thus confirming 
the existence of differences between the conditions, that is, (the samples 
are not all from populations with the same mean) the means for the 
dependent variables measured at a given angle for the four conditions 
were not from the same populations. Post hoc paired t tests were used to 
identify which condition differed from the others at each angle of flexion 
for each dependent variable.  
 
Comparing four conditions means a multiple of six paired comparisons 
will be made at a given angle of flexion. This method of performing 
multiple hypotheses tests results in an increased probability that one or 
more of the test will be significant due to chance (Type I error). The 
likelihood of these occurring increases as the number of comparisons 
increases. This occurrence is known as the familywise error rate (FWER) 
(another description: familywise type 1 error is the probability that, even if 
all samples come from the same population, one will wrongly conclude 
that at least one pair of populations differ) or cumulative Type I 
error/alpha inflation and is estimated with the following formula: 
 FWE 1 (1EC )c
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where  is the FWER,  is the desired significance level, and the 
number of comparisons. In this study the calculated FWER is ≤ 0.2649, 
that is, 1 in 4 significant tests will be due to a Type I error. This rate is 
unacceptable and therefore a multiplicity adjustment is required.  
 The Bonferroni factor was used to calculate an adjusted 
probability. This method of adjustment is very conservative and 
guarantees that the use of the adjusted alpha in pairwise comparisons 
keeps the actual probability of FWER no higher than the desired 
significance level, that is, 0.05. The formula is as follows: 
 
where  is the new alpha used to evaluate each comparison and 
is the maximum allowed FWER. The total number of pairs c = 4(4-1)/2 = 
6, therefore the  significance level is 0.00833 for comparison of the 
four knee conditions to each other.  
 
All data analysis was performed in IBM® SPSS® Statistics for Macintosh, 
Version 19.0 (Armonk, NY: IBM® Corp.) and Microsoft® Excel® Version 
14.3.9 (Microsoft® Corp.). 
 
  
FWE EC c
B  FWEc
B FWE
B
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2.19 Results 
Eight knees were analysed in total. The raw data collected for each knee 
had to undergo a series of computations, which varied depending on the 
outcome being assessed, prior to performing statistical analysis. 
Summary data for each parameter are recorded in Appendices I to V: 
Table 6-1 to Table 6-39.  
2.19.1 Extensor Mechanism Efficiency 
Each knee underwent a sequence of sixteen trials. Four trials were 
performed under each condition: native knee, PFA, CR-TKA and PS-
TKA. The raw data was converted into extensor mechanism efficiency 
(EME). 
 
Extensor mechanism efficiency results are summarised in Table 2-13 to 
Table 2-16. The data shows all four conditions demonstrate a similar 
pattern of increasing EME between 0° and 50°, highest in mid-range, and 
a decreasing EME between 60° and 120°, lowest in mid-range. This is 
clearly illustrated in  Figure 2-38. 
Table 2-13 Native Knee Extensor Mechanism Efficiency 
Flexion Angle (°) Mean Native Knee Nm/NQT Standard Deviation (±SD) 
120 0.11097 0.02299 
110 0.07843 0.01203 
100 0.07285 0.00995 
90 0.07421 0.00763 
80 0.07858 0.00544 
70 0.08613 0.00621 
60 0.09874 0.00406 
50 0.11177 0.00478 
40 0.12277 0.00874 
30 0.13317 0.01186 
20 0.13849 0.01239 
10 0.12475 0.01545 
0 0.04880 0.02150 
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Table 2-14 PFA Extensor Mechanism Efficiency 
Flexion Angle (°) Mean PFA Knee Nm/NQT Standard Deviation (±SD) 
120 0.10919 0.01344 
110 0.07350 0.01127 
100 0.06744 0.01061 
90 0.06670 0.01406 
80 0.06601 0.01408 
70 0.07839 0.01750 
60 0.09339 0.02555 
50 0.11978 0.02269 
40 0.13749 0.01655 
30 0.14452 0.01204 
20 0.14471 0.01717 
10 0.12222 0.02282 
0 0.05399 0.04269 
 
Table 2-15  CR-TKA Extensor Mechanism Efficiency 
Flexion Angle (°) Mean CR-TKA Knee Nm/NQT Standard Deviation (±SD) 
120 0.11166 0.02178 
110 0.08024 0.01780 
100 0.07366 0.01508 
90 0.07487 0.01391 
80 0.07577 0.01243 
70 0.08271 0.01366 
60 0.09214 0.01661 
50 0.09928 0.01758 
40 0.10852 0.01526 
30 0.11128 0.01519 
20 0.10814 0.01707 
10 0.07927 0.02061 
0 0.01639 0.01793 
 
Table 2-16 PS-TKA Extensor Mechanism Efficiency 
Flexion Angle (°) Mean PS-TKA Knee Nm/NQT Standard Deviation (±SD) 
120 0.10774 0.01673 
110 0.08276 0.01528 
100 0.07672 0.01534 
90 0.07592 0.01301 
80 0.07423 0.00948 
70 0.07846 0.00881 
60 0.08679 0.01271 
50 0.09318 0.01534 
40 0.10235 0.01824 
30 0.11180 0.01428 
20 0.11218 0.01391 
10 0.07981 0.02600 
0 0.01249 0.01523 
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One-way ANOVA analysis at each 10° increment of flexion showed no 
significant difference at 60°, 70°, 90° to 120° of knee flexion between any 
of the four conditions. The positive findings are listed in Table 2-17. The 
main significant differences occurred at lower degrees of knee flexion (0° 
to 50°). Throughout this range of motion, the PFA showed the greatest 
extensor mechanism efficiency and was found to be significantly different 
to the CR- and PS-TKA. Interestingly, the converse was true in the deep 
knee flexion range, although the differences were not statistically 
significant. There were no differences between the CR-TKA and PS-TKA 
at any of the measured points of knee flexion. The significant differences 
between the native and the arthroplasty conditions were similar to the 
PFA. The distribution appeared bimodal. 
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Table 2-17 Extensor Mechanism Efficiency Significant Differences 
Angle Condition 
(I) 
Condition 
(J) 
Mean 
difference 
(I-J) 
Std. 
Error 
Sig.  99.166667% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
80° Native  PFA 0.1256 0.00265 0.000 0.0039   0.0212 
80° PFA CRTKA -0.00976 0.00265 0.002 -0.0184 -0.0011
50° Native PSTKA 0.1859 0.00399 0.000 0.0055   0.0317 
50° PFA CRTKA 0.02049 0.00399 0.000 0.0074   0.0336 
50° PFA PSTKA 0.02660 0.00399 0.000 0.0135   0.0397 
40° Native PFA -0.01472 0.00396 0.002 -0.0277  -0.0018
40° Native CRTKA 0.01425 0.00396 0.003 0.0013   0.0272 
40° Native PSTKA 0.02042 0.00396 0.000 0.0075   0.0334 
40° PFA CRTKA 0.02897 0.00396 0.000 0.0160   0.0419 
40° PFA PSTKA 0.03514 0.00396 0.000 0.0222   0.0481 
30° Native PFA -0.01135 0.00345 0.008 -0.0226  -0.0001
30° Native CRTKA 0.02189 0.00345 0.000 0.0106   0.0332 
30° Native PSTKA 0.02137 0.00345 0.000 0.0101   0.0327 
30° PFA CRTKA 0.03324 0.00345 0.000 0.0220   0.0445 
30° PFA PSTKA 0.03272 0.00345 0.000 0.0214   0.0440 
20° Native CRTKA 0.03035 0.00383 0.000 0.0178   0.0429 
20° Native PSTKA 0.02631 0.00383 0.000 0.0138   0.0389 
20° PFA CRTKA 0.03657 0.00383 0.000 0.0240   0.0491 
20° PFA PSTKA 0.03253 0.00383 0.000 0.0200   0.0451 
10° Native CRTKA 0.04545 0.00521 0.000 0.0284   0.0625 
10° Native PSTKA 0.04490 0.00521 0.000 0.0279   0.0619 
10° PFA CRTKA 0.04296 0.00521 0.000 0.0259   0.0600 
10° PFA PSTKA 0.04241 0.00521 0.000 0.0254   0.0594 
0° Native CRTKA 0.03241 0.00636 0.000 0.0116   0.0532 
0° Native PSTKA 0.03631 0.00636 0.000 0.0155   0.0571 
0° PFA CRTKA 0.03761 0.00636 0.000 0.0168   0.0584 
0° PFA PSTKA 0.04151 0.00636 0.000 0.0207   0.0623 
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 Figure 2-38 Extensor Mechanism Efficiency 
The extensor mechanism efficiency (EME) graph illustrates the change in EME during the flexion-extension cycle for all four conditions. There
is an increased efficiency from mid- to early knee flexion demonstrated by all conditions. Interestingly, the PFA condition appears to produce
higher EME than the native knee during this range of motion.  
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2.19.2 Patellofemoral Resultant Forces 
The resultant force was assessed at five angles: 0°, 30°, 60° 90° and 
120°. Two trials were performed at each angle of knee flexion. The 
resultant force was generally higher for both the native knee and PFA 
than CR-TKA and PS-TKA at each angle of knee flexion assessed. The 
results are summarised in Table 2-18 to Table 2-21 and illustrated in 
Figure 2-39. 
Table 2-18 Native Knee Resultant Force 
Flexion angle (°) Mean Native Knee Resultant Force (N) Standard Deviation (±SD) 
120 83.38981 28.14018 
90 92.12675 30.56885 
60 91.10694 21.27003 
30 68.64461 9.65437 
0 36.27739 4.44379 
 
Table 2-19 PFA Resultant Force 
Flexion angle (°) Mean PFA Resultant Force (N) Standard Deviation (±SD) 
120 97.27299 30.78750 
90 101.91813 29.26406 
60 71.39603 16.47219 
30 54.66419 12.67899 
0 30.08964 9.98869 
 
Table 2-20 CR-TKA Resultant Force 
Flexion angle (°) Mean CR-TKA Resultant Force (N) Standard Deviation (±SD) 
120 83.20236 24.47742 
90 82.95448 15.21989 
60 82.23976 13.62166 
30 51.09061 8.23142 
0 22.86889 4.03475 
 
Table 2-21 PS-TKA Resultant Force 
Flexion angle (°) Mean PS-TKA Resultant Force (N) Standard Deviation (±SD) 
120 73.35268 12.93741 
90 76.23976 14.65527 
60 81.64296 12.63351 
30 51.06743 5.85306 
0       25.47978 4.57338 
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One way ANOVA analysis showed no evidence of a difference in 
resultant force generated between the three arthroplasty conditions at 
any of the five angles of knee flexion assessed: 0°, 30°, 60°, 90° and 
120°. The significant differences found occurred in full extension and 
early flexion, between the native knee and the arthroplasty conditions as 
shown in Table 2-22. 
 
Table 2-22 Resultant Force Significant Differences 
Angle Condition 
(I) 
Condition 
(J) 
Mean 
difference 
(I-J) 
Std. 
Error 
Sig.  99.166667% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
30° Native PFA 13.98042 3.81236 0.003 1.1762 26.7847 
30° Native CRTKA 17.55400 3.81236 0.000 4.7497 30.3583 
30° Native PSTKA 17.57717 3.81236 0.000 4.7729 30.3814 
0° Native CRTKA 13.40849 2.42206 0.000 5.2737 21.5433 
0° Native PSTKA 10.62119 2.42206 0.000 2.4864 18.7560 
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Figure 2-39 Resultant Force 
 
The resultant force graph illustrates the change in force during the flexion-extension cycle for all four conditions. The force generated decreases with
decrease in knee flexion angle for all conditions.  
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2.19.3 Peak Pressures 
The peak pressure was assessed at five angles: 0°, 30°, 60° 90° and 
120°. Two trials were performed at each angle of knee flexion. The peak 
pressures were lowest for the native knee condition. All three arthroplasty 
conditions were comparable at 0°, 30° and 60°. The peak pressure 
generated by the PFA at 90° and 120° was lower than the CR-TKA and 
PS-TKA but higher than the native knee. These findings are summarised 
in Table 2-23 to Table 2-26. 
Table 2-23 Native Knee Peak Pressure 
Flexion angle (°) Mean Native Knee Peak Pressure (MPa) Standard Deviation (±SD) 
120 1.73071 1.76180 
90 1.43142 0.63990 
60 1.18642 0.56963 
30 1.19429 0.62976 
0 1.65143 0.56323 
 
Table 2-24 PFA Peak Pressure 
Flexion angle (°) Mean PFA Peak Pressure (MPa) Standard Deviation (±SD) 
120 3.05688 0.92771 
90 4.43688 1.55034 
60 8.25250 0.75889 
30 7.83563 0.54030 
0 7.13063 1.32606 
 
Table 2-25 CR-TKA Peak Pressure 
Flexion angle (°) Mean CR-TKA Peak Pressure (MPa) Standard Deviation (±SD) 
120 8.10125 1.17239 
90 8.02688 1.19806 
60 7.56875 1.15427 
30 7.25875 0.99843 
0 6.69250 0.88663 
 
Table 2-26 PS-TKA Peak Pressure 
Flexion angle (°) Mean PS-TKA Peak Pressure (MPa) Standard Deviation (±SD) 
120 8.24688 0.60251 
90 8.05813 1.01778 
60 7.52063 0.92186 
30 7.00625 0.70840 
0 6.90688 1.23878 
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One-way ANOVA analysis showed statistically significant differences in 
peak pressure between the native knee and CR-TKA and PS-TKA 
conditions at all angles assessed. Similarly, the native knee generated 
significantly lower peak pressures compared with PFA at 0°, 30°, 60° and 
90° but no difference was demonstrated at 120°. The PFA condition 
generated significantly lower peak pressures than the CR-TKA and PS-
TKA at 90° and 120°. This sudden decrease at higher angles of knee 
flexion is illustrated clearly in Figure 2-40. The highest peak pressures 
were generated at the deepest knee flexion in the native knee, CR-TKA 
and PS-TKA. In the PFA condition, the highest peak pressure was 
observed at 60°. Interestingly, all three arthroplasty conditions generated 
high peak pressures in full extension. No differences in peak pressures 
were seen between the CR-TKA and PS-TKA conditions at any of the five 
angles of knee flexion assessed. A summary of the positive findings is 
listed in Table 2-27. 
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Table 2-27 Peak Pressure Significant Differences 
Angle Condition 
(I) 
Condition 
(J) 
Mean 
difference 
(I-J) 
Std. 
Error 
Sig.  99.166667% 
Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
120° Native CRTKA -6.36662 0.43712 0.000 -7.8374 -4.8958 
120° Native PSTKA -6.51616 0.43712 0.000 -7.9646 -5.0677 
120° PFA CRTKA -4.96000 0.43712 0.000 -6.4052 -3.5148 
120° PFA PSTKA -5.10954 0.43712 0.000 -6.5320 -3.6871 
90° Native PFA -3.00545 0.43443 0.000 -4.4645 -1.5463 
90° Native CRTKA -6.59545 0.43443 0.000 -8.0545 -5.1363 
90° Native PSTKA -6.59982 0.43443 0.000 -8.0589 -5.1407 
90° PFA CRTKA -3.59000 0.43443 0.000 -4.9996 -2.1804 
90° PFA PSTKA -3.59438 0.43443 0.000 -5.0040 -2.1847 
60° Native PFA -7.06607 0.35378 0.000 -8.2543 -5.8779 
60° Native CRTKA -6.38232 0.35378 0.000 -7.5705 -5.1941 
60° Native PSTKA -6.33420 0.35378 0.000 -7.5224 -5.1460 
30° Native PFA -6.64134 0.32909 0.000 -7.7466 -5.5361 
30° Native CRTKA -6.06446 0.32909 0.000 -7.1697 -4.9592 
30° Native PSTKA -5.81196 0.32909 0.000 -6.9172 -4.7067 
0° Native PFA -5.47920 0.43569 0.000 -6.9425 -4.0159 
0° Native CRTKA -5.04107 0.43569 0.000 -6.5044 -3.5777 
0° Native PSTKA -5.25545 0.43569 0.000 -6.7188 -3.7921 
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Figure 2-40 Peak Pressure 
The peak pressure graph illustrates the consistently low pressure associated with the native knee. The PFA condition demonstrates the point of 
transition of the patellar component, from articulation with the native femoral condyle to articulation with the trochlear component, as a significant 
rise in peak pressure at 60° knee flexion.
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2.19.4 Contact Areas 
The contact area was assessed at five angles: 0°, 30°, 60° 90° and 120°. 
Two trials were performed at each angle of knee flexion. The contact area 
was greatest at 60° for the native knee, CR-TKA and PS-TKA. The results of 
all four conditions are summarised in Table 2-28 to Table 2-31. 
Table 2-28 Native Knee Contact Area 
Flexion angle (°) Mean Native Knee Contact Area (mm2) Standard Deviation (±SD) 
120 288.01786 59.20396 
90 308.40952 56.85874 
60 338.13296 69.95493 
30 229.03180 31.99483 
0 117.39608 25.11181 
 
Table 2-29 PFA Contact Area 
Flexion angle (°) Mean PFA Contact Area (mm2) Standard Deviation (±SD) 
120 108.16511 20.40374 
90 106.14898 37.36854 
60 44.25389 9.98395 
30 38.60879 17.50168 
0 19.65722 9.96067 
 
Table 2-30 CR-TKA Contact Area 
Flexion angle (°) Mean CR-TKA Contact Area (mm2) Standard Deviation (±SD) 
120 32.25800 8.86571 
90 36.29025 14.12686 
60 47.78211 6.12280 
30 30.76607 11.69635 
0 13.91124 4.91020 
 
Table 2-31 PS-TKA Contact Area 
Flexion angle (°) Mean PS-TKA Contact Area (mm2) Standard Deviation (±SD) 
120 28.12492 5.44299 
90 32.05633 6.66050 
60 44.85878 15.62539 
30 17.94351 7.88685 
0 13.30643 6.05029 
 
The contact area was significantly higher for the native knee at all angles of 
knee flexion compared with the three arthroplasty conditions. The contact 
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area for the PFA condition increased markedly at 90° and 120°, which 
corresponded with a decrease in peak pressure and significant difference 
was seen between these values and those recorded for CR-TKA and PS-
TKA. The contact areas for both CR-TKA and PS-TKA were consistently low 
at each angle of knee flexion and no difference was identified between 
these two conditions. 
Table 2-32 Contact Area Significant Differences 
Angle Condition 
(I) 
Condition 
(J) 
Mean 
difference 
(I-J) 
Std. Error Sig.  99.166667% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
120° Native PFA 178.7708 12.2037 0.000 137.7093 219.8323 
120° Native CRTKA 255.2222 12.2037 0.000 214.1607 296.2837 
120° Native PSTKA 259.8929 12.0182 0.000 219.4556 300.3302 
120° PFA CRTKA 76.4515 11.9915 0.000 36.1041 116.7988 
120° PFA PSTKA 81.1222 11.8026 0.000 41.4103 120.8341 
90° Native PFA 202.2605 13.1175 0.000 158.2038 246.3172 
90° Native CRTKA 272.1193 13.1175 0.000 228.0626 316.1760 
90° Native PSTKA 276.3532 13.1175 0.000 232.2965 320.4099 
90° PFA CRTKA 69.8587 12.6727 0.000 27.2959 112.4215 
90° PFA PSTKA 74.0927 12.6727 0.000 31.5298 116.6555 
60° Native CRTKA 290.3509 13.5962 0.000 244.6864 336.0153 
60° Native PSTKA 293.2742 13.5962 0.000 247.6097 338.9386 
30° Native PFA 190.4230 8.1145 0.000 163.1696 217.6764 
30° Native CRTKA 198.2657 8.1145 0.000 171.0123 225.5191 
30° Native PSTKA 211.0883 8.1145 0.000 183.8349 238.3417 
0° Native PFA 97.7389 5.2917 0.000 79.9661 115.5117 
0° Native CRTKA 103.4848 5.2917 0.000 85.7120 121.2576 
0° Native PSTKA 104.0897 5.2917 0.000 86.3168 121.8625 
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Figure 2-41 Contact Area  
The contact area graph illustrates the change in contact area for all four conditions during the flexion-extension cycle. The contact area is 
highest for the native knee throughout the entire range of motion due to joint congruency and elastic deformation. PFA demonstrates higher 
contact area in deep flexion when the patellar component articulates with the native femoral condyle before transitioning to articulate with the 
trochlear component. 
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2.19.5 Results Analysis 
Proof of adequate sample size 
Using the Cohen’s d equation for calculating effect size: 
  1 2  
σ = spooled 
spooled  (s1
2  s22)
2






 
 
The effect sizes calculated for randomly chosen comparisons were as 
follows: 
EME 30° PFA = 0.1445; σ = 0.0119 
EME 30° native = 0.1332; σ = 0.0120 
Effect size = 0.9481 
 
EME 80° native = 0.0786; σ = 0.0054 
EME 80° PFA = 0.0660; σ = 0.0141 
Effect size = 1.1780 
 
EME 20° PFA = 0.1447; σ = 0.0172 
EME 20° CR-TKA = 0.1081; σ = 0.0171 
Effect size = 2.1357 
(Calculations verified using PS – Power and Sample Size Calculations, 
software, version 3.0.0043, (Dupont & Plummer, 2009)) 
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These effect sizes were close to the expected effect size of 1.17 thus 
demonstrating a similarity in data behaviour to that used to ascertain the 
sample size and justifying the use of the same sample size of 8 cadaveric 
knees. Furthermore, the large effect size of 2.13 demonstrates that a 
higher number of samples would not have been necessary to detect a 
difference between the conditions. 
 
In summary, the key findings were: 
 
1. Extensor mechanism efficiency (primary outcome) was greatest in 
the first 50° of knee flexion for all four conditions. In this range of 
knee flexion PFA offered the highest EME. This difference was 
statistically significant (p < 0.00833) compared with the native 
knee, CR-TKA and PS-TKA at 10°, 20°, 30°, 40° and 50° and also 
at 0° when compared with CR-TKA and PS-TKA. Conversely, in 
deeper flexion PFA was the least efficient at 80° of knee flexion 
and this finding was statistically significant when compared with 
the native knee and CR-TKA. 
 
2. The resultant force produced was not different for the three 
arthroplasty conditions, although the trend demonstrated higher 
forces were generated by the PFA compared with CR-TKA and 
PS-TKA. The only significant differences seen were between the 
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native and CR-TKA and PS-TKA at 0° and between the native and 
all three arthroplasty conditions at 30° of knee flexion. 
 
3. The peak pressure was comparable for all three arthroplasty 
conditions at 0°, 30° and 60° of knee flexion. At 90° and 120° the 
PFA peak pressure significantly reduced in comparison to CR-TKA 
and PS-TKA. There was no significant difference in peak pressure 
at 120° between native knee and PFA. At 0° the peak pressures 
for all arthroplasty conditions were relatively high. 
 
4. The contact area results demonstrated an inverse relationship to 
the peak pressure, that is, an increase in contact area was 
associated with a decrease in peak pressure. Similarly, no 
difference was found between the three arthroplasty conditions at 
0°, 30° and 60° of knee flexion. The contact area in the PFA 
condition increased significantly at 90° and 120° in comparison to 
CR-TKA and PS-TKA. The native knee area was significantly 
greater than all three arthroplasty conditions at each angle of knee 
flexion. 
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2.20 Discussion 
Knee extensor mechanism function is an integral aspect of having a 
successful outcome following knee arthroplasty surgery. Previous studies 
have demonstrated weakness of the extensor mechanism hinders 
activities of daily living for a number of years following TKA (Berman et 
al., 1991; Gore et al., 1986; Huang et al., 1996; Silva et al., 2003). Some 
investigators have found CR-TKA to be less efficient at accommodating 
the weak extensor mechanism in comparison with PS-TKA due to the 
retention of a poor-functioning/insufficient posterior cruciate ligament 
(Hirsch et al., 1994). However, other studies have not demonstrated a 
difference in quadriceps function between the two TKAs (Becker et al., 
1991; Bolanos et al., 1998). The function of the extensor mechanism 
following PFA has not previously been reported. The aim of this study 
was to determine whether the biomechanical and geometrical differences 
between CR-TKA, PS-TKA and PFA result in dissimilar extensor 
mechanism efficiencies primarily and secondarily, whether differences in 
patellofemoral joint forces, peak pressures and contact areas exist 
between the conditions, during the flexion-extension cycle of knee 
motion. 
The hypothesis made at the start of the study, regarding PFA 
EME, was as follows: 
 
‘The extensor mechanism efficiency will be greater following PFA 
compared with TKA throughout the range of flexion-extension cycle, 120° 
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to 0°. The extensor moment produced at a given quadriceps tension 
would be greater following PFA compared with TKA due to the more 
posterior tibiofemoral contact point associated with the native tibiofemoral 
joint resulting in a relatively longer extensor moment arm and therefore 
lower quadriceps force requirements and lower patellofemoral joint 
reaction forces.’ 
 
The results in early to mid-flexion fulfil this hypothesis. However, 
the relationship between knee flexion-extension cycle and EME is not 
linear. The relationship is more complex, appearing bimodal in 
distribution, which most likely reflects the changing length in extensor 
moment arm.  
 The results of this study demonstrated PFA produced greater 
extensor mechanism efficiency (EME) between 50° to full extension than 
all the other conditions. The highest mean EME, 0.1447Nm/NQT 
(±0.0172), was seen at 20° of knee flexion for PFA and the greatest mean 
difference in this range, significant at p < 0.00833, was observed at 10° of 
knee flexion when compared with CR-TKA and PS-TKA, as shown in 
Table 2-33 and Table 2-34. 
 
Table 2-33 Extensor mechanism efficiency mean differences: PFA versus CR-TKA  
Flexion angle (°) PFA vs CR-TKA EME Mean difference (Nm/NQT) 99% CI 
50 0.0205 (0.0074, 0.0336) 
40 0.0290 (0.0160, 0.0419) 
30 0.0332 (0.0220, 0.0445) 
20 0.0366 (0.0240, 0.0491) 
10 0.0430 (0.0259, 0.0600) 
0 0.0376 (0.0168, 0.0584) 
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Table 2-34 Extensor mechanism efficiency mean differences: PFA versus PS-TKA 
Flexion angle (°) PFA vs PS-TKA EME Mean difference (Nm/NQT)  99% CI 
50 0.0266 (0.0135, 0.0397) 
40 0.0351 (0.0222, 0.0481) 
30 0.0327 (0.0214, 0.0440) 
20 0.0325 (0.0200, 0.0451) 
10 0.0424 (0.0254, 0.0594) 
0 0.0415 (0.0207, 0.0623) 
 
Unexpectedly, the PFA condition also produced significantly greater EME 
than the native knee in this range of motion (see Table 2-17). One 
possible reason for this is the PFA offset the patella more than the native 
knee, thus lengthening the extensor moment arm beyond its pre-existing 
length. Since all the knees were non-arthritic, very little bone would have 
been resected and therefore the possibility of increasing the offset is 
plausible. A large increase in extensor moment arm would in theory 
cause a reduction in resultant force due to the lower quadriceps force 
required to extend the knee. The resultant force data supports this theory 
when compared with the native knee results. The PFA resultant force at 
60°, 30° and 0° was 71.40N (±16.47), 54.66N (±12.68) and 30.09N 
(±9.99), respectively, compared with the native knee data, 91.11N 
(±21.27), 68.64N (±9.65) and 38.28N (±4.44). However, this clear 
difference is not seen when compared with CR-TKA and PS-TKA despite 
there being a significant difference in EME at all three angles of knee 
flexion. The reason for this may be related to the altered knee kinematics 
in terms of the posterior cruciate ligament function and tibial translation 
during mid flexion to full extension resulting in greater magnitude of the 
patellar tendon force, which contributes to the resultant force. 
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This apparent advantage of PFA in mid flexion to full extension 
would theoretically make activities of daily living, which are performed in 
that range of motion, such as level walking, ascending and descending a 
slope, functionally less challenging. However, beyond this range of 
motion, that is, deep to mid flexion the EME of PFA was found to be lower 
than the other conditions and a significant difference was demonstrated 
at 80° when compared with the native knee and CR-TKA. This lower EME 
was associated with a higher resultant force, thus the extensor 
mechanism was much less efficient. The reason for this occurring may 
have been related to the new offset between the patellar button and the 
femoral condyle in deeper flexion, as the patellar button is no longer in 
articulation with the trochlear component and sits deep in the 
intercondylar notch. As a result, the distance between the centre of 
rotation (approximately the transepicondylar axis) and the patella may 
have been relatively shorter than that existing in the native knee, CR-TKA 
and PS-TKA, thus requiring a greater quadriceps force to extend the 
knee. 
The hypothesis regarding CR-TKA and PS-TKA EME was as 
follows: 
 
‘There will be no difference between the extensor moment efficiency for 
CR-TKA compared with PS-TKA. The effect of the intact PCL in the CR-
TKA compared with the cam-post mechanism will not result in a 
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significantly shorter extensor moment arm. Both prostheses will give rise 
to higher patellofemoral resultant forces than PFA or native knee.’ 
 
The results confirm the hypothesis was correct in relation to the 
EME; no difference was identified between CR-TKA and PS-TKA (see 
Table 2-17). In the experimental set up all other variables were constant, 
the only known geometric difference between these two prostheses is the 
cam-post mechanism therefore the conclusion can be drawn that no 
significant difference exists. This finding further corroborates previous 
studies that have also shown no advantage of PS-TKA over CR-TKA 
(Becker et al., 1991; Bolanos et al., 1998). It is also important to consider 
that the subphysiological load used in this experiment may have been too 
small to elicit a difference (although this is unlikely) or another possible 
explanation is the high kinematic variability within the CR-TKA group may 
have resulted in no difference being detected (Stiehl et al., 1995). The 
bimodal variation in EME for both CR-TKA and PS-TKA throughout the 
flexion-extension cycle was consistent with the pattern seen with PFA 
and the native knee, although the degree of variation was less extreme. 
Differences in knee kinematics are likely to play a role but determining the 
specifics of this and the importance of these differences are beyond the 
capabilities of this experimental setup. 
Contrary to the hypothesis, no statistical difference was identified 
between the resultant forces for PFA, CR-TKA and PS-TKA. The force 
data for CR-TKA and PS-TKA were not consistently higher than PFA and 
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the native knee. The only statistical differences detected were for the 
native knee, which showed greater resultant forces than CR-TKA and PS-
TKA at 30° and 0°. The general trend for CR-TKA and PS-TKA resultant 
forces was lower than PFA and the native knee at 120°, 90°, 30° and 0°. 
Only at 60° knee flexion was the resultant force for both TKAs higher. The 
reason for this may be related to the transition point of the patellar button 
onto the trochlear component. Only when the patellar button comes into 
contact with the trochlear prosthesis does the extensor moment arm 
lengthen and consequentially, the resultant force decrease. Prior to that, 
in deep flexion, the patellar button articulates with the native femoral 
condyle within the intercondylar notch resulting in a shorter extensor 
moment arm. 
The peak pressure hypothesis was as follows: 
 
‘Peak pressures will be greater for CR-TKA and PS-TKA compared with 
PFA and native knee throughout the range of knee flexion. The native 
knee will generate the lowest peak pressures.’ 
 
The data confirmed this assumption was correct. The peak 
pressures were consistently high for both TKAs and there was no 
difference between them. The hard bearing surfaces: polyethylene and 
cobalt chrome coupled with the non-congruent patellar button results in 
the transmission of a large force to a small contact area and hence high 
peak pressures. The native knee peak pressures were consistently 
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significantly lower than all three arthroplasty conditions. The main reason 
for this is that the force is distributed over a larger contact surface area 
due to the relative congruency of the native patellofemoral joint. In 
addition, the cartilage of the native patella and trochlea undergo elastic 
deformation when force is applied, which further increases the surface 
area. Previous research has shown that the degree of patellar cartilage 
deformation that occurs is dependent on the load applied (Eckstein et al., 
2005). In this current experiment, the load was kept constant which is 
reflected in the very small variations in peak pressure data for the native 
knee between the data recorded at each flexion angle. This interpretation 
also applies to the PFA data recorded in deep flexion at 120° and 90°. At 
these angles the patellar button articulates with the native femoral 
condyle. Due to the articular cartilage undergoing deformation when in 
contact with the patellar button, the peak pressure generated was 
significantly lower than CR-TKA and PS-TKA. The pressure remained 
greater than the native knee since the patellar button is non-conforming 
and the contact area significantly smaller. 
Interestingly, the peak pressures at 0° were high for all the 
arthroplasty conditions: 7.13MPa(±1.33) (PFA), 6.69MPa(±0.89) (CR-
TKA) and 6.91MPa(±1.24) (PS-TKA). Compared to the native knee peak 
pressure in extension (1.65MPa±0.56) these pressures are four times as 
high. High peak pressures have also been reported by Steinbrück et al., 
(2013) and Becher et al., (2009) with the latter study reporting 
6.28MPa±2.78 for CR-TKA and 5.00MPa±2.67 for PS-TKA. In both of 
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these studies the patella was not resurfaced, which may explain the 
slightly lower pressures reported. Such high peak pressures do not mimic 
normal anatomy, which may explain the association with anterior knee 
pain following TKA (Fuchs et al., 2005; Kulkarni et al., 2000). 
Contrary to previous studies, no difference in peak pressures was 
found between CR-TKA and PS-TKA. Becher et al., (2009) found 
significantly lower peak pressures with PS-TKA compared with CR-TKA 
over a continuous extension cycle from 120° flexion to full extension 
using the Genesis II system (Smith & Nephew, Memphis, Tennessee, 
USA). This study identified lower patellofemoral resultant force 
associated with PS-TKA and attributed this finding to the higher degree 
and more consistent posterior femoral rollback that has previously been 
reported. This theory is also supported by the finite element model study, 
which demonstrated greater posterior femoral rollback reduced 
patellofemoral pressure by increasing the extensor mechanism efficiency 
(D'Lima et al., 2003). The difference in findings between the Becher et al., 
(2009) study and the current investigation are: hamstring loading, 
continuous dynamic motion through the extension cycle rather than at 5 
angles only, different TKA prostheses (Genesis II) and physiological 
extension moment instead of subphysiological load. Any one of these 
factors may account for the differences in the results.  
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The contact area hypothesis was as follows: 
 
‘The contact area will be greater for PFA compared with CR-TKA and 
PS-TKA at higher levels of knee flexion when the patellar button 
begins to articulate with the native femoral condyle. There will be no 
difference between CR-TKA and PS-TKA. The native knee will 
produce the highest contact area throughout the entire range of knee 
flexion.’ 
 
 The postulations regarding contact area for all four conditions were 
correct. The contact area for PFA at 90° was approximately 3 times the 
area seen with CR-TKA and PS-TKA (due to articulation with the native 
femoral condyle), and nearly a third of the contact area size seen with the 
native knee, as shown in Table 2-35. 
 
Table 2-35 Mean Contact Areas at 90° flexion 
Condition Mean Contact Area at 90° flexion (mm2) Standard Deviation 
Native knee 308.41 56.86 
PFA 106.15 37.37 
CR-TKA 36.29 14.13 
PS-TKA 32.06 6.66 
 
 The lack of difference between CR-TKA and PS-TKA at each 
angle of flexion was predictable given the patellofemoral geometry and 
bearing surfaces were identical. This is also true for the PFA at 60°, 30° 
and 0°, when the patellar button transitions from native femoral condyle to 
articulation with the trochlear component. This is summarised in Table 
2-36. 
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Table 2-36 Mean Contact Areas at 60°, 30° and 0° for arthroplasty conditions 
Condition Contact Area (mm2) at 
60° (mean±SD) 
Contact Area (mm2) at 
30° (mean±SD) 
Contact Area (mm2) at 
0° (mean±SD) 
PFA 44.25 (±9.98) 38.61 (±17.50) 19.66 (±9.96) 
CR-TKA 47.78 (±6.12) 30.77 (±11.70) 13.91 (±4.91) 
PS-TKA 44.86 (±15.63) 17.94 (±7.89) 13.31 (±6.05) 
 
 
2.21 Limitations  
The main limitation of this study is the use of cadaveric knees only offers 
an approximation of what actual occurs in vivo. Therefore, applicability to 
the clinical setting is limited especially in this instance where the rig did 
not simulate stair climbing or walking involving the hip, foot and ankle 
motions. 
 The simulation of the flexion-extension cycle in this study was not 
continuous and did not include a weight bearing component. Static 
measurements at the five angles chosen in this study does not allow 
inference to be drawn on what is happening between those angles. 
Therefore, the graphical representations are assumptions of the model 
rather than based on exact data. 
  The experiments were carried out under subphysiological loads, 
which may have been too low to elicit a difference between the TKA 
conditions. Although this is unlikely because the geometry of the load-
carrying specimen would not change greatly due to an increase in the 
load applied. Soudry et al. (1986) investigated the effects of varying load 
application/forces (partially loaded knee representing the seated position 
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and fully loaded simulating stair climbing) at the knee joint on femoral 
rollback and found the difference in TKA function to be negligible. 
Therefore, the extensor mechanism loaded in the physiological cross-
sectional distribution and direction of pull should have been sufficient 
enough to detect a difference. In addition, the rationale for using 
subphysiological loads was a detectable difference at this load is likely to 
infer a difference exists at higher, physiological loads. Furthermore, the 
advantage of using a smaller load allowed for adequate experiment 
repetition while not compromising the experimental construct or causing 
premature sensor degradation. 
 The hamstrings were not loaded in this study and therefore this 
may have caused a degree of imbalance. Lack of hamstring loading may 
increase the risk of the paradoxical anterior tibial translation which may in 
turn change/reduce the lever arm and further reduce EME (Steinbrück et 
al., 2013). However, Gomez-Barrena et al. (2010) found prosthetic 
geometry and cruciate function have a greater influence on changes in 
extensor moment arm length than the effect of the hamstrings. Since the 
hamstrings were unloaded for all the conditions, it is unlikely that this 
would have altered the comparison outcomes significantly.  
 Maintenance of soft tissue tension between and within condition 
testing was essential for accurate data acquisition. Although precautions 
were taken to maintain the retinaculum, such as using the transpatellar 
approach, inadvertent stretching or wear of the soft tissues may have 
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occurred during the sixteen trials per arthroplasty procedure that were 
carried out on each knee.  
 The resultant force, peak pressure and contact area were all 
determined using the Tekscan system. The reliability of the I-Scan sensor 
has been substantiated by a number of studies (Brimacombe et al., 2009; 
Drewniak et al., 2007; Gill et al., 2004; Ostermeier et al., 2006; Wilson et 
al., 2003). Limitations of the sensor include the thickness (0.1mm) and 
sensor output (sensitivity) to alterations in humidity and temperature and 
over time (sensor degradation). The sensors had a tendency to crease or 
become damaged/degraded with repeated use because the flat sensor 
was not contoured to the surface being assessed. In addition, maintaining 
sensor position and confirming sensor orientation were frequent 
challenges (Beck et al., 2005). 
 Other technical limitations that may have affected the results 
include the difference between calibration surface and actual test 
conditions. The calibration surfaces used did not mirror the actual test 
conditions in terms of prosthetic and native joint geometry. The calibration 
set up did not allow for calibration using curved surfaces. The calibration 
could not be performed in an actual knee as it was not feasible to carry 
this out in an Instron load device. 
 Equilibration of the sensors was not performed. Equilibration is the 
process of normalising the output of each sensel to the average 
output of all the sensels on the pad. This is accomplished by applying 
a known uniform pressure to all the sensels and allowing the software 
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to define a scale factor, which is applied to each sensel, resulting in a 
uniform output at that pressure. The bladder device applies the known 
pressure. Performing equilibration without this bladder device is more 
likely to cause unevenness of the sensor’s sensitivity and thus 
erroneous results. However, if the same area on a sensor is loaded 
repeatedly, the unloaded region holds a higher sensitivity and the 
loaded sensels degrade over time. If equilibration is not carried out the 
sensor sensitivity remains uneven. The extent to which repeated 
loading of the same location on the sensor occurred and affected the 
accuracy of sensor output is unknown. 
 
2.22 Conclusion 
I believe this is the first in vitro study to assess the extensor mechanism 
efficiency following patellofemoral arthroplasty. The results show extensor 
mechanism efficiency was significantly greater for PFA between mid 
flexion to full extension (measured at 10° increments from 50° to 0°) 
when compared with the native knee, CR-TKA and PS-TKA. Despite 
previous reports in the literature, no difference was found between CR-
TKA and PS-TKA to support the posterior femoral rollback theory. 
 Due to the nature of the study design, applicability to the clinical 
setting is limited. Instead, the methodology and results of this study will 
provide a benchmark for future, more complex studies that simulate 
activities of daily living and take into consideration motion at the hip, 
ankle and foot. 
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Chapter 3 Systematic Review of the Survival 
Proportions and Complications 
following the Use of Patellofemoral 
Arthroplasty and Total Knee 
Arthroplasty for the Treatment of 
Severe Isolated Patellofemoral 
Arthritis  
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3.1 Abstract 
Objectives 
Patellofemoral joint arthroplasty (PFA) and total knee arthroplasty (TKA) 
are both considered the most effective treatment choices for severe 
isolated patellofemoral arthritis. A previous meta-analysis reported higher 
reoperation and revision rates following PFA and suggested this may be 
related to prosthetic design although this hypothesis has yet to be tested. 
Therefore, the objectives of this study were to identify the survival and 
complication proportions associated with PFA using a new categorisation 
system based on design principles, comparing these proportions with 
those associated with TKA for the treatment of severe isolated 
patellofemoral arthritis, using systematic review methodology. 
 
Methods 
The literature was systematically reviewed to identify studies reporting 
survival and complication proportions following PFA or TKA for the 
treatment of patellofemoral arthritis with minimum follow-up of 0.5 years. 
The National Library of Health search engine was used to search 
MEDLINE from PubMed, EMBASE and CINAHL electronic bibliographic 
databases from date of inception to 1st June 2013. The eligibility criteria 
consisted of Population: skeletally mature patients with symptomatic 
isolated patellofemoral arthritis, Intervention: patellofemoral arthroplasty 
Comparison: total knee arthroplasty and Outcomes: survival data as 
primary outcome and complications, reoperation and functional data as 
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secondary outcomes. Each study was evaluated for quality using the 
GRADE system. Data extraction included patient demographics, 
prosthetic design type (grouped by a combination of design principles: 
inlay/onlay, symmetrical/asymmetrical, anatomical/non-anatomical, 
patient-specific), survival proportions and proportions of disease 
progression, malpositioning/misalignment, persistent pain, aseptic 
loosening, infection and other complications. Number of reoperations and 
functional outcome data were also recorded. The data was analysed 
within the assigned groups and comparisons were made between the 
groups. 
 
Results 
Forty articles met the inclusion criteria. Thirty-six of the studies were 
uncontrolled retrospective case series’, which lowered the quality of the 
evidence, ranging from ‘low’ to ‘very low’ in accordance with the GRADE 
evaluation tool. The data could not be pooled for meta-analysis due to the 
clinical heterogeneity of the data and confounding effect of the variability 
in study designs and length of follow-up time within and between the 
groups. 
 
Analysis based on design showed the inlay patellofemoral arthroplasties 
generally had poorer survival and complication outcomes than the onlay 
designs. Out of the PFA design groups the survival proportion A (revision 
to TKA for disease progression) and survival proportion B (any revision 
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for any reason) were higher in the onlay designs, ranging between 87% 
and 100% in the short term (0 to 5 years) compared with the range 54% 
to 100% associated with the inlay designs. Less data was available for 
mid-term (5 to 10 years) and long-term (greater than 10 years) 
comparison between the groups, although the inlay designs consistently 
demonstrated lower survival proportions in both categories. The lowest 
survival proportions were reported in the inlay asymmetrical non-
anatomical group; long-term survival ranging from 49% to 75%. The 
survival proportions for the onlay, symmetrical non-anatomical group 
(Avon) was the most comparable to TKA. The proportion of complications 
and reoperations was highest in the inlay symmetrical non-anatomical 
group (358 complications and 265 reoperations occurred in 432 knees). 
Functional outcomes between the groups could not be compared due to 
variations in reporting. Overall, where pre- and post-operative scores 
were available, an improvement in function was detected. 
 
 
Conclusions 
This systematic review is the first to analysis the survival and 
complication proportions following PFA with this new design based 
categorisation. The results show inlay, non-anatomical designs do not 
give desirable outcomes. The latest onlay, anatomical design results are 
encouraging, although the follow-up times are relatively short and sample 
sizes small thus limiting the generalisability of the outcomes. The onlay, 
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symmetrical prosthesis provides survival proportions most comparable to 
TKA. The limitations of this study are considerable, such as the degree of 
reporting and selection biases, confounding factors and the clinical 
heterogeneity, and therefore weaken the conclusions drawn.  
 
Further studies that enable data pooling without the need for 
standardising models are required. Ultimately, future research should 
consist of more robust studies in the form of a randomised clinical trial.  
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3.2 Introduction 
The first patellofemoral joint arthroplasties (PFA) were the Lubinus and 
Richards I, designed in 1974 and 1975, respectively, for the treatment of 
severe patellofemoral arthritis. Overall, the clinical outcomes were less 
than satisfactory, mainly due to inappropriate patient selection and 
prosthetic design. Limited understanding of the biomechanics of the 
patellofemoral joint resulted in relatively small, inlaid femoral components 
with deep constraining trochlear grooves. In some instances the groove 
was very shallow causing the patellar component to skid about the 
surface of the trochlear component and maltrack. Symptoms of snapping, 
clunking and subluxation were not uncommonly associated with these 
designs. The lack of fully instrumented systems and an insufficient 
appreciation of the methods needed to balance the soft tissues may have 
also contributed to the high rates of patellar instability and anterior knee 
pain. These complications were the catalyst to changes in design. Newer 
prosthetic designs have larger medial-lateral widths, longer anterior 
flanges and are mainly onlay. These design modifications, along with 
better patient selection have led to improved clinical outcomes. 
Despite these improvements, recent reports have led some 
surgeons to believe TKA is the gold standard treatment. The National 
Joint Registry for England and Wales (NJR) previously suggested the 
revision rate of PFA is almost four times that of TKA at 3 years (Wales, 
2012). Analysis of the NJR data covering 7 years, found unexplained 
pain, rather than disease progression, to be the main cause of early 
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revision following PFA (Baker et al., 2012). However, the cause of this 
pain and accuracy of coding could not be determined from the recorded 
data. Therefore, the questions regarding survival and the occurrence of 
specific complications associated with PFA compared with TKA, and 
whether these vary depending on prosthetic design, still remain 
unanswered.  
Previous authors (Argenson, 2003; Kolettis & Stern, 1992; 
Leadbetter, 2008; Lonner, 2004; Montserrat, 2010; Newman, 2007) have 
attempted to summarise the literature although little inference can be 
drawn with confidence from narrative reviews (Bhandari et al., 2004). A 
recent meta-analysis (Dy et al., 2012) suggested more complications 
occurred following PFA and concluded that the number of complications 
was dependent on prosthetic design. However, the meta-analysis was 
performed using data with high clinical heterogeneity, which may have 
resulted in misleading inferences. The extent of data manipulation that 
was performed on this low quality data, that is, back-transform logistics 
regression using DerSimonian-Laird having stabilised the data using 
Freeman-Tukey-type arcsine square root transformation,  indicates is not 
ideal and increases the risk of misleading data interpretation. 
Furthermore, the study design pooled the groups by ‘generation’ rather 
than design. This term ‘generation’ only bears relation to the inception 
date of the prosthesis and not prosthetic design features; analysis using 
this categorisation method can therefore be misleading. A more practical 
approach is to classify by design characteristics such as inlay/onlay, 
  
213
symmetrical/asymmetrical, non-anatomical/anatomical and patient-
specific. This allows for more appropriate comparisons to be made 
between the PFA prostheses and TKA and ultimately, a more accurate 
determination of whether complications and prosthesis survival are 
associated with implant design.  
This systematic review is the first report to classify and assess 
outcomes by design principles. The aim of this study is to determine the 
primary outcome: survival proportion and secondary outcomes: number 
of complications, reoperations including revisions and functional results 
following PFA and TKA in patients with isolated patellofemoral arthritis. 
 
3.3 Research Questions  
 The following research questions were addressed in this 
systematic review: 
1. What are the survival proportions A and B for the six design 
categories of PFA compared with each other and with TKA in 
patients with severe isolated patellofemoral arthritis? 
2. What are the proportions of the six complications associated with 
the six design categories of PFA compared with each other and 
with TKA in patients with severe isolated patellofemoral arthritis? 
3. What are the reoperation occurrence and functional outcome 
results associated with the six design categories of PFA compared 
with each other and with TKA in patients with severe isolated 
patellofemoral arthritis? 
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3.4 Eligibility Criteria (PICO) 
The eligibility criteria were based on the following PICO 
(population/intervention/comparison/outcome) and study design criteria 
summary. 
 
3.4.1 Population 
 Skeletally mature patients who had received PFA or TKA for 
symptomatic isolated severe patellofemoral arthritis. The underlying 
diagnosis of primary arthritis- idiopathic disease, secondary arthritis due 
to trochlear dysplasia and other patellar instability diagnoses, trauma and 
other conditions resulting in isolated patellofemoral disease. Studies 
involving patients with greater than grade 2 tibiofemoral arthritis 
(bicompartmental disease) at the time of the index procedure were 
excluded. In addition, basic patient demographics such as age, gender, 
underlying diagnosis/aetiology, loss to follow-up and mean follow-up time 
were required to perform a meaningful analysis of the data. 
3.4.2 Intervention 
Commercial patellofemoral arthroplasty (cemented and uncemented) 
involving replacement of both the trochlear and patellar surfaces 
implanted in and after 1974 (year first patellofemoral prosthesis was 
implanted). All studies including trochlear or patellar replacement only 
were excluded. Intervention performed by multiple or single orthopaedic 
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surgeon(s); level of experience was not restricted. The arthroplasty fit into 
one of the following six categories: 
(1) Inlay, symmetrical, non-anatomical (ISN) 
(2) Inlay, asymmetrical, non-anatomical (IAN) 
(3) Inlay, asymmetrical, anatomical (IAA) 
(4) Onlay, symmetrical, non-anatomical (OSN) 
(5) Onlay, asymmetrical, anatomical (OAA) 
(6) Onlay, asymmetrical, patient-specific (OAP) 
Rehabilitation following surgery followed standard local procedure and 
applied to all the patients within the study. 
3.4.3 Comparison 
Commercial total knee arthroplasty (cemented and uncemented) 
involving replacement of femoral and tibial surfaces +/- patellar 
replacement. Intervention performed by multiple or single orthopaedic 
surgeon(s) - level of experience was not restricted. Rehabilitation 
following surgery followed standard local procedure and applied to all the 
patients within the study. 
3.4.4 Outcomes 
3.4.4.1 Primary Outcome Measure 
The survival proportion rather than the survival rate was chosen as the 
primary outcome. The true definition of rate (event/time) requires survival 
data for each year of follow-up. The studies available were expected to 
be predominantly retrospective case series’ and therefore true rate data 
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would not have been reported. In order to accommodate this anticipated 
variation in reporting, without compromising the value of the inferences 
drawn, the survival was accurately defined and calculated as a 
proportion. 
 Specifically, two survival proportions were analysed as the primary 
outcome: 
1. Survival Proportion A, defined as the surviving number of implants, 
that is, the total number of knees minus the number of knees that 
suffered the endpoint event - revision to TKA due to disease 
progression, divided by the total number of knees assessed in the 
sample population. 
2. Survival Proportion B, as the surviving number of implants, that is, 
the total number of knees minus the number of knees that suffered 
the endpoint events - revision any reason to TKA, revision to 
another PFA, additional unicompartmental arthroplasty (UKA), 
removal of PFA or arthrodesis due to any complication (listed in 
secondary outcomes below), divided by the total number of knees 
assessed in the sample population. 
The mean follow-up time for each survival proportion was also recorded 
so that the proportions were appropriately compared in the context of 
time (short-term less than 5 years, mid-term five to ten years and long-
term more than 10 years). 
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(In the event that true survivorship analysis was performed or survival 
rate (event/time) was reported, these were recorded for further 
discussion). 
 
3.4.4.2 Secondary Outcome Measures 
Secondary outcomes consisted of complications, number of reoperations 
including revisions, and functional outcomes. The complications were 
defined as those occurring intra-operatively or post-operatively at any 
time point during the follow-up period. These intra- and post-operative 
complications were categorised into one of the following six commonly 
reported failure mechanisms: 
1. Disease progression 
2. Malpositioning/misalignment (of either the prosthesis or soft tissue 
imbalancing) 
3. Persistent pain 
4. Aseptic loosening of component(s) 
5. Infection (superficial and deep) 
6. Other complications- stiffness, fracture, trauma- dislocation etc. 
 
Any reoperation that took place in the post-operative period was also 
recorded including revisions. All functional outcome data consisting of 
validated scores (such as the WOMAC score, Oxford Knee Score, 
Lysholm Score, American Knee Society Score, UCLA Score and 
Melbourne Patellar Knee Score (Bellamy et al., 1988; Dawson et al., 
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1998; Feller et al., 1996; Insall et al., 1989; Tegner & Lysholm, 1985; 
Zahiri et al., 1998)) and satisfaction data reported was summarised. No 
radiological data was included. 
 
3.4.5 Study Designs 
Randomised clinical trial, non-randomised comparative studies- 
prospective and retrospective, prospective non-comparative and 
retrospective non-comparative studies (case series) with a minimum of 10 
cases to provide true inferences from the data (Guyatt et al., 2008) and 
with at least 0.5 years follow-up were included. All peer-reviewed articles, 
published in English between the inception date of each database and 1st 
June 2013 that met the above PICO eligibility criteria, were included. 
Grey literature, case reports and studies published before 1974 were 
excluded, since prior replacement surgery was likely to involve only a 
patellar prosthesis. All studies had to meet the population, intervention, 
comparison and primary outcome criteria to be included. If the secondary 
outcomes were reported in part, the study was still included providing the 
essential criteria were fulfilled. Studies that involved the use of more than 
one prosthesis were also included to identify whether the results from a 
‘mixed prosthesis’ study were grossly different to any of the single design 
groups. 
 
  
219
3.5 Material and Methods 
3.5.1 Identification of Eligible Studies 
 The National Library of Health search engine was used to search 
MEDLINE from PubMed, EMBASE and CINAHL electronic bibliographic 
databases. These databases were chosen based on credibility and the 
large number of records held. In addition, searches were conducted in 
Web of Science and The Cochrane Library. Two independent academic 
and electronic systems/resources librarians evaluated the systematic 
search strategies and deemed them appropriate. The searches were 
executed on all five databases for eligible literature published between 
the date of their inception and 1st June 2013. In combination with the 
boolean operators  'AND', 'OR' and 'NOT', the following search terms 
were used with truncation, represented by an asterisk, to yield a greater 
number of results: patellofemoral joint, patell*, patellofemoral, patello-
femoral, femoropatell*, femoro-patell*, arthritis, osteoarthritis, arthrosis, 
arthroplasty, replacement, knee and total as shown in section 3.5.2. The 
referenced literature in the included articles was hand searched for other 
eligible articles. The relevance of the referenced literature was 
determined by title first, followed by analysis of the abstract and then full 
text. All duplicates and ineligible articles were excluded. Articles that met 
the eligibility criteria described in section 3.4 were included. 
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3.5.2 Literature Search Strategy 
MEDLINE 
1. MEDLINE; exp PATELLOFEMORAL JOINT/; 235 results. 
2. MEDLINE; (patell* OR patellofemoral OR femoropatell* OR femoro-patell* OR femor 
AND patell*).ti,ab; 15182 
results. 
3. MEDLINE; 1 OR 2; 15193 results. 
4. MEDLINE; exp OSTEOARTHRITIS, KNEE/; 9066 results. 
5. MEDLINE; exp ARTHRITIS/; 191754 results. 
6. MEDLINE; arthrosis.ti,ab; 4191 results. 
7. MEDLINE; 4 OR 5 OR 6; 193960 results. 
8. MEDLINE; (patellofemoral AND arthroplasty).ti,ab; 559 results. 
9. MEDLINE; (patellofemoral AND replacement).ti,ab; 256 results. 
10. MEDLINE; (total AND knee AND arthroplasty).ti,ab; 9489 results. 
11. MEDLINE; (total AND knee AND replacement).ti,ab; 5258 results. 
12. MEDLINE; exp ARTHROPLASTY/ OR exp ARTHROPLASTY, REPLACEMENT, 
KNEE/ OR exp 
ARTHROPLASTY, REPLACEMENT/; 35362 results. 
13. MEDLINE; 8 OR 9 OR 10 OR 11 OR 12; 40040 results. 
14. MEDLINE; 3 AND 7; 2037 results. 
15. MEDLINE; 13 AND 14; 785 results. 
16. MEDLINE; 15 [Limit to: Humans and English Language]; 718 results. 
 
EMBASE 
1. EMBASE; exp PATELLOFEMORAL JOINT/; 2405 results. 
2. EMBASE; (patell* OR patellofemoral OR femoropatell* OR femoro AND patell*).ti,ab; 
17070 results. 
3. EMBASE; 1 AND 2; 2031 results. 
4. EMBASE; exp KNEE OSTEOARTHRITIS/; 14103 results. 
5. EMBASE; exp KNEE ARTHRITIS/; 2324 results. 
6. EMBASE; arthrosis.ti,ab; 5199 results. 
7. EMBASE; 4 OR 5 OR 6; 20952 results. 
8. EMBASE; (patellofemoral AND arthroplasty).ti,ab; 616 results. 
9. EMBASE; (patellofemoral AND replacement).ti,ab; 285 results. 
10. EMBASE; (total AND knee AND arthroplasty).ti,ab; 11022 results. 
11. EMBASE; (total AND knee AND replacement).ti,ab; 6414 results. 
12. EMBASE; exp ARTHROPLASTY/ OR exp KNEE ARTHROPLASTY/; 66801 results. 
13. EMBASE; exp TOTAL KNEE REPLACEMENT/; 11891 results. 
14. EMBASE; 8 OR 9 OR 10 OR 11 OR 12 OR 13; 68046 results. 
15. EMBASE; 3 AND 7; 346 results. 
16. EMBASE; 14 AND 15; 158 results. 
17. EMBASE; 16 [Limit to: Human and English Language]; 146 results. 
 
CINAHL 
1. CINAHL; exp KNEE JOINT/; 4355 results. 
2. CINAHL; (patell* OR patellofemoral OR femoropatell* OR femoro AND patell*).ti,ab; 
2786 results. 
3. CINAHL; 1 AND 2; 606 results. 
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4. CINAHL; OSTEOARTHRITIS, KNEE/; 1581 results. 
5. CINAHL; exp ARTHRITIS/; 25086 results. 
6. CINAHL; arthrosis.ti,ab; 366 results. 
7. CINAHL; 4 OR 5 OR 6; 25335 results. 
8. CINAHL; (patellofemoral AND arthroplasty).ti,ab; 75 results. 
9. CINAHL; (patellofemoral AND replacement).ti,ab; 60 results. 
10. CINAHL; (total AND knee AND arthroplasty).ti,ab; 1781 results. 
11. CINAHL; (total AND knee AND replacement).ti,ab; 1090 results. 
12. CINAHL; exp ARTHROPLASTY/ OR exp ARTHROPLASTY, REPLACEMENT/ OR 
exp ARTHROPLASTY, 
REPLACEMENT, KNEE/; 10893 results. 
13. CINAHL; 8 OR 9 OR 10 OR 11 OR 12; 11194 results. 
14. CINAHL; 3 AND 7; 94 results. 
15. CINAHL; 13 AND 14; 45 results. 
16. CINAHL; 15 [Limit to: (Language English)]; 45 results. 
 
Web of Science 
SET Web of Science Core Collection 
Search History - " PhD SR PFA vs TKA" 
#15 #14 AND Language=(English)  
DocType=All document types; Language=All languages; 
#14 #12 AND #13  
DocType=All document types; Language=All languages;
#13 #3 AND #7  
DocType=All document types; Language=All languages; 
#12 #8 OR #9 OR #10 OR #11  
DocType=All document types; Language=All languages;
#11 TS=(total AND knee AND arthoplasty) OR TI=(total AND knee AND arthroplasty)  
DocType=All document types; Language=All languages; 
#10 TS=(total AND knee AND replacement) OR TI=(total AND knee AND 
replacement)  
DocType=All document types; Language=All languages;
#9 TS=(patellofemoral AND arthroplasty) OR TI=(patellofemoral AND arthroplasty)  
DocType=All document types; Language=All languages; 
#8 TS=(patellofemoral AND replacement) OR TI=(patellofemoral AND replacement)  
DocType=All document types; Language=All languages; 
#7 #4 OR #5 OR #6  
DocType=All document types; Language=All languages;
#6 TS=arthrosis  
DocType=All document types; Language=All languages; 
#5 TS=arthritis  
DocType=All document types; Language=All languages; 
#4 TS=knee osteoarthritis  
DocType=All document types; Language=All languages;
#3 #1 OR #2  
DocType=All document types; Language=All languages; 
#2 TS=(patell* OR patellofemoral OR femoropatell* OR femoro-patell*)  
DocType=All document types; Language=All languages;
#1 TS=patellofemoral joint  
DocType=All document types; Language=All languages; 
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Cochrane Online Wiley Library 
ID Search Total 
#1 patellofemoral arthroplasty OR patellofemoral replacement 67 
#2 patellofemoral osteoarthritis or patellofemoral arthritis or patellofemoral 
arthrosis 
92 
#3 total knee arthroplasty or total knee replacement 2818 
#4 #1 and #2 49 
#5 #2 and #3 47 
#6 #4 or #5 49 
 
3.5.3 Data Extraction 
 Two reviewers (MJ and MFe) (see abbreviation section) 
independently assessed all titles and abstracts for eligibility based on the 
set eligibility criteria. Another reviewer (MC) was available to resolve any 
disparity between selected articles. A more in-depth assessment was 
performed on the full-texts of the selected abstracts. In the event that 
more than one article reported the exact same group of patients, only the 
most up-to-date report was included. 
 The data extracted by the two reviewers included study design, 
patient population details such as baseline demographics and aetiology, 
the type of prostheses used, follow-up time, prosthesis survival, number 
of complications, reoperations including revision, the mechanisms of 
failure for these revisions and functional outcome scores.  
 Reviewer MFe, an orthopaedic academic clinical fellow and MC, 
Professor of Trauma and Orthopaedic Surgery, both had previous 
experience in systematic reviews and therefore were appropriate to be 
involved in the study. Since there was no disparity between eligibility of 
literature included, MC did not participate in selection of the articles 
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assessed. Contributions made by MJ specifically included study design, 
data extraction from the text, figures and tables of all the eligible articles, 
data analysis and interpretation. Data extraction from the eligible articles 
was also performed by MFe. The data summaries were compared and 
any disparities were rechecked. Final validation of the data was 
performed by both MJ and MFe (the reviewers checked an equal number 
of articles each; the allocation of the articles was chosen at random 
except for the article written by MJ). 
3.5.4 Quality Assessment of the Eligible Literature 
Quality assessment of the selected literature was performed using the 
Grading of Recommendations Assessment, Development and 
Evaluations (GRADE) approach. This method of evaluation determined 
the quality of the evidence (as high, moderate, low or very low) and thus 
how confident we were in the results. Each study was independently 
appraised by both reviewers (MJ and MFe). 
3.5.5 Method for Data Analysis 
The clinical heterogeneity between the studies within the groups and 
between the groups, in terms of population/patients (e.g. patient’s pre-
operative history, co-morbidities), intervention (e.g. surgeon 
skill/technique, concomitant procedures, post-operative management), 
outcomes (e.g. length of follow-up) as well as unknown variables, 
negated pooling the data and performing a meta-analysis (see Figure 
3-2). 
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The only data that was summarised within the groups were the patient 
demographics for ease of initial overview comparison. The survival and 
complications data were represented in weighted forest plots for all six 
PFA groups and TKA group. These outcomes were calculated as a 
proportion of the total number of knees within each individual study. The 
data synthesis and forest plots were generated using StatsDirect Ltd. 
StatsDirect statistical software. http://www.statsdirect.com. England: 
StatsDirect Ltd. 2013. 
 
 
3.6 Results 
In total, 1384 publications were identified from the search strategy 
(including those identified in the hand search) prior to removal of 
duplicates. After evaluation, 40 articles were identified as eligible for 
inclusion as summarised in Figure 3-1 PRISMA (Preferred Reporting 
Items for Systematic reviews and Meta-Analyses) flow diagram. Thirty-
seven were retrospective case series of which only one was a 
comparative study, two were prospective case series and one was a 
mixed prospective/retrospective case series. Thirty-three studies reported 
on the use of PFA, 6 on the use of TKA and 1 compared both treatments. 
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3.6.1 PRISMA Flow Diagram 
 
 
Figure 3-1 PRISMA flow diagram 
 
  
 
1364 citations identified  
Database searches: 
- MEDLINE n = 718 
- EMBASE n = 146 
- CINAHL n = 45 
- Web of Science n = 406  
    - Science Citation Index Expanded (SCI-EXPANDED)- 1970-present 
    - Conference Proceedings Citation Index-Science (CPCI-S)- 1990-present 
 
- Cochrane n = 49 
 - Cochrane Reviews 
 - Other Resources (other reviews, clinical trials) 
 
20 citations identified  
 
Hand search: 
- Article references n = 20 
 
 
 
898 citations identified after duplicates removed 
 
105 citations 
screened 
54 full-text articles 
assessed for 
eligibility 
 
40 studies included in 
quantitative synthesis 
 
 
14 full-text articles 
excluded: 
 
1. A narrative review or no 
survivorship data (Argenson, 
2003; Kolettis & Stern, 1992; 
Leadbetter, 2008; Lonner, 2004; 
Montserrat, 2010; Newman, 
2007) 
2. Up-to-date data available 
(Ackroyd, 2005; Argenson et al., 
1995; Sisto & Sarin, 2006; Sisto & 
Sarin, 2007; Sisto & Sarin, 2008) 
3. Revision joint replacement data 
(Hendrix et al., 2008; van 
Jonbergen et al., 2009) 
4. Correspondence letter (Coleridge, 
2002) 
 
 
793 excluded 
based on title and abstract
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3.6.2 Quality Assessment 
A summary of the evaluation is shown in Table 3-1. Each category of 
quality assessment is further discussed below. 
 
3.6.2.1 Study Design Limitations 
Study design limitations assess the risk of bias. All the studies 
demonstrated ‘unclear to high’ risk of bias. The high likelihood of 
reporting and selection bias associated with uncontrolled case series’ 
raised some concern about the results and the applicability to the general 
population. These potential limitations as well as the lack of a comparator 
group for all but one of the studies maintained the low quality rating of all 
of the groups assessed for both outcomes. Therefore, apart from one 
comparative study, the remaining uncontrolled case series’ studies in the 
other groups were deemed as having serious study design limitations. 
3.6.2.2 Inconsistency 
Inconsistency is an assessment of variability or unexplained 
heterogeneity of the outcomes (treatment effects) between the studies 
within each group. The degree of heterogeneity was formally assessed 
using the I2 calculation. An example of the heterogeneity is shown in 
Figure 3-2. This calculation shows an I2 of 79.9%, which represents a 
lack of consistency and thus confirmed the data should not have been 
pooled for meta-analysis. 
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Proportion meta-analysis   
Stratum Responding Total 
1 57 57 Blazina 
2 16 16 Krajca-Radcliffe 
3 24 26 de Winter 
4 35 45 Kooijman 
5 51 59 Cartier 
6 20 20 Utukuri 
7 158 181 van Jonbergen 
 
Stratum Proportion 95% CI (exact) % Weights (fixed, random) 
1 1 0.94 1 14.11 15.66 Blazina 
2 1 0.79 1 4.14 10.91 Krajca-
Radcliffe 
3 0.92 0.75 0.99 6.57 12.97 de Winter 
4 0.78 0.63 0.89 11.19 14.96 Kooijman 
5 0.86 0.75 0.94 14.6 15.76 Cartier 
6 1 0.83 1 5.11 11.88 Utukuri 
7 0.87 0.82 0.92 44.28 17.86 van 
Jonbergen 
 
Fixed effects (inverse variance) 
Pooled proportion = 0.9 (95% CI = 0.87 to 0.93) 
 
Non-combinability of studies 
Cochran Q = 29.83  (df = 6)  P < 0.001 
Moment-based estimate of between studies variance = 0.08 
I² (inconsistency) = 79.9% (95% CI = 51.8% to 88.6%)  
 
(StatsDirect statistical software. http://www.statsdirect.com) 
Figure 3-2 Example of Heterogeneity in ISN Survival Proportion 
This figure shows the degree of statistical heterogeneity found in the the ISN group for 
survival proportion. Represented as I2 and Q values. Both calculations demonstrate high 
heterogeneity, suggesting pooling of the data is not appropriate. 
 
The I2 values for survival proportion A and B and complications are 
summarised in Appendix VI Table 6-44. The level of inconsistency 
demonstrated in this table shows the variation in outcome among the 
studies within each group. This may be secondary to the differences in 
clinical variables such as patient demographics and pre-intervention 
treatments. Due to the degree of inconsistency, each study was labelled 
as ‘unexplained heterogeneity’ and the low quality of evidence rating 
maintained. 
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3.6.2.3 Indirectness 
Indirectness is the assessment of applicability of the evidence to the 
research questions and a determination of whether the outcomes are 
identified directly from a comparative study or a combination of two 
comparative studies. The four sources of indirectness are: 
1. Differences in population applicability 
2. Differences in intervention 
3. Differences in outcomes 
4. Indirect comparison 
The sample populations in each of the studies matched the eligibility 
criteria and were therefore not found to be grossly different. All 
interventions in the studies reviewed were directly relevant. All the 
outcome data was obtained directly, no surrogate outcomes or endpoints 
were used in place of the primary outcome. All the groups were labelled 
as direct, except for those that did not offer any complication data and 
thus the low quality rating upheld.  
 
3.6.2.4 Imprecision 
Imprecision is the assessment of the investigator’s confidence in the 
estimate of effect. Normally, the factors considered are confidence 
interval widths and optimal information size. Since none of the studies 
were randomised clinical trials or offered inferential statistics, applying 
this quality assessment to case series data becomes challenging. 
However, general observations can be made regarding sample size. 
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Based on the outcomes of interest, the majority of studies had reasonable 
sample sizes for case series’. However, two groups (which also had the 
lowest number of studies) inlay asymmetrical anatomical and onlay 
asymmetrical patient-specific had very low patient numbers- 51 and 43, 
respectively (see Table 3-2). Although formal optimal information size 
was not calculated, such low numbers are unlikely to reflect a true 
estimation of survival proportions in these groups. This limitation supports 
the low quality of evidence rating. 
3.6.2.5 Publication Bias 
Publication bias assessment is the detection of systematic over-
estimation or under-estimation of benefit or harm of an intervention as a 
result of the selective publication of literature. Formal computation of 
publication bias was not performed for this systematic review for three 
reasons: 
1. The heterogeneity of the data 
2. Only peer-reviewed studies were included and therefore 
unpublished data would not have been detected based on the 
search strategy used. The decision not to include data from 
unpublished studies was based on the associated risk of 
introducing bias. The absence of peer-reviewing, that is, the 
refereeing process means there is no systematic method of 
vetting the quality of the study prior to inclusion in the systematic 
review. 
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3.  An inadequate number of studies per group were available to 
assess bias using the funnel plot method 
For these reasons, all the groups were rated as ‘unclear’ risk of 
publication bias. This risk is plausible due to the majority of the studies 
involved the operating surgeon(s) reporting their outcomes; failed or poor 
outcomes are less likely to be published. The associated risk of 
publication bias with this level of research maintained the low quality of 
evidence grading. 
3.6.2.6 Overall Quality of Evidence 
All the studies identified were observational and therefore automatically 
defined as low quality evidence. None of the quality assessment factors 
warranted upgrading the quality of evidence to moderate and therefore 
the low rating was maintained in six out of nine of the groups. The 
remaining three groups were further downgraded to very low for the 
following reasons. The inlay asymmetrical anatomical and onlay 
asymmetrical patient-specific groups were further downgraded because 
of the likely imprecision (overall small samples). The onlay asymmetrical 
anatomical group was downgraded due to three out of five of the studies 
omitting complication data. 
 
  
231
Table 3-1 GRADE Quality Assessment of Studies 
 
Quality Assessment 
 
 
Quality 
 
No. of  
Observational 
Studies 
 
 
Study Design 
 
Outcomes 
 
Study 
Design 
Limitations 
 
Inconsistency 
 
Indirectness 
 
Imprecision 
 
Publication 
bias 
 
No. of 
treated 
patients 
 
No. of 
comparators 
 
Inlay, symmetrical, non-anatomical 
7 Retrospective Survival Yes Yes No Unclear Unclear 432 - Low 
Complications Yes Yes No Unclear Unclear Low 
Inlay, asymmetrical, non-anatomical 
5 Retrospective Survival Yes Yes No Unclear Unclear 203 - Low 
Complications Yes Yes No Unclear Unclear Low 
Inlay, asymmetrical, anatomical 
2 Retrospective (1) 
Retro/Prospective 
(1) 
Survival Yes Yes No Yes Unclear 67 - Very Low 
Complications Yes Yes No Yes Unclear Very Low 
Onlay, symmetrical, non-anatomical 
9 Retrospective (8) 
Prospective (1) 
Survival Yes Yes No Unclear Unclear 488 - Low 
Complications Yes Yes No Unclear Unclear Low 
Onlay, asymmetrical, anatomical 
5 Retrospective (4) 
Prospective (1) 
Survival Yes Yes No Unclear Unclear 164 - Very Low 
Complications Yes Yes No Unclear Unclear Very Low 
Onlay, asymmetrical, patient-specific 
2 Retrospective Survival Yes Yes No Yes Unclear 47 - Very Low 
Complications Yes Yes No Yes Unclear Very Low 
Mixed group 
3 Retrospective Survival Yes Yes No Unclear Unclear 239 - Low 
Complications Yes Yes No Unclear Unclear Low 
Total knee arthroplasty 
6 Retrospective Survival Yes Yes No Unclear Unclear 212 - Low 
Complications Yes Yes No Unclear Unclear Low 
Comparison 
1 Retrospective Survival No - No Unclear Unclear 23 22 Low 
Complications No - No Unclear Unclear Low 
1Study Design Limitations: Yes = serious limitations; No = no limitations   2Inconsistency: Yes = unexplained heterogeneity; - = not applicable 
3Indirectness: No = Direct   4Imprecision: Yes = Uncertainty; Unclear = Potential uncertainty   5Publication bias: Unclear = plausible bias 
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3.6.3 Study Characteristics 
The specific prostheses in each category are listed in Appendix VI in 
Table 6-40. The numbers of studies and knees in each group varied 
considerably: a total of seven studies and 432 knees were included in the 
Inlay Symmetrical Non-anatomical (ISN) PFA group, five studies and 203 
knees in the Inlay Asymmetrical Non-anatomical (IAN) PFA group, two 
studies and 67 knees in the Inlay Asymmetrical Anatomical (IAA) PFA 
group, ten studies and 511 knees in the Onlay Symmetrical Non-
anatomical (OSN) PFA group, five studies and 164 knees in the Onlay 
Asymmetrical Anatomical (OAA) PFA group and two studies and 47 
knees in the Onlay asymmetrical patient-specific (OAP) PFA group. A 
total of seven studies and 234 knees were included in the TKA group. 
Three studies had a mixture of PFA designs and were therefore 
combined as a separate category with a total of 239 knees. The 
comparative study, comprised of 23 Onlay symmetrical non-anatomical 
PFAs and 22 TKA, were included and analysed in the respective groups 
above. Across all the groups the percentage of female patients was 
higher than males, reflecting the known gender disparity demographics in 
the wider population. The mean ages and age ranges varied between the 
groups. For example, a twenty-year difference was found between the 
mean age of the OAP group (47.0 years) compared with the TKA group 
(67.7 years). In addition, the follow-up time differed between the groups, 
the ISN group had the longest mean follow-up (10.1 years) and the OAA 
group had the shortest (1.9 years). These differences in patient 
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characteristics and follow-up time were taken into consideration in the 
interpretation of the results, particularly the survival data. In addition, the 
number of lost to follow-up/excluded cases was much higher in the ISN 
group (over 26%) compared with all the other groups. Such high 
quantities of data losses are likely to introduce a degree of reporting bias. 
The summary demographics are shown in Table 3-2. The most common 
aetiology was idiopathic arthritis followed by patellar instability across all 
the groups that reported underlying pathology, as shown in Table 3-3. 
 The number of surgeons performing surgery was often not 
reported; where this information was recorded the number varied from 
single to multiple surgeons (see Appendix VI, Table 6-41). The prosthesis 
type and fixation method, and procedures performed prior to, 
concomitantly and after the index procedure, including soft tissue and 
bony realignment, are also recorded in Appendix VI in Table 6-41. The 
number of procedures performed prior to the index operation was 
greatest in the ISN group; a total of 513 procedures were carried out. 
However, this figure is disproportionately high compared to the other 
groups assessed. 
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Table 3-2 Summary of population demographics based on designated groups 
 
Category 
 
ISN 
 
 
IAN 
 
IAA 
 
OSN 
 
OAA 
 
OAP 
 
Mixed 
 
TKA 
Studies 7 5 2 10* 5 2 3 7* 
References (Blazina et al., 1979; 
Cartier et al., 2005; 
de Winter et al., 
2001; Kooijman et 
al., 2003; Krajca-
Radcliffe & Coker, 
1996; Utukuri et al., 
2008; van 
Jonbergen et al., 
2010b) 
(Argenson et 
al., 2005; 
Board et al., 
2004; Smith 
et al., 2002; 
Tauro et al., 
2001; van 
Wagenberg 
et al., 2009) 
(Charalambous 
et al., 2011; 
Merchant, 2005) 
(Ackroyd et al., 2007; 
Hollinghurst et al., 2007; 
Nicol et al., 2006) 
(Dahm et al., 2010; Gao 
et al., 2010; Leadbetter 
et al., 2009; Mont et al., 
2012; Odumenya et al., 
2010; Sarda et al., 2011; 
Starks et al., 2009) 
(Beitzel et al., 
2013; 
Hofmann et 
al., 2009; 
Mofidi et al., 
2012; Monk et 
al., 2012; 
Williams et al., 
2013) 
(Butler & 
Shannon, 
2009; Sisto 
& Sarin, 
2010) 
(Arciero & 
Toomey, 
1988; 
Arnbjörnsso
n & Ryd, 
1998; 
Mohammed 
et al., 2008) 
(Dahm et al., 
2010; Dalury, 
2005; Laskin & 
van Steijn, 
1999; Meding 
et al., 2007; 
Mont et al., 
2002; Parvizi 
et al., 2001; 
Thompson et 
al., 2001) 
Patients 480 191 51 431 143 43 225 214 
Knees 587 228 67 529 167 47 254 245 
Knees LTF§/excluded 155 25 0 18 3 0 15 11 
Remaining knees 432 203 67 511 164 47 239 234 
Age (yrs) 54.3 64.8 55.5 62.4 59.8 47 60.7 67.7 
Weighted Age (yrs) 
(mean, range) 
52.5 
(22.0, 90.0) 
63.6 
(21.0, 87.0) 
58.7 
(26.0, 84.0) 
63.2 
(27.0, 88.0) 
59.1 
(34.0, 84.0) 
47.0 
(23.0, 63.0) 
60.4 
(22.0, 86.0) 
67.7 
(44.0, 89.0) 
% of females  74.9 77.1 85.2 78.1 61.6 67.3 69.8 75.1 
Weighted % of females  
(mean, range) 
67.0 
(47.1, 94.1) 
73.0 
(54.4, 87.5) 
84.3 
(82.9, 87.5) 
80.5 
(70.5, 88.2) 
62.3 
(36.4, 75.0) 
67.4 
(61.9, 72.7) 
70.5 
(66.0, 75.2) 
75.4 
(66.7, 83.9) 
Follow-up (yrs) 9.1 6.8 3.3 4.2 2.1 8.2 4.8 5.0 
Weighted Follow-up (yrs) 
(mean, range) 
10.1 
(0.7, 30.6) 
9.2 
(0.2, 20.0) 
2.9 
(0.4, 6.3) 
4.8 
(1.0, 10.0) 
1.9 
(0.5, 4.3) 
8.2 
(3.0, 14.9) 
4.8 
(0.5, 13.0) 
5.3 
(2.0, 12.0) 
*Includes data from comparative study 
§Lost to follow-up  
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Table 3-3 Detailed population demographics for each study 
Author 
Year 
 
 
Study Design Implant  No. of 
knees/ 
subjects 
No. of 
knees/ 
subjects 
excluded 
Mean age 
(yrs) 
M:F 
ratio 
Primary PFOA*/ 
Secondary PFOA- 
patellar instability/ 
Secondary PFOA- 
trauma/ Other 
Knees or subjects 
Isolated 
(I) or ≤ 
Grade 2 
TFOA (T) 
Mean 
follow-up 
(yrs) 
Lost to 
follow-up 
(LTF) or not 
included 
  
Inlay, symmetrical, non-anatomical 
Blazina 
1979 
Retrospective Richards I and II 85/85 
57/55 
28/- 39 
(19-81) 
- - I 1.8 
(0.7-3.5) 
28 not 
reviewed 
Krajca-
Radcliffe 
1996 
Retrospective Richards I and II 
(Bechtol I and II) 
32/25 
16/13 
16/12 64 
(42-84) 
2:11 10/1/2/0 I 5.8 
(2.0-18.1) 
5 LTF 
4 excluded 
2 deceased 
1 declined 
de Winter 
2001 
Retrospective Richards II 35/33 
26/24 
9/9 59 
(22-90) 
5:19 18/7/1/0 T 11.1 
(0.9-19.8) 
9 deceased 
Kooijman 
2003 
Retrospective Richards II 56/51 
45/43 
11/8 50 
(30-77) 
27:24 - T 17.0 
(15.0-21.0) 
7 deceased 
1 excluded  
Cartier 
2005 
Retrospective Richards II 117/108 
59/50 
-/38 60 
(36-81) 
9:41 7/41/3/8 
 
I 10.0 
(6.0-16.0) 
33 LTF 
5 deceased 
Utukuri 
2008 
Retrospective Richards II 20/17 0 56 
(43-65) 
1:16 16/0/1/0 
 
I 4.4 
(2.0-7.0) 
0 
van Jonbergen 
2010 
Retrospective Richards II 185/161 
181/157 
4/4 52 
(±14) 
59:98 
 
138/21/22/0 
 
T 13.3 
(2.0-30.6) 
4 LTF 
 
Inlay, asymmetrical, non-anatomical 
 
Tauro 
2001 
Retrospective Lubinus 76/59 
62/48 
14/11 66 
(50-87) 
10:49 74/0/2/0 T 7.5 
(5.0-10.0) 
11 deceased 
Smith 
2002 
Retrospective Lubinus 45/34 
29/21 
16/13 72 
(42-86) 
- 44/0/1/0 T 4.1 
(0.5-7.5) 
5 deceased 
7 excluded 
1 LTF 
Board 
2004 
Retrospective Lubinus 17/12 0 66 
(37-82) 
2:10 13/3/1/0 
76/18/6/0 
I 1.6 
(0.2-4.7) 
0 
Argenson 
2005 
Retrospective Autocentric  66/66 
57/57 
9/9 57 
(21-82) 
26:31 18/21/18/0 I 16.2 
(12.0-20.0) 
9 deceased 
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Van 
Wagenberg 
2009 
Retrospective Autocentric II 24/20 0 63 
(38-81) 
3:21 20/0/4/0 T 4.8 
(2.0-11.0) 
0 
Inlay, asymmetrical, anatomical 
Merchant 
2005 
Retrospective (8) 
Prospective (8) 
LCS 16/16 0 47  
(26-81) 
2:14 0/12/2/1  
1 unknown 
T 4.5 
(2.8-6.3) 
0 
Charalambous 
2011 
Retrospective LCS  51/35 0 64 
(47-84) 
6:29 51/0/0/0 T 2.1 
(0.4-5.0) 
0 
Onlay, symmetrical, non-anatomical 
Nicol 
2006 
Prospective 
(appears 
retrospective) 
Avon 103/79 0 68 
(46-84) 
10:69 99/3/1/0 
96/3/1/0 
I 7.1 
(5.5-8.5) 
0 
Ackroyd 
2007 
Prospective Avon 109/85 
83/63 
26/22 
 
68 
(46-86) 
10:75 106/2/1/0 
 
T 5.2 
(5.0-8.0) 
 
10 deceased 
  5 LTF 
  7 excluded 
Hollinghurst 
2007 
Retrospective 
(data retrieved 
from a database) 
Avon 12/12 0 73 
(55-88) 
- - I 3.8 
(2.0-4.8) 
0 
Leadbetter 
2009 
Retrospective Avon 79/70 0 58 
(34-77) 
18:52 52/22/5/0 T 3.0 
(2.0-5.5) 
0 
Starks 
2009 
Prospective Avon 37/29 0 66 
(30-82) 
8:21 - I 2.0 
(2yr f/up) 
0 
Odumenya 
2010 
Retrospective Avon 67/44 
50/32 
17/12 66 
(42-88) 
9:23 37/0/3/0 
10 unknown 
T 5.3 
(2.0-10.0) 
6 deceased 
6 LTF 
Gao 
2010 
Retrospective Avon 11/11 0 54 
(46-74) 
2:9 11/0/0/0 I 2.0 
(1.0-3.9) 
0 
Sarda 
2011 
Retrospective Avon 45/41 
44/40 
1/1 62 
(43-84) 
13:31 - T 4.5 
(3.0-8.0) 
1 deceased 
Mont 
2012 
Retrospective Avon 43/37 0 49 
(27-67) 
8:29 39/0/4/0 I 7.0 
(4.0-8.0) 
0 
Onlay, asymmetrical, anatomical 
Hofmann 
2009 
Retrospective Natural Knee II 40/34 0 61 
(34-84) 
- - I 2.5 0 
Monk 
2012 
Retrospective FPV 15/8 0 69 
(61-80) 
2:6 - I 3.5 
(1.5-4.3) 
0 
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Mofidi 
2012 
Retrospective FPV 34/28 0 - 10:18 - I - 
(0.5-1.0) 
0 
Williams 
2013 
Retrospective FPV 53/48 0 63 
(48-81) 
14:34 ?/34/0/0 T 2.1 
(0.5-4.1) 
0 
Beitzel 
2013 
Prospective Journey 25/25 
22/22 
3/3 46 
(28-67) 
14:8 8/14/0/0 T 2.0 1 late infection 
1 converted to 
TKR (18m) 
1 prostate Ca 
Onlay, asymmetrical, patient-specific 
Butler 
2009 
Retrospective Custom Performa 
Knee 
22/21 0 49 
(35-63) 
8:13 12/6/4/0 I 5.0 
(3.0-nr) 
0 
 
  
Sisto 
2010 
Retrospective Kinematch 25/22 0 45 
(23-51) 
@time of 
index PFA 
6:16 - T 11.3 
(7.8-14.9) 
0 
Mixed group 
Arciero 
1988 
Retrospective Richards II (14) 
CSF-Wright (11) 
31/28 
25/22  
6/6 62 
(33-86) 
7:15 5/14/2/4 
 
T 5.3 
(3.0-9.0) 
6 LTF 
Arnbjornsson 
1998 
Retrospective Richards I and II 
(85) 
Lubinus (18) 
Miscellaneous 
other (10) 
-/106 
113/97 
-/9 63 
(22-86) 
33:64 83*/0/10/20 
23pts had rec. 
dislocation 
I 7.0 
(3.0-13.0) 
9 deceased 
Mohammed 
2008 
Retrospective Lubinus (46) 
Avon (25) 
FPV (30) 
101/91 0 57 ≈ 
25:76 
- T 2.0 
(0.5-8.0) 
0 
Total knee arthroplasty 
Meding  
2007 
Retrospective AGC (26) 
Legacy (7) 
33/27 1/1 52 
 
6:21 - T 6.2 
(2.0-12.0) 
1 deceased 
Laskin 
1999 
Retrospective Genesis 53/53 
48/48 
5/5 67 
(54-85) 
- - T 7.4 
(3.0-9.5) 
2 deceased  
2 excluded 
1 LTF 
 
Thompson 
2001 
Retrospective LCS 33/31 0 73 
(58-89) 
5:26 - T 1.7 0 
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Mont 
2002 
Retrospective Porous Coated 
Anatomic (9) 
Duracon (18) 
Insall-Burstein II 
(3) 
34/27 0 73 
(59-88) 
9:18 - T 6.8 
(4.0-11.1) 
0 
Dalury 
2005 
Retrospective Press Fit Condylar 33/25 0 70 
(54-81) 
8:17 - T 5.2 
(3.8-8.4) 
0 
Parvizi 
2001 
Retrospective Press Fit Condylar 
(21) 
Genesis (6) 
Total Condylar (4) 
37/29 
31/24 
6/5 70 
(47-85) 
5:19 - I 5.2 
(2.0-12.0) 
4 excluded 
1 declined 
 
Comparison 
Dahm 
2010 
Retrospective Avon (23) 
 
-/23 0 60 
(39-81) 
- - T 2.4 
(2.0-4.1) 
0 
Dahm 
2010 
Retrospective Zimmer (22) 
SIGMA 
-/22 0 69 
(44-83) 
- - T 2.3 
(2.0-2.8) 
0 
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3.6.4  Survival Proportion Outcome 
Survival Proportion A (endpoint revision to TKA for disease progression) 
and Survival Proportion B (endpoint revision surgery to TKA for any 
reason, PFA, additional unicompartmental knee arthroplasty (UKA) 
arthrodesis or removal of prosthesis) and survivorship analysis (where 
reported) are recorded in Table 3-4. A general overview of the survival 
proportions for each group is clearly illustrated in Figure 3-3 and Figure 3-
4 forest plots (corresponding with Table 3-5 and Table 3-6). Each forest 
plot consists of the studies analysed within a design group. The size of 
the black square signifies the relative proportional representation (sample 
size) of the study within the group. Each black square (study) has 
horizontal bars, which represent the confidence intervals between which 
the estimated mean survival proportion lies. Studies lying to the far right 
of the forest plot illustrate high survival proportion such as the OSN and 
TKA groups in Figure 3-3. In contrast, the ISN and IAN groups have lower 
and more varied survival proportions and this difference between the 
groups becomes more evident in the survival proportion B forest plots 
Figure 3-4. Particularly for the IAN group, the survival proportions have 
lowered considerably to between the 50% and 75% mark (Figure 3-4). 
 
The following analysis assessed the data in more depth, taking into 
consideration the degree of variation in follow-up time within and between 
the groups. For example, the ISN group ranged from 1.8 years to 17 
years follow-up with 78% to 100% survival proportion, whereas the OAA 
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group was 0.5 to 3.5 years with 92% to 100% survival proportion. A 
comparative evaluation of these survival proportions, without taking into 
account the disparity in follow-up time would be meaningless. For this 
reason the survival proportions results were interpreted in the context of 
short-term (less than 5 years), mid-term (5 to 10 years) and long-term 
(greater than 10 years) follow-up. 
 
Inlay symmetrical non-anatomical 
Prostheses: Richards I and II (two studies); Richards II (five studies) 
Survival Proportion A: The short-term survival proportion A result for two 
studies (Blazina et al., 1979; Utukuri et al., 2008) were 100% at mean 
follow-up times 1.8 years and 4.4 years. The mid-term results were 100% 
and 86% at mean follow-up 5.8 years and 10 years, respectively (Cartier 
et al., 2005; Krajca-Radcliffe & Coker, 1996). Beyond 10 years the 
survival proportion A was lower, 78%, 87% and 92% at 17.0, 13.3 and 
11.1 years follow-up, respectively (de Winter et al., 2001; Kooijman et al., 
2003; van Jonbergen et al., 2010b). 
 
Survival Proportion B: The results for survival proportion B (all reasons for 
revision) were lower, suggesting other reasons for failure other than 
disease progression were the cause. The short-term survival proportion B 
results varied from 87% at 1.8 years with the Richards I and II (Blazina et 
al., 1979) to 100% at 4.4 years follow-up with the Richards II (Utukuri et 
al., 2008). The main known differences between the two studies that 
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could have influenced the results were sample size and prostheses type. 
The Blazina study involved 57 knees whereas the Utukuri study only 
assessed 20 knees. The former study used both Richards I and II 
prostheses whereas the latter only implanted the Richards II. The mid-
term survival proportion B in the Krajca-Radcliffe & Coker study revealed 
a reduction from 100% survival proportion A to 94%. Interestingly, this 
study also involved the use of both the Richards I and II prostheses. The 
number of cases reported to have malpositioning/misalignment 
complications in this study and the Blazina study was disproportionally 
higher than the proportions reported in the other studies in this group (see 
Table 3-10 and complications analysis section 3.6.5). The other mid-term 
study (Cartier et al., 2005) reported a survival proportion B of 85% at 10 
years; a reduction of 1% compared to survival proportion A was seen due 
to malpositioning/misalignment. Long-term follow-up results showed 
survival proportion B remained the same at 92% at 11.1 years (de Winter 
et al., 2001), 76% at 13.3 years compared to 85% survival proportion A 
(van Jonbergen et al., 2010b) and 62% at 17 years from 78% survival 
proportion A (Kooijman et al., 2003). Malpositioning/misalignment and 
‘other’ complications appeared to be associated with the decrease in 
survival in both of these studies, resulting in a high number of revision 
PFAs. 
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Inlay asymmetrical non-anatomical 
Prostheses: Lubinus (three studies); Autocentric (one study); Autocentric 
II (one study) 
Survival Proportion A: Three short-term follow-up studies reported 
survival proportion A as 71% (Autocentric II), 76% (Lubinus) and 90% 
(Lubinus) at 4.8, 1.6 and 4.1 years, respectively (Board et al., 2004; 
Smith et al., 2002; van Wagenberg et al., 2009). The survival appears to 
vary considerably. Disease progression in 30% of patients as 
demonstrated in the former study (van Wagenberg et al., 2009) is very 
high and may be the result of poor patient selection given the presence of 
grade II tibiofemoral disease noted in this patient population. The mid-
term results from a single study demonstrated 93% survival at 7.5 years 
(Tauro et al., 2001) and the long-term study reported survival proportion 
of 75% at 16.2 years (Argenson et al., 2005).   
 
Survival Proportion B: The short-term results showed large decreases in 
survival 71% to 54%, 76% to 71% and 90% to 76% (Board et al., 2004; 
Smith et al., 2002; van Wagenberg et al., 2009). The main cause for this 
decrease in all three studies was malpositioning/misalignment. The mid-
term study demonstrated a 21% reduction in survival to 72% (Tauro et al., 
2001) due to a considerable number of knees suffering 
malpositioning/misalignment (15 knees) and persistent pain (7 knees) 
requiring revision mainly to another PFA. The long-term result was 49% 
at 16.2 years follow-up, reduced from 75% survival proportion A 
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(Argenson et al., 2005). Aseptic loosening and ‘other’ complications were 
associated with this decrease in survival and led to revisions to TKA and 
another PFA. This group demonstrated the lowest survival proportions 
when compared with the other five PFA design groups and TKA. The 
complications resulting in the most revisions were disease progression 
(31 knees) and malpositioning (24 knees). 
 
Inlay asymmetrical anatomical 
Prosthesis: LCS (two studies) 
Survival Proportion A: Two studies reported on the short-term outcomes 
of the LCS prosthesis (Charalambous et al., 2011; Merchant, 2005), one 
of which was performed by the designing surgeon (Merchant, 2005). This 
article stated 100% survival proportion A at 4.5 years; the independent 
study reported 96% survival at 2.1 years. 
 
Survival Proportion B:  Whilst the designing surgeon’s study maintained 
100% survival, the independent study demonstrated a significant 
decrease to 67% at 2.1 years. Persistent pain was the most common 
complication associated with revision, occurring in 12 out of the 17 knees 
revised. 
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Onlay symmetrical non-anatomical 
Prosthesis: Avon (nine studies) 
Survival Proportion A: Five studies reported short-term follow-up survival 
data ranging from 95% to 100% between 2.0 to 4.5 years (Gao et al., 
2010; Hollinghurst et al., 2007; Leadbetter et al., 2009; Sarda et al., 2011; 
Starks et al., 2009). The four mid-term follow-up studies demonstrated 
88% to 96% survival for mean follow-up time 5.2 to 7.1 years (Ackroyd et 
al., 2007; Mont et al., 2012; Nicol et al., 2006; Odumenya et al., 2010). 
No long-term follow-up studies were available for evaluation.  
 
Survival Proportion B: There was not a large difference in the survival 
proportion B compared to survival proportion A, short-term follow-up 
results ranged from 94% to 100% and mid-term from 86% to 96%. The 
small decrease in survival was not associated with one specific 
complication. There were no reports of infection; all other complications 
(malpositioning/misalignment (3 knees), persistent pain (5 knees), aseptic 
loosening (5 knees) and other (3 knees)) contributed in comparable 
proportions. 
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Onlay asymmetrical anatomical 
Prostheses: Natural Knee II (one study), Femoro Patella Vialla (three 
studies), Journey (one study) 
 
Survival Proportion A: All the follow-up times for the five studies reviewed 
were short ranging from 0.5 years to 3.5 years (Beitzel et al., 2013; 
Hofmann et al., 2009; Mofidi et al., 2012; Monk et al., 2012; Williams et 
al., 2013). Survival proportion A was 100% for all but one study, which 
reported survival of 92% at 2.1 years (Williams et al., 2013). 
 
Survival Proportion B: The survival proportion B remained at 100% for 
three of the studies (Beitzel et al., 2013; Mofidi et al., 2012; Monk et al., 
2012) with follow-up times of 0.5-1.0, 2.0 and 3.5 years. A decrease in 
survival from 100% to 98% at 2.5 years due to ‘other’ complications (2 
knees) was seen in one study (Hofmann et al., 2009). In another study, 
two knees requiring revision surgery for persistent pain resulting in a drop 
in survival from 92% to 87% at 2.1 years (Williams et al., 2013). 
 
Onlay asymmetrical patient-specific 
Prostheses: Custom Performa Knee (one study), Kinematch (one study) 
Survival Proportion A: Two customised prostheses were reviewed in this 
group: mid-term results of the Custom Performa Knee showed 100% 
survival proportion A at mean 5.0 years (Butler & Shannon, 2009) and 
long-term results for the Kinematch was also 100%(Sisto & Sarin, 2010). 
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Survival Proportion B: The Kinematch study maintained the reported 
100% survival at 11.3 years, however the Custom Performa Knee study 
showed a drop to 95% survival proportion B due to one knee requiring 
revision to another PFA for an ‘other’ complication. 
 
Mixed group 
Prostheses: Richards I and II, CSF-Wright, Lubinus, Avon, FPV and 
miscellaneous other (not specified) 
Survival Proportion A: The mixed group consisted of three studies 
involving more than six different prostheses, belonging to different design 
groups. One study involving the use of Lubinus, Avon and FPV reported a 
96% survival proportion A at 2.0 years (Mohammed et al., 2008). The 
mid-term results of the remaining two papers were 97% and 100% for 
survival proportion A at 7.0 and 5.3 years follow-up, respectively (Arciero 
& Toomey, 1988; Arnbjörnsson & Ryd, 1998).  
 
Survival Proportion B: The short-term study remained at 96% survival. 
One mid-term study demonstrated a decrease in survival from 100% to 
80%. Three revisions involving additional unicompartmental arthroplasties 
were performed for disease progression and two other revisions to 
another PFA were carried out for malpositioning. The other mid-term 
study survival decreased to 92% due to ten knees (out of 113 knees 
assessed) suffering persistent pain requiring revision surgery. Six knees 
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underwent another PFA, two knees had TKA surgery and one had the 
prosthesis removed or arthrodesed. 
 
Total Knee Arthroplasty 
Prostheses: Anatomical Graduated Component (AGC), Legacy, Genesis, 
Low Contact Stress (LCS), Porous Coated Anatomic, Duracon, Insall-
Burstein II, Press Fit Condylar (PFC), Total Condylar 
Survival Proportion B: All but one of the six studies in this group reported 
100% survival proportion B (Dalury, 2005; Laskin & van Steijn, 1999; 
Meding et al., 2007; Mont et al., 2002; Thompson et al., 2001). Parvizi et 
al. 2001 reported 94% survival proportion due to one case of 
malpositioning and another suffering aseptic loosening, both requiring 
revision surgery. 
 
Comparison 
Prostheses: Avon, Zimmer TKA and SIGMA 
Survival Proportion: The only comparative study in this systematic review 
demonstrated 100% survival proportion for both the PFA and TKA groups 
at short-term follow-up of 2.4 and 2.3 years, respectively as shown in 
Table 3-5, Table 3-6, Figure 3-3 and Figure 3-4. 
 
  
248
 
Table 3-4 Survival Proportions and Survivorship 
Author 
Year 
Implant Follow-
up 
(yrs) 
Survival 
Proportion 
(A) 
 
End point = 
revision to 
TKA for 
disease 
progression 
Survival 
Proportion 
(B) 
 
End point 
= revision 
to TKA for 
any 
reason, 
revision to 
another 
PFA, 
removal of 
PFA or 
arthrodesis
Survivorship 
revision 
Survivorship 
Revision any 
reason+pain 
 
Inlay, symmetrical, non-anatomical 
 
Blazina 
1979 
Richards I 
and II 
1.8 100% 87%  - - 
Krajca-
Radcliffe 
1996 
Richards I 
and II 
5.8 100% 94% 
 
- - 
de Winter 
2001 
Richards II 11.1 92% 92%  - - 
Kooijman 
2003 
Richards II 17.0 78% 62%  Mean survival 
time (yrs) 
19.5±0.45 
(95%CI18.6-20) 
 
Mean survival 
time 
17.8±0.8 
(95CI16.3-
19.4) 
Cartier 
2005 
Richards II 10 
 
86% 85% - *At 6years 
93.2% 
*At 10years 
84.4% 
*At 11years 
75.5% 
Utukuri 
2008 
Richards II 4.4 100% 100% - - 
van 
Jonbergen 
2010 
Richards II 13.3 87% 76% - At 10 years  
84% 
(95CI78%-
90%) 
At 20 years  
69% (95CI 
59%-79%) 
 
Inlay, asymmetrical, non-anatomical 
 
Tauro 
2001 
Lubinus 7.5 93% 72%  At 8 years 
65%(CI 49-77) 
At 6 years 
48%(CI 36-59) 
Smith 
2002 
Lubinus 4.1 90% 76% - - 
Board 
2004 
Lubinus 1.6 76% 71% - - 
Argenson 
2005 
Autocentric  16.2 75% 49% - §At 16 years 
58% (95%CI 
not given) 
Van 
Wagenberg 
2009 
Autocentric II 4.8 71% 54% - - 
 
Inlay, asymmetrical, anatomical 
 
Merchant 
2005 
LCS 4.5 100% 100% - - 
Charalambous 
2011 
LCS  2.1 96% 67% Estimated 
survival at 3yrs 
63%(95CI47-80) 
Estimated 
survival at 3yrs 
46%(95CI30-
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median survival 
3.3yrs (95CI2.2-
4.5) 
 
63) 
 
median 
survival 2.9yrs 
(95CI2.2-3.7) 
 
Onlay, symmetrical, non-anatomical 
 
Nicol 
2006 
Avon 7.1 88% 86% - - 
Ackroyd 
2007 
Avon 5.2 96% 96% At 5yrs  
95.8%(95CI91.8-
99.8) 
 
(this does not 
take into account 
the 11 revisions 
that occurred 
after 5 yrs) 
 
inc. LTF at 5yrs 
90.3%(95CI84.6-
96) 
At 5yrs 
88%(95CI80.9-
94.1) 
Hollinghurst 
2007 
Avon 3.8 100% 100% - - 
Leadbetter 
2009 
Avon 3.0 96% 94% - - 
Starks 
2009 
Avon 2.0 100% 95% - - 
Odumenya 
2010 
Avon 5.3 94% 94% At 5yr 
100%(95CI100-
100) 
 
Taking into 
account the 
three failures 
that occurred 
after 5 yrs: (5.6, 
5.9, 7.1) 
At 8yrs 
89%(95CI72.9-
100) 
- 
Gao 
2010 
Avon 3.0 100% 100% - - 
Sarda 
2011 
Avon 4.5 95% 95% At 4.5 yrs 
95.5% CI not 
given 
- 
Mont 
2012 
Avon 7.0 88% 88% At 5 yrs 
95% CI not 
given 
 
At 7 yrs 
82% CI not 
given 
 
 
Onlay, asymmetrical, anatomical 
 
Hofmann 
2009 
Natural Knee 
II
2.5 100% 98% - - 
Monk 
2012 
FPV 3.5 100% 100% - - 
Mofidi 
2012 
FPV 0.5-1.0 100% 100% - - 
Williams 
2013 
FPV 2.1 92% 87% At 1.8yrs 
85% (CI not 
given) 
At 1.8yrs 
79% (CI not 
given) 
Beitzel 
2013 
Journey 2.0 100% 100% 1 pt excluded as 
converted to 
TKR at 18m.  
- 
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Onlay, asymmetrical, patient-specific 
 
Butler 
2009 
Custom 
Performa 
Knee 
5.0 100% 95% - - 
Sisto 
2010 
Kinematch 11.3 100% 100% - - 
 
Mixed Group 
 
Arciero 
1988 
Richards and 
CSF-Wright 
5.3 100% 80% - - 
Arnbjornsson 
1998 
Richards I 
and II 
Lubinus 
Miscellaneous 
other 
7.0 97% 92% - - 
Mohammed 
2008 
Lubinus 
Avon 
FPV 
2.0 96% 96%   
 
Total Knee Arthroplasty 
 
Meding  
2007 
AGC 
Legacy 
6.2 - 100% - - 
Laskin 
1999 
Genesis 7.4 - 100% - - 
Thompson 
2001 
LCS 1.7 - 100% - - 
Mont 
2002 
Porous 
Coated 
Anatomic 
Duracon 
Insall-Burstein 
II
6.8 - 100% - - 
Dalury 
2005 
Press Fit 
Condylar 
5.2 - 100% - - 
Parvizi 
2001 
Press Fit 
Condylar 
Genesis 
Total 
Condylar 
5.2 - 94% - - 
 
Comparison 
 
Dahm 
2010 
Avon 
 
2.4 100% 100% - - 
Dahm 
2010 
Zimmer 
SIGMA 
2.3 - 100% - - 
* an extra 20 patients were contacted by phone and included in the survivorship analysis 
§ includes the 9 patients who died; not including patients with pain 
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ISN survival proportion A 
 
 
IAN Survival Proportion A 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Jonbergen 0.873 (0.815, 0.918)
Utukuri 1.000 (0.832, 1.000)
Cartier 0.864 (0.750, 0.940)
Kooijman 0.778 (0.629, 0.888)
de Winter 0.923 (0.749, 0.991)
Krajca-Radcliffe 1.000 (0.794, 1.000)
Blazina 1.000 (0.937, 1.000)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Wagenberg 0.708 (0.489, 0.874)
Argenson 0.754 (0.622, 0.859)
Board 0.882 (0.636, 0.985)
Smith 0.897 (0.726, 0.978)
Tauro 0.919 (0.822, 0.973)
1.0 0 (0.937, 1.000)
1. 00 (0.794, 1.000)
0.923 (0.74 , 0.991) 
0.778 (0.629, 0.888)
0.864 ( .750, 0.940)
1. 00 (0.832, 1.000)
0.873 (0.815, 0.918)
0.919 (0.822, 0.973)
0.897 (0.726, 0.978)
0. 82 (0.636, 0.985)
0.754 (0.622, 0.859)
0.708 (0.489, 0.874)
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IAA Survival Proportion A 
 
 
OSN Survival Proportion A 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Charalambous 0.96
Merchant 1.00
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Dahm 1.000 (0.852, 1.000)
Mont 0.953 (0.842, 0.994)
Sarda 0.977 (0.880, 0.999)
Gao 1.000 (0.715, 1.000)
Odumenya 0.940 (0.835, 0.987)
Starks 1.000 (0.905, 1.000)
Leadbetter 0.949 (0.875, 0.986)
Hollinghurst 1.000 (0.735, 1.000)
Ackroyd 0.963 (0.909, 0.990)
Nicol 0.884 (0.805, 0.938)
1.000 (0.794, 1.000) 
0.961 (0.865, 0.995) 
0.963 (0.909, 0.990)
1. 0  (0.735, 1.000) 
0.949 (0.875, 0.986) 
1. 00 (0.905, 1.000)
0.94  (0.835, 0.987)
1. 0  (0.715, 1.000)
0.977 (0.880, 0.999)
0.953 (0.842, 0.994)
1. 00 (0.852, 1.000)
0. 84 ( .8 5, 0.938) 
  
253
 OAA Survival Proportion A 
 
 
OAP Survival Proportion A 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Beitzel 1
Mofidi 1
Monk 1
Hofmann 1
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Sisto 1.000 (0.863, 1.000)
Butler 1.000 (0.846, 1.000)
 
 
  1.000 (0.912, 1.000) 
 
1.000 (0.782, 1.000) 
 
1.000 (0.897, 1.000)
 
1.000 (0.846, 1.000)
1.000 (0.846, 1.000)
 
1.000 (0.863, 1.000)
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Mixed Survival Proportion A 
 
 
TKA Survival Proportion A 
 
 
Figure 3-3 Survival Proportion A  
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Mohammed 0.970 (0.916, 0.994)
Arnbjornsson 1.000 (0.968, 1.000)
Arciero 0.920 (0.740, 0.990)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Dahm 1.000 (0.846, 1.000)
Parvizi 0.935 (0.786, 0.992)
Dalury 1.000 (0.894, 1.000)
Mont 1.000 (0.884, 1.000)
Thompson 1.000 (0.894, 1.000)
Laskin 1.000 (0.926, 1.000)
Meding 1.000 (0.894, 1.000)
 
 
 
1.000 (0.968, 1.000) 
 
    0.970 (0.916, 0.994)
   0 920 (0.740, 0.990) 
11.000 (0.894, 1.000) 
 
 
 
1.00  (0.926, 1.000) 
 
 
 
1.00  (0.894, 1.000) 
 
 
 
1.000 (0.884, 1.000) 
 
 
1.00  (0.894, 1.000) 
 
0.935 (0.786, 0.992) 
1. 0 (0.846, 1.000) 
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Table 3-5 Survival Proportion A data with confidence intervals 
Study Proportion* 95% CI 
 Lower Level 
95% CI 
Upper Level 
% weight 
(fixed) 
ISN 
Blazina 1979 1 0.94 1 14.11 
Krajca-Radcliffe 1996 1 0.79 1 4.14 
de Winter 2001 0.92 0.75 0.99 6.57 
Kooijman 2003 0.78 0.63 0.89 11.19 
Cartier 2005 0.86 0.75 0.94 14.60 
Utukuri 2008 1 0.83 1 5.11 
van Jonbergen 2010 0.87 0.82 0.92 44.28 
IAN 
Tauro 2001 0.92 0.82 0.97 32.47 
Smith 2002 0.90 0.73 0.98 15.46 
Board 2004 0.88 0.64 0.99 9.28 
Argenson 2005 0.75 0.62 0.86 29.90 
van Wagenberg 2009 0.71 0.49 0.87 12.89 
IAA 
Merchant 2005 1 0.79 1 24.64 
Charalambous 2011 0.96 0.87 1 75.36 
OSN 
Nicol 2006 0.88 0.81 0.94 19.96 
Ackroyd 2007 0.96 0.91 0.99 21.10 
Hollinghurst 2007 1 0.74 1 2.50 
Leadbetter 2009 0.95 0.88 0.99 15.36 
Starks 2009 1 0.91 1 7.29 
Odumenya 2010 0.94 0.83 0.99 9.79 
Gao 2010 1 0.72 1 2.30 
Sarda 2011 0.98 0.88 1 8.64 
Mont 2012 0.95 0.84 0.99 8.45 
Dahm 2010 1 0.85 1 4.61 
OAA 
Hofmann 2009 1 0.91 1 35.65 
Monk 2012 1 0.78 1 13.91 
Mofidi 2012 1 0.90 1 30.44 
Beitzel 2013 1 0.85 1 20.00 
OAP 
Butler 2009 1 0.85 1 46.94 
Sisto 2010 1 0.86 1 53.06 
Mixed 
Arciero 1988 0.92 0.74 0.99 10.74 
Arnbjornsson 1998 1 0.97 1 47.11 
Mohammed 2008 0.97 0.92 0.99 42.15 
TKA 
Meding 2007 1 0.89 1 14.35 
Laskin 1999 1 0.93 1 20.68 
Thompson 2001 1 0.89 1 14.35 
Mont 2002 1 0.88 1 13.08 
Dalury 2005 1 0.89 1 14.35 
Parvizi 2001 0.94 0.79 0.99 13.50 
Dahm 2010 1 0.85 1 9.71 
*number of knees that were not revised to TKA for disease progression divided by the 
total number of knees assessed 
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ISN Survival Proportion B 
 
 
 
 
IAN Survival Proportion B 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Jonbergen 0.757 (0.688, 0.817)
Utukuri 1.000 (0.832, 1.000)
Cartier 0.847 (0.730, 0.928)
Kooijman 0.578 (0.422, 0.723)
de Winter 0.923 (0.749, 0.991)
Krajca-Radcliffe 0.938 (0.698, 0.998)
Blazina 0.807 (0.681, 0.900)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Wagenberg 0.542 (0.328, 0.744)
Argenson 0.491 (0.356, 0.627)
Board 0.706 (0.440, 0.897)
Smith 0.759 (0.565, 0.897)
Tauro 0.548 (0.417, 0.675)
0.807 (0.681, .900) 
 
 
 
0.938 (0.698, 0.998) 
 
 
 
 
0.923 (0.74 , 0.991) 
 
 
0.578 (0.422, 0.723) 
 
 
 
 
0.847 (0.730, 0.928) 
 
 
 
 
 
1. 0  (0.832, 1.000) 
 
 
0.757 (0.68 , 0.817) 
0.  (0.417, 0.675) 
 
 
 
 
0.  (0.565, 0.897) 
 
 
 
 
 
0.  (0. 4 , 0.897) 
 
 
 
 
 
0.491 (0.356, 0.627) 
 
 
 
0.542 (0.328, 0.744) 
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IAA Survival Proportion B 
 
 
 
 
 
OSN Survival Proportion B 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Dahm 1.000 (0.852, 1.000)
Mont 0.953 (0.842, 0.994)
Sarda 0.955 (0.845, 0.994)
Gao 1.000 (0.715, 1.000)
Odumenya 0.940 (0.835, 0.987)
Starks 0.946 (0.818, 0.993)
Leadbetter 0.924 (0.842, 0.972)
Hollinghurst 1.000 (0.735, 1.000)
Ackroyd 0.963 (0.909, 0.990)
Nicol 0.864 (0.782, 0.924)
1.000 (0.794, 1.000) 
 
 
 
 
 
 
 
 
 
 
0.667 (0.521, 0.792) 
 
 
 
0.864 (0.782, 0.924) 
 
 
0.963 ( .9 9, .990) 
 
 
1. 0 (0.735, 1.000) 
 
 
0.924 (0.842, 0.972) 
 
 
0.946 (0.818, 0.993) 
 
 
0.940 (0.835, 0.987) 
 
 
1. 0 (0.7 5, 1.000) 
 
 
0.9 5 (0.845, 0.994) 
 
 
0.953 (0.842, 0.994) 
 
 
1. 0 (0.852, 1.000) 
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OAA Survival Proportion B 
 
 
 
 
OAP Survival Proportion B 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Beitzel 1.000 (0.846, 1.000)
Mofidi 1.000 (0.897, 1.000)
Monk 1.000 (0.782, 1.000)
Hofmann 0.950 (0.831, 0.994)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Sisto 1.000 (0.863, 1.000)
Butler 0.955 (0.772, 0.999)
.950 ( .831, 0.994) 
 
 
 
 
 
1. 00 (0 782, 1.000) 
 
 
 
 
 
 
 
1.000 (0.897, 1.000) 
 
 
 
 
 
 
1. 00 (0 842, 1.000) 
0.955 (0.772, 0.999) 
 
 
 
 
 
 
 
 
 
 
 
1.000 (0.863, 1.000) 
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Mixed Survival Proportion B 
 
 
 
TKA Survival Proportion B 
 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Mohammed 0.960 (0.902, 0.989)
Arnbjornsson 0.912 (0.843, 0.957)
Arciero 0.800 (0.593, 0.932)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Dahm 1.000 (0.846, 1.000)
Parvizi 0.935 (0.786, 0.992)
Dalury 1.000 (0.894, 1.000)
Mont 1.000 (0.884, 1.000)
Thompson 1.000 (0.894, 1.000)
Laskin 1.000 (0.926, 1.000)
Meding 1.000 (0.894, 1.000)
0.800 ( .593, 0.932) 
 
 
 
 
 
 
 
0.912 ( .843, 0.957) 
 
 
 
 
 
 
 
0.960 (0.902, 0.989) 
 
 
 
1. 00 (0.894, 1.000) 
 
 
 
1. 00 (0.926, 1.000) 
 
 
 
1. 00 (0.894, 1.000) 
 
 
 
1. 00 (0.884, 1.000) 
 
 
 
1. 00 (0.894, 1.000) 
 
 
 
0.935 ( .786, 0.992) 
 
 
 
1. 00 (0.846, 1.000) 
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Figure 3-4 Survival Proportion B 
Table 3-6 Survival Proportion B data with confidence intervals 
Study Proportion* 95% CI 
Lower Level 
95% CI 
Upper Level 
% weight 
(fixed) 
ISN 
Blazina 1979 0.81 0.68 0.90 14.11 
Krajca-Radcliffe 1996 0.94 0.70 1 4.14 
de Winter 2001 0.92 0.75 0.99 6.57 
Kooijman 2003 0.58 0.42 0.7 11.19 
Cartier 2005 0.85 0.73 0.93 14.60 
Utukuri 2008 1 0.83 1 5.11 
van Jonbergen 2010 0.76 0.69 0.82 44.28 
IAN 
Tauro 2001 0.55 0.42 0.68 32.47 
Smith 2002 0.76 0.56 0.90 15.46 
Board 2004 0.71 0.44 0.90 9.28 
Argenson 2005 0.49 0.36 0.63 29.90 
van Wagenberg 2009 0.54 0.33 0.74 12.89 
IAA 
Merchant 2005 1 0.79 1 24.64 
Charalambous 2011 0.67 0.52 0.79 75.36 
OSN 
Nicol 2006 0.86 0.78 0.92 19.96 
Ackroyd 2007 0.96 0.91 0.99 21.11 
Hollinghurst 2007 1 0.74 1 2.50 
Leadbetter 2009 0.92 0.84 0.97 15.36 
Starks 2009 0.95 0.82 0.99 7.29 
Odumenya 2010 0.94 0.83 0.99 9.79 
Gao 2010 1 0.72 1 2.30 
Sarda 2011 0.95 0.85 0.99 8.64 
Mont 2012 0.95 0.84 0.99 8.45 
Dahm 2010 1 0.85 1 4.61 
OAA 
Hofmann 2009 0.95 0.83 0.9 35.65 
Monk 2012 1 0.78 1 13.91 
Mofidi 2012 1 0.90 1 30.43 
Beitzel 2013 1 0.85 1 20.01 
OAP 
Butler 2009 0.95 0.77 1 46.94 
Sisto 2010 1 0.86 1 53.06 
Mixed 
Arciero 1988 0.8 0.59 0.9 10.74 
Arnbjornsson 1998 0.91 0.84 0.96 47.11 
Mohammed 2008 0.96 0.90 0.99 42.15 
TKA 
Meding 2007 1 0.89 1 14.35 
Laskin 1999 1 0.93 1 20.68 
Thompson 2001 1 0.89 1 14.35 
Mont 2002 1 0.88 1 13.08 
Dalury 2005 1 0.89 1 14.35 
Parvizi 2001 0.94 0.79 0.99 13.50 
Dahm 2010 1 0.85 1 9.70  
*number of knees that were not revised to TKA for disease progression, PFA, 
arthrodesed or metal work removed divided by the total number of knees assessed 
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3.6.5 Complications and Reoperations 
All complications, including reoperations were summarised in Table 3-8 
based on the six previously described modes of failure listed in section 
3.4.4.2. The number of reoperations, and number and type of revisions 
were recorded in Table 3-7. Mechanisms of failure for all the revisions 
were recorded in Appendix VI in Table 6-42. The complication data was 
also presented as forest plots for all six mechanisms in the same format 
as the survival data. Studies towards the far left of the forest plots 
exemplified low or no occurrence of the complication. Those that were 
towards the right demonstrated a high occurrence of the complication. 
For example, disease progression appears to have been reported 
frequently in the ISN, IAN and OSN groups as illustrated in Figure 3-5. In 
contrast, the occurrence of infection was very low or zero for the majority 
of studies in all the groups as illustrated in Figure 3-9.  
 
Inlay symmetrical non-anatomical 
Prostheses: Richards I and II (two studies); Richards II (five studies) 
 
The most common complications reported in this group were 
malpositioning/misalignment, ‘other’ complications and disease 
progression, in order of frequency. Figure 3-5, Figure 3-6 and Figure 3-10 
forest plots illustrated the high proportion of these complications 
compared with the other groups. Blazina et al. (1979) stated 54% (46 out 
of 85) of the knees assessed had malpositioning and Krajca-Radcliffe & 
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Coker (1996) found 94 % (15 out of 16 knees) had 
malpositioning/misalignment. The remaining five studies in this group 
reported lower numbers of this complication, ranging from 0% to 10% of 
the knees assessed. This distinguishable difference between the studies 
may be related to the prostheses used; these five studies only involved 
the use of the Richards II whereas the other two studies used both 
Richards I and II. 
 
While taking into account this group had the largest patient population, 
the number of complications reported was still disproportionally higher 
than that found in all the other groups analysed. Two of the studies 
(Blazina et al., 1979; van Jonbergen et al., 2010b) in this group reported 
over 100 complications of which one study had only 1.8 years follow-up 
(Blazina et al., 1979). The majority of these complications required 
operative management, as shown in Table 3-7 and Table 3-8. 
 
Despite the high proportion of malpositioning/misalignment cases, 
disease progression was the most common mode of failure in this group. 
Forty-three knees were converted to TKA for disease progression 
compared with 30 knees that required revision surgery for 
malpositioning/misalignment. 
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Inlay asymmetrical non-anatomical 
Prostheses: Lubinus (three studies); Autocentric (one study); Autocentric 
II (one study) 
 
The most common mode of failure requiring revision surgery was disease 
progression (see Table 3-7). However, malpositioning/misalignment was 
the commonest complication; 57 cases were reported of which 24 
patients required operative management. A high number of ‘other’ 
complications were also reported (41 cases), such as diagnostic 
arthroscopy/debridement, patella fracture, stiffness, manipulation under 
anaesthesia and lateral patellar facet resection. 
 
Inlay asymmetrical anatomical 
Prosthesis: LCS (two studies) 
 
Disease Progression was the most frequently recorded complication but 
not the main cause of revision. Persistent pain was the most common 
mechanism of failure resulting in all 12 cases with this complication 
requiring revision surgery to TKA. 
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Onlay symmetrical non-anatomical 
Prosthesis: Avon (nine studies) 
 
Disease progression was the most common mode of failure requiring 
revision surgery and the most frequently reported complication in this 
group. Although many of the patients had dual pathology, 26 out of 33 
knees that underwent revision surgery were revised to TKA due to 
disease progression (see Table 3-7). A similar number of cases reported 
malpositioning (12 knees), persistent pain (13 knees) and other 
complications (18 knees). All five cases of aseptic loosening were 
revised. There were no cases of infection. 
 
Onlay asymmetrical anatomical 
Prostheses: Natural Knee II (one study), Femoro Patella Vialla (three 
studies), Journey (one study) 
 
Fewer complications were reported, although this observation is likely to 
have been influenced by the relatively shorter follow-up and smaller 
patient population in this group. The majority of the complications (14 out 
of 18) were reported by the largest study in the group (Williams et al., 
2013). The main complications were persistent pain, disease progression 
and ‘other’, in order of frequency. There was one case of infection that did 
not require revision surgery. 
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Onlay anatomical patient-specific 
Prostheses: Custom Performa Knee (one study), Kinematch (one study) 
 
Only two studies were included in this category. Eight ‘other’ 
complications were reported by one study of which one knee required 
revision to another PFA (Butler & Shannon, 2009). These complications 
consisted of arthrofibrosis, patellar component wear and fracturing and 
occurred in a third of the patients observed. The other study reported no 
complications in the 25 patients at mean 11.3 years follow-up (Sisto & 
Sarin, 2010). 
 
Mixed group 
Prostheses: Richards I and II, CSF-Wright, Lubinus, Avon, FPV and 
miscellaneous other (not specified) 
 
Ten revisions were performed for persistent pain, whereas six were 
carried out for disease progression. The ‘other’ category was the most 
common complication (such as patellectomy, arthroscopy, MUA, lateral 
release), followed by persistent pain and malpositioning/misalignment. 
The total reoperation number for this group was also relatively high, 107 
reoperations were performed of which 18 were for revision surgery (only 
three TKAs were carried out for disease progression). This is shown in 
Table 3-7 and Table 3-8. 
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Total knee arthroplasty 
Prostheses: Anatomical Graduated Component (AGC), Legacy, Genesis, 
Low Contact Stress (LCS), Porous Coated Anatomic, Duracon, Insall-
Burstein II, Press Fit Condylar (PFC), Total Condylar 
 
Out of the 208 knees assessed in this group only two required revision 
surgery to TKA, one for malpositioning and the other for persistent pain. 
Both these cases were from the same study (Parvizi et al., 2001). The 
main complication in this group was malpositioning associated with the 
Genesis prosthesis (Laskin & van Steijn, 1999; Parvizi et al., 2001) as 
recorded in Table 3-8 and illustrated in the forest plot Figure 3-6. 
 
Comparison 
Prostheses: Avon, Zimmer TKA and SIGMA 
 
There were only two complications in the TKA group of patients, both 
were categorised as ‘other’ (one required manipulation for stiffness and 
the other suffered a deep vein thrombosis). No revision surgery was 
required in either group of patients. 
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Table 3-7 Number of Reoperations and Revisions 
Author 
Year 
Implant Number of 
Reoperations 
Revisions to 
TKA for 
disease 
progression
Revisions to TKA 
for other pathology 
Revisions to 
PFA 
Additional UKA Removal of 
prosthesis/arthrodesis 
 
Inlay, symmetrical, non-anatomical 
 
Blazina 
1979 
Richards I and II 101 0 0 9 0 2 
Krajca-Radcliffe 
1996 
Richards I and II 4 0 0 1 0 0 
de Winter 
2001 
Richards II 12 2 0 0 0 0 
Kooijman 
2003 
Richards II 30 10 0 7 0 2 
Cartier 
2005 
Richards II 13 8 0 1 0 0 
Utukuri 
2008 
Richards II 0 0 0 0 0 0 
van Jonbergen 
2010 
Richards II 105 23 0 18 0 3 
 
Inlay, asymmetrical, non-anatomical 
 
Tauro 
2001 
Lubinus 36 5 6 10 0 0 
Smith 
2002 
Lubinus 10 3 2 2 0 0 
Board 
2004 
Lubinus 7 2 2 1 0 0 
Argenson 
2005 
Autocentric  36 14 8 7 0 0 
Van Wagenberg 
2009 
Autocentric II 26 7 0 4 0 0 
 
Inlay, asymmetrical, anatomical 
 
Merchant 
2005 
LCS 0 0 0 0 0 0 
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Charalambous 
2011 
LCS  18 2 14 1 0 0 
 
Onlay, symmetrical, non-anatomical 
 
Nicol 
2006 
Avon 14 12 2 0 0 0 
Ackroyd 
2007 
Avon 8 4 0 0 0 0 
Hollinghurst 
2007 
Avon 0 0 0 0 0 0 
Leadbetter 
2009 
Avon 7 4 2 0 0 0 
Starks 
2009 
Avon 2 0 0 2 0 0 
Odumenya 
2010 
Avon 4 3 0 0 0 0 
Gao 
2010 
Avon 0 0 0 0 0 0 
Sarda 
2011 
Avon 10 1 1 0 0 0 
Mont 
2012 
Avon 11 2 0 0 0 0 
 
Onlay, asymmetrical, anatomical 
 
Hofmann 
2009 
Natural Knee II 4 0 0 2 0 0 
Monk 
2012 
FPV 0 0 0 0 0 0 
Mofidi 
2012 
FPV 0 0 0 0 0 0 
Williams 
2013 
FPV 8 4 2 1 0 0 
Beitzel 
2013 
Journey 0 0 0 0 0 0 
 
Onlay, asymmetrical, patient-specific 
 
Butler 
2009 
Custom 
Performa Knee 
3 0 0 1 0 0 
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Sisto 
2010 
Kinematch 0 0 0 0 0 0 
 
Mixed group 
 
Arciero 
1988 
Richards and 
CSF-Wright 
11 0 0 2 3 0 
Arnbjornsson 
1998 
Richards I and II 
Lubinus 
Miscellaneous 
other 
61 0 3 6 0 1 
Mohammed 
2008 
Lubinus 
Avon 
FPV 
35 3 1 0 0 0 
 
Total knee arthroplasty 
 
Meding  
2007 
AGC 
Legacy 
0 0 0 0 0 0 
Laskin 
1999 
Genesis 0 0 0 0 0 0 
Thompson 
2001 
LCS 0 0 0 0 0 0 
Mont 
2002 
Porous Coated 
Anatomic 
Duracon 
Insall-Burstein II 
1 0 0 0 0 0 
Dalury 
2005 
Press Fit 
Condylar 
0 0 0 0 0 0 
Parvizi 
2001 
Press Fit 
Condylar 
Genesis 
Total Condylar 
4 0 2 0 0 0 
 
Comparison 
 
Dahm 
2010 
Avon 
 
0 0 0 0 0 0 
Dahm 
2010 
Zimmer 
SIGMA 
1 0 0 0 0 0 
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Table 3-8 Summary of all Complications 
Author 
Year 
Implant Knees Disease 
Progression 
(TFOA) 
Number of 
Malposition/ 
misalignment 
Number of 
persistent pain 
Aseptic 
loosening 
 
Infection 
Other 
(stiffness, 
trauma 
etc) 
 
Inlay, symmetrical, non-anatomical 
 
Blazina 
1979 
Richards I 
and II 
85 0 46 (9) 1(1) 0 2(1) 52 
Krajca-
Radcliffe 
1996 
Richards I 
and II 
16 0 15(1) 0 0 0 2 
de Winter 
2001 
Richards II 26 2(2) 2 3 0 0 5 
Kooijman 
2003 
Richards II 45 13(10) 3(3) Unknown/nr (not 
reported) 
1(1) 0 13(5) 
Cartier 
2005 
Richards II 59 8(8) 5(5) 11* (6 poly wear, 2 
snapping, 2 due to 
prosthesis edge 
projecting and 1 due 
to patellar 
subluxation- same pts 
as 
malposition/alignment) 
0 0 0 
Utukuri 
2008 
Richards II 20 0 0 0 0 0 0 
van 
Jonbergen 
2010 
Richards II 181 84 (23) 
(additional 
61 knees 
had changes 
in med 
comp.) 
19(12) 0 4(4) 1(1) 66(5) (11 
MUAs, 14 
arthrot, 27 
arthros, 
10 other, 
4 wear) 
 TOTAL 432 107(43) 90(30) 15(1) 5(5) 3(2) 138(10) 
 
Inlay, asymmetrical, non-anatomical 
 
Tauro 
2001 
Lubinus 76 7(5) 39(15) 0 0 0 14(1) 
Smith Lubinus 29 4(3) 6(3) 1(1) 0 0 0 
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2002 
Board 
2004 
Lubinus 17 2(2) 5(2) 0 2 1(1) 2 
(arthrosc ) 
Argenson 
2005 
Autocentric  57 14(14) 0 0 3(3) 3(3) 16(9) 
Van 
Wagenberg 
2009 
Autocentric II 24 7(7) 7(4) 15 0 1 9 
 TOTAL 203 34(31) 57(24) 16(1) 5(3) 4(4) 41(9) 
 
Inlay, asymmetrical, anatomical 
 
Merchant 
2005 
LCS 16 0 0 0 0 0 0 
Charalambous 
2011 
LCS  51 20(2*) 4 12(12*) 0 0 3(3) 
 TOTAL 67 20(2) 4 12(12) 0 0 3(3) 
 
Onlay, symmetrical, non-anatomical 
 
Nicol 
2006 
Avon 103 12(12) 1(1*) 1(1*) 0 0 1(1) 
Ackroyd 
2007 
Avon 109 29(4) 1 0 0 0 6 
Hollinghurst 
2007 
Avon 12 0 0 0 0 0 0 
Leadbetter 
2009 
Avon 79 5(4) 1(1) 5 0 0 3(1) 
Starks 
2009 
Avon 37 1 0 1(1) 0 0 1(1) 
Odumenya 
2010 
Avon 50 14(3*) 1 2(2*) (same as TFOA 
pts) 
0 0 0 
Gao 
2010 
Avon 11 0 0 0 0 0 0 
Sarda 
2011 
Avon 44 8(1) 8(1*) 4(1*) 0 0 2 
Mont 
2012 
Avon 43 3(2*) 0 0 5(5*) 0 5 
 TOTAL 488 72(26) 12(3) 13(5) 5(5) 0 18(3) 
 
Onlay, asymmetrical, anatomical 
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Hofmann 
2009 
Natural Knee 
II 
40 0 0 0 0 0 4(2) 
Monk 
2012 
FPV 15 0 0 0 0 0 0 
Mofidi 
2012 
FPV 34 0 0 0 0 0 0 
Williams 
2013 
FPV 53 4(4) 0 5(2) 0 1 4(1) 
Beitzel 
2013 
Journey 22 0 0 0 0 0 0 
  TOTAL 164 4(4) 0 5(2) 0 1 8(3) 
 
Onlay, asymmetrical, patient-specific 
 
Butler 
2009 
Custom 
Performa 
Knee 
22 0 0 0 0 0 8(1) 
Sisto 
2010 
Kinematch 25 0 0 0 0 0 0 
 TOTAL 47 0 0 0 0 0 8(1) 
 
Mixed Group 
 
Arciero 
1988 
Richards and 
CSF-Wright 
25 3(3) 5(2) 1 0 0 6 
Arnbjornsson 
1998 
Richards I 
and II 
Lubinus 
Miscellaneous 
other 
113 4 12 15(10) 0 3 27 
Mohammed 
2008 
Lubinus 
Avon 
FPV 
101 3(3) 8 18 0 1(1) 4 
 TOTAL 239 10(6) 25(2) 34(10) 0 4(1) 37 
 
Total Knee Replacement 
 
Meding  
2007 
AGC 
Legacy 
33 0 0 0 0 0 0 
Laskin Genesis 48 0 10 3 0 0 0 
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1999 
Thompson 
2001 
LCS 33 0 0 0 0 2 2 
Mont 
2002 
Porous 
Coated 
Anatomic 
Duracon 
Insall-Burstein 
II 
30 0 0 0 0 0 0 
Dalury 
2005 
Press Fit 
Condylar 
33 0 4 0 0 0 0 
Parvizi 
2001 
Press Fit 
Condylar 
Genesis 
Total 
Condylar 
31 0 7*(1) 6*(1) same pt as 
misalignment 
1 0 5 
 
 TOTAL 208 0 21(1) 9(1) 1 2 7 
 
Comparison 
 
Dahm  
2010 
Avon 
 
23 0 0 0 0 0 0 
Dahm  
2010 
Zimmer 
SIGMA 
22 0 0 0 0 0 2 
 TOTAL 45 0 0 0 0 0 2 
*knees with dual pathology 
(x) numbers in brackets represent the number that underwent revision surgery 
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ISN Disease Progression 
 
 
 
 
IAN Disease Progression 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Jonbergen 0.464 (0.390, 0.540)
Utukuri 0.000 (0.000, 0.168)
Cartier 0.136 (0.060, 0.250)
Kooijman 0.289 (0.164, 0.443)
de Winter 0.077 (0.009, 0.251)
Krajca-Radcliffe 0.000 (0.000, 0.206)
Blazina 0.000 (0.000, 0.042)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Wagenberg 0.292 (0.126, 0.511)
Argenson 0.246 (0.141, 0.378)
Board 0.118 (0.015, 0.364)
Smith 0.138 (0.039, 0.317)
Tauro 0.113 (0.047, 0.219)
 
 
0.  (0. 0 , 0.042) 
 
 
 
0.000 (0.000, 0.206) 
 
 
 
0.  (0. 09, 0.251) 
 
 
 
0.  (0.164, 0.443) 
 
 
 
0.136 (0.060, 0.250) 
 
 
 
0.000 (0.000, 0.168) 
 
 
0.  (0.39 , 0.540)
0.  (0.047, 0.219) 
 
 
 
 
 
0.  (0.039, 0.317) 
 
 
 
 
 
0.  (0.015, 0.364) 
 
 
 
 
 
0.246 (0.141, 0.378) 
  
 
 
 
0.  (0.126, 0.511) 
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IAA Disease Progression 
 
 
 
 
OSN Disease Progression 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Charalambous 0.392 (0.258, 0.539)
Merchant 0.000 (0.000, 0.206)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Dahm 0.000 (0.000, 0.148)
Mont 0.070 (0.015, 0.191)
Sarda 0.182 (0.082, 0.327)
Gao 0.000 (0.000, 0.285)
Odumenya 0.280 (0.162, 0.425)
Starks 0.027 (6.8E-4, 0.142)
Leadbetter 0.063 (0.021, 0.142)
Hollinghurst 0.000 (0.000, 0.265)
Ackroyd 0.266 (0.186, 0.359)
Nicol 0.117 (0.062, 0.195)
0.  (0. 0 , .206) 
 
 
 
 
 
0.392 (0.258, 0.539) 
 
. 17 ( .062, 0.195) 
 
 
.2 6 (0.186, 0.359) 
 
 
 
. 0 ( . 00, 0.265) 
 
 
.063 ( .021, 0.142) 
 
 
.027 (6.8E-4, 0.142) 
 
 
 
.280 (0.162, 0.425) 
 
 
. 0 ( . 00, 0.285) 
 
 
.182 ( .082, 0.327) 
 
 
.070 ( .015, 0.191) 
 
 
 
 
. 0 ( . 00, 0.148)
Merchant 
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OAA Disease Progression 
 
 
 
 
OAP Disease Progression 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Beitzel 0.000 (0.000, 0.154)
Mofidi 0.000 (0.000, 0.103)
Monk 0.000 (0.000, 0.218)
Hofmann 0.000 (0.000, 0.088)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Sisto 0.000 (0.000, 0.137)
Butler 0.000 (0.000, 0.154)
Hofmann 
Monk 
Mofidi 
Beitzel 
 
 
0.  (0. 0 , 0.088) 
 
 
 
 
 
0.  (0. 0 , 0.218) 
 
 
 
 
 
0.  (0. 0 , .103) 
 
 
 
 
 
0.  (0. 0 , 0.154) 
 
Sisto 
Butler . 0 ( . 00, 0.154) 
 
 
 
 
 
 
 
 
 
 
 
0.000 (0.000, 0.137) 
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Mixed Disease Progression 
 
 
 
Figure 3-5 Proportion of Disease Progression 
  
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Mohammed 0.030 (0.006, 0.084)
Arnbjornsson 0.035 (0.010, 0.088)
Arciero 0.120 (0.025, 0.312)
Arnbjornssonn 
Mohammed 
 
0.  (0.025, 0.312) 
 
 
 
 
 
 
 
0.035 (0.010, 0.088) 
 
 
 
 
 
 
 
0.  (0. 06, 0.084) 
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Table 3-9 Proportion of Disease Progression 
Study Proportion* 95% CI 
Lower Level 
95% CI 
Upper Level 
% weight 
(fixed) 
ISN 
Blazina 1979 0 0 0.04 19.59 
Krajca-Radcliffe 1996 0 0 0.21 3.87 
de Winter 2001 0.08 0.01 0.25 6.15 
Kooijman 2003 0.29 0.16 0.44 10.48 
Cartier 2005 0.14 0.06 0.25 13.67 
Utukuri 2008 0 0 0.17 4.78 
van Jonbergen 2010 0.46 0.39 0.54 41.46 
IAN 
Tauro 2001 0.11 0.05 0.22 32.47 
Smith 2002 0.14 0.04 0.32 15.46 
Board 2004 0.12 0.01 0.36 9.28 
Argenson 2005 0.25 0.14 0.38 29.90 
van Wagenberg 2009 0.29 0.13 0.51 12.89 
IAA 
Merchant 2005 0 0 0.21 24.64 
Charalambous 2011 0.39 0.26 0.54 75.36 
OSN 
Nicol 2006 0.12 0.06 0.19 19.96 
Ackroyd 2007 0.27 0.19 0.36 21.11 
Hollinghurst 2007 0 0 0.26 2.50 
Leadbetter 2009 0.06 0.02 0.14 15.36 
Starks 2009 0.03 0 0.14 7.29 
Odumenya 2010 0.28 0.16 0.42 9.79 
Gao 2010 0 0 0.28 2.30 
Sarda 2011 0.18 0.08 0.33 8.64 
Mont 2012 0.07 0.01 0.19 8.44 
Dahm 2010 0 0 0.15 4.61 
OAA 
Hofmann 2009 0 0 0.09 35.65 
Monk 2012 0 0 0.22 13.91 
Mofidi 2012 0 0 0.10 30.43 
Beitzel 2013 0 0 0.15 20.01 
OAP 
Butler 2009 0 0 0.15 46.94 
Sisto 2010 0 0 0.14 53.06 
Mixed 
Arciero 1988 0.12 0.03 0.31 10.74 
Arnbjornsson 1998 0.04 0.01 0.09 47.11 
Mohammed 2008 0.03 0.01 0.08 42.15 
*number of knees with disease progression divided by the total number of knees 
assessed 
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ISN Malpositioning 
 
 
 
 
IAN Malpositioning 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Jonbergen 0.105 (0.064, 0.159)
Utukuri 0.000 (0.000, 0.168)
Cartier 0.085 (0.028, 0.187)
Kooijman 0.067 (0.014, 0.183)
de Winter 0.077 (0.009, 0.251)
Krajca-Radcliffe 0.938 (0.698, 0.998)
Blazina 0.541 (0.430, 0.650)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Wagenberg 0.292 (0.126, 0.511)
Argenson 0.000 (0.000, 0.063)
Board 0.294 (0.103, 0.560)
Smith 0.207 (0.080, 0.397)
Tauro 0.629 (0.497, 0.748)
0.  (0.43 , 0.650) 
 
 
 
0.  (0.698, 0.998) 
 
 
 
0.  (0. 09, 0.251) 
 
 
 
0.  (0.014, 0.183) 
 
 
 
0.  (0.028, 0.187) 
 
 
 
0.  (0. 0 , 0.168) 
 
 
 
0.  (0.064, 0.159) 
 
Argenson 
 .629 (0.497, 0.748) 
 
 
 
 
0.  (0.08 , 0.397) 
 
 
 
 
0.  (0.103, 0.560) 
 
 
 
 
0.  (0. 0 , 0.063) 
  
 
 
 
0.  (0.126, 0.511) 
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IAA Malpositioning 
 
 
 
 
OSN Malpositioning 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Charalambous 0.078 (0.022, 0.189)
Merchant 0.000 (0.000, 0.206)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Dahm 0.000 (0.000, 0.148)
Mont 0.000 (0.000, 0.082)
Sarda 0.182 (0.082, 0.327)
Gao 0.000 (0.000, 0.285)
Odumenya 0.020 (5.1E-4, 0.106)
Starks 0.000 (0.000, 0.095)
Leadbetter 0.013 (3.2E-4, 0.069)
Hollinghurst 0.000 (0.000, 0.265)
Ackroyd 0.009 (2.3E-4, 0.050)
Nicol 0.010 (2.5E-4, 0.053)
Merchant 
Charalambous 
0.000 (0.000, 0.206) 
 
 
 
 
 
 
 
 
 
 
 
0.078 (0.022, 0.189) 
.010 (2.5E-4, 0.053) 
 
 
. 09 (2.3E-4, .050) 
 
 
. 0 ( . 00, 0.265) 
 
 
.013 (3.2E-4, 0.069) 
 
 
. 0 ( . 00, 0.095) 
 
 
.020 (5.1E-4, 0.106) 
 
 
. 0 ( . 00, 0.285) 
 
 
.182 ( .082, 0.327) 
 
 
. 0 ( . 00, 0.082) 
 
 
. 0 ( . 00, 0.148) 
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OAA Malpositioning 
 
 
 
 
OAP Malpositioning 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Beitzel 0.000 (0.000, 0.154)
Mofidi 0.000 (0.000, 0.103)
Monk 0.000 (0.000, 0.218)
Hofmann 0.000 (0.000, 0.088)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Sisto 0.000 (0.000, 0.137)
Butler 0.000 (0.000, 0.154)
0.  (0. 0 , 0.088) 
 
 
 
 
 
 
 
 
 
 
 
 
0.  (0. 0 , 0.218) 
 
 
 
 
 
 
 
0.  (0. 0 , .103) 
 
 
 
 
 
0.000 (0.000, 0.154) 
Hofmann 
Monk 
Mofidi 
Beitzel 
Butler 
Sisto 
0.  (0. 0 , 0.154) 
 
 
 
 
 
 
 
 
 
 
 
0.000 (0.000, 0.137) 
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Mixed Malpositioning 
 
 
 
TKA Malpositioning 
 
Figure 3-6 Proportion of Malpositioning 
0.00 0.20 0.40 0.60 0.80 1.00
Proportion (95% confidence interval)
Mohammed 0.109 (0.056, 0.187)
Arnbjornsson 0.106 (0.056, 0.178)
Arciero 0.200 (0.068, 0.407)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Dahm 0.000 (0.000, 0.154)
Parvizi 0.226 (0.096, 0.411)
Dalury 0.121 (0.034, 0.282)
Mont 0.000 (0.000, 0.116)
Thompson 0.000 (0.000, 0.106)
Laskin 0.208 (0.105, 0.350)
Meding 0.000 (0.000, 0.106)
.2 0 ( .068, 0.407) 
 
 
 
 
 
 
 
0.106 (0.056, 0.178) 
 
 
 
 
 
 
 
0.109 (0.056, 0.187) 
 
 
0.  (0. 0 , .106) 
 
 
0.208 (0.105, 0.350) 
 
 
 
0.  (0. 0 , .106) 
 
 
 
0.  (0. 0 , 0.116) 
 
 
 
0.  (0.034, 0.282) 
 
 
 
0.  (0.096, 0.411) 
 
 
 
0.000 (0.000, 0.154) 
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Table 3-10 Proportion of Malpositioning 
Study Proportion* 95% CI 
Lower Level 
95% CI 
Upper Level 
% weight 
(fixed) 
ISN 
Blazina 1979 0.54 0.43 0.65 19.59 
Krajca-Radcliffe 1996 0.94 0.70 1 3.87 
de Winter 2001 0.08 0.01 0.25 6.15 
Kooijman 2003 0.07 0.01 0.18 10.48 
Cartier 2005 0.08 0.03 0.19 13.67 
Utukuri 2008 0 0 0.17 4.78 
van Jonbergen 2010 0.10 0.06 0.16 41.46 
IAN 
Tauro 2001 0.63 0.50 0.75 32.47 
Smith 2002 0.21 0.08 0.40 15.46 
Board 2004 0.29 0.10 0.56 9.28 
Argenson 2005 0 0 0.06 29.90 
van Wagenberg 2009 0.29 0.13 0.51 12.87 
IAA 
Merchant 2005 0 0 0.21 24.64 
Charalambous 2011 0.08 0.02 0.19 75.36 
OSN 
Nicol 2006 0.01 0 0.05 19.96 
Ackroyd 2007 0.01 0 0.05 21.11 
Hollinghurst 2007 0 0 0.26 2.50 
Leadbetter 2009 0.01 0 0.07 15.36 
Starks 2009 0 0 0.09 7.29 
Odumenya 2010 0.02 0 0.11 9.79 
Gao 2010 0 0 0.28 2.30 
Sarda 2011 0.18 0.08 0.33 8.64 
Mont 2012 0 0 0.082 8.45 
Dahm 2010 0 0 0.15 4.61 
OAA 
Hofmann 2009 0 0 0.09 35.65 
Monk 2012 0 0 0.22 13.91 
Mofidi 2012 0 0 0.10 30.43 
Beitzel 2013 0 0 0.15 20.01 
OAP 
Butler 2009 0 0 0.15 46.94 
Sisto 2010 0 0 0.14 53.06 
Mixed 
Arciero 1988 0.2 0.07 0.41 10.74 
Arnbjornsson 1998 0.11 0.06 0.18 47.11 
Mohammed 2008 0.11 0.06 0.19 42.15 
TKA 
Meding 2007 0 0 0.11 14.35 
Laskin 1999 0.21 0.10 0.35 20.68 
Thompson 2001 0 0 0.11 14.35 
Mont 2002 0 0 0.12 13.08 
Dalury 2005 0.12 0.03 0.28 14.35 
Parvizi 2001 0.23 0.10 0.41 13.50 
Dahm 2010 0 0 0.15 9.70 
*number of knees with malpositioning divided by the total number of knees assessed 
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ISN Persistent Pain 
 
 
 
 
IAN Persistent Pain 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Jonbergen 0.000 (0.000, 0.020)
Utukuri 0.000 (0.000, 0.168)
Cartier 0.186 (0.097, 0.309)
Kooijman 0.000 (0.000, 0.079)
de Winter 0.115 (0.024, 0.302)
Krajca-Radcliffe 0.000 (0.000, 0.206)
Blazina 0.012 (2.98E-4, 0.064)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Wagenberg 0.625 (0.406, 0.812)
Argenson 0.000 (0.000, 0.063)
Board 0.000 (0.000, 0.195)
Smith 0.034 (8.73E-4, 0.178)
Tauro 0.113 (0.047, 0.219)
van Jonbergen
. 12 (2.98E-4, 0.064) 
 
 
 
. 0 ( . 0 , 0.206) 
 
 
 
. 15 ( .024, 0.302) 
 
 
 
. 0 ( . 0 , 0.079) 
 
 
 
. 86 ( .097, 0.309) 
 
 
 
. 0 ( . 0 , 0.168) 
 
 
 
. 0 ( . 0 , 0.020) 
Argenson 
. 13 ( .047, 0.219) 
 
 
 
 
 
.034 (8.73E-4, 0.178) 
 
 
 
 
 
. 0 ( . 00, 0.195) 
 
 
 
 
 
. 0 ( . 00, 0.063) 
  
 
 
 
 
.625 (0.406, 0.812) 
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IAA Persistent Pain 
 
 
 
 
OSN Persistent Pain 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Charalambous 0.235 (0.128, 0.375)
Merchant 0.000 (0.000, 0.206)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Dahm 0.000 (0.000, 0.148)
Mont 0.000 (0.000, 0.082)
Sarda 0.091 (0.025, 0.217)
Gao 0.000 (0.000, 0.285)
Odumenya 0.040 (0.005, 0.137)
Starks 0.027 (6.8E-4, 0.142)
Leadbetter 0.063 (0.021, 0.142)
Hollinghurst 0.000 (0.000, 0.265)
Ackroyd 0.000 (0.000, 0.033)
Nicol 0.010 (2.5E-4, 0.053)
.0 0 ( . 00, 0.206) 
 
 
 
 
 
 
 
 
 
 
 
0.235 (0.128, 0.375) 
Argenson 
.010 (2.5E-4, 0.053) 
 
 
. 0 ( . 00, 0.033) 
 
 
. 0 ( . 00, 0.265) 
 
 
.063 ( .021, 0.142) 
 
 
 
.027 (6.8E-4, 0.142) 
 
 
.040 ( .005, 0.137) 
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OAA Persistent Pain 
 
 
 
 
OAP Persistent Pain 
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Proportion (95% confidence interval)
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Mixed Persistent Pain 
 
 
 
TKA Persistent Pain 
 
Figure 3-7 Proportion of Persistent Pain 
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Table 3-11 Proportion of Persistent Pain 
Study Proportion* 95% CI 
Lower Level 
95% CI 
Upper Level 
% weight 
(fixed) 
ISN 
Blazina 1979 0.012 0 0.06 19.59 
Krajca-Radcliffe 1996 0 0 0.21 3.87 
de Winter 2001 0.12 0.02 0.30 6.15 
Kooijman 2003 0 0 0.08 10.48 
Cartier 2005 0.19 0.097 0.31 13.67 
Utukuri 2008 0 0 0.17 4.78 
van Jonbergen 2010 0 0 0.02 41.46 
IAN 
Tauro 2001 0.12 0.05 0.22 32.47 
Smith 2002 0.034 0 0.18 15.46 
Board 2004 0 0 0.20 9.28 
Argenson 2005 0 0 0.06 29.90 
van Wagenberg 2009 0.63 0.41 0.81 12.89 
IAA 
Merchant 2005 0 0 0.21 24.64 
Charalambous 2011 0.24 0.13 0.37 75.36 
OSN 
Nicol 2006 0.01 0 0.05 19.96 
Ackroyd 2007 0 0 0.03 21.11 
Hollinghurst 2007 0 0 0.26 2.50 
Leadbetter 2009 0.06 0.02 0.14 15.36 
Starks 2009 0.03 0 0.14 7.29 
Odumenya 2010 0.04 0 0.14 9.79 
Gao 2010 0 0 0.28 2.30 
Sarda 2011 0.09 0.03 0.22 8.63 
Mont 2012 0 0 0.08 8.45 
Dahm 2010 0 0 0.15 4.61 
OAA 
Hofmann 2009 0 0 0.09 35.65 
Monk 2012 0 0 0.22 13.91 
Mofidi 2012 0 0 0.10 30.43 
Beitzel 2013 0 0 0.15 20.01 
OAP 
Butler 2009 0 0 0.15 46.94 
Sisto 2010 0 0 0.14 53.06 
Mixed 
Arciero 1988 0.04 0 0.20 10.74 
Arnbjornsson 1998 0.13 0.08 0.21 47.11 
Mohammed 2008 0.18 0.11 0.27 42.15 
TKA 
Meding 2007 0 0 0.11 14.35 
Laskin 1999 0.06 0.01 0.17 20.68 
Thompson 2001 0 0 0.11 14.35 
Mont 2002 0 0 0.12 13.08 
Dalury 2005 0 0 0.11 14.35 
Parvizi 2001 0.19 0.07 0.37 13.50 
Dahm 2010 0 0 0.15 9.70 
*number of knees with persistent pain divided by the total number of knees assessed 
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ISN Aseptic Loosening 
 
 
 
 
IAN Aseptic Loosening 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Jonbergen 0.022 (0.006, 0.056)
Utukuri 0.000 (0.000, 0.168)
Cartier 0.000 (0.000, 0.061)
Kooijman 0.022 (5.62E-4, 0.118)
de Winter 0.000 (0.000, 0.132)
Krajca-Radcliffe 0.000 (0.000, 0.206)
Blazina 0.000 (0.000, 0.042)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Wagenberg 0.000 (0.000, 0.142)
Argenson 0.123 (0.051, 0.237)
Board 0.118 (0.015, 0.364)
Smith 0.000 (0.000, 0.119)
Tauro 0.000 (0.000, 0.058)
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IAA Aseptic Loosening 
 
 
 
 
OSN Aseptic Loosening 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Charalambous 0.235 (0.128, 0.375)
Merchant 0.000 (0.000, 0.206)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
Dahm 0.000 (0.000, 0.148)
Mont 0.116 (0.039, 0.251)
Sarda 0.000 (0.000, 0.080)
Gao 0.000 (0.000, 0.285)
Odumenya 0.000 (0.000, 0.071)
Starks 0.000 (0.000, 0.095)
Leadbetter 0.000 (0.000, 0.046)
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OAA Aseptic Loosening 
 
 
 
 
OAP Aseptic Loosening 
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Proportion (95% confidence interval)
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Mixed Aseptic Loosening 
 
 
 
TKA Aseptic Loosening 
 
Figure 3-8 Proportion of Aseptic Loosening  
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Table 3-12 Proportion of Aseptic Loosening 
Study Proportion* 95% CI 
Lower Level 
95% CI 
Upper Level 
% weight 
(fixed) 
ISN 
Blazina 1979 0 0 0.04 19.59 
Krajca-Radcliffe 1996 0 0 0.21 3.87 
de Winter 2001 0 0 0.13 6.15 
Kooijman 2003 0.02 0 0.12 10.48 
Cartier 2005 0 0 0.06 13.67 
Utukuri 2008 0 0 0.17 4.78 
van Jonbergen 2010 0.02 0.01 0.06 41.46 
IAN 
Tauro 2001 0 0 0.06 32.47 
Smith 2002 0 0 0.12 15.46 
Board 2004 0.12 0.01 0.36 9.28 
Argenson 2005 0.12 0.05 0.24 29.90 
van Wagenberg 2009 0 0 0.14 12.89 
IAA 
Merchant 2005 0 0 0.21 24.64 
Charalambous 2011 0.24 0.13 0.37 75.36 
OSN 
Nicol 2006 0 0 0.04 19.96 
Ackroyd 2007 0 0 0.03 21.11 
Hollinghurst 2007 0 0 0.26 2.50 
Leadbetter 2009 0 0 0.05 15.36 
Starks 2009 0 0 0.09 7.29 
Odumenya 2010 0 0 0.07 9.79 
Gao 2010 0 0 0.28 2.30 
Sarda 2011 0 0 0.08 8.64 
Mont 2012 0.15 0.04 0.25 8.45 
Dahm 2010 0 0 0.15 4.61 
OAA 
Hofmann 2009 0 0 0.09 35.65 
Monk 2012 0 0 0.22 13.91 
Mofidi 2012 0 0 0.10 30.43 
Beitzel 2013 0 0 0.15 20.01 
OAP 
Butler 2009 0 0 0.15 46.94 
Sisto 2010 0 0 0.14 53.06 
Mixed 
Arciero 1988 0 0 0.14 10.74 
Arnbjornsson 1998 0 0 0.03 47.11 
Mohammed 2008 0 0 0.04 42.15 
TKA 
Meding 2007 0 0 0.11 14.35 
Laskin 1999 0 0 0.07 20.68 
Thompson 2001 0 0 0.11 14.35 
Mont 2002 0 0 0.12 13.08 
Dalury 2005 0 0 0.11 14.35 
Parvizi 2001 0.03 0 0.17 13.50 
Dahm 2010 0 0 0.15 9.70 
* number of knees with aseptic loosening divided by the total number of knees assessed 
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ISN Infection 
 
 
 
 
IAN Infection 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Jonbergen 0.006 (1.4E-4, 0.030)
Utukuri 0.000 (0.000, 0.168)
Cartier 0.000 (0.000, 0.061)
Kooijman 0.000 (0.000, 0.079)
de Winter 0.000 (0.000, 0.132)
Krajca-Radcliffe 0.000 (0.000, 0.206)
Blazina 0.024 (0.003, 0.082)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Wagenberg 0.042 (0.001, 0.211)
Argenson 0.053 (0.011, 0.146)
Board 0.059 (0.001, 0.287)
Smith 0.000 (0.000, 0.119)
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IAA Infection 
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OAA Infection 
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Mixed Infection 
 
 
 
TKA Infection 
 
Figure 3-9 Proportion of Infection  
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Table 3-13 Proportion of Infection 
Study Proportion* 95% CI 
Lower Level 
95% CI 
Upper Level 
% weight 
(fixed) 
ISN 
Blazina 1979 0.02 0 0.08 19.59 
Krajca-Radcliffe 1996 0 0 0.21 3.87 
de Winter 2001 0 0 0.13 6.15 
Kooijman 2003 0 0 0.08 10.48 
Cartier 2005 0 0 0.06 13.67 
Utukuri 2008 0 0 0.17 4.78 
van Jonbergen 2010 0.01 0 0.03 41.46 
IAN 
Tauro 2001 0 0 0.06 32.47 
Smith 2002 0 0 0.12 15.46 
Board 2004 0.06 0 0.29 9.28 
Argenson 2005 0.05 0.01 0.15 29.90 
van Wagenberg 2009 0.04 0 0.21 12.89 
IAA 
Merchant 2005 0 0 0.21 24.64 
Charalambous 2011 0 0 0.07 75.36 
OSN 
Nicol 2006 0 0 0.04 19.96 
Ackroyd 2007 0 0 0.03 21.11 
Hollinghurst 2007 0 0 0.26 2.50 
Leadbetter 2009 0 0 0.05 15.36 
Starks 2009 0 0 0.09 7.29 
Odumenya 2010 0 0 0.07 9.79 
Gao 2010 0 0 0.28 2.30 
Sarda 2011 0 0 0.08 8.64 
Mont 2012 0 0 0.08 8.45 
Dahm 2010 0 0 0.15 4.61 
OAA 
Hofmann 2009 0 0 0.09 35.65 
Monk 2012 0 0 0.22 13.91 
Mofidi 2012 0 0 0.10 30.43 
Beitzel 2013 0 0 0.15 20 
OAP 
Butler 2009 0 0 0.15 46.94 
Sisto 2010 0 0 0.14 53.06 
Mixed 
Arciero 1988 0 0 0.14 10.74 
Arnbjornsson 1998 0.03 0 0.08 47.11 
Mohammed 2008 0.01 0 0.05 42.15 
TKA 
Meding 2007 0 0 0.11 14.35 
Laskin 1999 0 0 0.07 20.68 
Thompson 2001 0.06 0.01 0.20 14.35 
Mont 2002 0 0 0.14 13.08 
Dalury 2005 0 0 0.11 14.35 
Parvizi 2001 0 0 0.11 13.50 
Dahm 2010 0 0 0.15 9.70 
*number of knees with infection divided by the total number of knees assessed 
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ISN Other Complications 
 
 
 
 
IAN Other Complications 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Jonbergen 0.365 (0.295, 0.439)
Utukuri 0.000 (0.000, 0.168)
Cartier 0.000 (0.000, 0.061)
Kooijman 0.289 (0.164, 0.443)
de Winter 0.192 (0.066, 0.394)
Krajca-Radcliffe 0.125 (0.016, 0.383)
Blazina 0.612 (0.500, 0.716)
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
van Wagenberg 0.375 (0.188, 0.594)
Argenson 0.211 (0.114, 0.339)
Board 0.118 (0.015, 0.364)
Smith 0.000 (0.000, 0.119)
Tauro 0.113 (0.047, 0.219)
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IAA Other Complications 
 
 
 
 
OSN Other Complications 
 
0.00 0.25 0.50 0.75 1.00
Proportion (95% confidence interval)
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Proportion (95% confidence interval)
Dahm 0.000 (0.000, 0.148)
Mont 0.116 (0.039, 0.251)
Sarda 0.045 (0.006, 0.155)
Gao 0.000 (0.000, 0.285)
Odumenya 0.000 (0.000, 0.071)
Starks 0.027 (6.8E-4, 0.142)
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OAA Other Complications 
 
 
 
 
OAP Other Complications 
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Mixed Other Complications 
 
 
 
TKA Other Complications 
 
Figure 3-10 Proportion of Other Complications  
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Table 3-14 Proportion of Other Complications 
Study Proportion* 95% CI 
Lower Level 
95% CI 
Upper Level 
% weight 
(fixed) 
ISN 
Blazina 1979 0.61 0.50 0.72 19.59 
Krajca-Radcliffe 1996 0.13 0.02 0.38 3.87 
de Winter 2001 0.19 0.07 0.39 6.15 
Kooijman 2003 0.29 0.16 0.44 10.48 
Cartier 2005 0 0 0.06 13.67 
Utukuri 2008 0 0 0.17 4.78 
van Jonbergen 2010 0.36 0.29 0.44 41.46 
IAN 
Tauro 2001 0.11 0.05 0.22 32.47 
Smith 2002 0 0 0.12 15.46 
Board 2004 0.12 0.01 0.36 9.28 
Argenson 2005 0.21 0.11 0.34 29.90 
van Wagenberg 2009 0.38 0.19 0.59 12.89 
IAA 
Merchant 2005 0 0 0.21 24.64 
Charalambous 2011 0.06 0.01 0.16 75.36 
OSN 
Nicol 2006 0.01 0 0.05 19.96 
Ackroyd 2007 0.06 0.02 0.12 21.11 
Hollinghurst 2007 0 0 0.26 2.50 
Leadbetter 2009 0.04 0.01 0.11 15.36 
Starks 2009 0.03 0 0.14 7.29 
Odumenya 2010 0 0 0.07 9.79 
Gao 2010 0 0 0.28 2.30 
Sarda 2011 0.05 0.01 0.15 8.64 
Mont 2012 0.12 0.04 0.25 8.45 
Dahm 2010 0 0 0.15 4.61 
OAA 
Hofmann 2009 0 0 0.09 35.65 
Monk 2012 0 0 0.22 13.91 
Mofidi 2012 0 0 0.10 30.43 
Beitzel 2013 0 0 0.15 20.01 
OAP 
Butler 2009 0.36 0.17 0.59 46.94 
Sisto 2010 0 0 0.14 53.06 
Mixed 
Arciero 1988 0.24 0.09 0.45 10.74 
Arnbjornsson 1998 0.24 0.16 0.33 47.11 
Mohammed 2008 0.04 0.01 0.10 42.15 
TKA 
Meding 2007 0 0 0.11 14.35 
Laskin 1999 0 0 0.07 20.68 
Thompson 2001 0.06 0.01 0.20 14.35 
Mont 2002 0.03 0 0.17 13.08 
Dalury 2005 0 0 0.11 14.35 
Parvizi 2001 0.16 0.05 0.34 13.50 
Dahm 2010 0.09 0.01 0.29 9.70 
*number of knees with other complications divided by the total number of knees 
assessed 
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3.6.6 Functional Outcomes 
The reporting of functional outcomes varied considerably from study to 
study therefore limiting the comparisons and inferences that could be 
drawn. For example, the specific score values were often not presented, 
instead a percentage of the sample population that reached a certain 
score range was stated. Others devised a secondary categorical scale to 
represent the original nominal data as ‘excellent, good, fair, poor/failure’. 
In additional, the majority of the selected articles were retrospective and 
therefore not all had pre-operative data available for assessment of 
improvement. Furthermore, the follow-up times varied within and between 
the groups considerably which also added to the difficulty in drawing 
conclusions. A summary of the functional outcome data is in Appendix VI 
in Table 6-43. All references made in the summary of findings below 
correspond with this table. 
 
Inlay symmetrical non-anatomical 
Prostheses: Richards I and II (two studies); Richards II (five studies) 
 
Five out of seven studies (Cartier et al., 2005; de Winter et al., 2001; 
Kooijman et al., 2003; Krajca-Radcliffe & Coker, 1996; Utukuri et al., 
2008) reported functional data of which one had pre-operative scores 
(Utukuri et al., 2008). The most common score used was the AKSS 
although a summary of findings was limited due to variations in reporting 
style; other scores reported were the Hungerford and Kenna Scale, HSS, 
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SF-36 and KOOS. Overall, the studies suggested excellent outcomes, 
rated as approximately 85 to 100 (for all scores with maximum 100 best 
outcome) occurred in the majority of the sample populations. Satisfaction 
was also reported by three studies, all of which found good to excellent 
outcome majority. 
 
Inlay asymmetrical non-anatomical 
Prostheses: Lubinus (three studies); Autocentric (one study); Autocentric 
II (one study) 
 
All five studies reported functional results of which three had pre-
operative data in selected scores (Argenson et al., 2005; Board et al., 
2004; Tauro et al., 2001). The studies with pre- and postoperative scores 
showed functional improvement although the range of the data was wide. 
For example, the Bristol Knee Score improved from mean 55 (29 - 86) to 
mean 72 (42 - 100) at mean 7.5 years follow-up (Tauro et al., 2001) and 
AKSS function/clinical results improved from mean 41 (10 - 80)/53 (43 - 
70) to mean 81 (40 - 100)/79 (60 – 100) at 16.2 years (Argenson et al., 
2005). The KOOS score was presented as separate scores for the 
individual subsections, ranging from 22 - 60 each out of 100 at 4.8 years 
follow-up with sport and recreation function scoring the lowest at 22±13 
(van Wagenberg et al., 2009). The low mean functional outcome scores, 
such as the Lysholm and the KOOS, were also reflected in the lower 
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survival proportions and higher number of complications associated with 
these studies. 
 
Inlay asymmetrical anatomical 
Prosthesis: LCS (two studies) 
 
Four validated scores were used to assess function post-operatively in 
both studies. Merchant (2005) used The Activity of Daily Living Scale to 
measure function pre- and post-operatively in only half of the patients 
(eight knees), reporting post-operative mean 84% (the equivalent of 
excellent; scores ranged between 74% and 96%) compared to pre-
operative mean 42% (the equivalent of poor; scores ranged between 23% 
and 73%). The applicability of this data is limited by the small sample, 
therefore little inference can be made based on these results. The other 
study in this group (Charalambous et al., 2011), reported post-operative 
scores for AKSS Function/Clinical: 80 (63 - 100)/ 87 (63 - 88), OKS (35 
(26 - 44) and Melbourne Patellar Score 25 (16 - 30), all of which were 
satisfactory. However, without pre-operative data there is no indication 
whether the intervention led to an improvement in function. Satisfaction 
was also measured and the majority of patients deemed their level as 
‘better’. 
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Onlay symmetrical non-anatomical 
Prosthesis: Avon (nine studies) 
 
Five out of the nine studies had pre- and post-operative data (Ackroyd et 
al., 2007; Gao et al., 2010; Leadbetter et al., 2009; Mont et al., 2012; 
Sarda et al., 2011). One study (Nicol et al., 2006) did not report any 
functional scores and the remaining three (Hollinghurst et al., 2007; 
Odumenya et al., 2010; Starks et al., 2009) presented post-operative data 
only. Four out of the five studies with pre- and post-operative data 
reported the AKSS outcome and demonstrated an improvement post-
operatively. Pre-operative AKSS function mean range of 42 - 57 and 
AKSS clinical mean range of 49 - 64 compared to the post-operative 
AKSS function mean range of 67 - 95 and AKSS clinical mean range of 
80 - 96. There was no association between higher scores and shorter 
follow-up time; generally the post-operative scores were similar for all four 
studies. Satisfaction data also revealed the majority of patients were 
satisfied with the procedure. 
 
Onlay asymmetrical anatomical 
Prostheses: Natural Knee II (one study), Femoro Patella Vialla (three 
studies), Journey (one study) 
 
Two out of five studies reported pre- and post-operative OKS and AKSS 
scores both of which demonstrated improvements in function (Mofidi et 
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al., 2012; Monk et al., 2012). Hofmann et al. (2009) reported an 
improvement in Tegner score from level three pre-operatively to level five, 
implying patients were able to carry out heavy duty tasks and participate 
in competitive and recreational sports post-operatively. This finding 
supported the KOOS subsection satisfactory scores of between 70 and 
94 determined post-operatively in the same study. This study also 
assessed patient satisfaction and reported all the patients were satisfied. 
Out of the remaining two articles, one study (Williams et al., 2013) did not 
analyse function using scores and the other (Beitzel et al., 2013) reported 
improvements in WOMAC, Lysholm and VAS (pain) but did not offer 
specific values allowing for objective assessment of the results by the 
reader. 
 
Onlay asymmetrical patient-specific 
Prostheses: Custom Performa Knee (one study), Kinematch (one study) 
 
One out of two of the studies in this group reported the WOMAC score, a 
validated functional outcome, both pre- and post-operatively and showed 
an improvement from mean 63 to 28 (Butler & Shannon, 2009). The 
major limitation with this data is that both the pre- and post-operative data 
were collected at the same post-operative time point and therefore is 
susceptible to recall bias. The other study presented only satisfaction 
outcome and found all 25 patients were very satisfied. Ideally, a validated 
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patient-reported outcome would have offered more robust evidence of 
clinical outcome. 
 
Mixed group 
Prostheses: Richards I and II, CSF-Wright, Lubinus, Avon, FPV and 
miscellaneous other (not specified) 
 
Mohammed et al. (2008) did not report any functional scores. One study 
(Arnbjörnsson & Ryd, 1998) presented unsatisfactory Lysholm scores, 
suggesting at least one patient was worse after surgery (pre- and post-
operative as mean 45 (20 - 64) and 62 (6 - 100), respectively). In 
addition, 25% of the patients (28 out of 113) in this study were dissatisfied 
with the outcome following surgery. The remaining study (Arciero & 
Toomey, 1988) in this group presented post-operative Modified 
Hungerford and Kenna scale scores, with a majority rating good or 
excellent (nine knees: 80 - 89; nine knees: ≥ 90), however, seven knees 
rated as poor, scoring < 70. No indication was given to suggest these 
less satisfactory results were associated with one particular prosthesis. 
  
  
310
Total knee arthroplasty 
Prostheses: Anatomical Graduated Component (AGC), Legacy, Genesis, 
Low Contact Stress (LCS), Porous Coated Anatomic, Duracon, Insall-
Burstein II, Press Fit Condylar (PFC), Total Condylar 
 
Five out of six of these studies (Dalury, 2005; Laskin & van Steijn, 1999; 
Meding et al., 2007; Mont et al., 2002; Parvizi et al., 2001) reported pre- 
and post-operative AKSS scores, the remaining study (Thompson et al., 
2001) did not report any validated functional outcome data. Each study 
demonstrated an improvement in function and clinical outcomes: function 
pre-op mean range 36 to 71 and post-op mean range 83 to 96, clinical 
pre-op mean range 25 to 54 and post-op mean range 47 to 93. The high 
survival proportions and low number of complications are reflected in 
these relatively high post-operative functional scores. 
 
Comparison 
Prostheses: Avon, Zimmer TKA and SIGMA 
 
One comparison study (Dahm et al., 2010) reported pre- and post-
operative AKSS, Tegner and UCLA scores following Avon PFA in one 
group and Zimmer or SIGMA TKA in another group. All three scores 
improved for both groups significantly, however there were no statistically 
significant differences between the groups at short follow-up of means 2.3 
years (PFA) and 2.4 years (TKA). 
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3.7 Discussion and Critical Appraisal 
The principal aim of this systematic review was to determine the survival 
proportions and complications following PFA and TKA using the new 
design categorisation system introduced in this study. 
 Two survival proportions were assessed, Survival Proportion A, 
defined as the surviving number of implants, that is, the total number of 
knees minus the number of knees that suffered the endpoint event - 
revision to TKA due to disease progression, divided by the total number 
of knees assessed in the sample population and Survival Proportion B, as 
the surviving number of implants, that is, the total number of knees minus 
the number of knees that suffered the endpoint events - revision any 
reason to TKA, revision to another PFA, removal of PFA or arthrodesis, 
divided by the total number of knees assessed in the sample population. 
The design categories were: inlay symmetrical non-anatomical (ISN), 
inlay asymmetrical non-anatomical (IAN), inlay asymmetrical anatomical 
(IAA), onlay symmetrical non-anatomical (OSN), onlay asymmetrical 
anatomical (OAA), onlay asymmetrical patient-specific (OAP), mixed and 
TKA. 
 The forty studies reviewed in this systematic review were placed in 
the respective design categories and analysed within and between the 
groups. Due to the heterogeneity of the studies within each group a meta-
analysis and inferential statistics were not performed, instead the analysis 
carried out was descriptive. The studies were all observational, the 
majority (36) being retrospective uncontrolled case series’. This type of 
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study design is subject to a number of biases and limitations. This 
discussion focuses on evidence in relation to the prosthetic designs, the 
quality of the evidence presented in each group and the limitations of 
drawing conclusions from these studies. 
 
 
Inlay symmetrical non-anatomical 
Prostheses: Richards I and II (two studies); Richards II (five studies) 
 
The overall quality of the literature presented in this group was ‘low’ in 
accordance with the GRADE assessment system due to all the studies 
being uncontrolled retrospective case series’. The majority of the studies 
did define the study objectives, population and eligibility criteria. However, 
the data collection and analyses were often carried out by or involved the 
operating surgeon, which increased the risk of selective reporting bias. In 
addition, only the more recent studies clearly defined the intervention 
(surgeon, surgical approach, post-operative rehabilitation). The outcomes 
used in the studies were appropriate and the conclusions drawn were 
supported by the results presented. The length of follow-up varied greatly 
between the studies although three out of seven were long-term studies 
(de Winter et al., 2001; Kooijman et al., 2003; van Jonbergen et al., 
2010b). The loss to follow-up was very high in this group. Approximately, 
26% (155 out of 587) of knees within this group were excluded from data 
analysis. Cartier et al. (2005) reported a 35% loss to follow-up (33 
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patients lost to follow-up and five deceased), such large numbers omitted 
from the analysis ultimately compromises the validity of the findings 
presented. It is therefore possible that the survival and complication 
outcomes were poorer than those presented. The results, albeit 
undermined by the missing data, showed disease progression was the 
commonest mode of failure although ‘other’ and 
malpositioning/misalignment were the most frequently recorded 
complications. These may have been related to the Richards I prosthetic 
design. 
 The Richards prostheses, also known as, Blazina and Bechtol I, II 
and III (Smith & Nephew Richards Inc., Memphis, Tennessee) have a 
deep trochlear groove, which provides great stability. However, this high 
level of stability is not always advantageous, because it can sustain 
higher shear forces, if the soft tissues are unbalanced, possibly leading to 
loosening and rapid wear. Other drawbacks include increased bone loss 
to inset the prosthesis and prominent edges, which may cause soft tissue 
impingement. Cartier et al. (2005) reported patellar snapping and lateral 
patellar pain due this prominence. The deep constraining geometry of the 
trochlea requires accurate alignment of both the trochlear and patellar 
components, failure to do so may have resulted in the high number of 
reported cases of maltracking and catching of the patellar component on 
the already prominent edge of the trochlear prosthesis. De Winter et al. 
(2001) followed 26 patients for a mean of 11.1 years and recorded that 11 
had undergone further surgery (three patellectomies, three arthroscopic 
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washouts, two patellar realignments, two TKAs and two manipulations 
under anaesthesia). Kooijman et al. (2003) reported, at a mean of 17.0 
years follow-up, 27 reoperations in 45 PFAs, of which seven involved 
corrective surgery for either patellofemoral symptoms such as catching or 
prosthesis malpositioning. The most recent series, at 13.3 years median 
follow-up, identified 95 further operations performed in 67 out of 157 
patients of which at least 20 were for malpositioning, loosening or wear 
(van Jonbergen et al., 2010b). 
 This category had the highest number of pre index arthroplasty 
operations. It is therefore difficult to determine which complications are 
partly related to or a result of previous surgeries. Blazina et al. (1979) 
suggested patellar tendon shortening prior to arthroplasty surgery may 
have resulted in raised patellofemoral compression pressure causing 
persistent pain on knee flexion beyond 90°. Patella baja has been 
suggested as a contraindication to PFA surgery (Cartier et al., 2005). 
However, it is difficult to be certain this was the main problem as over 200 
procedures were carried out post index procedure compared to 31 
concomitantly which would suggest that problems also arose secondary 
to prosthesis implantation (see Table 6-41). 
 The importance of patient selection is highlighted in this category. 
De Winter et al. (2001) found none of the 19 PFAs that had no medial or 
lateral tibiofemoral arthritis pre-operatively were revised. Only one of the 
19 knees developed tibiofemoral arthritis grade 2 at 18.8 years follow-up 
unlike those with pre-operative medial or lateral tibiofemoral arthritis. Out 
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of those seven PFAs with evidence of tibiofemoral disease two were 
revised to TKAs. Whilst this is not conclusive evidence, it does support 
the argument for further research into the indications for PFA surgery. In 
addition, inadequately treated patellar instability, abnormal Q angles and 
increased tibial tuberosity trochlear groove (TTTG) distance would have 
also impacted the outcomes. 
 
Inlay asymmetrical non-anatomical 
Prostheses: Lubinus (three studies); Autocentric (one study); Autocentric 
II (one study) 
 
The articles in this category were also graded as ‘low’ in accordance with 
the GRADE assessment system. All five retrospective studies clearly 
stated study objectives and defined the study population 
(inclusion/exclusion criteria). The authors were explicit about the 
interventions and the outcome tools used to assess the treatment. The 
length of follow-up was clearly stated in each study. Unlike the previous 
group (inlay symmetrical non-anatomical) there were fewer patients lost 
to follow-up (including deceased) thus comparatively the applicability of 
the data was not compromised by this potential weakness. The majority 
of the studies based the conclusions on the study findings presented 
except Argenson et al. (2005). The authors of this study declared first line 
treatment for elderly patients should be TKA even though this was not 
assessed in this study. 
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Higher numbers of complications occurred with the Lubinus PFA 
(Waldemar Link, Hamburg, Germany) (Tauro et al., 2001) as reflected by 
poorer survival proportions than the Richards prostheses (see Table 3-4, 
Table 3-5 and Table 3-6). The dimensions of the Lubinus trochlear 
prosthesis and matching patellar component both varied depending on 
the size. The ‘extra-large’ size had a very shallow groove and was 
described as a ‘skid prosthesis’ (Ackroyd, 1996). The patellar component 
skidded about the surface of the trochlear component and was 
susceptible to maltracking. The other two sizes had a narrow medial-
lateral width, and a deep constraining groove in the axial plane. 
Additionally, these sizes had a relatively short anterior flange allowing the 
patellar component to contact the anterior cortex of the femur in full knee 
extension. The transition from the anterior femur to the trochlear 
component was not always smooth because in the sagittal plane the 
implant was less curved than the distal femur. Either the implant was 
fixed flush in the notch, which elevated the proximal end causing 
symptoms of patellar catching on engagement at the start of flexion, or it 
was placed with the proximal end flush on the femur, which risked 
impingement on the tibia or anterior cruciate ligament in extension. Tauro 
et al. (2001) found out of 76 Lubinus arthroplasties, 24 had patellar 
misalignment and a further 21 required revision surgery of which 15 were 
for patellar maltracking. Therefore 51% of knees had patellofemoral 
dysfunction, matching the high rate of unsatisfactory clinical outcome 
(55%) (Tauro et al., 2001). Although the designs of these prostheses 
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contributed to the complaints of patellar instability, it is plausible that this 
prevalence of patellar maltracking also resulted from lack of 
instrumentation to align the PFA components, and insufficient 
appreciation of the methods needed to balance the soft tissues. Tauro et 
al. (2001) reversed the trochlear component in an attempt to resolve 
issues of instability, however eight of the 21 patients that required 
revision surgery had reversed trochlear components. Snapping, clunking 
or subluxation and anterior knee pain were the most common symptoms 
(Smith et al., 2002; Tauro et al., 2001). Smith et al. (2002) highlighted the 
importance of patient selection, reporting the worse results were identified 
in the patients with evidence of medial tibiofemoral compartment arthritis 
pre-operatively. Out of these eight patients six underwent revision surgery 
or had unsatisfactory results.  
 The Autocentric (Depuy, Warsaw, Indiana) prosthesis was 
developed in 1980 by Grammont and Millon. The trochlear component 
was asymmetric, curved in both the sagittal and frontal planes, and the 
patellar component was designed as a self-centering device. The poor 
clinical outcomes and failure proportions, as high as 51% (Argenson et 
al., 2005), mainly due to loosening, stiffness, instability and disease 
progression, led to the withdrawal of this prosthesis (Argenson et al., 
2005; Gadeyne et al., 2008; van Wagenberg et al., 2009). Argenson et al. 
(2005) found disease progression most commonly occurred in patients 
with primary arthritis, compared with three out of 21 patients with patellar 
instability and three out of 18 patients with post-traumatic arthritis. 
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Inlay asymmetrical anatomical 
Prosthesis: LCS (two studies) 
 
The ‘very low’ GRADE classification was assigned to this group because 
of the degree of study limitations (biases) and imprecision (low patient 
numbers) identified. In general, both studies stated clear objectives, 
explicit inclusion and exclusion criteria and specified the time when 
recruitment occurred or dates of the index procedures. Clinically relevant 
outcomes were used in both studies and neither reported any loss to 
follow-up. However, consecutive patient inclusion was not explicitly stated 
and there was no comparator group in either study. The main criticism of 
this group lies with the study performed by the designing surgeon. The 
design surgeon, who also carried out 50% of the procedures, collected 
the pre- and post-operative data and sourced the additional eight cases 
from five other surgeons. No indication is given as to how these patients 
were selected and therefore the data is susceptible to selection and 
reporting bias. The ‘large’ statistically significant difference found between 
the pre- and post-operative ADL score was misinterpreted as an indicator 
of the benefits for stringent patient selection. The p value size is not an 
indicator of strength of association, it is rather a measure of the chance of 
getting this result when no real difference in scores actually existed. In 
order to prove the effects of this patient selection, with such a small 
cohort (16 patients), a modified study design with a statistical power 
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calculation showing that this was an adequate number would need to be 
performed to validate the author’s interpretation.  
 
 The Low Contact Stress (LCS) Patello-Femoral Joint (Depuy 
Orthopedics, Warsaw, Indiana) was based on the LCS total knee 
arthroplasty, and adopted the inlaid trochlear design of the Richards but 
produced less favourable results mainly due to patellar component failure 
(Amanatullah & Jamali, 2012; Arumilli et al., 2010; Charalambous et al., 
2011) despite early reports of success (Merchant, 2004; Merchant, 2005).  
The LCS modular two-part patellar component consisted of a 
metal plate for bone fixation and a mobile polyethylene bearing (Garcia et 
al., 2008). The concept was that the patella would be self-aligning within 
the trochlear groove to enhance tracking. However, the independent 
study revealed at two years 31% (17 out of 51) had already undergone 
revision of which only two were related to tibiofemoral disease 
progression (Charalambous et al., 2011) leading to survival proportion B 
of 67% or only 46% (95%CI 30% to 63%) survivorship at three years  with 
severe pain or revision as the endpoint. The high failure proportion was 
most likely a result of dissociation of the polyethylene from the metal base 
and loss of mobility, and significant metallosis due to metal-on-metal 
articulation of the trochlea with the metal base of the patellar component. 
This prosthesis has now been discontinued due to these poor results 
(Charalambous et al., 2011). 
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Onlay symmetrical non-anatomical 
Prosthesis: Avon (nine studies) 
 
The GRADE classification for this group was ‘low’. The main criticism of 
these studies was the lack of comparator group and retrospective 
evaluation. Only two out of the nine studies were prospective. The issue 
with the remaining seven retrospective studies were the high risk of 
biases. The quality of these studies was dependent on the accuracy and 
accessibility of the medical notes and patients (reporting bias). In 
addition, the investigator selected (selection bias) the cases even though 
the patients were stated to be consecutive. Other weaknesses include the 
majority of follow-up was short-term; only four studies presented mid-term 
results (Ackroyd et al., 2007; Mont et al., 2012; Nicol et al., 2006; 
Odumenya et al., 2010). The authors of two of the studies involved the 
design surgeon and therefore the results may not be as reproducible in 
an independent centre. The small loss to follow-up (18 in the entire 
group) maintained the generalisability of each study’s findings and 
minimised the potential biases that occur due to incomplete follow-up. For 
each study, the basic study objectives, sample population defined and 
location of data collection were clearly stated. The outcomes were stated 
explicitly and relevant to the predetermined objectives. The statistical 
analyses described were appropriate for the data collected and the 
interpretation of these results was consistent with the findings. 
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The Avon Patello-Femoral Joint Replacement System (Stryker® 
Howmedica Osteonics, Allendale, New Jersey) was based on the 
Kinemax total knee replacement (Hsu & Walker, 1989; Walker, 1991) and 
was designed with the aim of addressing the limitations of the earlier 
designs (see Appendix VI: Differences in Geometry) and thus produced 
better clinical results with fewer patellofemoral symptoms (Ackroyd, 2005; 
Ackroyd et al., 2007; Hendrix et al., 2008; Odumenya et al., 2010; Starks 
et al., 2009). The survival proportions and survivorship data, summarised 
in Table 3-4, suggested higher survival was associated with this design 
group. Ackroyd et al. (2007) reported less than 1% incidence of patellar 
maltracking. Complications such as malpositioning/misalignment 
occurred far less frequently than with the ISN and IAN designs as 
illustrated in the six complication forest plots Figure 3-5 to Figure 3-10. 
Progression of tibiofemoral degeneration was the most significant mode 
of failure for this implant (see Table 3-8). Studies with pre- and post-
operative functional outcomes showed significant improvements in all 
scores recorded. 
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Onlay, asymmetrical, anatomical designs 
Prostheses: Natural Knee II (one study), Femoro Patella Vialla (three 
studies), Journey (one study) 
 
The GRADE classification for this group was ‘very low’ due to reporting 
bias and omission of complication data. The majority of the studies were 
retrospective (four articles) compared with only one prospective study. 
The data available (Beitzel et al., 2013; Mofidi et al., 2012) consisted of 
small sample sizes with short follow-up and therefore little inference could 
be drawn. This problem was further perpetuated by the quality of 
reporting in some of the studies, for example, Beitzel et al. (2013) 
converted one knee to TKA but did not include this knee in the follow-up 
which was otherwise 100%. This illustration of reporting bias undermined 
the overall study findings. In addition, Beitzel et al. (2013) performed an a 
priori power analysis to show that the sample size was adequate. 
However, the point difference and standard deviation (S.D.) chosen were 
unnecessarily large, 25 points and S.D. 20 points and thus produced a 
very small sample size.  Although the MCID for the Lysholm score has 
yet to be defined, previous studies have shown that a clinically detectable 
change in knee injuries is between 8.9 and 10.1 with a standard error 
range of 9.7 to 12.5 (Collins et al., 2011). Unlike previous reports of high 
levels of aseptic loosening associated with FPV (Baker et al., 2012), this 
complication was not found in this systematic review. This may have 
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been due to the short follow-up or because three out of five of the studies 
did not report complication data. 
 
The onlay, asymmetrical, anatomical prostheses were designed to 
emulate the normal anatomical trochlea: asymmetrical 60:40 loading 
pattern on the trochlea between the lateral and medial facets of the 
patella, respectively. The Natural Knee II (Zimmer, Warsaw, Indiana, 
USA) is based on the NexGen TKA. The trochlear groove is recessed to 
reduce patellofemoral joint pressure and is designed to be compatible 
with an unresurfaced patella. The FPV lateral facet has a larger surface 
area and is relatively steeper than the medial facet. The sulcus angle is 
wider than in earlier prostheses (such as those in the ISN and IAN 
groups), measuring 140°, which is nearly as wide as the natural geometry 
at a mean of 145° (Shih et al., 2004). The sagittal arc of curvature is 90°, 
which matches the distal femur. The FPV patellar component is sided and 
facetted with an off-centre longitudinal ridge that becomes increasingly 
more medialised from proximal to distal. Similar to the Natural Knee II, 
the Journey PFA, based on the GENESIS® II Total Knee System (Smith 
& Nephew (Reconstructive) Ltd, Memphis, USA), offers patellar 
resurfacing as optional because the trochlear component (oxidised 
zirconium) has a significantly lower coefficient of friction than cobalt 
chrome. Literature discussing the impact of design on outcome is not 
largely available on these newer prostheses. However, Mofidi et al. 
(2012) found the FPV, with its onlay design, restored patellofemoral 
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height rather than caused overstuffing; an argument used by the 
advocates of inlay prostheses. 
 
 
Onlay, asymmetrical, patient-specific 
Prostheses: Custom Performa Knee (one study), Kinematch (one study) 
 
The GRADE rating for this category was ‘very low’. The main concern 
was the low number of patients and the quality of the data in the 
KineMatch study. This investigation was performed by the design team 
and therefore lacked independent assessment. In addition, no validated 
clinical outcomes were used and no complications were reported. A zero 
complication rate seems less plausible than the alternative explanations 
of missed complications due to infrequent patient follow-up and the 
exclusion of complications from reporting. The other investigation offered 
better quality research: independent study, survival and complication 
proportions were reported and a validated outcome was used to assess 
function (WOMAC score). The main limitations with this study were the 
pre- and post-operative functional outcome data were both collected post-
operatively and the sample size was small.  
 
The patient-specific prostheses were designed to overcome the 
limitations of size and lack of variability with off-the-shelf prostheses. 
Kinamed, the KineMatch® Patello-Femoral Replacement (Kinamed Inc., 
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Camarillo, California) design utilises the patient’s bony anatomy, 
identified using CT imaging, to determine the bony contact surface. When 
the bony anatomy is abnormal (e.g. trochlear dysplasia), the subchondral 
bone profile is used and the articular surface created to accommodate the 
domed patellar component. The Q angle and medial-lateral articular 
surface thickness are also patient-specific. The Custom Perform Knee 
(Biomet® Inc, Warsaw, Indiana) is an uncemented implant produced by 
similar methods. Despite the clear theoretical advantages of restoring an 
individual’s patellofemoral anatomy, the data available in this group for 
analysis did not sufficiently prove superior in terms of survival, 
complications and clinical outcomes. 
 
 
Mixed group 
Prostheses: Richards I and II, CSF-Wright, Lubinus, Avon, FPV and 
miscellaneous other (not specified) 
 
The purpose of including the mixed group was to determine whether 
there was a difference between this group and the single design groups. 
However, due to the level of evidence and heterogeneity of the data 
available, formal assessment (meta-analysis) was not possible. 
 
The GRADE level of evidence was classified as ‘low’. The main 
limitations in all three studies were retrospective data collection, no 
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comparator group and conclusions not supported by data presented. The 
strengths of the Arciero et al. (1988) study were the clear objectives 
stated and use of a relevant validated outcome. The main weakness was 
the authors concluded older patients with isolated patellofemoral arthritis 
have a high rate of success following PFA. The patient numbers were too 
low to accept this conclusion as truth rather than chance. Furthermore, 
there were many potential confounding factors, such as prosthesis used, 
concomitant surgery, patient activity, underlying diagnoses and other limb 
co-morbidities, which may have influenced this result. Mohammed et al. 
(2008) also concluded the FPV prosthesis was superior to the others 
assessed in the series, however, this was not sufficiently supported by 
the results. No attempt was made by the authors to demonstrate the 
patients that received the FPV were demographically the same as those 
that received the other prostheses. Despite this, this series had a large 
number of patients and involved multiple surgeons thus increasing the 
applicability of the data. Arnbjörnsson et al. (1998) reported the largest 
study in the group and involved multiple centres and surgeons. This study 
concluded that PFA was not as good as TKA although this was not 
assessed. Another weakness was the additional analyses of the Lysholm 
score in various subgroups: age, underlying diagnosis and pre index 
surgeries. Multiple analyses inevitably increase the risk of a Type I error. 
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Total knee arthroplasty 
Prostheses: Anatomical Graduated Component (AGC), Legacy, Genesis, 
Low Contact Stress (LCS), Porous Coated Anatomic, Duracon, Insall-
Burstein II, Press Fit Condylar (PFC), Total Condylar 
 
The GRADE level of evidence for this group was ‘low’. The strengths of 
the studies were clear study objectives and eligibility criteria and minimal 
loss to follow-up. However, there were general weaknesses such as 
retrospective data collection and lack of a PFA comparator group. Some 
studies restricted age to less than 60 years (Meding et al., 2007), others 
restricted selection to patients who had not undergone any pre index 
surgery procedures (Mont et al., 2002) and surgical interventions also 
varied from all receiving patellar resurfacing (Dalury, 2005) to no patellar 
resurfacing (Thompson et al., 2001). Parvizi et al. (2001) reported a 
number of complications related to prosthesis misalignment but no 
indication was given as to which of the three different prosthetic designs- 
posterior substituting, cruciate retaining and cruciate sacrificing were 
implicated. Thompson et al. (2001) did not use any validated outcomes to 
objectively assess patient function. In view of these general and individual 
study weaknesses the applicability of the findings were limited. 
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Comparison 
Prostheses: Avon, Zimmer TKA and SIGMA 
 
Only one comparative study was identified in this systematic review. The 
strengths of this study (Dahm et al., 2010) were no loss to follow-up, good 
data analysis, the authors reported validated scores pre- and post-
operatively and attempted to match the groups of patients. They 
acknowledged the statistically significant difference in mean age and 
performed a multivariate regression analysis powered to >90% and 
stated it had no effect on the post-operative functional scores. However 
there were a number of limitations, the investigation was retrospective, 
the groups consisted of small sample sizes and the follow-up was 
relatively short. For these reasons the GRADE level was ‘low’. In addition, 
although the groups were proven matched over a number of variables, 
the PFA group was a single surgeon series (except for two PFAs) and 
one prosthetic design (Avon) and the TKA group involved eight surgeons 
and two types of TKA design. Furthermore, this type of study design does 
not control for differences in unknown confounding factors between the 
groups. 
3.8 Summary and Conclusion 
 
This is the first systematic review to evaluate PFA by design features. 
Analysis of the primary outcome, survival proportions A and B, found non-
anatomical inlay designs, ISN and IAN, produced the poorest results. 
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Though these inlay design groups had some of the longest follow-up, 
failures also occurred at shorter time points suggesting factors other than 
disease progression also contributed to the higher number of 
complications and revisions associated with these groups. The most 
common reason for failures was disease progression for all the groups. 
Early studies suggested patient selection should have been more 
rigorous, due to patients with evidence of primary/idiopathic arthritis or 
tibiofemoral degeneration undergoing a higher number of revisions 
(Argenson et al., 2005; de Winter et al., 2001; Smith et al., 2002). The 
proportion of failure related to disease progression was not always 
dependent on length of follow-up. For example, Board et al. (2004) 
reported 76% survival proportion A at 1.6 years mean follow-up. In 
contrast, the OSN group (Avon prosthesis), which had the largest number 
of studies, demonstrated survival proportion A range of 88% to 96% at 
5.2 to 7.1 years mid-term follow-up. This group was the most comparable 
to the TKA group, which had a survival proportion range of 94% to 100% 
at 5.2 to 7.4 years mid-term follow-up. The lowest survival proportion B 
results were evident in the ISN and IAN groups. The ISN group (Richards 
prostheses) and the IAN group (Lubinus and Autocentric prostheses) 
were the earliest PFA designs and therefore subject to free-hand 
implantation methods, lack of appreciation for soft tissue balancing and 
less stringent patient selection. 
 The most common complication (in terms of proportion) was 
malpositioning/misalignment (most common in ISN, IAN and TKA groups) 
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followed by disease progression (most common in IAA and OSN groups) 
then ‘other’ (most common in OAP and mixed groups). 
Malpositioning/misalignment was recorded most frequently in the ISN and 
IAN groups. Persistent pain was a relatively common problem in the IAA 
and mixed groups and was the most common complication reported in 
the OAA group. Aseptic loosening and infection were a rare occurrence 
across all the groups. The number of reoperations was greatest in the 
ISN group; over 250 secondary surgical procedures (including revisions) 
were performed after the index surgery. 
 The functional outcome reporting varied considerably within and 
between the groups thus limiting the evaluation. Generally, when both 
pre- and post-operative outcome data was presented, improvements 
were seen and deemed significant in all the groups. Only one study in the 
mixed group (Arnbjörnsson & Ryd, 1998) found a poorer outcome in a 
patient post-operatively. 
 The applicability of the findings in this systematic review to the 
wider population was limited by a number of major weaknesses. Thirty-six 
out of forty studies were uncontrolled retrospective case series’ and 
overall the quality of evidence was rated as low or very low. The clinical 
heterogeneity within and between the groups was substantial. For 
example, some authors chose to restrict patients by age, aetiology, 
proven isolated disease and/or absence of antecedent surgery. Whereas 
others were more inclusive and performed PFA on any patient with 
symptomatic patellofemoral arthritis, including patients with asymptomatic 
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grade 2 or less tibiofemoral degeneration. The variation in follow-up time, 
sample size, number of studies evaluated in each design group, 
antecedent and concomitant surgery, patient activity levels prior to 
surgery, underlying diagnoses and other limb co-morbidities all limited the 
extent of the comparisons. Due to these known disparities it is impossible 
to determine the extent to which these factors influenced the survival and 
complication differences between the design groups compared to the 
effect of variation in prosthetic design. 
 The majority of the studies were subject to selection and reporting 
biases due to the retrospective (and on occasion non-consecutive) 
patient selection and data collection. The loss to follow-up varied 
considerably. For instance, 26% of the patients in the ISN group were lost 
to follow-up. Such high loses compromise the external validity of the 
results presented in this group. 
 The conclusions that can be drawn from this systematic review are 
limited due to the discussed limitations. The decision to only include 
published literature narrowed the potential inferences further due to 
publication bias. In addition, the understanding of patellofemoral arthritis 
has evolved over the decades and there is a greater appreciation for 
patient selection, soft tissue balancing, underlying alignment pathology 
and instrumentation improvements with the newer prostheses, all of 
which could have influenced outcomes more than prosthetic design. 
Whilst bearing in mind these drawbacks, the data indicate the inlay 
designs produced poor survival and high complication proportions and 
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the onlay symmetrical non-anatomical group was the most comparable to 
the TKA group. 
 In order to evaluate further survival and complication outcomes 
following PFA and TKA, a more robust study design that eliminates the 
issue of confounding factors, selection and reporting bias and focuses on 
comparing current PFA prostheses to TKA is required. A prospective 
randomised trial is the most rigorous way to determine the difference 
between PFA and TKA in terms of survival and complication. Whilst it is 
not feasible to compare each design group with TKA, a pragmatic 
randomised clinical trial comparing currently used PFA prostheses and 
TKA would address this question. 
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3.9 PRISMA Checklist 
Section/topic Item No Checklist item 
Reported in 
section 
Title 
Title 1 Identify the report as a systematic review, meta-analysis, or both Chapter 3 
Abstract 
Structured 
summary 2 
Provide a structured summary including, as applicable, background, 
objectives, data sources, study eligibility criteria, participants, 
interventions, study appraisal and synthesis methods, results, 
limitations, conclusions and implications of key findings, systematic 
review registration number 
3.1 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known 3.2 
Objectives 4 
Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, and 
study design (PICOS) 
3.3 
Methods 
Protocol and 
registration 5 
Indicate if a review protocol exists, if and where it can be accessed 
(such as web address), and, if available, provide registration 
information including registration number 
N/A 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, 3.4 
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publication status) used as criteria for eligibility, giving rationale 
Information 
sources 7 
Describe all information sources (such as databases with dates of 
coverage, contact with study authors to identify additional studies) in 
the search and date last searched 
3.5.1 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated 3.5.2 
Study selection 9 
State the process for selecting studies (that is, screening, eligibility, 
included in systematic review, and, if applicable, included in the 
meta-analysis) 
3.5.3 
Data collection 
process 10 
Describe method of data extraction from reports (such as piloted 
forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators 
3.5.3 
Data items 11 
List and define all variables for which data were sought (such as 
PICOS, funding sources) and any assumptions and simplifications 
made 
3.4.4 
Risk of bias in 
individual studies 12 
Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the study 
or outcome level), and how this information is to be used in any data 
synthesis 
3.5.4 
Summary 
measures 13 
State the principal summary measures (such as risk ratio, difference 
in means). 3.5.5 
Synthesis of 
results 14 
Describe the methods of handling data and combining results of 
studies, if done, including measures of consistency (such as I2 
statistic) for each meta-analysis 
3.5.5 
Risk of bias 
across studies 15 
Specify any assessment of risk of bias that may affect the 
cumulative evidence (such as publication bias, selective reporting 
within studies) 
3.5.4 
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Additional 
analyses 16 
Describe methods of additional analyses (such as sensitivity or 
subgroup analyses, meta-regression), if done, indicating which were 
pre-specified 
N/A 
Results 
Study selection 17 
Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram 
3.6.1 
Study 
characteristics 18 
For each study, present characteristics for which data were 
extracted (such as study size, PICOS, follow-up period) and provide 
the citations 
3.6.3 
Table 3-2 
Table 3-3 
Risk of bias 
within studies 19 
Present data on risk of bias of each study and, if available, any 
outcome-level assessment (see item 12). 3.6.2 
Results of 
individual studies 20 
For all outcomes considered (benefits or harms), present for each 
study (a) simple summary data for each intervention group and (b) 
effect estimates and confidence intervals, ideally with a forest plot 
3.6.4 
3.6.5 
3.6.6 
Synthesis of 
results 21 
Present results of each meta-analysis done, including confidence 
intervals and measures of consistency N/A 
Risk of bias 
across studies 22 
Present results of any assessment of risk of bias across studies (see 
item 15) 3.6.2.6 
Additional 
analysis 23 
Give results of additional analyses, if done (such as sensitivity or 
subgroup analyses, meta-regression) (see item 16) N/A 
Discussion 
Summary of 
evidence 24 
Summarise the main findings including the strength of evidence for 
each main outcome; consider their relevance to key groups (such as 
health care providers, users, and policy makers) 
3.7 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified 3.8 
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research, reporting bias) 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research 3.8 
Funding 
Funding 27 
Describe sources of funding for the systematic review and other 
support (such as supply of data) and role of funders for the 
systematic review 
N/A 
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Chapter 4 The Warwick Patellofemoral 
Arthroplasty Trial: A Randomised 
Clinical Trial of Total Knee 
Arthroplasty versus Patellofemoral 
Arthroplasty in Patients with Severe 
Arthritis of the Patellofemoral Joint 
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4.1 Abstract 
Objectives 
Many surgeons believe total knee arthroplasty is the ‘gold standard’ 
treatment for all severe knee arthritis. However, patellofemoral 
arthroplasty has been recognised as a ‘less invasive’ procedure for the 
treatment of severe patellofemoral arthritis, preserving the tibiofemoral 
joint and cruciate ligaments, thus enabling a more rapid recovery. There 
are currently no published randomised clinical trials comparing these two 
interventions. The main objective of the current study was to determine 
whether there is a difference in functional knee scores and quality of life 
outcome assessments at one year post intervention between 
patellofemoral arthroplasty and total knee arthroplasty. The secondary 
objective was to assess the complication rates for both procedures. 
 
Methods 
Parallel, two-arm, double-blinded randomised clinical trial. This study was 
designed as a superiority trial. The sample size was determined using the 
functional section of the WOMAC score. Based on a two sample t-test 
(5%) using a minimal clinically important difference of 8 points and 
standard deviation of 10.8 points the number of participants required in 
each arm of the trial was 29. To allow for a 10% loss to follow-up, 32 
patients were recruited in each arm. The study was powered at 80% to 
detect a difference at the 5% significance level. Skeletally mature 
patients, who were deemed suitable for patellofemoral arthroplasty by an 
  
340
orthopaedic arthroplasty consultant and medically fit for surgery, were 
eligible for the trial. Consenting participants were randomised in a 1:1 
allocation to either patellofemoral or total knee arthroplasty. The 
randomisation was computer generated and administered by a central 
independent randomisation centre. All participants had knee function, 
quality of life and physical activity assessed through the following 
outcomes. The primary outcome measure was the WOMAC (Western 
Ontario and McMaster Universities Osteoarthritis Index Score). The 
secondary outcome measures were OKS (Oxford Knee Score), AKSS 
(American Knee Society Score), EuroQol and UCLA Physical Activity 
Rating Scale and complication rates (related and unrelated serious 
adverse events). All participants were assessed using these outcomes 
following the initial trial participation consent (0 months). All baseline data 
was collected prior to randomisation. Subsequent data collection was 
carried out at 3, 6 and 12 months after the surgical intervention. All 
complications were recorded at each time point. The primary endpoint of 
the trial was 12 months. The intervention consisted of either 
patellofemoral arthroplasty or total knee arthroplasty. The surgical 
technique used was determined by surgeon preference. The participants 
and research associates remained blinded for the duration of the trial. 
 
Results 
Thirty-two patients were allocated to each treatment group. There were 
five protocol violations resulting in participants receiving treatment to 
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which they were not allocated (two in TKA group; three in PFA group). 
Three participants withdrew following allocated treatment and one 
declined treatment following allocation. These four participants formally 
withdrew from the trial and therefore were not included in the intention-to-
treat analysis. A remainder of 60 participants completed the trial. On an 
intention-to-treat basis there were 31 participants in the PFA group and 
29 in TKA group; per-protocol – 28 in PFA group and 27 in TKA group. 
No difference in participant demographics was identified. The 
complication rate was higher in the TKA group but numbers were small 
and no inferential statistics were performed. Endpoint (12 months) 
analyses showed no difference in functional outcomes, physical activity or 
quality of life between the treatment groups. The intention-to treat 
adjusted analysis estimated treatment difference for the WOMAC score 
was -3.31 with 95% CI (-14.34, 7.73) and p-value of 0.550, per- protocol 
was 0.0594 with 95% CI (-11.02, 11.14) and p-value of 0.991.  
However, the adjusted 95% confidence interval for the treatment 
effect (intention-to-treat) on the WOMAC function score (-9.19, 6.80) 
confirms that an effect size of 8 points in favour of PFA cannot be 
rejected. The variability in the outcomes was greater than expected. 
 
 
Conclusion 
The results of this trial failed to show statistical evidence of a difference in 
treatment group outcome between TKA and PFA. Despite the trial being 
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underpowered the data does not support evidence for superiority of PFA 
over TKA. Therefore a non-inferiority trial involving a larger sample size 
across multiple centres is required. 
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4.2 Funding 
Action Medical Research 01.05.09- 30.04.13 
Grant Reference: AP1170 
Amount: £91, 470 
Grant title: A randomised clinical trial of total knee arthroplasty versus 
patellofemoral arthroplasty in patients with severe arthritis of the 
patellofemoral joint 
 
The funders had no involvement or influence on the study design, 
conduct, analysis and reporting of the trial. 
 
Annual interim reports were generated including the following information: 
1. Background to the project and aims of the research 
2. Details of work completed 
3. Plan of work to be performed 
4. Difficulties impeding project progression 
5. Identified patentable or commercially exploitable aspects of the 
research 
6. Publication details in full as result of the research 
 
Annual lay reports for the public were generated including: 
1. Progress 
2. Anticipated outcomes 
3. Likely benefits of the research 
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4.3 Trial Registration and Assignment Number 
The assigned International Standard Randomised Controlled Trial 
Number (ISRCTN) is ISRCTN34863373. The trial formerly received 
notification of the assignment number on 2nd September 2009. 
 
4.4 Intellectual Ownership 
The original trial protocol and grant application was a joint effort of the 
trial team. Aspects of the trial that I conducted were: 
1. Protocol background research and writing 
2. Publication of trial protocol 
3. Ethics Committee REC submission 
4. Patient information sheets 
5. GP information sheets 
6. Patient recruitment 
7. Data management: data collection on case report forms, database 
updates, recording of decision pending, missed, declined patients 
8. Trial Management Group member 
9. Ethics updates: submission of substantial changes 
10. Submissions to Action Medical Research: application for no-cost 
grant extension, interim reports and final report 
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4.5 Introduction 
Severe knee arthritis is a highly debilitating disease. According to the 
National Joint Registry, at the start of this trial in 2009 over 70,000 knee 
replacements were carried out over a year in the UK at an estimated cost 
of 280 million pounds. Currently, this value has since risen to over 90,000 
replacements at a cost of nearly 400 million pounds (Wales, 2014). 
Isolated patellofemoral arthritis occurs in a number of patients diagnosed 
with severe arthritis. The radiological prevalence of this disorder is 13.6 to 
24.3% in women and 11.0 to 15.4% in men over the age of 55 
(McAlindon et al., 1992). Current evidence no longer supports the use of 
arthroscopy or patellectomy for patients with severe isolated 
patellofemoral arthritis (Lennox et al., 1994). Therefore, definitive 
treatment choice for patients is between patellofemoral arthroplasty and 
total knee arthroplasty. 
 While most surgeons believe total knee arthroplasty is the ‘gold 
standard’ procedure for all presentations of severe knee arthritis, 
patellofemoral arthroplasty offers potential advantages. This operation 
preserves the majority of the patient’s own knee joint; minimal bone loss 
and retention of ligamentous stability. Patellofemoral arthroplasty has 
also been recognised as a less invasive operation, enabling a shorter 
recovery time (Ackroyd, 2005). Furthermore, the presentation and 
aetiology of patients with isolated patellofemoral arthritis tends to differ to 
those with tricompartmental disease and thus may justify the more 
targeted intervention offered by patellofemoral arthroplasty (Cicuttini et 
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al., 1997; Clark, 2008; Tamm et al., 2008). Despite these theoretical 
advantages the initial designs did not produce acceptable results, mainly 
due to patellar misalignment, polyethylene wear and early failure due to 
disease progression (Arciero & Toomey, 1988). More recent studies have 
yielded more favourable results as demonstrated in Chapter 3. However, 
the inferences drawn from this systematic review did not provide sufficient 
evidence for deciding between total knee arthroplasty and patellofemoral 
arthroplasty; a randomised clinical trial is required. 
4.6 Background 
4.6.1 Rationale for Trial 
There are currently no published results of randomised clinical trials 
comparing total knee arthroplasty and patellofemoral arthroplasty. One 
UK based trial had been registered (ISRCTN22478626) but not 
performed. Another trial is currently underway in Denmark. This trial 
consists of a comparison between two prostheses: Avon versus PFC, 50 
participants per arm, 1:1 allocation. However, the results of this trial are 
yet to be established although the applicability of these findings may be 
limited to the prostheses used. Therefore, the question remains 
unanswered as to whether there is a functional difference in the outcome 
between total knee arthroplasty and patellofemoral arthroplasty. This 
deficit in the evidence is clearly demonstrated in chapter 3: systematic 
review, which showed the literature does not provide a satisfactory 
answer to the question. Furthermore, Arthritis UK have highlighted 
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research into joint replacement, in terms of survival, function and 
complication rates as a key research goal (UK, 2010). Therefore, the 
purpose of this trial was to address this shortfall in the literature, providing 
surgeons and patients with more robust and accurate information 
regarding knee function and complication rates. 
4.7 Null Hypothesis 
There is no difference in functional score (WOMAC- Western Ontario and 
McMaster Universities Osteoarthritis Index Score) at one year post-
operation between total knee arthroplasty and patellofemoral arthroplasty. 
4.8 Study Design 
A two-arm, double-blinded, randomised clinical trial carried out in a single 
centre- University Hospitals Coventry and Warwickshire NHS Trust. The 
participants and research associates were blinded for the duration of the 
trial. The study was conducting in agreement with Good Clinical Practice 
(GCP) guidelines. All collaborators and research associates were GCP 
certified. The study was granted Ethical Approval by the Coventry 
Research Ethics Committee on 3rd March 2009 under the reference 
09/H1210/9. Three subsequent substantial amendments were made to 
the trial once granted by the committee: 
1. 8th April 2009: Addition of the UCLA knee rating scale; specifically 
the physical activity scale 
2. 16th March 2011: The trial protocol was updated to comply with the 
University of Warwick Clinical Trials Unit Standard Operating 
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Procedure for ‘trial protocols’. Three small amendments were 
made to the methodology:  
a. The randomisation sequence was held by the Clinical Trials 
Unit at the University of Warwick 
b. The randomisation was no longer stratified by surgeon 
c. No health economics analysis due to limited funding. 
3. 20th June 2011: All patients that undergo arthroplasty surgery are 
routinely followed up at five-year intervals as part of standard 
clinical surveillance at University Hospitals Coventry and 
Warwickshire NHS Trust. In order to keep closer monitoring of the 
trial participants, permission for annual postal questionnaires (the 
same as the trial outcomes) was sought and granted. This was 
edited in the protocol and a new version (version 3) was submitted 
along with the annual review questionnaires. The trial protocol has 
been published; reference is as stated in Publications.  
 
The research was carried out in compliance with the Helsinki Declaration. 
4.9 Aims and Objectives 
The aim of this randomised clinical trial was to determine whether a 
difference in functional outcome (WOMAC – Western Ontario and 
McMaster Universities Osteoarthritis Index Score) exists between TKA 
and PFA at one year post intervention. 
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There were two main objectives of this randomised clinical trial: 
1. To quantify and draw inferences on observed differences in 
primary and secondary outcome measures between the trial 
treatment groups at one year post intervention. 
2. To determine the complication rate of PFA versus TKA at one year 
post intervention. 
4.10 Material and Methods 
4.10.1 Eligibility Criteria 
Inclusion Criteria: skeletally mature patients who were able to give 
informed consent, medically fit for an operation and had severe isolated 
patellofemoral arthritis deemed suitable for a PFA by their orthopaedic 
consultant were eligible for the trial. Severe disease was determined 
clinically and radiologically by the orthopaedic consultant in keeping with 
their standard practice. It was accepted that patients eligible for a PFA 
were also suitable for a TKA. These wide criteria meant that the results 
were readily generalisable to the varied population of patients with severe 
isolated patellofemoral arthritis. Exclusion criteria: included patients with 
tibiofemoral arthritis and those unfit for surgery. This was defined as the 
following: 
 
1. Severe cardiac impairment e.g. heart or valve replacement, 
arrhythmia, previous severe myocardial infarction 
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2.  Severe respiratory impairment e.g. chronic obstructive pulmonary 
disease, asthma that has required intensive care admission 
3. Any other systemic medical condition that would prohibit 
administration of a general anaesthetic 
 
Additionally, patients unable to adhere to trial procedures or complete 
questionnaires due lack of mental capacity (e.g. dementia) or intravenous 
drug abuse were excluded. 
For patients who required contra-lateral knee arthroplasty during the 
duration of the trial, the second knee was not considered eligible for the 
study as the results of the second intervention would not have been 
independent of the first intervention.  
4.10.2 Patient Selection 
Patients were recruited from the orthopaedic clinics at University 
Hospitals Coventry and Warwickshire NHS Trust. Each arthroplasty clinic 
list was reviewed one to five days before the clinic date. All patients with 
patellofemoral pathology were brought to the attention of the orthopaedic 
consultant who then determined the patient’s eligibility. Following 
identification of an eligible patient, the research associate, already 
present in clinic, was informed. The research associate provided the 
patient with a verbal explanation of what the trial entails and patient 
information sheet (see Appendix VII). The patients were given adequate 
time to discuss any aspects of the trial and raise queries with the 
research associate, their orthopaedic consultant, GP, family and friends. 
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This time frame was not restricted to allow ample opportunity for all 
issues to be addressed and for the patient to make an informed decision 
about participation in the trial. 
4.10.3 Consent 
Informed consent was obtained by the research associates. A system 
was set up to ensure any new information that emerged during the trial, 
which may have impacted participants’ commitment to partake, was 
reviewed by the Trial Steering Committee.  
All participants who decide to decline their treatment or withdraw 
post randomisation were followed up as normal in accordance with 
departmental guidelines. In the event these patients reconsidered their 
decision a signed updated consent form was required. 
4.10.4 Trial Withdrawals 
Participants were able to withdraw from the trial at any time without 
prejudice. When withdrawals occurred post randomisation, attempts were 
made to follow-up these patients and collect data as per protocol, until 
trial completion. The plan for this data was to include it in the primary 
intention-to-treat analysis and secondary per-protocol analysis. This 
strategy of follow-up and data collection also applied to those who did not 
receive treatment, with the intent of including their data in the intention-to-
treat analysis. 
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4.10.5 Randomisation 
The participants were randomised in a 1:1 allocation to TKA or PFA. The 
type of randomisation was simple, that is, not restricted, blocked or 
stratified. A secure centralised, telephone randomisation service provided 
the computer generated randomisation sequence. This service was 
based at the University of Warwick Clinical Trials Unit. An independent 
researcher contacted the service via telephone to establish the treatment 
allocation. This information was then emailed to the medical secretary of 
the operating consultant by the randomisation service. The medical 
secretary then entered the treatment allocation on the participants 
operation booking form but not on the operation list as to preserve 
concealment. This system ensured that the research associated 
collecting outcome data remained blind to the treatment allocation. 
4.10.6 Blinding 
The participants were also blinded to their treatment allocation to allow for 
an unbiased comparison to be made between the two interventions for 
the duration of the trial. To ensure participant blinding was not 
compromised, the participant GP, all ward staff including doctors, nurses, 
healthcare assistants, physiotherapists and theatre staff were informed of 
the trial protocol and therefore all necessary precaution was taken to 
avoid divulging the treatment allocation. The surgeons were, of course, 
not blinded and therefore did not partake in data collection.  
  
353
4.10.7 Interventions 
The two treatments in this study were patellofemoral arthroplasty (PFA) 
and total knee arthroplasty (TKA). Due to the pragmatic nature of the trial, 
the preferred prosthesis and preferred surgical technique was surgeon 
dependent. This decision was made in order to ensure the generalisability 
of the trial results to a broad group of patients and surgeons. All 
operations were carried out by or under the supervision of a consultant 
surgeon. Seven consultant orthopaedic surgeons, five registrars and two 
arthroplasty fellows were involved in performing the surgery. Each 
operation was either performed by or under the supervision of the 
consultant. 
Patellofemoral Arthroplasty: During the trial the implants used were 
Avon, FPV, and Zimmer PFJ prostheses. 
Total Knee Arthroplasty: During the trial the implants used were 
NexGen, Vanguard, Medial Pivot and Triathlon prostheses. Replacement 
of the patella was decided by the operating surgeon. 
Rehabilitation: All patients received the same rehabilitation programme 
described in the departmental ‘Knee Replacement: A Guide for Patients’ 
Booklet’. This consisted of early exercises, specific precautions for the 
first three months, how to perform functional activities and advanced 
exercises.  
4.10.8 Primary Outcome Measure 
The key criteria for choosing the primary outcome measure were: 
1. Meets standards for validity, reliability and responsiveness 
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2. Patient-reported 
3. Tolerable questionnaire length to ensure maximum response and 
compliance 
4. Widely-used to allow for comparability 
 
One of the most commonly used assessment tools for patients with knee 
arthritis is the Western Ontario McMaster Universities Osteoarthritis Index 
(WOMAC) (Angst et al., 2001; Bellamy, 1995; Bellamy et al., 1988; 
Bellamy et al., 1990). This scale has been shown to be responsive 
(sensitive to change), valid for patients with arthritis (Kirkley et al., 1999; 
Sun et al., 1997; Theiler et al., 1999) and user-friendly (Angst et al., 
2001). 
The WOMAC score was chosen as the primary outcome. This 
patient reported outcome measure consists of 24 items (5 for pain, 2 for 
stiffness and 17 for physical function), all related to daily activities, which 
are directly impacted by poor function secondary to osteoarthritis. The 
best score achievable is 0 and the worst score is 96 (Bellamy et al., 
1988). 
4.10.9 Secondary Outcome Measures 
The choice of secondary outcome measures was based on 
identifying scores that potentially support the primary outcome and 
evaluate additional effects of the interventions. Scores that met closely 
the ideal criteria: validated, joint-specific and/or disease-specific and an 
effective measure over time, were considered. In addition, an appropriate 
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measure required for evaluating health economics was selected. Based 
on these requirements the following five secondary outcomes were 
chosen: Oxford Knee Score (OKS), American Knee Society Score 
(AKSS), EuroQol (EQ5D and EQ VAS), Disability Rating Index (DRI) and 
complications. Following receipt of ethics approval but prior to 
commencement of recruitment the UCLA Physical Activity Questionnaire 
(including walking and function ratings) was added as a substantial 
amendment in addition to the five existing outcomes. This outcome 
measure was added because it had been proven to be the most 
appropriate measure of activity for arthroplasty patients (Naal et al., 
2009). 
The number of outcome measures used created high participant 
burden. In addition, there was significant overlap between some of the 
questionnaires. To encourage compliance, the decision was made via the 
appropriate channels (following proposal by Trial Management Group to 
the Trial Steering Committee) to exclude the Disability Rating Index 
(Salén et al., 1994) from the collection of outcome measures. This 
outcome was chosen over the OKS and AKSS as these were deemed 
knee-specific and at the time, the EuroQol (EQ5D and EQ VAS) was kept 
as there was still a possibility of calculating health economics. The Trial 
Steering Committee were confident that the remaining outcome 
measures would capture sufficient information to answer the objectives 
outlined at the start of the project. 
Therefore the final five secondary outcomes used in the trial were: 
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1. Oxford Knee Score (OKS): this patient reported outcome is a 
validated knee arthroplasty functional score consisting of 12 items 
related to daily tasks. The minimum (best outcome) score was 
originally described as 12 and the maximum (worst outcome) 
score, 60 (Dawson et al., 1998). However, for this study the 0 to 48 
method of scoring has been used, whereby 48 was considered the 
maximum and worst outcome. 
2. American Knee Society Score (AKSS): this is also a validated 
knee function score, which consists of two parts: knee score and 
function score. Unlike the WOMAC and OKS, this outcome is not 
completely patient reported. The knee score involves assessment 
of pain, range of motion, stability and alignment. The function 
score includes assessment of daily activities to analysis functional 
capacity. Both scores range from 0 (worst outcome) to 100 (best 
outcome) (Insall et al., 1989). 
3. EuroQol (EQ5D): this patient reported validated health assessment 
consists of five 3-tiered questions related to daily activities and 
mental health. The combination of answers produces the quality of 
life score. The EQ Visual Analogue Scale (EQ VAS) is a patient 
reported health rating outcome on a 20cm vertical visual analogue 
scale. The scale ranges from 0 – worst imaginable health state 
and 100 – best imaginable health state. 
4. UCLA Physical Activity Questionnaire: The University of California, 
Los Angeles activity rating scale is a patient reported assessment 
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on a 1 to 10 scale, whereby 1 is the worst outcome (no physical 
activity) and 10 is the best outcome (regular participation in impact 
sports) (Zahiri et al., 1998). The walking and function rating aspect 
of the UCLA score are also calculated on the same scale. 
5. Complications: all complications from time of intervention to 
completion of the trial were recorded. 
4.10.10 Sample size 
As stated above, previous work has suggested that the WOMAC score is 
the most sensitive condition-specific tool for assessing interventions in 
knee and hip osteoarthritis (Bellamy, 1995; Bellamy et al., 1988). Angst et 
al., (2001) successfullly demonstrated the use of the 17-item functional 
section of the WOMAC score to determine sample size.   
 
Assuming the score follows a normal distribution, the required number of 
patients in each arm of the trial is 29, based on a two-sample t-test (5%) 
using a standard deviation of 10.8 points (Rooks et al., 2006) and a 
minimum clinically important difference of 8 points, as shown in the 
calculation below (Rooks et al., 2006). This number of patients will 
provide 80% power to detect a difference at the 5% level. To allow for a 
10% loss to follow-up we will aim to recruit 32 patients in each arm. 
 
The calculation was performed using PS Power and Sample Size 
Calculation Software version 2.1 30th February 2003 and further verified 
using a biostatistics reference as shown below (Chow et al., 2008).  
  
358
 
Calculations 
Two arm trial; parallel groups 
Calculation for Minimal Clinically Importance Difference (MCID): 
Twelve percent of the absolute baseline value for the WOMAC functional 
score (68) equates to the MCID (Angst et al., 2002; Angst et al., 2001). 
MCID  680.12
MCID  8.16
 8
 
Therefore, an 8 point difference was deemed clinically meaningful. 
 
Calculation for Standard Deviation: 
Effect size = mean of treatment group – mean of control group 
    standard deviation 
therefore using mean difference of 8 points and effect size of 0.74 (Rooks 
et al., 2006), 
0.74  8
sd
sd  8
0.74
sd 10.8
 
 
Population standard deviation = 10.8 points WOMAC functional score 
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Calculation for Sample Size: 
MCID = 8 points 
Standard deviation = 10.8 points 
Significance level = 5%  
Power = 80%  
n  2(Z 2 Z )
22
2
Z 2 1.96
Z  0.84
2 10.82
2  82
n  27.84116.64
64
n  29
 
    
 
Accounting for a 10% loss,  
n  29
0.9
n  32
 
 
Therefore, 32 participants in each group. 
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4.10.11 Data Collection 
For trial analysis, the primary time point for outcome results was at 12 
months. In addition, data collection was performed at the planned time 
points: baseline (0 months), 3 months and 6 months post operation to 
allow for data monitoring and subsequent comparison analysis. At each 
time point the patients attended clinic and were reviewed by the research 
associate or fellow, and if necessary an orthopaedic surgeon. All the 
participants were reviewed by an orthopaedic surgeon at the standard 6 
weeks follow-up appointment.  
In order to minimise loss at recruitment, multiple contact addresses, 
telephone numbers and email addresses were collected. Considerable 
efforts were made by the trial team to keep in touch with patients. The 
target was for completion of follow-up for all 64 participants. Every 
possible effort was made to ensure loss to follow-up was kept at a 
minimum of no more than 10%. A system of reminders were introduced to 
ensure that return to clinic at three, six and twelve months was as 
complete as possible: 
1. Research associate contacted the participant via telephone to 
make an appointment 
2. If no response within two weeks a letter was sent out to the 
participant 
3. If no response within two weeks the participant was contacted by 
telephone 
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4. If no response from the participant, the status of the participant 
was classified as a ‘non-responder’ and the case was closed. 
In addition to this contingency plan, if loss to follow-up occurred at the 12 
month time point, the plan was to inform the trial statistician so that the 
missing data could be determined using the interim scores. 
4.10.12 Adverse Events Management 
Adverse events (AEs) were defined as: any untoward medical occurrence 
in a clinical trial subject and which does not necessarily have a causal 
relationship with the treatment. 
At each data collection time point the participants were asked whether 
they had experienced any adverse events since their last visit. 
All AEs (excluding pre-planned procedures and pre-existing conditions) 
were listed on the appropriate Case Report Form and returned to the trial 
central office. 
 
Serious adverse events (SAEs) were defined as any untoward and 
unexpected medical occurrence that:  
1. Resulted in death, 
2. Life-threatening 
3. Required hospitalisation or prolongation of existing inpatients´ 
hospitalisation, 
4. Resulted in persistent or significant disability or incapacity, 
congenital anomaly or birth defect 
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5. Any other important medical condition, which, although not 
included in the above, required medical or surgical intervention to 
prevent one of the outcomes listed. 
 
SAEs that were expected as part of the surgical interventions and 
therefore did not require immediate reporting to REC were: 
1. Related in general to surgery and anaesthetic: 
a. Chest Infection 
b. Urinary tract infection 
c. Myocardial infarction 
d. Stroke 
2. Related to the arthroplasty surgery: 
a. Infection 
b. Delayed wound healing 
c. Bleeding 
d. Thromboembolic events 
e. Damage to nerves in the surgical area 
f. Damage to blood vessels in the surgical area 
 
All SAEs were entered onto the SAE reporting form and given to the trial 
central office within 24 hours of the investigator becoming aware of them. 
Once received causality and expectedness were determined by the Chief 
Investigator, Professor Costa. As per trial protocol, if any SAEs were 
deemed unexpected and related to the trial, the main Research Ethics 
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Committee (REC) was notified within 15 days for a non-life-threatening 
event and within seven days for a life-threatening event. All such events 
were reported to the Trial Steering Committee and Data Monitoring 
Committee at their next meeting. 
4.10.13 End of Trial 
The end of the trial was defined as the final visit to the clinic of the last 
participant. This date was approximately 30.04.14. 
 
4.10.14 Data Management 
The Case Report Forms were designed by the trial coordinator in 
conjunction with the Chief Investigator and Statistician. All forms were 
filled out in the presence of the participant by the research associate 
(either myself as the research fellow or the research assistant). The forms 
were anonymised and securely stored; this was managed centrally by the 
trial coordinator. 
4.10.14.1 Data Storage, Access and Quality Assurance 
Personal data collected during the trial were handled and stored in 
accordance with the 1998 Data Protection Act.  
All data collected was anonymised after the collection of baseline 
demographic data, and all participants were given a unique trial number. 
All electronic patient-identifiable information was held on a secure, 
password-protected database accessible only on university computers. 
All paper forms and trial records with patient-identifiable information were 
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stored in secure locked filing cabinets within a restricted access area of 
Warwick Medical School. Each participant’s data was coded using the 
assigned unique trial number, linking the identifiable details to the 
outcome data. Access to both the database and stored identifiable 
information was restricted to authorised personnel. 
Direct access to secure data and documentation was required for 
trial-related monitoring and auditing by Warwick Clinical Trials Unit (CTU).  
The retention of all paper and electronic data were authorised for a 
minimum of five years following completion of the trial. 
 The trial coordinator and research fellow monitored quality control 
by ensuring adherence to the trial protocol. Formal quality assurance 
checks were performed by Warwick CTU to ensure the integrity of 
randomisation, study entry procedures and data collection was upheld 
throughout the trial. A quality assurance manager performed annual 
inspections of the Trial Master File and provided recommendations where 
necessary. Written reports were provided to the REC at regular intervals 
during the trial.  
 
Archiving of Trial Data 
Data was handled in accordance with Warwick CTU guidelines and 
Standard Operating Procedures (SOPs). 
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4.10.14.2 Trial Oversight and Supervision 
The day-to-day management of the trial was overseen by the Trial 
Coordinator and other members of the Trial Management Group (TMG), 
who met on a regular basis to assess trial progress.  
 
 
The Trial Management Group consisted of:  
1. Chief Investigator 
2. Trial Coordinator 
3. Trial Statistician 
4. Two research associates (research fellow- myself and research 
assistant- research physiotherapist/nurse) 
 
Independent oversight of the trial was carried out by the Trial Steering 
Committee (TSC). 
 
The Trial Steering Committee consisted of:  
1. Independent chair (Orthopaedic Consultant) 
2. Independent member (Orthopaedic Consultant) 
3. Chief Investigator (TMG representative) 
4. Trial Coordinator (TMG representative) 
5. Trial Statistician (TMG representative) 
6. Research associate (TMG representative) 
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The four main objectives of the TSC were: 
1. Monitoring and supervising the progress of the trial towards its 
interim and overall objectives. Ensured main trial objectives were 
not compromised and participants were protected from harm. 
2. Reviewing at regular intervals relevant information from other 
sources 
3. Consider the recommendations of the DMC, approve changes to 
the trial design, approve abstracts and manuscripts 
4. Inform the funding body on the progress of the trial via annual 
report. 
 
A Data Monitoring and Ethics Committee (DMC) was formed and 
consisted of: 
1. Independent Chair (Orthopaedic Consultant with DMC experience) 
2. Independent Clinical Expert (Orthopaedic Consultant) 
3. Independent Statistician 
4. Trial Statistician (attends DMC meeting as a non-voting TMG 
observer) 
 
The DMC was independently chaired and established in accordance with 
the principles of Good Clinical Practice and the Warwick CTU SOPs. The 
three main objectives of the DMC were to: 
1. Review data according to randomised treatment groups, at specific 
intervals, to ensure safe continuation of the trial. That is, 
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insufficient evidence of harm or benefit that would warrant stopping 
the trial  
2. Review at regular intervals relevant information from other sources 
3. Advise the TSC 
4. Inform the funding body on the progress of the trial via interim 
progress report.  
5. Formulation of a detailed statistical analysis plan (SAP). 
 
4.10.14.2.1 Interim analyses 
The detailed content of the interim analyses was identified following final 
data analysis for the purpose of complete reporting in this thesis. Prior to 
this, the meeting records remained confidential. Three interim analyses 
were performed throughout the duration of the trial. Interim reports were 
submitted to the funding body, AMR on the following dates: 14th May 
2012, 20th June 2011 and 13th May 2010. The TSC was informed of all 
recommendations made in the report by the DMC. 
 In May 2010 the DMC reviewed the progress of the trial (12 
months post-recruitment of first participant), specifically recruitment rate 
and complication rate. The complication rate was deemed within normal 
range and therefore not of concern. The recruitment rate was analysed 
and a decision was made to review the rate closely over the subsequent 
6 months. 
 After twelve months of recruitment, it was established that the 
recruitment rate was lower than the target set at the beginning of the trial. 
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In the original trial application, it was predicted that 64 participants would 
be recruited in 20 months – 3.2 participants per month. However, the 
actual recruitment at this point was 2 participants per month, 67% of the 
target. Investigations were performed to determine why the rate was 
slower than expected.  
 
 The factors assessed were: 
1. Number of eligible missed patients. This number was determined 
by checking theatre lists for patients who received patellofemoral 
arthroplasty but were not approached regarding trial participation. 
Three patients were identified. As a result of this loss of potential 
recruitment, a rolling programme of trial updates was issued to all 
staff to prevent this problem reoccurring. 
2. Number of eligible patients who declined participation. Over the 
12 month recruitment period 4 patients (15%) declined to enter 
the trial. This rate was expected, based on experience with similar 
trials within the research group. 
3. Number of eligible patients referred to the trial centre. The fall in 
predicted numbers recruitable was likely due to a change in the 
referral pattern to the trial centre (University Hospitals Coventry 
and Warwickshire NHS Trust). Prior to the trial commencing, the 
majority of the patellofemoral arthroplasty operations for the 
Warwickshire region were provided by University Hospitals 
Coventry and Warwickshire NHS Trust. However, as 
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patellofemoral arthroplasty had gained popularity, the nearby 
district general hospitals started to also provide this operation as 
part of their arthroplasty service. Unfortunately, since this is a 
single centre trial, these patients could not be included in the 
study. 
Based on this close monitoring, the DMC proposed that, if the same rate 
of recruitment were to continue, a 12 month extension was required in 
order to complete recruitment. The TSC was informed and the 
recommendation accepted. An application to the funders (Action Medical 
Research) was submitted for the project end date to be adjusted from 
30.04.12 to 30.04.13. This requested was granted by Action Medical 
Research as a ‘No-cost Grant Extension’. Additional finances were 
resourced from within the unit and from the support of the local 
Comprehensive Local Research Network (CLRN). 
The final interim report in May 2012 confirmed completion of the trial 
recruitment. No further changes, requests or recommendations were 
made for the final year of recruitment. 
 
In addition to the interim analysis of recruitment and complication rates, 
assessment of the outcome measures for both treatment groups was also 
evaluated by the DMC. Interim analyses of the primary and secondary 
outcome measures showed no evidence of a difference between the 
treatment groups, based on summary statistics and box plot analysis. 
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Since no evidence of clear benefit or harm was found to be associated 
with one treatment allocation the trial was continued to completion. 
4.10.14.3 Statistical Analysis 
A detailed SAP, constructed by the Trial Statistician, Dr Parsons, was 
agreed with the DMC at the beginning of the study.  
Standard descriptive analyses were performed such as mean and 
standard deviation based on the normal distribution of the outcomes. 
Graphical representation of the data demonstrating correlation between 
the treatment groups was also produced for both primary and secondary 
outcome measures. Baseline data was summarised to check 
comparability between treatment arms, and to highlight any characteristic 
differences between those individuals in the study.  
The main analysis was focused on determining differences in the 
primary outcome measure, the WOMAC score, between the two 
treatment groups on an intention-to-treat basis at 12 months post-
operation. The significance in responses between treatment groups was 
assessed using an independent samples t-test; based on an assumed 
normal distribution for this outcome measure. Tests were two-sided and 
deemed to provide evidence for a significant difference if the P value was 
less than 0.05 (5% significance level). Estimates of treatment effects 
were presented with 95% confidence intervals. A linear regression 
analysis was also undertaken to assess the impact of participant age and 
gender. Selection of these covariates was made a priori based on 
previous knowledge of gender and age disparity. The primary analysis 
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was the adjusted analysis. Complication data were low for the various 
categories and therefore not appropriate for statistical analysis. Results 
from the unadjusted and adjusted analyses were presented graphically, 
together with diagnostic plots that illustrated trends and data distribution 
(that is, the underlying model assumptions). Missing data were not a 
problem experienced in this study and therefore the imputing methods 
described in the protocol to overcome missing data points were not 
required. The statistical analyses were carried out by the Trial Statistician, 
Dr Parsons, using R software (http://www.r-project.org/). 
4.11 Results 
No new information emerged during the trial that warranted 
communication with the trial participants. All three participants that 
withdrew were no longer willing to complete interim and primary end point 
outcomes. The one participant who declined treatment post 
randomisation also declined data collection. Therefore, these patients 
were not included in the primary intention-to-treat analysis or per-protocol 
analysis. 
There were no unexpected or trial related SAEs that required REC 
notification. 
 
The recruitment dates for the trial were 30.04.09 to 30.04.13. The follow-
up time points were, as described in the methodology, 0, 3, 6 and 12 
months. A total of ninety-four patients were screened for eligibility, that is, 
met the criteria for age, capacity to give consent and suitable for PFA. Of 
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those patients, eighty-nine were deemed eligible in the first instance and 
five ineligible. The five that were not suitable had varying reasons not to 
undergo surgery (see section 4.11.1). Twenty-five patients were further 
excluded following consultation with the Orthopaedic Consultant or 
Research Associate. The most common reason was patient preference 
and surgeon concern regarding patient age. Out of the total of sixty-four 
patients recruited for the trial, three patients withdrew from further 
participation after receiving the allocated intervention and one patient 
declined surgery post allocation. The reasons for withdrawals were 
change of location for two participants and one found the commitment too 
burdensome. One participant no longer wanted surgery following 
randomisation and therefore declined further participation in the trial. The 
remaining sixty patients completed the study, although five patients did 
not receive their allocated treatment. 
Table 4-2 highlights these five protocol violations. Three protocol 
violations involving participants assigned to PFA treatment receiving TKA 
intervention occurred because intraoperative assessment by the 
operating consultant identified tibiofemoral arthritis warranting TKA 
operative intervention. The two other protocol violations were participants 
assigned to TKA who actually received PFA intervention. Similarly, 
intraoperative assessment by the operating consultant deemed TKA 
unsuitable in cases where an isolated small trochlear lesion was identified 
and the patella appeared preserved; this occurred in three cases. None of 
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the five protocol violations were predictable based on clinical assessment 
or radiological evidence. 
The CONSORT Flow Diagram (see section 4.11.1) demonstrates 
patient flow from screening to analysis. Table 4-1 and Table 4-2 show in 
more detail the participant numbers and status by allocation group and 
allocated intervention (intention-to-treat) and actual intervention received 
(per-protocol) for all trial participants, respectively. 
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Analysed ITT n = 29 
Analysed PP n = 27 
Excluded from analysis n = 0 
Lost to follow-up n = 0 
Declined intervention n = 1 
Received PFA intervention n = 2 
Withdrew after receiving allocated intervention n = 2
Allocated to TKA n = 32 
 
Received allocated intervention n = 29 
Did not receive allocated intervention n = 3 
Patients Screened n = 94 Patients Ineligible n = 5  
Severe patellar maltracking but only mild PFOA  1 
Previous Fulkerson’s osteotomy, no PFOA  1 
Sensitive to implant material    1 
Tricompartmental disease    1 
Discharged from surgical care 1
Patients Excluded n = 25 
 
Declined n = 10 
Patient preference PFA    4 
Patient preference TKA    3 
Not interested in research participation   3 
 
Missed n = 7 
Already listed for PFA    3 
Not referred to research team    4 
 
Other n =8 
Surgeon deemed too young    7 
Surgeon deemed unsuitable due to other knee pathology 1 
ENROLLMENT Patients Eligible n = 89
Randomised n = 64
Allocated to PFA n = 32 
 
Received allocated intervention n = 29 
Did not receive allocated intervention n = 3 
ALLOCATION 
Lost to follow-up n = 0 
Declined intervention n = 0 
Received TKA intervention n = 3 
Withdrew after receiving allocated intervention n = 1
FOLLOW-UP 
Analysed ITT n = 31 
Analysed PP n = 28 
Excluded from analysis n = 0 
ANALYSIS 
4.11.1 CONSORT Flow Diagram 
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4.11.2 Tables and Graphs 
Table 4-1 Trial participant numbers and status by allocated intervention group 
Status PFA TKA Total 
Participant 31 29 60 
Declined 0 1 1 
Withdrawn 1 2 3 
Total 32 32 64 
 
Table 4-2 Allocated interventions (ITT) and actual interventions received (PP) for all trial 
participants who completed the study 
 Per-protocol (PP) 
PFA TKA Total 
Intention-to-treat 
(ITT) 
PFA 28 3* 31 
TKA 2* 27 29 
Total 30 30 60 
*protocol violations 
number analysed per protocol 
 
Table 4-3 demonstrated the participant demographics. There was no 
evidence of difference between the groups for any of the characteristics 
analysed.  
Table 4-3 Participant Demographics 
 PFA TKA 
Participants n = 31 n = 29 
Age (mean(±SD)) 64.7 (±10.49) 64.4 (±12.84) 
Gender (M : F) 9 : 22 3 : 26 
Side (L : R) 15 : 16 18 : 11 
BMI (kg/m2) 28.9 (±6.72) 29.2 (±4.15) 
 
Table 4-4 shows the mean and standard deviations of the primary 
outcome: WOMAC Score and secondary outcomes: American Knee 
Society Score (AKSS), Oxford Knee Score (OKS), UCLA rating scale and 
EQ5D QoL Score for the 60 participants analysed in this study at 4 time 
intervals: 0 months (baseline), 3 months, 6 months and 12 months. The 
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number of participants analysed at each time point, that is, n, for each 
outcome, is stated. Missing data was deemed very low therefore multiple 
imputation facilities were not used to impute data. 
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Table 4-4 Outcome Scores at 0 months (baseline), 3 months, 6 months and 12 months 
 
Primary Outcome: 
WOMAC 
PFA TKA 
n Mean SD n Mean SD 
 Pain 0m 31 10.4 3.1 28 10.2 3.2 
 Pain 3m 29 5.7 4.2 24 7.2 4.6 
 Pain 6m 26 5.1 4.8 27 5.9 4.5 
WOMAC Pain 12m 29 6.0 4.7 25 4.7 3.8 
Stiffness 0m 31 4.7 1.6 28 4.5 1.6 
Stiffness 3m 29 3.2 1.8 24 3.5 2.3 
Stiffness 6m 26 2.7 2.0 27 3.2 2.2 
WOMAC Stiffness 12m 29 3.1 1.9 26 2.7 2.1 
Function 0m 31 36.3 12.0 28 36.3 10.6 
Function 3m 29 21.5 16.4 24 25.5 15.9 
Function 6m 26 20.9 16.1 27 21.1 15.6 
WOMAC Function 12m 29 21.9 15.7 26 20.2 12.7 
Total 0m 31 51.4 15.0 28 51.0 14.3 
Total 3m 29 30.3 21.3 24 36.2 22.1 
Total 6m 26 28.7 22.2 27 30.2 21.7 
WOMAC 12m 29 31.1 21.6 25 26.8 17.4 
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Secondary Outcome: 
AKSS 
PFA TKA 
n Mean SD n Mean SD 
Knee Score 0m 31 52.3 12.4 27 52.7 12.0 
Knee Score 3m 29 75.4 17.2 23 65.0 20.3 
Knee Score 6m 26 77.7 17.1 27 68.8 20.1 
AKSS Knee Score 12m 28 76.3 15.8 26 77.4 18.8 
Function Score 0m 31 53.7 16.4 28 57.5 18.2 
Function Score 3m 29 66.5 23.2 23 66.7 20.2 
Function Score 6m 26 72.9 20.4 27 68.0 21.9 
AKSS Function Score 12m 28 77.3 17.9 26 73.9 19.7 
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Secondary 
Outcome:  
UCLA 
PFA TKA 
n Mean SD n Mean SD 
Walking 0m 31 6.4 1.8 28 6.8 1.6 
Walking 3m 29 7.7 2.1 24 6.9 2.4 
Walking 6m 25 8.2 2.0 27 7.5 2.3 
UCLA Walking 12m 29 8.6 2.3 26 8.0 2.1 
Function 0m 31 5.0 1.6 28 5.4 1.9 
Function 3m 29 6.7 2.8 24 6.5 2.2 
Function 6m 25 7.4 2.2 27 7.1 2.6 
UCLA Function 12m 29 8.0 2.4 26 6.9 3.0 
Activity 0m 31 3.8 1.3 28 4.1 1.1 
Activity 3m 29 4.7 1.3 24 4.4 1.3 
Activity 6m 26 5.3 1.8 27 5.0 1.6 
UCLA Activity 12m 29 5.5 1.6 26 4.7 1.2 
Total 0m 31 17.8 4.5 28 18.8 4.4 
Total 3m 29 25.3 6.2 24 23.3 7.1 
Total 6m 26 27.0 7.6 28 24.7 9.3 
UCLA 12m 29 29.1 7.6 26 26.9 6.5 
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Secondary 
Outcome:  
EQ5D 
PFA TKA 
n Mean SD n Mean SD 
EQ5D 0m 31 0.4 0.3 28 0.4 0.3 
EQ5D 3m 29 0.7 0.3 24 0.6 0.3 
EQ5D 6m 23 0.8 0.3 26 0.7 0.3 
EQ5D 12m 29 0.8 0.3 25 0.7 0.2 
 
 
Secondary 
Outcome:  
OKS 
PFA TKA 
n Mean SD n Mean SD 
OKS 0m 31 26.2 6.5 28 25.2 6.3 
OKS 3m 28 15.6 9.0 24 17.5 9.5 
OKS 6m 26 13.9 9.3 27 13.6 9.9 
OKS 12m 29 11.5 8.9 26 10.7 8.2 
 
 
 
 
WOMAC – Western Ontario and McMaster Osteoarthritis Index Score. Primary Outcome Measure blue borders. Patient reported 24 items (5 for pain, 2 for stiffness 
and 17 for physical function. 0 = best score, 96 = worst score; AKSS – American Knee Society Score. Function score patient reported. Function and Knee scores 
range from 1 to 100. 1 = worst score, 100 = best score; UCLA – University of California Los Angeles walking, function and activity scales. Patient reported. All 
scales range from 1 to 10. 1 = worst score, 10 = best score; EQ5D – EuroQol five-tiered questionnaire: mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression. Patient reported. Quality of Life score. The scale ranges from -0.109 to 1.0. -0.109 = worst score, 1.0 = best score; OKS – Oxford Knee Score. 
Patient reported 12 items on knee function. Score ranges from 0 to 48. 0 = best score, 48 = worst score 
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The values in Table 4-4 have been represented graphically in the trend 
plots in Figure 4-1, which demonstrates the group means for the outcome 
scores, with 95% confidence intervals calculated using data from each 
assessment time point. 
 
Figure 4-1 Trends in mean outcome scores by allocation group and time point 
 
 
 
WOMAC – Western Ontario and McMaster Osteoarthritis Index Score. Primary Outcome 
Measure blue underline. Patient reported 24 items (5 for pain, 2 for stiffness and 17 for physical 
function. 0 = best score, 96 = worst score; AKSS – American Knee Society Score. Function score 
patient reported. Function and Knee scores range from 1 to 100. 1 = worst score, 100 = best 
score; UCLA – University of California Los Angeles walking, function and activity scales. Patient 
reported. All scales range from 1 to 10. 1 = worst score, 10 = best score; EQ5D – EuroQol five-
tiered questionnaire: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 
Patient reported. Quality of Life score. The scale ranges from -0.109 to 1.0. -0.109 = worst score, 
1.0 = best score; OKS – Oxford Knee Score. Patient reported 12 items on knee function. Score 
ranges from 0 to 48. 0 = best score, 48 = worse score 
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The primary endpoint for the clinical trial was the 12 months assessment. 
The primary and secondary outcome results are tabulated in Table 4-5; 
both the adjusted (in terms of age and gender) and unadjusted analyses 
are shown. Figure 4-2 is a series of box plots demonstrating the means, 
distribution of data and confidence intervals at 12 months for these 
outcome scores. All tabulated and graphically illustrated analyses were 
based on an ITT analysis except for Table 4-6, which shows the per-
protocol analysis for the outcome scores at 12 months. 
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Table 4-5 Outcome Scores at 12 months following intervention, adjusted (age and gender) and unadjusted intention-to-treat analyses of intervention group 
differences 
 TKA PFA Unadjusted Analysis Adjusted Analysis 
 n Mean SD n Mean SD Δ† 95% CI P value‡ Δ 95% CI P value‡ 
 
WOMAC 25 26.80 17.38 29 31.07 21.63 -4.27 (-15.10, 6.56) 0.43 -3.31 (-14.34, 7.73) 0.55 
WOMAC Pain 25 4.68 3.75 29 6.03 4.69 -1.35 (-3.70, 0.99) 0.25 -1.04 (-3.36, 1.28) 0.37 
WOMAC 
Stiffness 26 2.73 2.05 29 3.10 1.88 -0.37 (-1.44, 0.69) 0.49 -0.37 (-1.47, 0.73) 0.50 
WOMAC 
Function 26 20.15 12.70 29 21.93 15.68 -1.78 (-9.55, 5.99) 0.65 -1.20 (-9.19, 6.80) 0.77 
AKSS  
Knee Score 26 77.35 18.83 28 76.25 15.83 1.10 (-8.38, 10.57) 0.82 -0.91 (-10.36, 8.53) 0.85 
AKSS  
Function Score 26 73.85 19.66 28 77.32 17.87 -3.48 (-13.73, 6.77) 0.50 -3.33 (-13.96, 7.30) 0.53 
UCLA Walking 26 8.00 2.12 29 8.59 2.32 -0.59 (-1.79, 0.62) 0.33 -0.51 (-1.78, 0.76) 0.43 
UCLA Function 26 6.92 2.99 29 8.00 2.39 -1.08 (-2.54, 0.38) 0.14 -0.97 (-2.52, 0.57) 0.21 
UCLA Activity 26 4.65 1.23 29 5.52 1.64 -0.86 (-1.66, -0.07) 0.03 -0.82 (-1.66, 0.02) 0.06 
UCLA 26 26.92 6.50 29 29.10 7.59 -2.18 (-6.03, 1.67) 0.26 -2.05 (-6.14, 2.05) 0.32 
EQ5D 25 0.73 0.21 29 0.77 0.25 -0.04 (-0.17, 0.09) 0.53 -0.06 (-0.20, 0.07) 0.34 
EQ_VAS 25 76.36 21.82 29 72.86 22.31 3.50 (-8.60, 15.59) 0.56 1.49 (-11.11, 14.09) 0.81 
OKS 26 10.65 8.23 29 11.48 8.89 -0.83 (-5.48, 3.82) 0.72 -1.11 (-6.03, 3.81) 0.65 
  
Δ† unadjusted difference between means: TKA – PFA 
Δ adjusted difference between means: TKA – PFA 
‡ P values from independent samples t-test for unadjusted analysis and from linear regression including terms for age and gender in adjusted analysis 
 
WOMAC – Western Ontario and McMaster Osteoarthritis Index Score. Primary Outcome Measure blue underline. Patient reported 24 items (5 for pain, 2 for stiffness and 17 for 
physical function. 0 = best score, 96 = worst score; AKSS – American Knee Society Score. Function score patient reported. Function and Knee scores range from 1 to 100. 1 = 
worst score, 100 = best score; UCLA – University of California Los Angeles walking, function and activity scales. Patient reported. All scales range from 1 to 10. 1 = worst score, 
10 = best score; EQ5D – EuroQol five-tiered questionnaire: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Patient reported. Quality of Life score. The 
scale ranges from -0.109 to 1.0. -0.109 = worst score, 1.0 = best score; EQ VAS – EuroQol visual analogue scale. Patient reported. Range 0 to 100. 0 = worst imaginable health 
state, 100 = best imaginable health state; OKS – Oxford Knee Score. Patient reported 12 items on knee function. Score ranges from 0 to 48. 0 = best score, 48 = worst score 
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Table 4-6 Adjusted per-protocol analyses of intervention group differences at 12 months 
 Δ 95% CI P value‡ 
WOMAC 0.06 (-11.02, 11.14) 0.99 
WOMAC Pain -0.19 (-2.53, 2.15) 0.87 
WOMAC Stiffness -0.06 (-1.16, 1.05) 0.92 
WOMAC Function 0.94 (-7.07, 8.94) 0.82 
Knee Score -2.73 (-12.16, 6.71) 0.56 
Function Score -7.44 (-17.92, 3.04) 0.16 
UCLA Walking -0.40 (-1.68, 0.87) 0.53 
UCLA Function -0.93 (-2.48, 0.63) 0.24 
UCLA Activity -0.84 (-1.68, -0.00) 0.05 
UCLA -2.10 (-6.2, 1.99) 0.31 
EQ5D -0.06 (-0.19, 0.08) 0.40 
EQ_VAS -1.76 (-14.38, 10.85) 0.78 
OKS 0.66 (-4.27, 5.59) 0.79 
 
 
 
 
 
Δ adjusted difference between means: TKA – PFA 
‡ P values from linear regression including terms for age and gender in adjusted analysis 
 
WOMAC – Western Ontario and McMaster Osteoarthritis Index Score. Primary Outcome Measure blue underline. Patient reported 24 items (5 for pain, 2 for stiffness 
and 17 for physical function. 0 = best score, 96 = worst score; AKSS – American Knee Society Score. Function score patient reported. Function and Knee scores range 
from 1 to 100. 1 = worst score, 100 = best score; UCLA – University of California Los Angeles walking, function and activity scales. Patient reported. All scales range 
from 1 to 10. 1 = worst score, 10 = best score; EQ5D – EuroQol five-tiered questionnaire: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Patient 
reported. Quality of Life score. The scale ranges from -0.109 to 1.0. -0.109 = worst score, 1.0 = best score; EQ VAS – EuroQol visual analogue scale. Patient reported. 
Range 0 to 100. 0 = worst imaginable health state, 100 = best imaginable health state; OKS – Oxford Knee Score. Patient reported 12 items on knee function. Score 
ranges from 0 to 48. 0 = best score, 48 = worst score 
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Figure 4-2 Boxplots illustrating means, data distribution and confidence intervals (95%) for 
the Outcome Scores at 12 months 
 
 
 
 
 
 
 
 
 
  
WOMAC – Western Ontario and McMaster Osteoarthritis Index Score. Primary Outcome 
Measure blue underline. Patient reported 24 items (5 for pain, 2 for stiffness and 17 for physical 
function. 0 = best score, 96 = worst score; AKSS – American Knee Society Score. Function score 
patient reported. Function and Knee scores range from 1 to 100. 1 = worst score, 100 = best 
score; UCLA – University of California Los Angeles walking, function and activity scales. Patient 
reported. All scales range from 1 to 10. 1 = worst score, 10 = best score; EQ5D – EuroQol five-
tiered questionnaire: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. 
Patient reported. Quality of Life score. The scale ranges from -0.109 to 1.0. -0.109 = worst score, 
1.0 = best score; OKS – Oxford Knee Score. Patient reported 12 items on knee function. Score 
ranges from 0 to 48. 0 = best score, 48 = worst score 
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Data on all complications that occurred during the intra-operative and 
post-operative periods were recorded. The details of these complications 
are summarised in Table 4-7. 
Table 4-7 Complication Rates following interventions 
Complications No. of events in PFA 
group (n=31) 
No. of events TKA 
group (n=29) 
Deep infection 0 0 
Deep vein thrombosis 0 1 
Superficial wound 
complications 
4 5 
Revision 0 0 
Further related 
procedures 
0 4 
Other 1 2 
Total 5 15 
 
All recorded SAEs reported are shown below in Table 4-8. 
Table 4-8 Severe Adverse Events (SAEs) 
SAE PFA TKA 
Related in general to surgery and anaesthetic 
Chest infection 1 1 
Related to arthroplasty surgery 
Deep infection 0 0 
Superficial infection 4 5 
Delayed wound healing 0 1 
Thromboembolic event 0 1 (DVT) 
Further surgery 0 2 (MUA; facetectomy)
Pain requiring aspiration/injection 0 2 
Pain requiring admission for 
additional analgesia 0 1 
Other  
Leg ulcer operated limb 0 2 
Unrelated 
e.g. surgery, investigations 6 8 
Total (related only) 5 15 
Total (related and unrelated) 11 23 
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4.12 Results Analysis 
The statistical analysis performed by the Trial Statistician was in 
agreement with the original statistical analysis plan (SAP) set out with the 
Data Management Committee (DMC) at the start of the study and as 
stated in section 4.10.14.3. No subsequent amendments were made to 
the SAP. All analysis was carried out using R (http://www.r-project.org/). 
The principal analysis investigated differences in the primary 
outcome measure, the WOMAC score, between the two treatment groups 
(TKA and PFA) on an intention-to-treat (ITT) basis at 12 months post-
operation. The difference in responses between treatment groups was 
formally assessed using an independent samples t-test; based on an 
assumed approximate normal distribution for this outcome measure. 
Tests were two-sided and considered to provide evidence for a significant 
difference if p-values were less than 0.05 (5% significance level). 
Estimates of treatment effects are presented with 95% confidence 
intervals. Linear regression analyses were also undertaken, incorporating 
terms that model the effects of patient age and gender in addition to the 
effects of the treatment groups (TKA and PFA).  
There was no evidence that participant baseline demographics 
differed between treatment groups (see Table 4-3). A higher number of 
complications were reported in the TKA group. Although no deep 
infections were reported, the number of superficial infections requiring 
antibiotics was four and five in the PFA and TKA groups, respectively 
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(see Table 4-7 and Table 4-8). Four participants in the TKA group 
required further interventions: arthroscopic facetectomy (1), manipulation 
under anaesthesia (1) and aspiration/steroid injection (2); whilst there 
were no further interventions performed in the PFA group. 
All outcome measures improved post intervention in both 
treatment groups, demonstrated graphically in Figure 4-1. Generally, the 
PFA group had better outcomes than the TKA group; although the 
difference was moderate (EQ-5D) to small (OKS). This is illustrated in the 
boxplots in Figure 4-2, which generally show higher medians and 
narrower confidence intervals for the PFA group. Interestingly, the overall 
WOMAC score and individual sub sections (pain, stiffness and function) 
were all higher at three and six months but at 12 months the reverse was 
true. It is possible that recovery during the initial rehabilitation period 
following PFA is relatively quicker than following TKA and this is reflected 
in the scores. 
 Statistically assessing the primary and secondary outcome 
measures at a significant level of 0.05, at the primary endpoint of the trial 
(12 months), on an intention-to-treat-basis, showed no statistical 
evidence of a difference between the two interventions. With the 
exception of the UCLA Activity Score (unadjusted analyses, see Table 
4-5), both the unadjusted and adjusted analyses (adjustments made for 
age and gender using linear regression) showed no evidence of a 
significant clinical difference between the two treatment groups. Other 
than the UCLA Activity Score there were also no significant differences 
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found when the analyses were performed on the per-protocol allocation 
(see Table 4-6). This lack of difference is clearly demonstrated by the 
estimated treatment difference for the WOMAC score at 12 months, 
which was 0.0594 with 95% CI (-11.02, 11.14) and p-value of 0.991. In 
summary, the results of this trial failed to show statistical evidence of a 
difference in treatment group outcome between TKA and PFA. 
However, the adjusted 95% confidence interval for the treatment 
effect (intention-to-treat) on the WOMAC function score (-9.19, 6.80) 
confirms that an effect size of 8 points in favour of PFA, which is the 
minimal clinically important difference (MCID) for this study, cannot be 
rejected. The variability in the outcomes was greater than anticipated 
(approximately 16 points rather than 10.8 points). Using the new estimate 
for the variability of the primary outcome measure, the minimum sample 
size for a definitive trial would be double the number used in this study, 
that is, 64 participants in each arm. 
4.13 Discussion 
This randomised clinical trial found no evidence of a difference in knee 
function between patients receiving patellofemoral arthroplasty versus 
total knee arthroplasty for severe isolated patellofemoral arthritis. 
However, clinically meaningful differences cannot be definitively ruled out 
based on these results and the long-term outcomes of current 
patellofemoral arthroplasty remains unknown. 
Although the UCLA Activity Score (secondary outcome), showed 
evidence of a difference in activity levels 12 months after surgery, the 
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primary outcome and other secondary outcome scores failed to show a 
functional difference, despite all scores (except AKSS knee score) being 
consistently higher in the PFA group. The actual variance of the WOMAC 
was 1.5 times that anticipated, which therefore implies the study was 
underpowered to determine definitively whether a difference between the 
treatments truly exists. 
Though the study results are inconclusive the methodology of the 
analysis was appropriate for the trial. The intention-to-treat analysis was 
based on the results from all the participants assigned to each treatment 
group, including the protocol violation cases. In addition to randomisation, 
this method of analysis offers the best assurance that the groups of 
participants being compared have similar characteristics, that is, 
unbiased comparison. It also best reflects the effects of the treatment in 
normal day-to-day clinical practice. Due to the number of protocol 
violations (5) and withdrawals/decline (4), the per protocol analysis was 
likely susceptible to attrition bias, which means the participant 
characteristics may no longer be similar between the groups. Per protocol 
analysis results generally provide less robust evidence however, in the 
absence of this form of bias this evidence is better at reflecting the effects 
of treatment than intention-to-treat analysis. 
The overall rate of complications in the two groups was higher in 
the TKA group. The number of complications directly associated with 
arthroplasty was three times greater in the TKA group (12) compared with 
the PFA group (4). Although no statistical analysis was performed due to 
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the overall low number of complications, this factor is an important one 
that requires further exploration in a larger study. Complications have the 
potential to disrupt rehabilitation and therefore long-term functional 
outcome. This can limit the therapeutic benefits and profoundly affect the 
patient’s quality of life. It is possible that if these findings are reproduced 
there may be cost effectiveness implications that favour PFA over TKA. 
This difference in complication rate was also observed by Dahm et al. 
(2010) who found, in a retrospective comparative study, a higher number 
of complications in the TKA group compared with the PFA group. In the 
current study, none of the participants suffered undue harm or 
complications that were life or limb threatening. All superficial wound 
infections were successfully treatment with oral antibiotics. Similarly, all 
patients received significant functional benefit from both interventions as 
demonstrated by the improvement in all clinical scores.  
 The pragmatic design of the study was to ensure maximum 
generalisability both in patient population and surgeon preferences hence 
the broad eligibility criteria and intervention described, respectively. 
Generalisability (external validity), defined as the extent to which the 
research findings can be applied to settings other than the one in which 
this study was performed, was limited. Due to the greater than anticipated 
variance of the primary outcome (WOMAC), the sample size was too 
small to definitively establish whether no difference exists between the 
two treatments despite the pragmatic nature of the design. In addition, the 
research setting for this study was in a large specialist centre and 
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therefore the result may not be applicable to patients in smaller district 
general hospitals. A single centre study allows for close monitoring and 
uniformity of trial procedures that reduce bias such as, blinding, outcome 
measurement and follow-up. Despite these advantages a single centre 
study offers less generalisable findings than a multicentre study due to 
the broader and larger surgeon and patient population. 
 Randomisation of the participants within the study ensured a 
sufficient degree of internal validity was achieved. Through the 
randomisation process, potential confounding factors (both known and 
unknown variables) were balanced between the treatment groups. 
Therefore, the increase in outcome measure scores post intervention can 
be interpreted as a direct result of the interventions received. The use of 
validated outcome measures, all of which measured the intended 
construct, ensured adequate construct validity.  
To date, there are no published randomised clinical trials to 
compare with the findings of this study. Most recently, Dahm et al., (2010) 
published a retrospective, comparative two-year follow-up study and 
found patients in the PFA group had statistically significantly better AKSS, 
UCLA and Tegner scores compared with the TKA group. This study also 
showed that this difference was not dependent on the differences in age 
and presence/absence of trochlear dysplasia identified between the 
groups. Although useful, the generalisability of this study is limited by a 
number of weaknesses including small sample size, lack of 
randomisation, retrospective data acquisition and short follow-up. 
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There is currently one Danish multicentre randomised clinical trial 
comparing the Avon patellofemoral arthroplasty and the P.F.C. Sigma 
total knee arthroplasty. This trial consists of 50 participants in each arm 
with 1:1 allocation and the primary end point is five year data. The study 
is powered to 80% to detect a difference at the 5% level. At the time of 
writing the investigators are still recruiting. Five centres and seven 
surgeons are involved in the trial. Unlike the current study the surgical 
technique is very controlled. The chief investigator trained and assessed 
each trial operating surgeon before they performed solo surgery on trial 
participants. Another key difference is the decision to randomise, that is, 
whether the participant is suitable for a PFA, is made intraoperatively. 
The primary outcome measure is the Short Form 36 (SF-36) and 
secondary outcome measures are OKS, KOOS (Knee injury and 
Osteoarthritis Outcome Score), Kujala, EuroQol and ‘satisfaction’ 
questionnaire. The interim analysis, performed on patients recruited thus 
far (number unknown), showed significant differences in favour of PFA in 
all patient reported outcome measures at all time points up to 12 months. 
After one year, no difference between the treatment groups was 
identified. No difference in pain scores was seen at any time point. The 
loss to follow-up is minimal at present although six deaths have occurred 
in the PFA group; none in the TKA group. There is no indication to 
suggest these deaths were related to surgery. 
The study design, in terms of randomisation and multicentre based 
increases the generalisability of the results. Intraoperative randomisation 
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minimises the potential number of protocol violations. The sample size, 
based on the Short Form 36 (SF-36), is larger than the sample in this 
current study and is thus more likely to be representative of the 
population from which the sample was drawn. The specifics of the 
inclusion criteria and full intervention details are not available therefore 
the generalisability with regards to these factors cannot be discussed. 
However, only two prostheses were used and one surgical technique thus 
the applicability of this data in terms of implant and surgical method is 
limited to those used in the trial. In the current study there was no 
restriction on the brand design of prostheses used or surgical technique. 
This pragmatic approach was taken to ensure generalisability therefore 
allowing conclusions to be drawn based on procedure type rather than 
implant design or surgical technique. 
4.14 Limitations 
The key limitations of this current trial were sample size, trial design in 
terms of test for superiority, single centre, the number of outcome 
measures used, number of protocol violations and recruitment rate. The 
former two limitations have already been addressed; the latter three will 
now be discussed. 
 The trial was designed to detect superiority of PFA over TKA. Even 
though the trial was not adequately powered, there is sufficient evidence 
to suggest it is highly unlikely that one treatment is superior or inferior 
over the other. For a future study it may be more appropriate to test for 
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non-inferiority. This is discussed in more detail in the following chapter of 
this thesis. 
The number of outcome measures used was quite high. The impact 
of which was potentially two-fold: high patient burden and the increased 
risk of a positive result (less than 0.05 significant level) occurring due to 
chance being incorrectly interpreted as a difference between the 
treatment groups. Using a lower number of secondary outcome measures 
would have reduced the risk of a Type I error, that is, falsely rejecting the 
null hypothesis when it is true. 
In total there were five protocol violations. Unforeseen tibiofemoral 
arthritis developing between diagnosis of isolated patellofemoral arthritis 
and timing of surgery, or undetected tibiofemoral arthritis is not common, 
as suggested by the 4.6% occurrence (three participants received TKA 
instead of PFA) seen in this trial. However, the other two protocol 
violations are harder to justify. Intraoperatively, it was identified two 
participants had small lesions, predominantly located on the trochlea. In 
each case the operating consultant chose to override the allocation and 
performed PFA instead of TKA. This highlights the difficulties that can 
occur with patient selection and thus surgeon agreement (equipoise). 
Had randomisation been performed intraoperatively, it is likely none of 
these protocol violations would have occurred. 
Trial recruitment took longer than anticipated. Although this was 
mainly due to the change in referral of arthroplasty services, there were 
patients who declined participation. The patient’s perception of the 
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difference between the interventions, in terms of the amount of joint 
replacement, could have influenced patient decision-making. No formal 
assessment of the quality of blinding was performed. If a participant 
became aware of their allocation this may have altered their responses to 
the outcomes evaluated. No formal qualitative research was performed 
as part of this trial to confirm either of these potential limitations.  
 
4.15 Conclusion 
The use of patellofemoral arthroplasty has rapidly increased over the last 
decade. The perceived advantages of this procedure are to preserve 
bone and restore the patellofemoral joint while maintaining native 
tibiofemoral knee kinematics. Previous studies have consisted mainly of 
retrospective case series’ with varying results. More recent studies have 
produced results comparable with TKA. This literature does not 
sufficiently inform the debate regarding the true differences in clinical 
outcome between PFA and TKA in the treatment of severe isolated 
patellofemoral arthritis. Therefore, the aim of this study was to establish 
whether a difference in clinical outcomes exists between the two 
treatments. 
 
This trial did not show evidence that patellofemoral arthroplasty provides 
improved knee function or increased activity levels, compared with total 
knee arthroplasty. However a difference cannot be excluded as 
previously discussed. The results of this study can be accepted as a pilot 
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trial. Through performing this study a number of factors on how to 
improve future studies have been learnt, such as, patient burden, 
recruitment rate, sample sizing and appropriate statistical trial testing. 
The patients in this trial will be reviewed in the coming years to establish 
the long-term outcomes although a larger, multicentre randomised clinical 
trial is required to establish whether PFA is not much worse than TKA. It 
is the long-term follow-up of these patients that will more accurately 
determine if there is any advantage with regard to the need for revision 
surgery. Despite this current study not showing any evidence to justify 
change in current practice, it did not identify any concerning reason why 
this procedure should only be performed in the context of a randomised 
clinical trial. 
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4.16 CONSORT Checklist 
Table 4-9 CONSORT Checklist 
Number Section Evidence 
Location  
1a Title: identification as randomised trial in the title Chapter 4 
1b Abstract: structured summary of trial design, methods, 
results and conclusions 
4.1 
Introduction 
2a Background: scientific background and explanation of 
rationale 
4.6.1 
2b Objectives: specific objectives or hypotheses 4.9 
Methods 
3a Trial Design: description of trial design (e.g. parallel) 
including allocation ratio 
4.8 
4.10.5 
3b Changes to trial design: important changes to 
methods after trial commencement with reasons 
4.10.9 
4.10.14.2.1 
4a Participants: eligibility criteria for participants 4.10.1 
4b Study settings: settings and locations where the data 
were collected 
4.10.2 
5 Interventions: the interventions for each group with 
sufficient details to allow replication, including how and 
when they were actually administered/performed 
4.10.7 
6a Outcomes: completely defined pre-specified primary 
and secondary outcome measures, including how and 
when they were assessed 
4.10.8 
4.10.9 
6b Changes to outcomes: any changes to trial 
outcomes after the trial commenced, with reasons 
4.10.9 
7a Sample size: how sample size was determined 4.10.10 
7b Interim analyses and stopping guidelines: when 
applicable, explanation of any interim analyses and 
stopping guidelines 
4.10.14.2.1 
8a Randomisation: sequence generation Method 
used to generate the random allocation sequence 
4.10.5 
8b Randomisation: type Type of randomisation; details 
of any restriction (e.g. blocking and block size) 
4.10.5 
9 Randomisation: allocation concealment 
mechanism Method used to implement the random 
allocation sequence, describing any steps taken to 
conceal the sequence until interventions were assigned 
4.10.5 
10 Randomisation: implementation Who generated 
the allocation sequence, who enrolled participants, and 
who assigned participants to interventions 
4.10.5 
11a Blinding: If done, who was blinded after assignment to 
interventions (e.g. participants, care providers, those 
assessing outcomes) and how 
4.10.6 
11b Similarity of interventions: if relevant, description of 
the similarity of interventions 
4.10.7 
12a Statistical methods: statistical methods used to 4.10.14.3 
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compare groups for primary and secondary outcomes
12b Additional analyses: methods for additional analyses 
e.g. subgroup analyses and adjusted analyses 
4.10.14.3 
Results 
13a Participant Flow: for each group, the number of 
participants who were randomly assigned, received 
intended treatment, and were analysed for the primary 
outcome 
4.11.1 
13b Losses and exclusions: for each group, losses and 
exclusions after randomisation, together with reasons 
4.11.1 
14a Recruitment: dates defining the periods of recruitment 
and follow-up 
4.11 
14b Reason for stopped trial: why the trial ended or was 
stopped 
4.10.13 
15 Baseline data: a table showing baseline demographic 
and clinical characteristics for each group 
4.11.2 
Table 4-3 
16 Number analysed: for each group, number of 
participants (denominator) included in each analysis and 
whether the analysis was by original assigned groups 
4.11.2 
Table 4-2 
17a Outcomes and estimation: for each primary and 
secondary. results for each group, and the estimated 
effect size and its precision (such as 95% confidence 
interval) 
4.11.2 
17b Binary outcomes: for binary outcomes, presentation 
of both absolute and relative effect sizes is 
recommended 
N/A 
18 Ancillary analyses: results of any other analyses 
performed including subgroup analyses, distinguishing 
pre-specified from exploratory 
N/A 
19 Harms: all important harms or unintended effects in 
each group 
4.11.2 
Table 4-7 
Table 4-8 
Discussion 
20 Limitations: trial limitations, addressing sources of 
potential bias, imprecision, and, if relevant, multiplicity of 
analyses 
4.14 
21 Generalisability: generalisability (external validity, 
applicability) of the trial findings 
4.13 
22 Interpretation: interpretation consistent with results, 
balancing benefits and harms, and considering other 
relevant evidence 
4.13 
Other Information 
23 Registration: registration number and name of trial 
registry 
4.3 
24 Protocol: where the full trial can be accessed, if 
available 
see 
Publications
25 Funding: sources of funding and other support, role of 
funders 
4.2 
4.10.14.2 
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Chapter 5 Summary and Discussion 
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5.1 Introduction 
The overall aim of this thesis was to add to the current knowledge 
regarding the use of arthroplasty treatment for severe isolated 
patellofemoral arthritis. The broad question addressed in this thesis was: 
 
What are the differences in extensor mechanism efficiency, survival, 
number of complications and functional outcomes following TKA and PFA 
for the treatment of severe isolated patellofemoral arthritis? 
 
Through attempting to answer this question, this mixed methods thesis 
has generated new knowledge that has further informed the debate 
between the choice of arthroplasty treatments and provided direction for 
future research.  
 
This final chapter is divided into three sections: 
1. Summary of Pre-existing Knowledge  
2. Key Novel Conclusions 
3. Limitations and Direction of Future Research  
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5.2 Summary of Pre-existing Knowledge 
Previous literature on severe isolated patellofemoral arthritis has focused 
on the incidence and prevalence of this disorder, identifying a greater 
preponderance in females (Arendt, 2006; Dejour & Allain, 2004; Duncan 
et al., 2006; McAlindon et al., 1992; Mihalko et al., 2007; Saleh et al., 
2005). Published knowledge on aetiological factors has highlighted 
patellar instability, specifically trochlear dysplasia, as an important risk 
factor for the development of patellofemoral arthritis (Dejour et al., 2010; 
Mäenpää & Lehto, 1997b). Variations in Q angle have also been 
associated with progression of patellofemoral arthritis (Mihalko et al., 
2007). A systematic review on non-operative and operative management 
(van Jonbergen et al., 2010a) found physiotherapy, taping and injections 
offered only short-term relief. Joint preservation procedures, such as total 
and partial patellectomy, arthroscopic debridement and tibial tubercle 
osteotomies were found to produce inconsistent outcomes and offer no 
long-term improvement; such findings were also demonstrated in earlier 
studies (Heatley et al., 1986; Jenny et al., 1996; Schepsis et al., 1994). 
This review found outcomes following PFA (in selected patients) and TKA 
(with patellar resurfacing) were good but could not recommend one 
treatment over the other due to the weak methodological quality of the 
literature reviewed. This finding appears to reflect the general lack of 
consensus between the two arthroplasty choices. The majority of 
surgeons are aware of advantages of both arthroplasty treatments, some 
consider TKA the gold standard treatment because of the associated low 
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revision rate and good function (Dalury, 2005; Mont et al., 2002; 
Thompson et al., 2001), whereas others believe PFA preserves the 
tibiofemoral joint along with the native soft tissue constraints and is easier 
to revise to TKA, if required (Argenson et al., 2005; Cartier et al., 2005; 
Lonner et al., 2006). A more recent meta-analysis (Dy et al., 2012) 
compared the complications associated with PFA and TKA and 
concluded complications were more likely to occur following PFA 
compared with TKA and this association was thought to be related to 
prosthetic design. The main limitations with this investigation were: the 
weak methodological quality of the included studies and the subgroup 
analysis categorised by ‘generation’. First and second ‘generations’ were 
the subgroups described in this study; the term ‘generation’ was stated to 
infer a difference in implant design. However, the first generation group 
included prostheses with considerable design variations ranging from 
inlay symmetrical non-anatomical to onlay asymmetrical anatomical 
prostheses. The quality of the meta-analysis was undermined by the high 
clinical heterogeneity. Furthermore, the authors’ choice of analysis model 
(fixed or random) was based on the degree of heterogeneity calculated 
rather than establishing whether a common effect size exists between the 
studies for the specific variable of interest.  
 
 Until now, no systematic reviews have been performed assessing 
survival, complications and functional outcomes in terms of prosthetic 
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design and no randomised clinical trials had been performed to 
completion. 
 
 
Current knowledge on the biomechanics of the native patellofemoral joint 
is well documented (Amis et al., 2006; Amis & Farahmand, 1996; 
Christoforakis et al., 2006; Farahmand et al., 1998a; Farahmand et al., 
1998b; Feller et al., 2007). The extensor mechanism is the primary 
support of the knee during standing and walking (Amis & Farahmand, 
1996). Maintaining the integrity of the extensor mechanism following PFA 
and TKA is crucial for adequate performance of ADLs, such as rising from 
a chair, level walking and stair-climbing. Existing literature has 
investigated extensor mechanism function following TKA but not following 
PFA. 
 Quadriceps weakness following TKA is a well-reported problem. 
Studies have shown deficit in quadriceps strength in the short- and long-
term following TKA (Berman et al., 1991; Huang et al., 1996). Reduced 
stride length and slowed walking and stair-climbing were demonstrated 
by Walsh et al. (1998) and Mizner and Snyder-Mackler (2005) as 
manifestations of this weakness. The effects of this strength deficit are 
likely influenced by prosthetic geometry. 
 Studies exploring the impact of prosthesis design on extensor 
mechanism function have focused on evidence of clinical difference 
between CR-TKA and PS-TKA. No studies have shown a difference in 
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functional validated outcomes. The literature tends to favour the notion of 
an increased range of motion associated with PS-TKA (Bercik et al., 
2013; Hirsch et al., 1994). The size of the difference found in a recent 
meta-analysis (Bercik et al., 2013) was not large and may therefore be of 
no clinical importance. Furthermore, a high degree of variation is 
associated with the commonest method used to measure this outcome 
(Trappler et al., 2009). 
 The impact of prosthesis design on knee kinematics and 
biomechanics of the extensor mechanism has been investigated. The 
majority of the relevant literature has focused on the differences between 
CR-TKA and PS-TKA and femoral component condylar radii (multi-radius 
versus single). A number of studies have shown that the position of the 
tibiofemoral contact point in full knee extension is posterior to the mid-
sagittal line in CR-TKAs compared to the native knee in which the 
tibiofemoral contact point is anterior to this line (D'Lima et al., 2001; 
Dennis et al., 1996; Stiehl et al., 1995). During flexion the native knee 
demonstrates consistent posterior femoral rollback, in contrast, the CR-
TKAs exhibits highly erratic anterior translation (Dennis et al., 1996; Kim 
et al., 1997; Stiehl et al., 1995). PS-TKAs have not been shown to 
reproduce exact native knee kinematics although similarities have been 
demonstrated. In full extension the tibiofemoral contact position in PS-
TKAs is anterior to the mid-sagittal plane but relatively posterior to the 
tibiofemoral contact position found in the native knee and femoral rollback 
has been shown to be abnormal, occurring to a significantly lesser degree 
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than in the native knee (Dennis et al., 1996; Kim et al., 1997). More 
recent studies have focused on attempting to recreate native posterior 
femoral rollback, which is thought to promote high knee flexion and to be 
a surrogate indicator for optimal extensor mechanism function 
(Fallahiarezoodar et al., 2014). The theoretical value of posterior femoral 
rollback enhancing the extensor mechanism following PS-TKA compared 
to that occurring following CR-TKA has not been sufficiently 
demonstrated. 
 Investigations have been performed to determine whether there is 
a difference in extensor mechanism function associated with multi-radius 
femoral components compared with single radius femoral components. 
The results of the few studies assessing this generally varied depending 
on the cruciate design but no strong evidence exists in favour of one 
cruciate design. Literature that evaluated CR-TKAs found no kinematic 
difference between single radius and multi-radius femoral components on 
assessment of extensor mechanism function (D'Lima et al., 2001; Hall et 
al., 2008). However, Hall et al. (2008) did identify lower quadriceps tensile 
forces associated with the single radius components. In contrast, both 
studies evaluating PS-TKA reported single radius femoral component 
designs were more favourable than multi-radius in terms of extensor 
mechanism function (Gomez-Barrena et al., 2010; Mahoney et al., 2002). 
Overall no firm conclusions could be drawn due to various limitations 
associated with the studies, for example, confounding factors such as 
dissimilar surface geometry of femoral, tibial slope and polyethylene 
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insert components, retrospective comparison, inadequately matched 
groups, small sample size, use of unvalidated outcomes and risk of 
observer bias. 
 
Until the performance of this biomechanics study, a direct comparison 
between PFA and TKA had not been performed in relation to extensor 
mechanism function. 
5.3 Key Novel Findings and Conclusions 
5.3.1 Biomechanics Study 
This cadaveric study is the first investigation to date to assess the effect 
of PFA and TKA geometric differences on extensor mechanism 
efficiency, resultant force, peak pressure and contact area.  
 
The key findings of this study were as follows: 
 
1. Extensor Mechanism Efficiency (EME) 
a. The relationship between the knee flexion-extension cycle 
and extensor mechanism efficiency is bimodal: all four 
conditions (native knee, PFA, CR-TKA and PS-TKA) 
demonstrated a similar sinusoidal pattern of increasing EME 
between 0° and 50°, and a decreasing EME between 60° 
and 120°.  
  
408
b. PFA produced the highest mean EME between 0° and 50°, 
peaking at 20° knee flexion. The greatest significant mean 
difference in this range was observed at 10° of knee flexion 
when compared with CR-TKA and PS-TKA. 
c. PFA produced significantly greater EME than the native 
knee between 0° and 50° knee flexion. This may have been 
due to the increased offset lengthening the extensor 
moment arm beyond the native length. 
d. In deep to mid flexion the EME was less efficient for all four 
conditions. PFA was generally lower than all the conditions 
and significant differences were detected between PFA 
compared with both native knee and CR-TKA at 80° knee 
flexion. 
e. No significant difference in EME was found between CR-
TKA and PS-TKA. 
 
2. Patellofemoral Resultant Force 
a. No significant difference was detected between the three 
arthroplasty conditions at each angle of knee flexion tested, 
although the trend demonstrated higher forces were 
produced by PFA compared with CR-TKA and PS-TKA. 
b. The native knee produced significantly higher resultant 
force at 0° compared with CR-TKA and PS-TKA and at 30° 
knee flexion compared with all three arthroplasty conditions. 
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3. Peak Pressure 
a. The lowest peak pressures were produced by the native 
knee due to the elastic deformation of the articular cartilage, 
relative conformity of the native patellofemoral joint and the 
larger surface area. 
b.  Peak pressures generated by PFA were significantly lower 
than CR-TKA and PS-TKA at 90° and 120° flexion due to 
the transition of the patellar button articulating with the 
native femoral condyle. 
c. All three arthroplasty conditions generated peak pressures 
four times that produced by the native knee at 0°. 
d. No difference in peak pressures was detected between CR-
TKA and PS-TKA. These two arthroplasty conditions 
produced significantly greater peak pressures compared to 
PFA and native knee at each angle of knee flexion tested 
due to the hard bearing surfaces and non-congruent patellar 
component. 
 
4. Contact Area 
a. The contact area was significantly higher for the native knee 
at all angles of knee flexion compared with all three 
arthroplasty conditions. 
b. The contact area results demonstrated an inverse 
relationship to the peak pressure. The contact area for PFA 
  
410
increased markedly at 90° and 120° compared with values 
produced in early to mid flexion due to articulation of the 
patellar component with the native femoral condyle. The 
increase was significantly higher than the contact areas 
recorded for CR-TKA and PS-TKA. 
c. No difference in contact area was detected between CR-
TKA and PS-TKA. 
 
Key Conclusions: The evidence showed PFA produced the greatest 
extensor mechanism efficiency between mid flexion and 0° extension 
when compared with the native knee, CR-TKA and PS-TKA. No 
difference was found between CR-TKA and PS-TKA to support previous 
reports of enhanced extensor function associated with the posterior 
stabilising design. 
Applicability of the study findings to the clinical setting is limited. 
Rather, this study offers the benchmark methodology for future 
investigations involving simulation of activities of daily living whilst 
including hip, ankle and foot motion for more accurate interpretation. 
 
5.3.2 Systematic Review 
This systematic review evaluated PFA by design characteristics and TKA 
in terms of survival proportions and complications. The key findings were 
as follows: 
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1. Survival Proportion 
a. The survival proportion for the onlay symmetrical non-
anatomical (OSN) design group was the most comparable 
to the TKA group. Similar mid-term follow-up survival 
proportions of the newer, onlay asymmetrical anatomical 
(OAA) designs have yet to be established.  
b. The non-anatomical designs: inlay symmetrical and inlay 
asymmetrical non-anatomical (ISN and IAN) designs 
produced the lowest survival proportions (A: revision to TKA 
for disease progression and B: any revision for any reason).  
c. Besides prosthetic design, free-hand bony cuts and 
implantation methods, lack of appreciation for soft-tissue 
balancing and less stringent patient selection would have 
also impacted survival proportion outcomes; the extent of 
influence of each factor remains unknown. 
 
2. Complications 
a. The most common mode of failure (requiring revision 
surgery) was disease progression. The most common 
complications in order of frequency were: 
malpositioning/misalignment (ISN, IAN and TKA groups), 
disease progression (IAA and OSN groups) and ‘other’ 
(OAP and mixed groups). 
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b. Aseptic loosening and infection were rare occurrences in all 
the groups.  
c. The number of reoperations was greatest in the ISN group. 
 
Key Conclusion: This systematic review demonstrates the inlay non-
anatomical designs produced the poorest outcomes in terms of survival 
and complication proportions. The OSN group was the most comparable 
to the TKA group. However, the extent to which other factors such as 
patient selection, soft tissue balancing, underlying alignment pathology 
and instrumentation developments influenced these outcomes cannot be 
determined from this study.  
 
5.3.3 Randomised Clinical Trial 
This randomised clinical trial is the first PFA versus TKA trial to be 
completed assessing functional knee scores, quality of life evaluations 
and complication rates. The key findings were as follows: 
 
1. Functional and Quality of Life Outcomes 
a. This superiority trial did not find any evidence of a difference 
in knee function between patients receiving PFA versus 
TKA for severe isolated patellofemoral arthritis. The actual 
variance of the primary outcome (WOMAC) was 
considerably greater than that anticipated, therefore the 
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sample size was too small to determined definitively 
evidence of a difference between the two treatments. 
b. The trial demonstrated both interventions provided all 
patients with a significant improvement in function and 
quality of life outcomes. 
 
2. Complications 
a. The overall number of complications at one year follow-up 
was higher in the TKA group than the PFA group. None of 
the complications were life or limb threatening. 
Complications related specifically to the arthroplasty 
treatment were three times the number recorded in the PFA 
group although overall the numbers were low and therefore 
not analysed for statistical significance. A larger sample size 
would provide a more accurate representation of the 
complication rates associated with both interventions.  
 
Key Conclusion: This trial showed no evidence that PFA provides 
improved knee function or increased activity levels, compared with TKA. 
However a difference cannot be excluded, as the study was 
underpowered. Although this trial did not generate new evidence to justify 
change in current practice, the data did not indicate superiority or 
inferiority of one intervention over the other, rather it highlighted the 
functional benefits of both interventions. A large, multicentre randomised 
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clinical trial is required to definitively establish whether these two 
interventions are comparable in terms of functional outcome.  
 
 
5.4 Limitations and Directions for Future Research 
Each study had limitations specific to the study design as discussed in 
detail at the end of each chapter. These limitations are summarised 
below along with potential future research. 
 
5.4.1 Biomechanics Study 
Summary of Limitations: The use of cadaveric knees offers an 
approximation of activity in the clinical setting therefore limiting 
applicability. The age of the specimen in terms of frozen period before 
use may have influence on the soft tissue integrity. The rig was a 
simplified design involving motion at the knee joint only, the influence of 
hip, ankle and foot motions, all of which impact activities such as walking 
and stair climbing, were not assessed. The flexion-extension cycle 
consisted of static measurements, which were used to assume the 
graphical model rather than exact data. Lack of hamstring loading may 
have influenced the extensor mechanism efficiency due to the risk of 
paradoxical anterior tibial translation, although prosthetic geometry and 
cruciate function have been proven to have a greater impact on extensor 
function. Inadvertent stretching of the soft tissues may have altered this 
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test constant between and within test condition trials. The sensors used 
to measure resultant force, peak pressure and contact area were 
sensitive to changes in temperature and humidity and degradation and 
physical damage (creasing) with increased use thus limiting the number 
of repetitions performed. The sensor calibration surfaces were flat and 
therefore not identical to the curvature of the patellofemoral joint test 
condition, which may have impacted the sensor interpretation. 
 
Future Research: Despite the limitations of this study, the methodology 
and information gathered provides a platform from which more complex 
translational research can evolve.  Assessing the extensor mechanism 
under more clinical conditions, such as stair climbing and walking, will 
further inform the debate. Achieving this would require building a modified 
Oxford Rig to simulate each segment of the lower limb (hip, ankle and 
knee motion) as close to normal as feasible. Continuous flexion-extension 
cycle could be achieved by using a Polaris Optical Tracking System with 
one optical tracker on the femur and one on the tibia. The angle between 
the femur and tibia would be computed in the sagittal plane perpendicular 
to the medial-lateral axis, using Visual 3D Motion. Once the experimental 
set up is built, the conditions tested in the current study can be repeated 
under physiological load to determine more accurately the impact of 
geometrical differences between PFA and TKA on extensor mechanism 
efficiency.  
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Another useful investigation aimed at determining which prosthesis 
offers the greatest mechanical advantage to the extensor mechanism: 
single radius CR-TKA or PS-TKA or multi-radius CR-TKA or PS-TKA 
could be performed using the same experimental set-up. 
 
 
5.4.2 Systematic Review 
Summary of Limitations: The majority of the studies were uncontrolled 
retrospective series and the quality of these studies was general rated as 
low in accordance with the GRADE assessment system. The degree of 
clinical heterogeneity within and between the groups was too high to 
perform a meaningful meta-analysis. Follow-up times, sample sizes, 
number of studies per design group, antecedent and concomitant 
surgery, patient activity levels prior to surgery, underlying diagnoses and 
other limb co-morbidities varied significantly thus limiting the extent of 
comparison and conclusions drawn related to prosthetic design influence. 
Selection and reporting biases were associated with the majority of the 
studies due to the retrospective nature of data collection and patient 
selection. High loss to follow-up affected a few groups, which would have 
undermined the external validity of the results reported. 
 
Future Research: The execution of this systematic review was difficult 
due to the quality of the data and the inconsistencies in the outcomes 
reported. Performing further systematic reviews with the current data 
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available will not add to the current knowledge or resolve uncertainty due 
to the above weaknesses limiting applicability. In order to improve the 
quality of future studies that would be included in such systematic 
reviews, the use of Core Outcome Sets (COS) should ideally be adopted. 
Although, this methodology is currently being developed for trials, there is 
no reason why this cannot be extended to observational studies. The 
main advantage of utilising this system is that a set of outcomes or 
outcome measures and methods of measuring and reporting each 
outcome are standardised for the specific area of research. This enables 
the data from each study to be synthesised, compared and contrasted 
sufficiently, which ultimately leads to more decisive conclusions being 
drawn and more informed choices for surgeons and patients. If all future 
studies involving patellofemoral arthroplasty adopted the use of COS  and 
trials followed the Core Outcome Measures in Effective Trials (COMETS) 
Initiative this will increase the impact and quality of the research 
produced. 
 
5.4.3 Randomised Clinical Trial 
Summary of Limitations: This trial was relatively small and performed by a 
single centre, both factors reduce the generalisability. The anticipated 
variance of the primary outcome was much lower than the actual variance 
calculated, rendering the sample size inadequate. A large number of 
outcome measures were used, which increased participant burden and 
the risk of a Type I error. Patient perception of the differences between 
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the interventions was not formally assessed and no formal evaluation of 
the effectiveness of participant blinding was carried out. Therefore the 
impact of a participant becoming aware of the intervention they received 
on outcome assessment was unknown. The use of qualitative research to 
determine patient perception at the point of recruitment and following 
receipt of intervention may have enhanced the quality of this trial. There 
were five protocol violations of which the majority were likely due to a lack 
of equipoise. Intraoperative randomisation may have minimised the 
number of violations. The trial was designed to test superiority but the 
data indicates one treatment is unlikely to be superior to the other; 
therefore a test of non-inferiority would have been more appropriate.  No 
cost-effectiveness analysis was performed; such an analysis is 
particularly useful when no clear functional advantage in favour of one 
intervention has been established. 
 
Further research: The pilot trial provided very useful information for 
devising a larger, multi-centre trial. The most useful evidence was that 
non significant differences in outcomes between the interventions were 
detected, thus countering the assertion that PFA is superior to TKA. 
Therefore, rather than employing a statistical analysis to detect 
superiority, the aim for this proposed clinical trial is to test for non-
inferiority. A non-inferiority trial test would aim to show PFA treatment  
(the experimental treatment) is no worse than TKA (the standard 
treatment). There are a few reasons why this is the more suitable test to 
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apply: PFA is unlikely to be significantly better than TKA on primary 
outcome such as function/efficacy but is likely to be better on secondary 
outcomes such as implant costs and short to mid-term complication rates. 
Another factor in favour of PFA is the maintenance of more normal knee 
kinematics due to preservation of the tibiofemoral joint and cruciate 
ligaments and the relative ease of revision surgery to TKA. 
The statistical methodology for a non-inferiority test only requires 
defining the anticipated upper bound mean difference in effect between 
the PFA (experimental) and TKA (standard) treatments: NI. This in 
practice is a one-sided test with a significance level of 0.025, whereby a 
significant result (p < 0.025) means PFA is not (much) worse than TKA, 
determined by the chosen value for NI. Determining the non-inferiority 
boundary is challenging as it requires the chosen outcome score to be 
consistently greater in the TKA group than the PFA group but by a 
specific meaningful amount, that is, the minimum important difference 
(MID). Therefore, the precision of the outcome tool must be known. Using 
a patient reported outcome with robust evidence for the MID will be the 
most appropriate method in order for the trial to exhibit non-inferiority.  
The choice of outcome is also crucial because the non-inferiority 
boundary influences the sample size. Undoubtedly, using this trial test, 
especially with the one sided alpha, will increase the sample size 
significantly in comparison to that calculated for the pilot study, therefore 
the study will have to be multi-centre. The advantage of this is two-fold: 
the recruitment time will be within a realistic time frame and the more trial 
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sites are involved, the greater the generalisability to the broader NHS 
clinical setting.  
The trial sites should consist of a range of hospitals to represent 
the wider orthopaedic community, including experienced and less 
experienced surgeons in terms of PFA intervention. Although a minimum 
level of experience will be required. Surgeon equipoise is also another 
important factor to consider and establish in each trial site. In the pilot 
study two out of five of the protocol violations were related to this issue. 
Intra-operative randomisation may reduce the occurrence of such 
violations.  
Cost-effectiveness data collection, specifically for cost-utility 
analysis would be useful in determining the benefit of the interventions in 
terms of the number of years lived in full health by the trial participants 
(quality adjusted life years (QALYS)). Using QALYS to compare the 
interventions allows for a more complete comparison rather than the 
monetary comparison offered by a simple cost-benefit analysis. There are 
some pitfalls to performing cost-effectiveness analysis, which must be 
taken into consideration. The analysis is based on the trial results and 
therefore limited by the quality of the data. If the trial is biased, the same 
will be true for the cost-effectiveness analysis. The time horizon for the 
cost-effectiveness analysis may be 10 to 20 years and therefore beyond 
that which is feasible or intended for clinical data collection. Long-term 
modelling of this outcome rather than direct measurement would be 
required.  
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Another additional area for research alongside the trial is the use 
of qualitative methods to assess patient perception. Patient perception of 
the treatments may influence the decision to participate. Identifying the 
differences in the populations that chose to participate compared to those 
that decline may establish areas for development in recruiting style and 
approach. Participants with a preference for one intervention may 
influence outcome results, particularly if they become aware of the 
intervention received. The importance of knowing how participants react, 
that is, modification to their behaviour or approach to rehabilitation will 
further add to the knowledge gained from performing this trial.  
 
The ultimate aim of this research is to further inform the debate regarding 
choice of treatment between PFA and TKA for isolated patellofemoral 
arthritis. Therefore, it is important to continue developing new research 
ideas which may, in time, result in a definitive answer being established. 
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Chapter 6 Appendices
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Appendix I: Extensor Mechanism Efficiency Data for Each Individual Knee 
 
 
 
Table 6-1 Knee MO1 Native Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 137.25 85.52130687 0.25 21.38032672 205 0.104294277 
110 0.623106061 103 64.17992428 0.25 16.04498107 205 0.0782682 
100 0.623106061 99.5 61.99905307 0.25 15.49976327 205 0.075608601 
90 0.623106061 104.75 65.27035989 0.25 16.31758997 205 0.079598 
80 0.623106061 111 69.16477277 0.25 17.29119319 205 0.084347284 
70 0.623106061 117 72.90340914 0.25 18.22585228 205 0.088906597 
60 0.623106061 130.25 81.15956445 0.25 20.28989111 205 0.098975079 
50 0.623106061 144.5 90.03882581 0.25 22.50970645 205 0.109803446 
40 0.623106061 162 100.9431819 0.25 25.23579547 205 0.123101441 
30 0.623106061 168 104.6818182 0.25 26.17045456 205 0.127660754 
20 0.623106061 164.5 102.500947 0.25 25.62523676 205 0.125001155 
10 0.623106061 152 94.71212127 0.25 23.67803032 205 0.115502587 
0 0.623106061 39.25 24.45691289 0.25 6.114228224 205 0.029825504 
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Table 6-2 Knee MO1 PFA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 173 107.7973486 0.25 26.94933714 205 0.131460181 
110 0.623106061 108.25 67.4512311 0.25 16.86280778 205 0.082257599 
100 0.623106061 76.5 47.66761367 0.25 11.91690342 205 0.058131236 
90 0.623106061 68.5 42.68276518 0.25 10.67069129 205 0.052052153 
80 0.623106061 97 60.44128792 0.25 15.11032198 205 0.073708888 
70 0.623106061 118.25 73.68229171 0.25 18.42057293 205 0.089856453 
60 0.623106061 138.75 86.45596596 0.25 21.61399149 205 0.105434105 
50 0.623106061 169.25 105.4607008 0.25 26.36517521 205 0.128610611 
40 0.623106061 176.75 110.1339963 0.25 27.53349907 205 0.134309752 
30 0.623106061 172.25 107.330019 0.25 26.83250475 205 0.130890267 
20 0.623106061 152.25 94.86789779 0.25 23.71697445 205 0.115692558 
10 0.623106061 119 74.14962126 0.25 18.53740531 205 0.090426367 
0 0.623106061 15.5 9.658143946 0.25 2.414535986 205 0.011778224 
 
Table 6-3 Knee MO1 CR-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 153.5 95.64678036 0.25 23.91169509 205 0.116642415 
110 0.623106061 97.25 60.59706443 0.25 15.14926611 205 0.073898859 
100 0.623106061 92.25 57.48153413 0.25 14.37038353 205 0.070099432 
90 0.623106061 99.75 62.15482958 0.25 15.5387074 205 0.075798573 
80 0.623106061 91 56.70265155 0.25 14.17566289 205 0.069149575 
70 0.623106061 96.5 60.12973489 0.25 15.03243372 205 0.073328945 
60 0.623106061 112.25 69.94365535 0.25 17.48591384 205 0.085297141 
50 0.623106061 113.75 70.87831444 0.25 17.71957861 205 0.086436969 
40 0.623106061 156.25 97.36032203 0.25 24.34008051 205 0.1187321 
30 0.623106061 133.75 83.34043566 0.25 20.83510891 205 0.101634678 
20 0.623106061 135 84.11931824 0.25 21.02982956 205 0.102584534 
  
425
10 0.623106061 103.5 64.49147731 0.25 16.12286933 205 0.078648143 
0 0.623106061 30 18.69318183 0.25 4.673295458 205 0.022796563 
 
Table 6-4 Knee MO1 PS-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 151.5 94.40056824 0.25 23.60014206 205 0.115122644 
110 0.623106061 116 72.28030308 0.25 18.07007577 205 0.088146711 
100 0.623106061 105.5 65.73768944 0.25 16.43442236 205 0.080167914 
90 0.623106061 99.25 61.84327655 0.25 15.46081914 205 0.07541863 
80 0.623106061 90 56.07954549 0.25 14.01988637 205 0.06838969 
70 0.623106061 93.75 58.41619322 0.25 14.6040483 205 0.07123926 
60 0.623106061 100.75 62.77793565 0.25 15.69448391 205 0.076558458 
50 0.623106061 102.5 63.86837125 0.25 15.96709281 205 0.077888258 
40 0.623106061 106.5 66.3607955 0.25 16.59019887 205 0.080927799 
30 0.623106061 124.75 77.73248111 0.25 19.43312028 205 0.094795709 
20 0.623106061 139 86.61174248 0.25 21.65293562 205 0.105624076 
10 0.623106061 88.5 55.1448864 0.25 13.7862216 205 0.067249861 
0 0.623106061 30.75 19.16051138 0.25 4.790127844 205 0.023366477 
 
 
Table 6-5 Knee MO2 Native Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 126 78.51136369 0.25 19.62784092 205 0.095745565 
110 0.623106061 103.5 64.49147731 0.25 16.12286933 205 0.078648143 
100 0.623106061 103.25 64.3357008 0.25 16.0839252 205 0.078458172 
90 0.623106061 101.5 63.24526519 0.25 15.8113163 205 0.077128372 
80 0.623106061 109.75 68.38589019 0.25 17.09647255 205 0.083397427 
70 0.623106061 119 74.14962126 0.25 18.53740531 205 0.090426367 
60 0.623106061 134.75 83.96354172 0.25 20.99088543 205 0.102394563 
  
426
50 0.623106061 147 91.59659097 0.25 22.89914774 205 0.11170316 
40 0.623106061 154 95.95833339 0.25 23.98958335 205 0.117022358 
30 0.623106061 157.5 98.13920461 0.25 24.53480115 205 0.119681957 
20 0.623106061 162.75 101.4105114 0.25 25.35262786 205 0.123671355 
10 0.623106061 134.75 83.96354172 0.25 20.99088543 205 0.102394563 
0 0.623106061 34.75 21.65293562 0.25 5.413233905 205 0.026406019 
 
Table 6-6 Knee MO2 PFA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 149.5 93.15435612 0.25 23.28858903 205 0.113602873 
110 0.623106061 92.5 57.63731064 0.25 14.40932766 205 0.070289403 
100 0.623106061 84.75 52.80823867 0.25 13.20205967 205 0.064400291 
90 0.623106061 78 48.60227276 0.25 12.15056819 205 0.059271064 
80 0.623106061 50.75 31.6226326 0.25 7.905658149 205 0.038564186 
70 0.623106061 82.75 51.56202655 0.25 12.89050664 205 0.06288052 
60 0.623106061 121.75 75.86316293 0.25 18.96579073 205 0.092516052 
50 0.623106061 162 100.9431819 0.25 25.23579547 205 0.123101441 
40 0.623106061 192.25 119.7921402 0.25 29.94803506 205 0.146087976 
30 0.623106061 201.5 125.5558713 0.25 31.38896782 205 0.153116916 
20 0.623106061 198.25 123.5307766 0.25 30.88269415 205 0.150647289 
10 0.623106061 178.5 111.2244319 0.25 27.80610797 205 0.135639551 
0 0.623106061 116.5 72.59185611 0.25 18.14796403 205 0.088526654 
 
 
Table 6-7 Knee MO2 CR-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 123.5 76.95359853 0.25 19.23839963 205 0.093845852 
110 0.623106061 118 73.5265152 0.25 18.3816288 205 0.089666482 
100 0.623106061 114.75 71.5014205 0.25 17.87535512 205 0.087196854 
  
427
90 0.623106061 112.75 70.25520838 0.25 17.56380209 205 0.085677083 
80 0.623106061 111 69.16477277 0.25 17.29119319 205 0.084347284 
70 0.623106061 114.25 71.18986747 0.25 17.79746687 205 0.086816912 
60 0.623106061 124 77.26515156 0.25 19.31628789 205 0.094225795 
50 0.623106061 134.75 83.96354172 0.25 20.99088543 205 0.102394563 
40 0.623106061 153 95.33522733 0.25 23.83380683 205 0.116262472 
30 0.623106061 160.5 100.0085228 0.25 25.0021307 205 0.121961613 
20 0.623106061 160.25 99.85274628 0.25 24.96318657 205 0.121771642 
10 0.623106061 117.25 73.05918565 0.25 18.26479641 205 0.089096568 
0 0.623106061 0 0 0.25 0 205 0 
 
Table 6-8 Knee MO2 PS-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 152.75 95.17945082 0.25 23.7948627 205 0.116072501 
110 0.623106061 129.75 80.84801141 0.25 20.21200285 205 0.098595136 
100 0.623106061 114.5 71.34564398 0.25 17.836411 205 0.087006883 
90 0.623106061 113.25 70.56676141 0.25 17.64169035 205 0.086057026 
80 0.623106061 112.5 70.09943186 0.25 17.52485797 205 0.085487112 
70 0.623106061 113.5 70.72253792 0.25 17.68063448 205 0.086246997 
60 0.623106061 120.75 75.24005687 0.25 18.81001422 205 0.091756167 
50 0.623106061 124 77.26515156 0.25 19.31628789 205 0.094225795 
40 0.623106061 136 84.7424243 0.25 21.18560607 205 0.10334442 
30 0.623106061 145.25 90.50615536 0.25 22.62653884 205 0.11037336 
20 0.623106061 131.75 82.09422354 0.25 20.52355588 205 0.100114907 
10 0.623106061 48 29.90909093 0.25 7.477272732 205 0.036474501 
0 0.623106061 0 0 0.25 0 205 0 
 
 
 
  
428
Table 6-9 Knee MO3 Native Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 125.75 78.35558717 0.25 19.58889679 205 0.095555594 
110 0.623106061 90 56.07954549 0.25 14.01988637 205 0.06838969 
100 0.623106061 89.25 55.61221594 0.25 13.90305399 205 0.067819776 
90 0.623106061 91.5 57.01420458 0.25 14.25355115 205 0.069529518 
80 0.623106061 104.25 64.95880686 0.25 16.23970171 205 0.079218057 
70 0.623106061 120.5 75.08428035 0.25 18.77107009 205 0.091566196 
60 0.623106061 138.5 86.30018945 0.25 21.57504736 205 0.105244133 
50 0.623106061 151.5 94.40056824 0.25 23.60014206 205 0.115122644 
40 0.623106061 182.25 113.5610796 0.25 28.3902699 205 0.138489121 
30 0.623106061 197.25 122.9076705 0.25 30.72691763 205 0.149887403 
20 0.623106061 191.5 119.3248107 0.25 29.83120267 205 0.145518062 
10 0.623106061 162.25 101.0989584 0.25 25.2747396 205 0.123291413 
0 0.623106061 69.5 43.30587124 0.25 10.82646781 205 0.052812038 
Table 6-10 Knee MO3 PFA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 131.5 81.93844702 0.25 20.48461176 205 0.099924935 
110 0.623106061 97 60.44128792 0.25 15.11032198 205 0.073708888 
100 0.623106061 90.25 56.23532201 0.25 14.0588305 205 0.068579661 
90 0.623106061 113 70.41098489 0.25 17.60274622 205 0.085867055 
80 0.623106061 99.25 61.84327655 0.25 15.46081914 205 0.07541863 
70 0.623106061 132.25 82.40577657 0.25 20.60144414 205 0.100494849 
60 0.623106061 154.5 96.26988642 0.25 24.06747161 205 0.117402301 
50 0.623106061 182 113.4053031 0.25 28.35132578 205 0.13829915 
40 0.623106061 196.25 122.2845645 0.25 30.57114112 205 0.149127518 
30 0.623106061 188.5 117.4554925 0.25 29.36387312 205 0.143238405 
20 0.623106061 166 103.4356061 0.25 25.85890153 205 0.126140983 
10 0.623106061 120.5 75.08428035 0.25 18.77107009 205 0.091566196 
  
429
0 0.623106061 12 7.477272732 0.25 1.869318183 205 0.009118625 
 
 
Table 6-11 Knee MO3 CR-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 148 92.21969703 0.25 23.05492426 205 0.112463045 
110 0.623106061 98.5 61.37594701 0.25 15.34398675 205 0.074848716 
100 0.623106061 93 57.94886367 0.25 14.48721592 205 0.070669346 
90 0.623106061 93.5 58.2604167 0.25 14.56510418 205 0.071049289 
80 0.623106061 98 61.06439398 0.25 15.26609849 205 0.074468773 
70 0.623106061 98.75 61.53172352 0.25 15.38293088 205 0.075038687 
60 0.623106061 101.25 63.08948868 0.25 15.77237217 205 0.076938401 
50 0.623106061 106.5 66.3607955 0.25 16.59019887 205 0.080927799 
40 0.623106061 117.25 73.05918565 0.25 18.26479641 205 0.089096568 
30 0.623106061 115.25 71.81297353 0.25 17.95324338 205 0.087576797 
20 0.623106061 98.75 61.53172352 0.25 15.38293088 205 0.075038687 
10 0.623106061 59.5 37.07481063 0.25 9.268702657 205 0.045213184 
0 0.623106061 2 1.246212122 0.25 0.311553031 205 0.001519771 
 
Table 6-12 Knee MO3 PS-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 143.5 89.41571975 0.25 22.35392994 205 0.109043561 
110 0.623106061 105 65.42613641 0.25 16.3565341 205 0.079787971 
100 0.623106061 97 60.44128792 0.25 15.11032198 205 0.073708888 
90 0.623106061 99 61.68750004 0.25 15.42187501 205 0.075228659 
80 0.623106061 103 64.17992428 0.25 16.04498107 205 0.0782682 
70 0.623106061 107.25 66.82812504 0.25 16.70703126 205 0.081497713 
60 0.623106061 111.25 69.32054929 0.25 17.33013732 205 0.084537255 
50 0.623106061 118.5 73.83806823 0.25 18.45951706 205 0.090046425 
  
430
40 0.623106061 122.75 76.48626899 0.25 19.12156725 205 0.093275938 
30 0.623106061 130.5 81.31534096 0.25 20.32883524 205 0.09916505 
20 0.623106061 120.75 75.24005687 0.25 18.81001422 205 0.091756167 
10 0.623106061 76.5 47.66761367 0.25 11.91690342 205 0.058131236 
0 0.623106061 0 0 0.25 0 205 0 
 
Table 6-13 Knee MO4 Native Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 156 97.20454552 0.25 24.30113638 205 0.118542129 
110 0.623106061 119 74.14962126 0.25 18.53740531 205 0.090426367 
100 0.623106061 106 66.04924247 0.25 16.51231062 205 0.080547857 
90 0.623106061 106.5 66.3607955 0.25 16.59019887 205 0.080927799 
80 0.623106061 105 65.42613641 0.25 16.3565341 205 0.079787971 
70 0.623106061 112.75 70.25520838 0.25 17.56380209 205 0.085677083 
60 0.623106061 127 79.13446975 0.25 19.78361744 205 0.096505451 
50 0.623106061 139 86.61174248 0.25 21.65293562 205 0.105624076 
40 0.623106061 152.75 95.17945082 0.25 23.7948627 205 0.116072501 
30 0.623106061 165.25 102.9682766 0.25 25.74206915 205 0.125571069 
20 0.623106061 174 108.4204546 0.25 27.10511365 205 0.132220067 
10 0.623106061 170.5 106.2395834 0.25 26.55989585 205 0.129560468 
0 0.623106061 103 64.17992428 0.25 16.04498107 205 0.0782682 
 
Table 6-14 Knee MO4 PFA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 158.25 98.60653415 0.25 24.65163354 205 0.120251871 
110 0.623106061 97.25 60.59706443 0.25 15.14926611 205 0.073898859 
100 0.623106061 88.5 55.1448864 0.25 13.7862216 205 0.067249861 
90 0.623106061 87 54.21022731 0.25 13.55255683 205 0.066110033 
  
431
80 0.623106061 97.25 60.59706443 0.25 15.14926611 205 0.073898859 
70 0.623106061 119.25 74.30539777 0.25 18.57634944 205 0.090616339 
60 0.623106061 82.75 51.56202655 0.25 12.89050664 205 0.06288052 
50 0.623106061 122 76.01893944 0.25 19.00473486 205 0.092706024 
40 0.623106061 154.25 96.11410991 0.25 24.02852748 205 0.117212329 
30 0.623106061 183.75 114.4957387 0.25 28.62393468 205 0.13962895 
20 0.623106061 222.75 138.7968751 0.25 34.69921877 205 0.169264482 
10 0.623106061 202.5 126.1789774 0.25 31.54474434 205 0.153876802 
0 0.623106061 141.25 88.01373112 0.25 22.00343278 205 0.107333818 
 
Table 6-15 Knee MO4 CR-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 127.5 79.44602278 0.25 19.86150569 205 0.096885394 
110 0.623106061 91 56.70265155 0.25 14.17566289 205 0.069149575 
100 0.623106061 88.75 55.30066291 0.25 13.82516573 205 0.067439833 
90 0.623106061 92.25 57.48153413 0.25 14.37038353 205 0.070099432 
80 0.623106061 93.5 58.2604167 0.25 14.56510418 205 0.071049289 
70 0.623106061 108.5 67.60700762 0.25 16.9017519 205 0.08244757 
60 0.623106061 132 82.25000005 0.25 20.56250001 205 0.100304878 
50 0.623106061 155 96.58143946 0.25 24.14535986 205 0.117782243 
40 0.623106061 158 98.45075764 0.25 24.61268941 205 0.1200619 
30 0.623106061 168.5 104.9933713 0.25 26.24834282 205 0.128040697 
20 0.623106061 159.25 99.22964021 0.25 24.80741005 205 0.121011756 
10 0.623106061 106 66.04924247 0.25 16.51231062 205 0.080547857 
0 0.623106061 4.25 2.648200759 0.25 0.66205019 205 0.003229513 
 
 
 
 
 
  
432
Table 6-16 Knee MO4 PS-TKA Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 130 81.00378793 0.25 20.25094698 205 0.098785107 
110 0.623106061 92.5 57.63731064 0.25 14.40932766 205 0.070289403 
100 0.623106061 86.25 53.74289776 0.25 13.43572444 205 0.065540119 
90 0.623106061 92 57.32575761 0.25 14.3314394 205 0.069909461 
80 0.623106061 103.75 64.64725383 0.25 16.16181346 205 0.078838114 
70 0.623106061 114.25 71.18986747 0.25 17.79746687 205 0.086816912 
60 0.623106061 128 79.75757581 0.25 19.93939395 205 0.097265336 
50 0.623106061 140.25 87.39062506 0.25 21.84765626 205 0.106573933 
40 0.623106061 158.75 98.91808718 0.25 24.7295218 205 0.120631814 
30 0.623106061 179.25 111.6917614 0.25 27.92294036 205 0.136209465 
20 0.623106061 181.5 113.0937501 0.25 28.27343752 205 0.137919207 
10 0.623106061 148.75 92.68702657 0.25 23.17175664 205 0.113032959 
0 0.623106061 1.5 0.934659092 0.25 0.233664773 205 0.001139828 
 
 
Table 6-17 Knee MO5 Native Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 198.75 123.8423296 0.25 30.96058241 205 0.151027231 
110 0.623106061 111.75 69.63210232 0.25 17.40802558 205 0.084917198 
100 0.623106061 102.75 64.02414777 0.25 16.00603694 205 0.078078229 
90 0.623106061 104 64.80303034 0.25 16.20075759 205 0.079028086 
80 0.623106061 106.25 66.20501898 0.25 16.55125475 205 0.080737828 
70 0.623106061 116.75 72.74763262 0.25 18.18690816 205 0.088716625 
60 0.623106061 128.5 80.06912884 0.25 20.01728221 205 0.097645279 
50 0.623106061 141 87.8579546 0.25 21.96448865 205 0.107143847 
40 0.623106061 156 97.20454552 0.25 24.30113638 205 0.118542129 
30 0.623106061 169.5 105.6164773 0.25 26.40411933 205 0.128800582 
  
433
20 0.623106061 174.75 108.8877842 0.25 27.22194604 205 0.132789981 
10 0.623106061 155.75 97.048769 0.25 24.26219225 205 0.118352157 
0 0.623106061 63.5 39.56723487 0.25 9.891808718 205 0.048252725 
 
 
Table 6-18 Knee MO5 PFA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 140.5 87.54640157 0.25 21.88660039 205 0.106763904 
110 0.623106061 109.5 68.23011368 0.25 17.05752842 205 0.083207456 
100 0.623106061 99.75 62.15482958 0.25 15.5387074 205 0.075798573 
90 0.623106061 103.25 64.3357008 0.25 16.0839252 205 0.078458172 
80 0.623106061 92.25 57.48153413 0.25 14.37038353 205 0.070099432 
70 0.623106061 119.75 74.6169508 0.25 18.6542377 205 0.090996281 
60 0.623106061 157.5 98.13920461 0.25 24.53480115 205 0.119681957 
50 0.623106061 185 115.2746213 0.25 28.81865532 205 0.140578806 
40 0.623106061 190.25 118.5459281 0.25 29.63648203 205 0.144568205 
30 0.623106061 175.5 109.3551137 0.25 27.33877843 205 0.133359895 
20 0.623106061 181.75 113.2495266 0.25 28.31238165 205 0.138109179 
10 0.623106061 153 95.33522733 0.25 23.83380683 205 0.116262472 
0 0.623106061 76 47.35606064 0.25 11.83901516 205 0.057751293 
 
 
Table 6-19 Knee MO5 CR-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 198.75 123.8423296 0.25 30.96058241 205 0.151027231 
110 0.623106061 138 85.98863642 0.25 21.4971591 205 0.104864191 
100 0.623106061 123.25 76.79782202 0.25 19.1994555 205 0.093655881 
90 0.623106061 121.5 75.70738641 0.25 18.9268466 205 0.092326081 
80 0.623106061 121.5 75.70738641 0.25 18.9268466 205 0.092326081 
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70 0.623106061 131.5 81.93844702 0.25 20.48461176 205 0.099924935 
60 0.623106061 145.25 90.50615536 0.25 22.62653884 205 0.11037336 
50 0.623106061 154.5 96.26988642 0.25 24.06747161 205 0.117402301 
40 0.623106061 158 98.45075764 0.25 24.61268941 205 0.1200619 
30 0.623106061 163.25 101.7220645 0.25 25.43051611 205 0.124051298 
20 0.623106061 150.75 93.9332387 0.25 23.48330967 205 0.11455273 
10 0.623106061 122.25 76.17471596 0.25 19.04367899 205 0.092895995 
0 0.623106061 53.25 33.18039775 0.25 8.295099437 205 0.0404639 
 
 
Table 6-20 Knee MO5 PS-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 163.25 101.7220645 0.25 25.43051611 205 0.124051298 
110 0.623106061 129.75 80.84801141 0.25 20.21200285 205 0.098595136 
100 0.623106061 114.25 71.18986747 0.25 17.79746687 205 0.086816912 
90 0.623106061 103.5 64.49147731 0.25 16.12286933 205 0.078648143 
80 0.623106061 101.25 63.08948868 0.25 15.77237217 205 0.076938401 
70 0.623106061 103.5 64.49147731 0.25 16.12286933 205 0.078648143 
60 0.623106061 112.5 70.09943186 0.25 17.52485797 205 0.085487112 
50 0.623106061 120.75 75.24005687 0.25 18.81001422 205 0.091756167 
40 0.623106061 132.5 82.56155308 0.25 20.64038827 205 0.100684821 
30 0.623106061 150.25 93.62168567 0.25 23.40542142 205 0.114172787 
20 0.623106061 157.25 97.98342809 0.25 24.49585702 205 0.119491985 
10 0.623106061 146 90.97348491 0.25 22.74337123 205 0.110943274 
0 0.623106061 54.25 33.80350381 0.25 8.450875952 205 0.041223785 
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Table 6-21 Knee MO6 Native Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 100.25 62.46638262 0.25 15.61659565 205 0.076178515 
110 0.623106061 75.5 47.04450761 0.25 11.7611269 205 0.057371351 
100 0.623106061 70.75 44.08475382 0.25 11.02118845 205 0.053761895 
90 0.623106061 77.75 48.44649624 0.25 12.11162406 205 0.059081093 
80 0.623106061 88.25 54.98910988 0.25 13.74727747 205 0.06705989 
70 0.623106061 98 61.06439398 0.25 15.26609849 205 0.074468773 
60 0.623106061 121.5 75.70738641 0.25 18.9268466 205 0.092326081 
50 0.623106061 147.5 91.908144 0.25 22.977036 205 0.112083102 
40 0.623106061 170 105.9280304 0.25 26.48200759 205 0.129180525 
30 0.623106061 197.5 123.063447 0.25 30.76586176 205 0.150077374 
20 0.623106061 211.25 131.6311554 0.25 32.90778885 205 0.160525799 
10 0.623106061 206 128.3598486 0.25 32.08996214 205 0.156536401 
0 0.623106061 96.5 60.12973489 0.25 15.03243372 205 0.073328945 
 
 
Table 6-22 Knee MO6 PFA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 130.25 81.15956445 0.25 20.28989111 205 0.098975079 
110 0.623106061 74.5 46.42140154 0.25 11.60535039 205 0.056611465 
100 0.623106061 75.25 46.88873109 0.25 11.72218277 205 0.057181379 
90 0.623106061 77.5 48.29071973 0.25 12.07267993 205 0.058891122 
80 0.623106061 92.75 57.79308716 0.25 14.44827179 205 0.070479375 
70 0.623106061 73.75 45.954072 0.25 11.488518 205 0.056041551 
60 0.623106061 130.5 81.31534096 0.25 20.32883524 205 0.09916505 
50 0.623106061 169 105.3049243 0.25 26.32623108 205 0.128420639 
40 0.623106061 201.5 125.5558713 0.25 31.38896782 205 0.153116916 
30 0.623106061 216.5 134.9024622 0.25 33.72561555 205 0.164515198 
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20 0.623106061 198.5 123.6865531 0.25 30.92163828 205 0.15083726 
10 0.623106061 161 100.3200758 0.25 25.08001896 205 0.122341556 
0 0.623106061 45.5 28.35132578 0.25 7.087831444 205 0.034574788 
 
 
 
Table 6-23 Knee MO6 CR-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 126.5 78.82291672 0.25 19.70572918 205 0.096125508 
110 0.623106061 81 50.47159094 0.25 12.61789774 205 0.061550721 
100 0.623106061 74.25 46.26562503 0.25 11.56640626 205 0.056421494 
90 0.623106061 74.75 46.57717806 0.25 11.64429451 205 0.056801437 
80 0.623106061 83.25 51.87357958 0.25 12.96839489 205 0.063260463 
70 0.623106061 97.75 60.90861746 0.25 15.22715437 205 0.074278802 
60 0.623106061 108.25 67.4512311 0.25 16.86280778 205 0.082257599 
50 0.623106061 113.25 70.56676141 0.25 17.64169035 205 0.086057026 
40 0.623106061 127.5 79.44602278 0.25 19.86150569 205 0.096885394 
30 0.623106061 136 84.7424243 0.25 21.18560607 205 0.10334442 
20 0.623106061 123.25 76.79782202 0.25 19.1994555 205 0.093655881 
10 0.623106061 70 43.61742427 0.25 10.90435607 205 0.053191981 
0 0.623106061 1 0.623106061 0.25 0.155776515 205 0.000759885 
 
 
Table 6-24 Knee MO6 PS-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 109 67.91856065 0.25 16.97964016 205 0.082827513 
110 0.623106061 84.25 52.49668564 0.25 13.12417141 205 0.064020348 
100 0.623106061 82.75 51.56202655 0.25 12.89050664 205 0.06288052 
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90 0.623106061 88.25 54.98910988 0.25 13.74727747 205 0.06705989 
80 0.623106061 94.5 58.88352276 0.25 14.72088069 205 0.071809174 
70 0.623106061 100.75 62.77793565 0.25 15.69448391 205 0.076558458 
60 0.623106061 115.25 71.81297353 0.25 17.95324338 205 0.087576797 
50 0.623106061 125.25 78.04403414 0.25 19.51100854 205 0.095175651 
40 0.623106061 139.5 86.92329551 0.25 21.73082388 205 0.106004019 
30 0.623106061 154.5 96.26988642 0.25 24.06747161 205 0.117402301 
20 0.623106061 151.75 94.55634476 0.25 23.63908619 205 0.115312616 
10 0.623106061 104.25 64.95880686 0.25 16.23970171 205 0.079218057 
0 0.623106061 1.5 0.934659092 0.25 0.233664773 205 0.001139828 
 
 
 
Table 6-25 Knee MO9 Native Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 158.5 98.76231067 0.25 24.69057767 205 0.120441842 
110 0.623106061 98.25 61.22017049 0.25 15.30504262 205 0.074658745 
100 0.623106061 85.5 53.27556822 0.25 13.31889205 205 0.064970205 
90 0.623106061 91 56.70265155 0.25 14.17566289 205 0.069149575 
80 0.623106061 99.5 61.99905307 0.25 15.49976327 205 0.075608601 
70 0.623106061 119 74.14962126 0.25 18.53740531 205 0.090426367 
60 0.623106061 132.75 82.7173296 0.25 20.6793324 205 0.100874792 
50 0.623106061 159.25 99.22964021 0.25 24.80741005 205 0.121011756 
40 0.623106061 168.5 104.9933713 0.25 26.24834282 205 0.128040697 
30 0.623106061 184 114.6515152 0.25 28.66287881 205 0.139818921 
20 0.623106061 187.75 116.988163 0.25 29.24704074 205 0.142668491 
10 0.623106061 163.5 101.877841 0.25 25.46946024 205 0.124241269 
0 0.623106061 79.25 49.38115533 0.25 12.34528883 205 0.060220921 
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Table 6-26 Knee MO9 PFA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 117 72.90340914 0.25 18.22585228 205 0.088906597 
110 0.623106061 78.25 48.75804927 0.25 12.18951232 205 0.059461036 
100 0.623106061 78.25 48.75804927 0.25 12.18951232 205 0.059461036 
90 0.623106061 65.75 40.96922351 0.25 10.24230588 205 0.049962468 
80 0.623106061 65 40.50189397 0.25 10.12547349 205 0.049392554 
70 0.623106061 74.5 46.42140154 0.25 11.60535039 205 0.056611465 
60 0.623106061 62.5 38.94412881 0.25 9.736032203 205 0.04749284 
50 0.623106061 101.25 63.08948868 0.25 15.77237217 205 0.076938401 
40 0.623106061 141.75 88.32528415 0.25 22.08132104 205 0.107713761 
30 0.623106061 178.5 111.2244319 0.25 27.80610797 205 0.135639551 
20 0.623106061 200.25 124.7769887 0.25 31.19424718 205 0.152167059 
10 0.623106061 189.5 118.0785986 0.25 29.51964964 205 0.143998291 
0 0.623106061 142.75 88.94839021 0.25 22.23709755 205 0.108473647 
 
 
Table 6-27 Knee MO9 CR-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 120 74.77272732 0.25 18.69318183 205 0.091186253 
110 0.623106061 81.75 50.93892049 0.25 12.73473012 205 0.062120635 
100 0.623106061 71 44.24053033 0.25 11.06013258 205 0.053951866 
90 0.623106061 74.75 46.57717806 0.25 11.64429451 205 0.056801437 
80 0.623106061 78.75 49.0696023 0.25 12.26740058 205 0.059840978 
70 0.623106061 86 53.58712125 0.25 13.39678031 205 0.065350148 
60 0.623106061 92 57.32575761 0.25 14.3314394 205 0.069909461 
50 0.623106061 107.5 66.98390156 0.25 16.74597539 205 0.081687685 
40 0.623106061 112.75 70.25520838 0.25 17.56380209 205 0.085677083 
30 0.623106061 130 81.00378793 0.25 20.25094698 205 0.098785107 
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20 0.623106061 146 90.97348491 0.25 22.74337123 205 0.110943274 
10 0.623106061 114.75 71.5014205 0.25 17.87535512 205 0.087196854 
0 0.623106061 25.25 15.73342804 0.25 3.93335701 205 0.019187107 
 
 
Table 6-28 Knee MO9 PS-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 114.75 71.5014205 0.25 17.87535512 205 0.087196854 
110 0.623106061 84.5 52.65246215 0.25 13.16311554 205 0.06421032 
100 0.623106061 73 45.48674245 0.25 11.37168561 205 0.055471637 
90 0.623106061 73.25 45.64251897 0.25 11.41062974 205 0.055661608 
80 0.623106061 71.75 44.70785988 0.25 11.17696497 205 0.05452178 
70 0.623106061 80.5 50.16003791 0.25 12.54000948 205 0.061170778 
60 0.623106061 85 52.96401519 0.25 13.2410038 205 0.064590262 
50 0.623106061 92.5 57.63731064 0.25 14.40932766 205 0.070289403 
40 0.623106061 106 66.04924247 0.25 16.51231062 205 0.080547857 
30 0.623106061 129 80.38068187 0.25 20.09517047 205 0.098025222 
20 0.623106061 145.5 90.66193188 0.25 22.66548297 205 0.110563332 
10 0.623106061 121.25 75.5516099 0.25 18.88790247 205 0.09213611 
0 0.623106061 14.5 9.035037885 0.25 2.258759471 205 0.011018339 
 
 
Table 6-29 Knee MO10 Native Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 165.75 103.2798296 0.25 25.8199574 205 0.125951012 
110 0.623106061 124.75 77.73248111 0.25 19.43312028 205 0.094795709 
100 0.623106061 110 68.54166671 0.25 17.13541668 205 0.083587398 
90 0.623106061 104.25 64.95880686 0.25 16.23970171 205 0.079218057 
80 0.623106061 103.25 64.3357008 0.25 16.0839252 205 0.078458172 
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70 0.623106061 103.75 64.64725383 0.25 16.16181346 205 0.078838114 
60 0.623106061 126.25 78.6671402 0.25 19.66678505 205 0.095935537 
50 0.623106061 147 91.59659097 0.25 22.89914774 205 0.11170316 
40 0.623106061 147 91.59659097 0.25 22.89914774 205 0.11170316 
30 0.623106061 163 101.5662879 0.25 25.39157199 205 0.123861327 
20 0.623106061 191.5 119.3248107 0.25 29.83120267 205 0.145518062 
10 0.623106061 168.25 104.8375948 0.25 26.20939869 205 0.127850725 
0 0.623106061 28 17.44696971 0.25 4.361742427 205 0.021276792 
 
Table 6-30 Knee MO10 PFA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 149.5 93.15435612 0.25 23.28858903 205 0.113602873 
110 0.623106061 116.5 72.59185611 0.25 18.14796403 205 0.088526654 
100 0.623106061 116.75 72.74763262 0.25 18.18690816 205 0.088716625 
90 0.623106061 109.25 68.07433716 0.25 17.01858429 205 0.083017484 
80 0.623106061 100.75 62.77793565 0.25 15.69448391 205 0.076558458 
70 0.623106061 104.75 65.27035989 0.25 16.31758997 205 0.079598 
60 0.623106061 135 84.11931824 0.25 21.02982956 205 0.102584534 
50 0.623106061 170.5 106.2395834 0.25 26.55989585 205 0.129560468 
40 0.623106061 194.5 121.1941289 0.25 30.29853222 205 0.147797718 
30 0.623106061 205 127.7367425 0.25 31.93418563 205 0.155776515 
20 0.623106061 203.75 126.9578599 0.25 31.73946498 205 0.154826658 
10 0.623106061 162.75 101.4105114 0.25 25.35262786 205 0.123671355 
0 0.623106061 19 11.83901516 0.25 2.95975379 205 0.014437823 
 
Table 6-31 Knee MO10 CR-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 177.75 110.7571023 0.25 27.68927559 205 0.135069637 
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110 0.623106061 139.25 86.76751899 0.25 21.69187975 205 0.105814048 
100 0.623106061 118.25 73.68229171 0.25 18.42057293 205 0.089856453 
90 0.623106061 119 74.14962126 0.25 18.53740531 205 0.090426367 
80 0.623106061 120.75 75.24005687 0.25 18.81001422 205 0.091756167 
70 0.623106061 137.5 85.67708339 0.25 21.41927085 205 0.104484248 
60 0.623106061 155 96.58143946 0.25 24.14535986 205 0.117782243 
50 0.623106061 160 99.69696976 0.25 24.92424244 205 0.12158167 
40 0.623106061 159.75 99.54119324 0.25 24.88529831 205 0.121391699 
30 0.623106061 164.25 102.3451705 0.25 25.58629263 205 0.124811184 
20 0.623106061 165.25 102.9682766 0.25 25.74206915 205 0.125571069 
10 0.623106061 141.25 88.01373112 0.25 22.00343278 205 0.107333818 
0 0.623106061 56.75 35.36126896 0.25 8.84031724 205 0.043123499 
 
Table 6-32 Knee MO10 PS-TKA Mean Data 
Flexion Angle (°) Force Multiplication 
Factor 
Corrected 
Mean 
Force (N) Distance (m) Moment (Nm) Constant 
Force (N) 
Extensor Moment 
Efficiency (Nm/NQT) 
120 0.623106061 169.5 105.6164773 0.25 26.40411933 205 0.128800582 
110 0.623106061 129.5 80.6922349 0.25 20.17305872 205 0.098405165 
100 0.623106061 134.5 83.8077652 0.25 20.9519413 205 0.102204592 
90 0.623106061 130.75 81.47111748 0.25 20.36777937 205 0.099355021 
80 0.623106061 104.75 65.27035989 0.25 16.31758997 205 0.079598 
70 0.623106061 112.5 70.09943186 0.25 17.52485797 205 0.085487112 
60 0.623106061 140.25 87.39062506 0.25 21.84765626 205 0.106573933 
50 0.623106061 157.25 97.98342809 0.25 24.49585702 205 0.119491985 
40 0.623106061 175.5 109.3551137 0.25 27.33877843 205 0.133359895 
30 0.623106061 163.5 101.877841 0.25 25.46946024 205 0.124241269 
20 0.623106061 153.5 95.64678036 0.25 23.91169509 205 0.116642415 
10 0.623106061 107 66.67234853 0.25 16.66808713 205 0.081307742 
0 0.623106061 29.5 18.3816288 0.25 4.5954072 205 0.02241662 
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Appendix II: Extensor Mechanism Efficiency Summary Data for Conditions 
 
 
 
Table 6-33 Native Knee Data 
Flexion 
Angle (°) 
Extensor Moment Efficiency (Nm/NQT)  
Mean 
Standard 
Deviation 
(±SD)  MO1 MO2 MO3 MO4 MO5 MO6 MO9 MO10 
120 0.104294277 0.095745565 0.095555594 0.118542129 0.151027231 0.076178515 0.120441842 0.125951012 0.110967021 0.022992127 
110 0.0782682 0.078648143 0.06838969 0.090426367 0.084917198 0.057371351 0.074658745 0.094795709 0.078434425 0.012026183 
100 0.075608601 0.078458172 0.067819776 0.080547857 0.078078229 0.053761895 0.064970205 0.083587398 0.072854017 0.009947681 
90 0.079598 0.077128372 0.069529518 0.080927799 0.079028086 0.059081093 0.069149575 0.079218057 0.074207563 0.007628606 
80 0.084347284 0.083397427 0.079218057 0.079787971 0.080737828 0.06705989 0.075608601 0.078458172 0.078576904 0.005405666 
70 0.088906597 0.090426367 0.091566196 0.085677083 0.088716625 0.074468773 0.090426367 0.078838114 0.086128265 0.006213244 
60 0.098975079 0.102394563 0.105244133 0.096505451 0.097645279 0.092326081 0.100874792 0.095935537 0.098737614 0.004061441 
50 0.109803446 0.11170316 0.115122644 0.105624076 0.107143847 0.112083102 0.121011756 0.11170316 0.111774399 0.004777897 
40 0.123101441 0.117022358 0.138489121 0.116072501 0.118542129 0.129180525 0.128040697 0.11170316 0.122768991 0.008736765 
30 0.127660754 0.119681957 0.149887403 0.125571069 0.128800582 0.150077374 0.139818921 0.123861327 0.133169923 0.011864142 
20 0.125001155 0.123671355 0.145518062 0.132220067 0.132789981 0.160525799 0.142668491 0.145518062 0.138489121 0.012393356 
10 0.115502587 0.102394563 0.123291413 0.129560468 0.118352157 0.156536401 0.124241269 0.127850725 0.124716198 0.01545371 
0 0.029825504 0.026406019 0.052812038 0.0782682 0.048252725 0.073328945 0.060220921 0.021276792 0.048798893 0.021500585 
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Table 6-34 PFA Knee Data 
Flexion 
Angle (°) 
Extensor Moment Efficiency (Nm/NQT)  
Mean 
Standard 
Deviation 
(±SD)  MO1 MO2 MO3 MO4 MO5 MO6 MO9 MO10 
120 0.131460181 0.113602873 0.099924935 0.120251871 0.106763904 0.098975079 0.088906597 0.113602873 0.109186039 0.013441732 
110 0.082257599 0.070289403 0.073708888 0.073898859 0.083207456 0.056611465 0.059461036 0.088526654 0.07349517 0.011272952 
100 0.058131236 0.064400291 0.068579661 0.067249861 0.075798573 0.057181379 0.059461036 0.088716625 0.067439833 0.010614623 
90 0.052052153 0.059271064 0.085867055 0.066110033 0.078458172 0.058891122 0.049962468 0.083017484 0.066703694 0.014056574 
80 0.073708888 0.038564186 0.07541863 0.073898859 0.070099432 0.070479375 0.049392554 0.076558458 0.066015048 0.014078403 
70 0.089856453 0.06288052 0.100494849 0.090616339 0.090996281 0.056041551 0.056611465 0.079598 0.078386932 0.017502108 
60 0.105434105 0.092516052 0.117402301 0.06288052 0.119681957 0.09916505 0.04749284 0.102584534 0.09339467 0.025548134 
50 0.128610611 0.123101441 0.13829915 0.092706024 0.140578806 0.128420639 0.076938401 0.129560468 0.119776943 0.022688203 
40 0.134309752 0.146087976 0.149127518 0.117212329 0.144568205 0.153116916 0.107713761 0.147797718 0.137491772 0.016552211 
30 0.130890267 0.153116916 0.143238405 0.13962895 0.133359895 0.164515198 0.135639551 0.155776515 0.144520712 0.012042596 
20 0.115692558 0.150647289 0.126140983 0.169264482 0.138109179 0.15083726 0.152167059 0.154826658 0.144710684 0.017171667 
10 0.090426367 0.135639551 0.091566196 0.153876802 0.116262472 0.122341556 0.143998291 0.123671355 0.122222824 0.022818024 
0 0.011778224 0.088526654 0.009118625 0.107333818 0.057751293 0.034574788 0.108473647 0.014437823 0.053999359 0.042690844 
 
Table 6-35 CR-TKA Knee Data 
Flexion 
Angle (°) 
Extensor Moment Efficiency (Nm/NQT)  
Mean 
Standard 
Deviation 
(±SD)  MO1 MO2 MO3 MO4 MO5 MO6 MO9 MO10 
120 0.116642415 0.093845852 0.112463045 0.096885394 0.151027231 0.096125508 0.091186253 0.135069637 0.111655667 0.02177609 
110 0.073898859 0.089666482 0.074848716 0.069149575 0.104864191 0.061550721 0.062120635 0.105814048 0.080239153 0.017804957 
100 0.070099432 0.087196854 0.070669346 0.067439833 0.093655881 0.056421494 0.053951866 0.089856453 0.073661395 0.015077398 
90 0.075798573 0.085677083 0.071049289 0.070099432 0.092326081 0.056801437 0.056801437 0.090426367 0.074872462 0.013911315 
80 0.069149575 0.084347284 0.074468773 0.071049289 0.092326081 0.063260463 0.059840978 0.091756167 0.075774826 0.012428433 
70 0.073328945 0.086816912 0.075038687 0.08244757 0.099924935 0.074278802 0.065350148 0.104484248 0.082708781 0.013662829 
60 0.085297141 0.094225795 0.076938401 0.100304878 0.11037336 0.082257599 0.069909461 0.117782243 0.09213611 0.016607949 
50 0.086436969 0.102394563 0.080927799 0.117782243 0.117402301 0.086057026 0.081687685 0.12158167 0.099283782 0.017582048 
40 0.1187321 0.116262472 0.089096568 0.1200619 0.1200619 0.096885394 0.085677083 0.121391699 0.108521139 0.015263294 
30 0.101634678 0.121961613 0.087576797 0.128040697 0.124051298 0.10334442 0.098785107 0.124811184 0.111275724 0.015190159 
20 0.102584534 0.121771642 0.075038687 0.121011756 0.11455273 0.093655881 0.110943274 0.125571069 0.108141197 0.017074112 
10 0.078648143 0.089096568 0.045213184 0.080547857 0.092895995 0.053191981 0.087196854 0.107333818 0.07926555 0.020614112 
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0 0.022796563 0 0.001519771 0.003229513 0.0404639 0.000759885 0.019187107 0.043123499 0.01638503 0.017929843 
Table 6-36 PS-TKA Knee Data 
Flexion 
Angle (°) 
Extensor Moment Efficiency (Nm/NQT)  
Mean 
Standard 
Deviation 
(±SD)  MO1 MO2 MO3 MO4 MO5 MO6 MO9 MO10 
120 0.115122644 0.116072501 0.109043561 0.098785107 0.124051298 0.082827513 0.087196854 0.128800582 0.107737508 0.016725014 
110 0.088146711 0.098595136 0.079787971 0.070289403 0.098595136 0.064020348 0.06421032 0.098405165 0.082756274 0.015282598 
100 0.080167914 0.087006883 0.073708888 0.065540119 0.086816912 0.06288052 0.055471637 0.102204592 0.076724683 0.015335303 
90 0.07541863 0.086057026 0.075228659 0.069909461 0.078648143 0.06705989 0.055661608 0.099355021 0.075917305 0.013011874 
80 0.06838969 0.085487112 0.0782682 0.078838114 0.076938401 0.071809174 0.05452178 0.079598 0.074231309 0.009477784 
70 0.07123926 0.086246997 0.081497713 0.086816912 0.078648143 0.076558458 0.061170778 0.085487112 0.078458172 0.008813876 
60 0.076558458 0.091756167 0.084537255 0.097265336 0.085487112 0.087576797 0.064590262 0.106573933 0.086793165 0.01270941 
50 0.077888258 0.094225795 0.090046425 0.106573933 0.091756167 0.095175651 0.070289403 0.119491985 0.093180952 0.0153365 
40 0.080927799 0.10334442 0.093275938 0.120631814 0.100684821 0.106004019 0.080547857 0.133359895 0.10234707 0.01824255 
30 0.094795709 0.11037336 0.09916505 0.136209465 0.114172787 0.117402301 0.098025222 0.124241269 0.111798145 0.014283811 
20 0.105624076 0.100114907 0.091756167 0.137919207 0.119491985 0.115312616 0.110563332 0.116642415 0.112178088 0.013907816 
10 0.067249861 0.036474501 0.058131236 0.113032959 0.110943274 0.079218057 0.09213611 0.081307742 0.079811718 0.026003472 
0 0.023366477 -0.000379943 0 0.001139828 0.041223785 0.001139828 0.011018339 0.02241662 0.012490617 0.015231171 
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Appendix III: Patellofemoral Resultant Force Summary Data for Conditions 
Table 6-37 Patellofemoral Resultant Force Summary Data 
Native knee 
Flexion angle (°) Mean Patellofemoral Resultant Force (N) Standard deviation (±SD) 
0 36.27738597 4.443786551 
30 68.64461041 9.654367135 
60 91.10694451 21.27002882 
90 92.12674547 30.56885352 
120 83.38981248 28.14018458 
PFA 
Flexion angle (°) Mean Patellofemoral Resultant Force (N) Standard deviation (±SD) 
0 30.08964813 9.988692998 
30 54.66419394 12.67898517 
60 71.39603169 16.47218708 
90 101.9181354 29.26405569 
120 97.27299288 30.78750053 
CR-TKA 
Flexion angle (°) Mean Patellofemoral Resultant Force (N) Standard deviation (±SD) 
0 22.868891 4.034754054 
30 51.09061188 8.23142143 
60 82.2397565 13.6216609 
90 82.9544755 15.21988778 
120 83.20235925 24.47742336 
PS-TKA 
Flexion angle (°) Mean Patellofemoral Resultant Force (N) Standard deviation (±SD) 
0 25.47978425 4.573377099 
30 51.06743731 5.853063028 
60 81.64295675 12.63350876 
90 76.239756 14.6552731 
120 73.35268 12.9374087 
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Appendix IV: Peak Pressure Summary Data for Conditions 
Table 6-38 Peak Pressure Summary Data 
Native knee 
Flexion angle (°) Mean Peak Pressure (MPa) Standard deviation (±SD) 
0 1.651428571 0.563232592 
30 1.194285714 0.629758079 
60 1.186428571 0.569632296 
90 1.431428571 0.639900476 
120 1.730714286 1.761796972 
PFA 
Flexion angle (°) Mean Peak Pressure (MPa) Standard deviation (±SD) 
0 7.130625 1.326064094 
30 7.835625 0.540300429 
60 8.2525 0.758890167 
90 4.436875 1.550340832 
120 3.056875 0.927711999 
CR-TKA 
Flexion angle (°) Mean Peak Pressure (MPa) Standard deviation (±SD) 
0 6.6925 0.88663489 
30 7.25875 0.998426441 
60 7.56875 1.154270796 
90 8.026875 1.198057766 
120 8.10125 1.172386912 
PS-TKA 
Flexion angle (°) Mean Peak Pressure (MPa) Standard deviation (±SD) 
0 6.906875 1.238775137 
30 7.00625 0.708397336 
60 7.520625 0.921863166 
90 8.058125 1.017777472 
120 8.246875 0.602506298 
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Appendix V: Contact Area Summary Data for Conditions 
Table 6-39 Contact Area Summary Data 
Native knee 
Flexion angle (°) Mean Contact Area (mm2) Standard deviation (±SD) 
0 117.3960786 25.11180992 
30 229.0318 31.99483024 
60 338.1329643 69.95493072 
90 308.4095214 56.85874213 
120 288.0178571 59.20395571 
PFA 
Flexion angle (°) Mean Contact Area (mm2) Standard deviation (±SD) 
0 19.65721875 9.960671924 
30 38.60879375 17.5016771 
60 44.2538875 9.983952568 
90 106.1489813 37.36853831 
120 108.1651069 20.4037425 
CR-TKA 
Flexion angle (°) Mean Contact Area (mm2) Standard deviation (±SD) 
0 13.9112375 4.910196488 
30 30.76606875 11.69634516 
60 47.78210625 6.122803842 
90 36.29025 14.12685751 
120 32.258 8.865711765 
PS-TKA 
Flexion angle (°) Mean Contact Area (mm2) Standard deviation (±SD) 
0 13.306425 6.050294814 
30 17.9435125 7.886852467 
60 44.85878125 15.62538683 
90 32.05633125 6.660500529 
120 28.12491875 5.442999346 
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Appendix VI: Additional Systematic Review Tables 
 
Table 6-40 Details of Implant Characteristics 
Year of 
inception 
Implant  Implant Design characteristics Studies 
Onlay/ 
Inlay 
Asymmetri
c/ 
Symmetric 
Anatomical/ 
Non-anatomical 
1974/76/84 Richards I, II, III Inlay Symmetric Non-anatomical Blazina et al 1979 
Arciero et al 1988* 
Kradjca-Radcliffe et al 1996 
Arnbjornsson et al 1998* 
Kooijman et al 2003 
Cartier et al 2005 
Utukuri et al 2008 
van Jonbergen et al 2010 
1975 Lubinus Inlay Asymmetric Non-anatomical Arnbjornsson et al 1998* 
Tauro et al 2001 
Smith et al 2002 
Board et al 2004 
Mohammed et al 2008* 
1976 CSF-Wright Inlay Symmetric Non-anatomical Arciero et al 1988* 
1980 Autocentric I, II Inlay Asymmetric Non-anatomical Argenson et al 2005 
van Wagenberg et al 2009 
1987 Spherocentric Inlay Asymmetric Non-anatomical  
1997 LCS Inlay Asymmetric Anatomical Merchant 2005 
Charalambous et al 2011 
1996 Avon Onlay Symmetric Non-anatomical Nicol et al 2006 
Ackroyd et al 2007 
Hollinghurst et al 2007 
Mohammed et al 2008* 
Leadbetter et al 2009 
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Odumenya et al 2010 
Gao et al 2011 
Sarda et al 2011 
Mont et al 2012 
1997 Hermes Onlay Asymmetric Anatomical Goutailler et al 2008 
2004? Vanguard Onlay Asymmetric Anatomical  
2008 Natural Knee II Onlay Asymmetric Anatomical Hofmann et al 2009 
1996 FPV Onlay Asymmetric Anatomical Mohammed et al 2008* 
Monk et al 2012 
Mofidi et al 2012 
2005 Journey Onlay Asymmetric Anatomical Beitzel et al 2012 
2008? Zimmer Onlay Asymmetric Anatomical  
1994? Custom Performa 
Knee 
Onlay Asymmetric Anatomical- 
patient specific 
Butler et al 2009 
1995 Kinematch Onlay Asymmetric Anatomical- 
patient specific 
Sisto & Sarin 2010 
*Mixed group 
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Table 6-41 Surgery performed prior to, during and after PFA or TKA 
 
 
Author 
 
 
Implant 
 
 
List of procedures 
 
Inlay, symmetrical, non-anatomical 
 
 
Pre-operative 
 
Concomitant 
procedures 
 
Post-operative 
 
Blazina 
1979 
 
cemented – nr  
 
surgeons – nr 
 
 
Richards I 
and II 
 
25 patellaplasties 
2 secondary 
patellaplasties 
24 medial 
meniscetomies 
4 secondary medial 
menisectomies 
8 lateral 
menisectomies 
 
Proximal extensor 
realignment 
procedures: 
23 vastus medialis 
transposition 
3 secondary 
medialis 
transportion 
7 medial patellar 
retinaculum 
advancement 
2 secondary medial 
patellar retinaculum 
advancement 
23 vastus lateralis 
release 
2 vastus lateralis 
release 
 
Distal extensor 
realignment 
procedures: 
12 Tibial tubercle 
transfer 
4 Roux-Goldthwaite 
2 transfer medial ½ 
of patellar tendon 
 
Other: 
3 patella # ORIF 
6 Removal of loose 
bodies 
5 chondroplasty of 
lateral femoral 
condyle  
4 partial excision of 
fat pad 
3 chondroplasty of 
femoral groove 
2 Ellison 
2 partial 
synovectomy 
2 chondroplasty of 
medial femoral 
condyle  
2 Excision of 
neuroma of 
infrapatellar branch 
of saphenous nerve 
2 anteromedial 
capsular reefing 
2 posteromedial 
capsular reefing 
 
- 
 
13 lateral capsule 
release 
9 release of intra-
articular adhesions 
9 tibial tubercle 
transfer 
7 partial excision of 
fat pad 
6 V-plasty 
lengthening of 
patellar tendon 
6 medial capsule 
release 
5 
secondary(revision) 
femoral groove 
replacement 
4 vastus lateralis 
release 
3 secondary vastus 
lateralis release 
3 partial 
synovectomy 
3 PFR 
2 Z-plasty 
lengthening 
Of patellar tendon 
2 lateral 
facetectomy of 
patella 
2 debridement and 
irrigation of wound 
2 secondary vastus 
medialis 
transposition 
2 removal of PFR 
1 secondary 
patellar 
replacement 
21 miscellaneous 
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2 pes anserinus 
transfer 
21 miscellaneous 
  
 TOTAL 195 (in 66pts)  101 (in 30pts) 
 
Krajca-Radcliffe 
1996 
 
cemented – all 
 
surgeons - 1 
 
Richards I 
and II 
 
1 menisectomy 
1 arthroscopy and 
lateral release 
1 arthrotomy with 
loose body removal 
1 patella # ORIF 
 
13 lateral releases 
 
 
2 partial 
meniscetomies 
1 PFR 
1 Hauser 
procedure 
 
 TOTAL 4 (in 4pts) 13 4 (in 3pts) 
 
de Winter 
2001 
 
cemented – all 
 
surgeons - nr 
 
 
Richards II 
 
7 soft tissue patellar 
realignment  
3 TT transfer 
7 arthroscopies 
1 arthrotomy 
3 meniscetomies 
1 patella # ORIF 
 
- 
 
3 patellectomies 
3 nettoyages 
(arthroscopic 
washout) 
2 TKR 
2 realignment 
procedures (one 
soft tissue patellar 
realignment and 1 
TT transfer) 
2 MUAs 
 TOTAL 22 (in 12pts)  12 (in 11pts) 
 
Kooijman 
2003 
 
cemented – all 
 
surgeons - nr 
 
 
Richards II 
 
7 Maquet 
procedures  
5 realignment 
procedures 
2 patella # ORIF 
42 patella 
debridements 
 
- 
 
8 procedures: 
MUA, arthroscopic 
or open 
debridement of 
joint 
 
 7 revision PFRs: 
1 patellar loosening 
1 maltracking 
2 malpositioning 
3 patellectomies 
 
2 femoral 
component 
removed  
 
3 HTOs 
 
10 TKAs 
 TOTAL 74 (in 38pts)  30 (in 19pts) 
 
Cartier 
2005 
 
cemented – all 
 
surgeons - nr 
 
 
Richards II 
 
10 TT transfers 
3 soft tissue surgery 
1 PFR 
3 menisectomies 
1 HTO 
 
15 TT transfers 
2 HTOs 
1 medial 
retinaculum 
tightening 
 
1 realignment of 
trochlear prosthesis 
1 reduce thickness 
of old TT 
advancement 
3 lateral releases 
8 TKRs 
 TOTAL 18 (in 18 knees) 18 (in 18 knees) 13 (in 13 knees) 
 
Utukuri 
2008 
 
cemented – all 
 
surgeons - 1 
 
Richards II 
 
20 arthroscopic 
evaluations  
3 Lateral releases 
 
- - 
 TOTAL 23 (in 17pts)   
 
van Jonbergen 
2010 
 
cemented – all 
 
surgeons – 3 
 
 
Richards II 
 
25 realignment 
procedures 
109 patelloplasties 
24 menisectomies 
19 Other 
 
5 distal 
realignment 
1 debridement 
chondral lesion 
medial fem cond 
1 metal removal 
from previous 
 
11 MUAs 
14 arthrotomies 
27 arthroscopies 
10 Other 
 
Removal of 
prosthesis due to: 
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 realignment 1 infection 
2 malposition 
 
23 TKR for TFOA 
 
PFR: 
10 malposition 
  4 loosening 
  4 wear  
 TOTAL 177 (in 157pts) 7 (in 7pts) 105 (in 77pts) 
 
Inlay, asymmetrical, non-
anatomical 
    
 
Tauro 
2001 
 
cemented – all 
 
surgeons – nr 
 
 
  
- 
 
2 medial UKR (St 
George Sled) 
37 lateral releases 
 
15 revisions for 
patellar 
maltracking: 
 5 TKR 
10 PFR (Avons) 
 
 5 TKR for TFOA 
 1 TKR for # patella 
and SC femur # 
 
 3 Roux –
Goldthwaite 
 7 patellar buttons 
inserted as 
secondary 
    procedure 
 4 arthroscopies 
 1 patella # ORIF  
 TOTAL  39  36 
 
Smith 
2002 
 
cemented – nr 
 
surgeons – 5 
 
  
11 arthroscopies 
 
- 
 
 3 TKR for TFOA 
 1 TKR for pain 
 1 TKR for patellar 
instability 
 2 PFR for patellar 
maltracking 
 1 TT transfer 
 2 medial plications 
 TOTAL 11  10 
 
Board 
2004 
 
cemented – all 
 
surgeons – nr 
 
  
5 arthroscopy 
washouts 
1 lateral release 
1 tibial tubercle  
1 Roux-Goldthwaite 
1 patella # ORIF 
 
7 lateral releases 
 
 TKR: 
 2 for TFOA 
 1 for infection 
 1 for 10° extension 
block 
 
 1 PFR for 15° ext 
block 
 
 2 arthroscopies  
 TOTAL 9 7 7 
 
Argenson 
2005 
 
cemented – all 
 
surgeons – multiple 
 
  
12 patella # ORIF 
6 TT transfer 
(anterior TT 
elevation) 
 
8 osteotomies: 
- 3 HTO 
- 5 lower 
femoral 
osteoto
mies 
5 TT transfer 
(anterior TT for 
medialisation) 
 
TKR: 
14 for TFOA 
  4 for loosening 
  4 for stiffness 
 
PFR for loosening: 
3 infection 
3 aseptic loosening  
1 patella # 
 
2 MUA 
5 lateral releases + 
partial patellectomy 
(lateral patellar 
facet resection) 
 TOTAL 18 12 36 
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Van Wagenberg 
2009 
 
cemented – 3; others 
uncemented 
 
surgeons – nr 
 
  
20 arthroscopies 
 
2 lateral releases 
 
7 TKR 
7 arthroscopic 
nettoyage 
(washout) 
1 arthrotomic 
debridement 
1 excision of 
neuroma 
2 hydrops 
decompression 
punctuation 
13 intra-articular 
injection 
2 lateral release 
1 resurfacing 
patella edge  
4 revision patellar 
component 
1 surgical 
intervention wound 
infection 
 TOTAL 20 2 39 
 
Inlay, asymmetrical, 
anatomical 
 
    
 
Merchant 
2005 
 
cemented – all femoral; some 
press-fit patella 
 
surgeons – 6 
 
  
Multiple lateral 
retinacular releases  
Realignment 
procedures 
 
 
Multiple lateral 
retinacular 
releases  
Realignment 
procedures 
 
 
- 
 TOTAL nr nr  
 
Charalambous 
2011 
 
cemented – all 
 
surgeons – 2 
 
  
- 
 
- 
 
12 TKR for pain (2 
coexisting TFOA): 
- 6 
reduced 
mobility 
due to 
tissue 
overgro
wth 
- 3 
extensiv
e 
metalosi
s 
- 2 PE 
worn 
and 
fractured 
- 1 
maltracki
ng 
4 TKR for patellar 
instability or 
   dissociation of 
patellar bearing 
 
1 revision patellar 
component 
 
1 Lateral 
retinacular release 
for patella 
maltracking 
 TOTAL   18 
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Onlay, symmetrical, non-
anatomical 
 
    
 
Nicol 
2006 
 
cemented – all 
 
surgeons – 2 
 
  
13 arthroscopy 
 2 chondrectomy 
 2 patellar 
realignment 
 1 patella # ORIF 
 1 UKR 
 9 unknown 
 
- 
 
12 TKR for TFOA 
  1 TKR for lateral 
femoral condyle  
     necrosis 
  1 TKR persistent 
pain and patellar 
     subluxation 
 TOTAL 28  14 
 
Ackroyd 
2007 
 
cemented – all 
 
surgeons – multiple 
 
  
15 arthroscopies 
3 chondrectomy 
2 lateral releases 
2 patellar 
realignment 
1 patella # ORIF 
 
- 
 
2 arthroscopic 
haemarthrosis 
evacuations 
1 MUA 
1 distal soft tissue 
realignment 
4 TKR for TFOA 
 
(later 11 TKR for 
TFOA not included 
in analysis) 
 TOTAL 23  8 
 
Hollinghurst 
2007 
 
cemented – all 
 
surgeons – nr 
 
  
- 
 
- 
 
- 
 TOTAL    
 
Leadbetter 
2009 
 
cemented – all 
 
surgeons – multiple 
 
  
48 arthroscopic PF 
shaving or 
chondroplasty  
10 lateral releases 
9 
anteromedialisation 
TT osteotomies 
8 osteoarticular 
graftings 
3 soft tissue 
realignments 
2 ACL 
reconstructions 
1 HTO 
 
- 
 
4 TKR for TFOA 
1 TKR for instability 
1 TKR for trauma 
1 TT # ORIF 
following a fall 
 TOTAL 81  7 
 
Starks 
2009 
 
cemented – all 
 
surgeons – 1 
  
6 arthroscopies 
1 lateral release 
1 patella # ORIF 
1 autologous 
chondrocyte 
implantation 
 
- 
 
1 patellar 
resurfacing as a 
secondary 
procedure 
1 revision patellar 
component 
 TOTAL 9  2 
 
Odumenya 
2010 
 
cemented – all 
 
surgeons – 1 
  
22 arthroscopies 
5 lateral releases 
2 chondrectomies 
1 patella # ORIF 
 
 
- 
 
1 arthroscopic 
lateral release 
2 TKR for 
persistent pain/mild 
TFOA 
1 TKR for TFOA 
 TOTAL 30  4 
 
Gao 
2010 
 
cemented – all 
  
11 arthroscopies 
6 lateral releases 
 
 
1 arthroscopic 
menisectomy 
 
- 
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surgeons – 1 
 TOTAL 17 1  
 
Sarda 
2011 
 
cemented – all 
 
surgeons – 1 
  
6 lateral releases 
6 chondrectomy 
 
6 lateral releases 
 
1 TKR for TFOA 
1 TKR for clicking 
6 lateral releases 
2 arthroscopic 
excisions of 
nodular lesions 
 TOTAL 12 6 10 
 
Mont 
2012 
 
cemented – all 
 
surgeons – 3 
  
- 
 
- 
 
1 open arthrotomy 
4 arthroscopic lysis 
of adhesions 
5 TKR 
1 MUA 
 TOTAL   11 
 
Onlay, asymmetrical, 
anatomical 
 
    
 
Hofmann 
2009 
 
cemented – all 
 
surgeons – 4 
 
  
- 
 
- 
 
Following trauma in 
2 cases: 
1 medial retinacular 
repair 
1 lateral release 
1 medialisation of 
patellar component 
 
1 revision femoral 
component 
 TOTAL   4 
 
Monk 
2012 
 
cemented – all 
 
surgeons – 1 
 
 
 
 
 
- 
 
- 
 
- 
 TOTAL    
 
Mofidi 
2012 
 
cemented – all 
 
surgeons –  2 
  
- 
 
- 
 
- 
 TOTAL    
 
Williams 
2013 
 
cemented – all 
 
surgeons – 6 
 
  
2 patellar ORIF 
2 patellar 
realignment 
  
5 TKR: 
4 for TFOA 
1 for inflammatory 
arthritis 
 
1 PFR for 
persistent pain 
1 TKR for 
persistent pain 
1 patellar ORIF 
 TOTAL 4  8 
 
Beitzel 
2013 
 
cemented – all 
 
surgeons – 4 
  
8 retro-patellar 
debridement/shavin
g 
1 microfracture 
1 OATS 
1 TT transfer 
 
4 MPFL 
reconstructions 
2 medial 
tightening 
2 distal femur 
osteotomies 
 
none 
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 TOTAL 11 8  
 
Onlay, asymmetrical, patient-
specific 
 
    
 
Butler 
2009 
 
cemented – none 
 
surgeons – nr 
  
Multiple arthroscopy 
procedures 
 
- 
 
1 revision patellar 
component 
2 arthroscopic 
debridement for 
arthrofibrosis  
 TOTAL nr  3 
 
Sisto 
2010 
 
cemented – all 
 
surgeons – 1 
  
13 arthroscopic 
lateral release and 
debridement 
6 arthrotomy with 
lateral release and 
elevation of the tibial 
tubercle 
 
12 lateral release 
 
none 
 TOTAL 19 12  
 
Mixed group 
 
    
 
Arciero 
1988 
 
cemented – all 
 
surgeons – 9 
 
  
Realignment 
procedures: 
2 Hausers 
1 Maquet 
2 lateral releases 
 
4 arthroscopy 
meniscal 
procedures 
1 arthroscopic 
removal of loose 
body 
 
7 lateral releases 
2 TT transfers 
2 UKRs 
1 VMO ADV 
 
3 UKR 
2 arthroscopies 
2 revision PFA 
3 MUAs 
1 open lysis of 
adhesions 
 TOTAL 10 12 11 
 
Arnbjornsson 
1998 
 
cemented – nr 
 
surgeons – multiple 
 
  
30 arthroscopy +/- 
menisectomy 
2 tibial osteotomy 
18 lateral release 
2 TT transfer 
6 other alignment 
procedure 
11 TT elevation 
6 other ops 
 
none 
 
6  rev PFA (change 
or patellar comp) 
for pain 
3 TKR for pain 
1 arthrodesis for 
pain 
5 patellectomy for 
pain 
11 arthroscopy/-
tomy 
8 lateral release 
10 MUA 
4 medial TT 
transfer 
4 tibial osteotomy 
3 synovectomy for 
infection 
3 extr. 
osteosyntesm. 
3 other operations 
 TOTAL 75  61 
 
Mohammed 
2008 
 
cemented – all 
 
surgeons – multiple 
 
  
58 arthroscopy + 
debridement 
15 chondroplasty 
23 lateral 
retinalcular release 
3 TT transfer 
18 intra-articular 
injections 
 
23 lateral releases 
6 osteochondral 
autograft transfer 
system (OATS) 
procedure 
 
2 MUA 
18 arthroscopic 
debridement 
8 arthroscopic 
lateral release 
3 tibial tubercle 
transfer  
4 TKR 
 TOTAL 117 29 35 
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Total knee replacement 
 
 
Meding  
2007 
 
cemented – all 
 
AGC – CR-TKR 
Legacy – PS-TKR 
 
surgeons – 5 
  
unknown 
 
10 lateral release 
 
none 
 TOTAL nr 1  
 
Laskin 
1999 
  
cemented – all 
 
Genesis – CR-TKR 
 
surgeons – 1 
  
- 
 
 
18 lateral release 
 
- 
 TOTAL  18  
 
Thompson 
2001 
 
cemented – none 
 
LCS – PS-TKR without 
patellar resurfacing 
 
surgeons – 1 
  
7 injections 
1 operation for 
patellar dislocation 
 
Unknown number 
of lateral release 
 
- 
 TOTAL 8 nr  
 
Mont 
2002 
 
cemented – 
cemented/uncemented/hybrid
s 
 
(metal-back/all- poly patellar 
components) 
 
24 – PS-TKR 
 6 – CR-TKR 
 
surgeons – multiple 
  
none 
 
12 lateral releases 
 
1 patellar tendon 
reconstruction 
 TOTAL  12 1 
 
Dalury 
2005 
 
cemented – all 
 
Press Fit Condylar CR-TKR 
 
surgeons – 1 
  
- 
 
3 lateral release 
 
- 
 TOTAL  3  
 
Parvizi 
2001 
 
cemented – all 
 
PS-TKR 
CR-TKR 
 
surgeons – multiple 
  
2 arthroscopic 
menisectomy 
1 proximal extensor 
realignment 
1 open lateral 
release 
1 supracondylar 
femur # ORIF 
 
21 lateral release 
 
1 MUA 
1 revision of 
patellar component 
1 proximal extensor 
mechanism 
alignment 
1 tibial poly 
exchange 
 TOTAL 5 21 4 
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Comparison 
 
 
Dahm 
2010 
 
cemented – all 
 
Avon PFR 
 
surgeons – >1 
  
13 procedures 
 
19 lateral release 
 
none 
 TOTAL 13 19  
 
Dahm 
2010 
 
cemented – all 
 
PS-TKR 
CR-TKR 
 
surgeons – 8 
  
9 procedures 
 
 1 lateral release 
 
1 MUA 
 TOTAL 9 1 1 
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Table 6-42 Mechanism of failure for all knees requiring revision to TKA or other PFA, UKA, arthrodesis or removal 
Author 
Year 
Implant Knees Disease 
Progression 
(TFOA) 
Number of 
Malposition/ 
misalignment 
Number of 
persistent pain 
Aseptic 
loosening 
 Infection Other 
(stiffness, 
trauma etc) 
 
Inlay, symmetrical, non-anatomical 
 
Blazina 
1979 
Richards I and II 85 0 9 1 0 1 0 
Krajca-Radcliffe 
1996 
Richards I and II 16 0 1 0 0 0 0 
de Winter 
2001 
Richards II 26 2 0 0 0 0 0 
Kooijman 
2003 
Richards II 45 10 3 not reported 1 0 5 
Cartier 
2005 
Richards II 59 8 5 0 0 0 0 
Utukuri 
2008 
Richards II 20 0 0 0 0 0 0 
van Jonbergen 
2010 
Richards II 181 23 12 0 4 1 5 
 
Inlay, asymmetrical, non-anatomical 
 
Tauro 
2001 
Lubinus 76 5 15 7 0 0 1 
Smith 
2002 
Lubinus 29 3 3 1 0 0 0 
Board 
2004 
Lubinus 17 2 2 0 0 1 0 
Argenson 
2005 
Autocentric  57 14 0 0 7 3 5 
Van Wagenberg 
2009 
Autocentric II 24 7 4 0 0 0 0 
 
Inlay, asymmetrical, anatomical 
 
Merchant 
2005 
LCS 16 0 0 0 0 0 0 
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Charalambous 
2011 
LCS  51 2* 3 12* 0 0 3 
 
Onlay, symmetrical, non-anatomical 
 
Nicol 
2006 
Avon 103 12 1*  1* 0 0 1 
Ackroyd 
2007 
Avon 109 4 0 0 0 0 0 
Hollinghurst 
2007 
Avon 12 0 0 0 0 0 0 
Leadbetter 
2009 
Avon 79 4 1 0 0 0 1 
Starks 
2009 
Avon 37 0 0 1 0 0 1 
Odumenya 
2010 
Avon 50 3* 0 2*  0 0 0 
Gao 
2010 
Avon 11 0 0 0 0 0 0 
Sarda 
2011 
Avon 44 1 1*  1*  0 0 0 
Mont 
2012 
Avon 43 2*  0 0 5* 0 0 
 
Onlay, asymmetrical, anatomical 
 
Hofmann 
2009 
Natural Knee II 40 0 0 0 0 0 2 
Monk 
2012 
FPV 15 0 0 0 0 0 0 
Mofidi 
2012 
FPV 34 0 0 0 0 0 0 
Williams 
2013 
FPV 53 4 0 2 0 0 1 
Beitzel 
2013 
Journey 22 0 0 0 0 0 0 
 
Onlay, asymmetrical, patient-specific 
 
Butler Custom Performa 22 0 0 0 0 0 1 
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2009 Knee 
Sisto 
2010 
Kinematch 25 0 0 0 0 0 0 
 
Mixed Group 
 
Arciero 
1988 
Richards and 
CSF-Wright 
25 3 2 0 0 0 0 
Arnbjornsson 
1998 
Richards I and II 
Lubinus 
Miscellaneous 
other 
113 0 0 10 0 0 0 
Mohammed 
2008 
Lubinus 
Avon 
FPV 
101 3 0 0 0 1 0 
 
Total Knee Replacement 
 
Meding  
2007 
AGC 
Legacy 
33 0 0 0 0 0 0 
Laskin 
1999 
Genesis 48 0 0 0 0 0 0 
Thompson 
2001 
LCS 33 0 0 0 0 0 0 
Mont 
2002 
Porous Coated 
Anatomic  
Duracon 
Insall-Burstein II 
30 0 0 0 0 0 0 
Dalury 
2005 
Press Fit Condylar 33 0 0 0 0 0 0 
Parvizi 
2001 
Press Fit Condylar 
Genesis 
Total Condylar 
31 0 1 0 1 0 0 
 
Comparison 
 
Dahm  
2010 
Avon 
 
23 0 0 0 0 0 0 
Dahm  
2010 
Zimmer 
SIGMA 
22 0 0 0 0 0 0 
* knees with dual pathology 
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Table 6-43 Details of clinical outcomes 
Author 
Year 
Implant Knees/Subject
s 
(available for 
follow-up) 
Clinical Score Pre- operative 
Score 
Post-
operative 
Score 
 
Inlay, symmetrical, non-anatomical 
 
Blazina 
1979 
 
 
Richards I 
and II 
 
57/55 
 
nr 
 
nr 
 
nr 
 
Krajca-
Radcliffe 
1996 
 
Richards I 
and II 
 
16/13 
 
Modified Hungerford 
and Kenna Scale 
 
Satisfaction 
 
nr 
 
88% (90-100) 
 
 
14 (88%) 
satisfactory = 
excellent or 
good.  
12 excellent 
2 good 
1 fair 
1 poor 
 
de Winter 
2001 
 
Richards II 
 
21/21 
 
AKSS: Function/Clinical 
 
Satisfaction 
 
nr 
 
80(0-
100)/95(65-
100)  
 
9 excellent 
7 good  
4 improved 
1 unimproved 
 
Kooijman 
2003 
 
Richards II 
 
35/35  
 
AKSS: Function/Clinical 
 
Satisfaction 
 
nr 
 
167 
 
30 good to 
excellent 
5 fair to poor 
 
Cartier 
2005 
 
Richards II 
 
59/50 
 
AKSS: Function/Clinical 
 
 
nr 
 
Function:  
72% excellent 
19% fair 
9% failure 
 
Clinical: 
77% excellent 
14% fair  
9% failure  
 
Utukuri 
2008 
 
Richards II 
 
20/17 
 
HSS 
 
 
 
SF-36  
 Physical functioning 
 Social functioning 
 Role limitations due to 
   physical problems 
 Role limitations due to 
   emotional problems 
 Pain 
 General health 
perceptions 
 Mental health 
 Energy/vitality 
 
KOOS 
 Pain 
 Other symptoms 
 Function in daily living 
 Function in sports & 
 
64(51-79) 
 
 
 
 
nr 
 
 
 
 
 
 
 
 
 
 
 
 
nr 
 
 
 
 
90(71-100) 
14 excellent 
(85-100) 
 3 good (70-84) 
 
 
58 
73 
72 
 
68 
 
 
60 
61 
72 
63 
 
 
 
70 
68 
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recreation 
 Knee related quality of 
life 
73 
57 
51 
 
 
van 
Jonbergen 
2010 
 
 
Richards II 
 
181/157 
 
nr 
 
nr 
 
nr 
 
Inlay, asymmetrical, non-anatomical 
 
 
Tauro 
2001 
 
Lubinus 
 
62/48 
 
Bristol Knee Score 
> or 90 = excellent 
80-89 = good 
70-79 = fair 
< 70  = poor 
<80 or revised = 
unsatisfactory 
 
Bristol pain score 
 
 
Bristol movement score 
 
 
55(29-86) 
 
 
 
 
 
 
pain: 5(0-20) = 
continual 
severe 
 
 
100(90-120) 
 
72 (42-100) 
Satisfactory 
28/62 (45%) 
Unsatisfactory 
34/62 (55%) 
 
 
 
 
Pain: 30(15-40) 
= occasional 
mild 
 
 
112(70-120) 
 
Smith 
2002 
 
Lubinus 
 
29/21 
 
Modified Hungerford 
and Kenna score 
 
90 or > = excellent 
80-89 = good 
70-79 = fair 
<70 = poor 
 
Crosby and Insall 
grading system 
Excellent/good/fair/wors
e 
 
 
 
 
nr 
 
 
 
 
nr 
 
 
 
 
 
 
13 excellent 
10 good 
2 fair 
4 poor 
 
2 excellent 
21 good 
4 fair/poor 
2 worse 
 
Board 
2004 
 
Lubinus 
 
17/12 
 
Tegner score 
Lysholm score 
VAS (pain) 
 
Satisfaction 
 
nr 
nr 
5(5-9) 
 
2(1-3) 
46(16-84) 
7(1-9) 
 
10 knees 
(59%) 
satisfactory 
7 knees (41%) 
disappointed 
 
Argenson 
2005 
 
 
Autocentric  
 
29/29  
 
 
AKSS: Function/Clinical 
 
 
41(10-
80)/53(43-70) 
 
 
81(40-
100)/79(60-
100) 
 
 
Van 
Wagenberg 
2009 
 
Autocentric II 
 
10/10 
 
OKS 
 
KOOS 
 Pain 
 Other symptoms 
 Function in daily living 
 Function in sports & 
recreation 
 Knee related quality of 
life 
 
SF-36 
 Physical functioning 
 Social functioning 
 Role limitations due to 
 
nr 
 
nr 
 
 
 
 
 
 
 
 
 
nr 
 
 
 
36(±11)  
 
 
48(±22) 
60(±20) 
43(±18) 
22(±13) 
42(±20) 
 
 
 
 
32(±20) 
58(±22) 
20(±37) 
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   physical problems 
 Role limitations due to 
   emotional problems 
 Pain 
 General health 
perceptions 
 Mental health 
 Energy/vitality 
 
VAS (pain) 
 
 
 
 
 
 
 
 
 
 
 
nr 
 
47(±50) 
 
50(±27) 
53(±21) 
 
64(±17) 
50(±16) 
 
 
4(±3) 
 
 
Inlay, asymmetrical, anatomical 
 
 
Merchant 
2005 
 
LCS 
 
16/16 
  
Activities of Daily Living 
Scale 
85-100% = excellent 
70-84% = good 
55-69% = fair 
 
 
nr 
nr 
42%(23-73) 
*8pts 
 
 
 
8  [84%(74-
96)*8pts] 
7 
 
 
Charalambou
s 
2011 
 
LCS  
 
28/- 
 
OKS  
 
AKSS: Function/Clinical 
 
Melbourne Patellar 
Score 
 
 
Satisfaction: 
Compared with before 
surgery 
Much better 
Better 
Same  
Worse 
 
nr 
 
nr 
 
nr 
 
 
35(26-44) 
 
80(63-
100)/87(63-88) 
 
25(16-30) 
 
 
 
 
 
10 
12 
3 
3 
 
 
Onlay, symmetrical, non-anatomical 
 
 
Nicol 
2006 
 
Avon 
 
66/- 
 
nr 
 
 
nr 
 
 
 
nr 
 
 
Ackroyd 
2007 
 
Avon 
 
109/85 
 
OKS 
 
Bristol Pain Score 
 
Melbourne Patellar 
Score 
 
 
18(13-24) 
 
15(5-20) 
 
10(6-15) 
 
39(24-45) 
 
35(20-40) 
 
25(20-29) 
 
 
Hollinghurst 
2007 
 
Avon 
 
12/12 
 
AKSS: Function/Clinical 
 
OKS 
 
Bartlett (Melbourne) 
Patellar Score 
 
nr 
 
nr 
 
nr 
 
85(45-
100)/88(73-
100) 
 
37(19-47) 
 
26(18-30) 
 
Leadbetter 
2009 
 
Avon 
 
79/70 
 
AKSS: Function/Clinical 
 
 
56 
 
83 
(34 knees > 
90; 32 knees > 
80) 
 
Starks 
2009 
 
Avon 
 
37/29 
 
AKSS: Function/Clinical 
 
 
 
 
nr 
 
 
 
 
85(60-
100)/95(90-
100)  
32knees ≥ 80 
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OKS 
 
Melbourne Patellar 
Score 
 
Satisfaction 
 
nr 
 
nr 
in clinical score 
= excellent in 
86% 
 
39(32-44) 
 
28(21-30) 
 
28 pts satisfied 
 
Odumenya 
2010 
 
Avon 
 
50/32 
 
OKS 
 
EuroQol  
 
 
 
nr 
 
nr 
 
31(22-42) 
 
bilaterals: 
50(25-85) 
unilaterals: 
75(25-100) 
 
Gao 
2010 
 
Avon 
 
11/11 
 
WOMAC Score 
 
AKSS: Function/Clinical 
 
38(±8) 
 
54(±11)/70(±11
) 
 
21(±5) 
 
95(±4)/96(±4) 
 
Sarda 
2011 
 
Avon 
 
44/40 
 
Melbourne Patellar 
Score 
 
AKSS: Function/Clinical 
 
Satisfaction 
 
 
10(5-21) 
 
57(23-95) 
mean  
 
 
 
25(11-30) 
 
85(28-100) 
mean  
 
34 good or 
excellent 
3 fair 
2 poor/worse 
 
Mont 
2012 
 
 
Avon 
 
43/37 
 
AKSS: Function/Clinical 
 
48(45-
50)/64(57-68) 
 
82(20-
100)/87(50-
100) 
 
Onlay, asymmetrical, anatomical 
 
 
Hofmann 
2009 
 
Natural Knee 
II 
 
40/34 
 
KOOS 
 Pain 
 Other symptoms 
 Function in daily living 
 Function in sports & 
recreation 
 Knee related quality of 
life 
 
 
Tegner Score 
 
Satisfaction 
 
nr 
 
 
 
 
 
 
 
3 
 
 
 
 
93 
94 
94 
70 
82 
 
 
5 
 
40 satisfactory 
 
 
Monk 
2012 
 
FPV 
 
15/8 
 
OKS 
 
AKSS: Function / 
Clinical 
 
33(±8) 
 
53(±14)/62(±6) 
 
42(±3) 
 
86(±12)/88(±7) 
 
Mofidi 
2012 
 
FPV 
 
34/28 
 
OKS 
 
AKSS: Function/Clinical 
 
30(±6) 
 
42(±12)/49(±12
) 
 
21(±12) 
 
67(±16)/80(±20
) 
 
Williams 
2013 
 
 
FPV 
 
53/48 
 
nr 
 
nr 
 
Nr§ 
 
Beitzel 
2013 
 
Journey 
 
22/22 
 
WOMAC 
 
Lysholm Score 
 
VAS (pain) 
 
nr 
 
nr 
 
nr 
 
All scores 
improved 
significantly 
(no values 
given; just 
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 graphs) 
 
Onlay, asymmetrical, patient-specific 
 
 
Butler 
2009 
 
 
Custom 
Performa 
Knee 
 
22/21 
 
WOMAC 
 
63 
 
28 
 
Sisto 
2010 
 
 
Kinematch 
 
25/22 
 
Satisfaction 
 
 
 
25 very 
satisfied 
 
Mixed Group 
 
 
Arciero 
1988 
 
Richards and 
CSF-Wright 
 
25/22 
 
Modified Hungerford 
and Kenna Score 
 
90 or > = excellent 
80-89 = good 
70-79 = fair 
<70 = poor 
 
nr 
 
 
 
 
 
 
 
 
 
 
9 
9 
0 
7 
 
Arnbjornsson 
1998 
 
Richards I 
and II 
Lubinus 
Miscellaneou
s other 
 
113/97 
 
Lysholm Score 
 
Satisfaction 
 
45(20-64) 
 
62(6-100) 
 
85/113 
satisfied 
 
Mohammed 
2008 
 
Lubinus 
Avon 
FPV 
 
101/91 
 
nr 
 
nr 
 
nr 
 
Total Knee Arthroplasty 
 
 
Meding  
2007 
 
AGC 
Legacy 
 
33/27 
 
AKSS: 
Functional/Clinical 
 
55(35-
80)/49(20-64) 
 
83(45-
100)/88(33-99) 
 
Laskin 
1999 
 
Genesis 
 
48/48 
 
AKSS: 
Functional/Clinical (pain 
only) 
 
71(62-
80)/25(20-30) 
 
96(82-
100)/47(30-50) 
 
Thompson 
2001 
 
LCS 
 
33/31 
 
- 
 
- 
 
- 
 
Mont 
2002 
 
Porous 
Coated 
Anatomic  
Duracon 
Insall-
Burstein II 
 
30/27 
 
AKSS: 
Functional/Clinical 
 
 
49(20-
80)/50(20-64) 
 
86(60-
100)/93(67-
100) 
 
Dalury 
2005 
 
Press Fit 
Condylar 
 
33/25 
 
AKSS: 
Functional/Clinical (pain 
only) 
 
62(36-
80)/22(16-30) 
 
96(92-
100)/46(40-50) 
 
Parvizi 
2001 
 
Press Fit 
Condylar 
Genesis 
Total 
Condylar 
 
31/24 
 
AKSS: 
Functional/Clinical 
 
 
36(0-
80)/54(32-90) 
 
90(20-
100)/89(54-
100) 
 
Comparison 
 
 
Dahm 
2010 
 
 
Avon 
 
 
-/23 
 
 
AKSS: 
Functional/Clinical 
 
UCLA score 
 
42/58 
 
3 
 
 
84(51-
100)/89(69-
100) 
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Tegner score 
 
2 7(5-9) 
 
4(3-6) 
 
Dahm 
2010 
 
Zimmer  
SIGMA 
 
-/22 
 
 
AKSS: 
Functional/Clinical 
 
UCLA score 
 
Tegner score 
 
 
43/59 
 
3 
 
2 
 
73(59-
94)/90(47-100) 
 
4(3-6) 
 
3(2-3) 
VAS, Visual Analogue Scale; HSS, Hospital for Special Surgery score; SF-36, Short Form 
36; KOOS, Knee Injury and Osteoarthritis Outcome Score; AKSS, American Knee Society 
Score; OKS, Oxford Knee Score (0-worst, 48-best score; 12-best, 60-worst score); 
EuroQol- EuroQol VAS General Health Score; UCLA- University of California Los Angeles 
activity score 
 
Table 6-44 Heterogeneity Assessment for Survival Proportions A and B 
Design Category I2 Calculation % 
Survival 
Proportion A 
Survival 
Proportion B 
Inlay symmetrical non-anatomical 79.9% 79.2%  
Inlay asymmetrical non-anatomical 57.5% 44.8%  
Inlay asymmetrical anatomical *% *%  
Onlay symmetrical non-anatomical 30.2% 14.3%  
Onlay asymmetrical anatomical 0% 0%  
Onlay asymmetrical patient-specific *% *%  
Mixed  74.7% 68.3%  
Total Knee Arthroplasty 0% 0%  
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Differences in Geometry 
 
The Avon has an arc of curvature of approximately 90°, similar to the 
normal geometry of the distal femur, and an anterior flange that is straight in 
the sagittal plane, unlike the Lubinus (IAN group), Richards (ISN group) or 
Autocentric (IAN group). This allows the trochlear prosthesis to lie flat on 
the surface of the anterior femur, and flush within the intercondylar notch. 
The sulcus angle of the Avon is broader (approximately 125°) than the 
small Lubinus (approximately 110°) and is therefore less constraining in 
extension and more accommodating to slight patellar tilt or subluxation. The 
wider sulcus angle allows the patellar component greater freedom of 
medial-lateral translation when it enters the trochlear groove, unlike the 
narrower Lubinus, which offered less freedom of movement and could 
therefore be subjected to higher shear forces.  
 The trochlear component is symmetrical so one component is used 
for both left and right. The justification for this design was that the 
prosthesis aligned with the mechanical axis, not the anatomical one, and 
therefore sided prostheses were not necessary (Wright et al., 1990). This 
concept was supported by Iranpour et al. (2010a), who found that the 
patella moved in a circular path about the axis of the trochlea and this path 
was aligned with the mechanical axis of the femur ( see Figure 6-1). The 
patellar component is anatomical, mimicking the seven facets of the natural 
patella. It has a central crest offset towards the medial side. The medial and 
lateral sides each have a superior, central and inferior facet. The medial 
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edge is thicker than the lateral, due to the offset crest and is smoothed to 
create an articular surface similar to the odd facet. In the original design the 
medial edge scored the medial condyle, hence the change.  
 
 
 
Figure 6-1 [A] The bold black line highlights the circular path of the patella and its relationship 
to the anatomical axis (AB) illustrating it is more fitted to the mechanical axis. [B] Further 
demonstrates the circular nature of the path of the patella, illustrating the lateral deviation of 
the path near extension. 
 
  
BA 
A 
B 
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Appendix VII: Trial Documents 
 
 
Trial Documents 1: Patient Information Sheet 
 
Participant information sheet 
 
The Patellofemoral Arthroplasty Trial 
Chief Investigator: Mr Matt Costa 
 
Background information 
Over 50,000 patients with severe arthritis of the knee undergo Knee Arthroplasty 
(Replacement) each year in the UK. The majority of these patients have arthritis 
that affects all of the surfaces of the knee joint. Therefore they have a ‘Total’ Knee 
Arthroplasty, where the whole knee joint is replaced. However, approximately 10% 
of patients have arthritis that only affects the patellofemoral surfaces of the joint i.e. 
the area around the knee-cap. 
 
Traditionally patients with arthritis affecting only the patellofemoral part of the knee 
have still had a Total Knee Arthroplasty. However, it is also possible to replace only 
the patellofemoral part of the knee joint. This is called a Patellofemoral 
Arthroplasty. 
 
Both Total Knee Arthroplasty and Patellofemoral Arthroplasty are routinely available 
to NHS patients with severe arthritis of the patellofemoral part of the knee. The 
difference between the two involves the number of joint surfaces replaced. In Total 
Knee Arthroplasty all three major areas of the joint are replaced with metal and 
plastic surfaces. In Patellofemoral Arthroplasty only the back of the knee-cap and 
the groove that the knee cap sits in are replaced with metal and plastic surfaces.  
 
What is the purpose of this study? 
This study aims to determine the best type of arthroplasty for patients with severe 
arthritis of the patellofemoral part of the knee. We are comparing two treatments – 
Total Knee Arthroplasty and Patellofemoral Arthroplasty.  
 
Why have I been chosen? 
You have been chosen because you have severe arthritis of the patellofemoral 
part of the knee joint and your surgeon thinks that you may benefit from an 
arthroplasty operation. 
 
Do I have to take part? 
It is up to you whether or not to take part. If you decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time or a decision not to take part will not 
affect the standard of care you receive. 
 
Which treatment will I get? 
If you agree to take part, you will be randomly allocated to either the Total Knee 
Arthroplasty or the Patellofemoral Arthroplasty. The allocation process will be done 
by a computer and will be done purely by chance. In order that we can make a 
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fair comparison between the two types of operation, you will not be told which 
type of arthroplasty you have had for the duration of the study.  
 
What will happen after I have been placed in one of the two groups? 
Once you have agreed to take part, you will be asked to fill out some 
questionnaires and a doctor or physiotherapist will do some tests on your knee - 
such as test your range of movement. The questionnaires we will ask you to fill out 
contain questions about your activity level and how well you are able to perform 
certain day-to-day tasks and also about how you feel. 
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You will then be sent a date to have your surgery in the usual way. Whether you 
are allocated a Total Knee Arthroplasty or a Patellofemoral Arthroplasty, the 
operation will take place in the usual manner by your surgeon. 
   
After the operation, we will keep a careful check on your progress for a year. In this 
period you will be given the same questionnaires as you filled out before the 
operation on three occasions (3, 6 and 12 months after the operation).  
 
What are the possible disadvantages and risks of taking part? 
We do not know which of these treatments gives the best results. Since both types 
of arthroplasty involve surgery, there are risks for both groups. However, these risks 
are the same as for patients not taking part in the trial. There are no special risks 
over and above what your surgeon would normally inform you about. 
 
What are the possible benefits of taking part? 
Both Total Knee Arthroplasty and Patellofemoral Arthroplasty are already being 
used in the NHS for people with severe arthritis of the patellofemoral part of the 
knee joint. There is therefore no specific advantage to you for taking part in the 
study. However, the information we get from this study may help us to choose the 
best type of arthroplasty for patients with the same sort of arthritis as you. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the treatment that is being studied. If this happens, we will tell you 
about it and discuss with you whether you want to continue in the study. If you 
decide to withdraw your care will continue as normal for the hospital. If you decide 
to continue in the study you will be asked sign an updated consent form. On 
receiving new information we may consider it to be in your best interest to 
withdraw you from the study. We will explain the reasons and arrange for your care 
to continue. 
 
What happens when the research study ends? 
You will be in the study for 12 months. However, at the end of the study, we will 
continue to send you questionnaires each year and your surgeon will send you 
appointments for x-rays from time to time in the usual way for patients who have 
had a knee arthroplasty.  
 
What happens if something goes wrong? 
In the unlikely event of you being harmed by taking part in this research project, 
there are no special compensation arrangements. If you are harmed due to 
someone’s negligence, then you may have grounds for a legal action but you 
may have to pay for it. Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated 
during the course of this study, please contact Mr Peter Hedges at Research & 
Support Services, University House, University of Warwick, Kirby Corner Road, 
Coventry CV4 8UW. Direct telephone number 024 765 23716. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the hospital 
will have your name and address removed so that you cannot be recognised from 
it. Your GP and other doctors who may treat you, but are not part of this study will 
be notified that you are taking part in this study. 
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What will happen to the results of the research study? 
This study is expected to last 3 years. At the end of the study we will publish the 
findings in medical journals and at medical conferences. You will not be identified 
in any reports or publications resulting from the study. If you would like to obtain a 
copy of the published results, please ask your doctor. 
 
What will happen if I decide not to participate in the research study? 
If you decide not to participate in the research study you may choose to have a 
Total Knee Arthroplasty or a Patellofemoral Arthroplasty, after being informed by 
your doctor. 
 
Who has reviewed this study? 
This study has been reviewed by the Coventry Local Research Committee  
 
Contacts for further information 
If you would like further information please contact Mr Matt Costa, who is leading 
the project by telephoning 02476 968618 or Dr Juul Achten who is responsible for 
the day-to-day management of the study (02476 968614, 
J.Achten@warwick.ac.uk). 
 
Flow chart of the study 
 
 
 
 
Referral to your surgeon 
Standard rehabilitation  
Patellofemoral Arthroplasty 
Knee function assessment 
and Questionnaires pre-
operation 
Total Knee Arthroplasty 
Knee function questionnaires at 3 months 
post-operation 
Knee function questionnaires at 6 months 
post-operation 
Knee function questionnaires at 12 months 
post-operation 
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